text,chunk_id,title,publication_date,authors,disease
"What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review We conducted a scoping review of the methodological framework proposed by Arksey and O’Malley [<xref ref-type=""bibr"" rid=""CR17"">17</xref>] (2005) and later improved upon that of Levac et al. [<xref ref-type=""bibr"" rid=""CR18"">18</xref>] (2010) and Peters et al. [<xref ref-type=""bibr"" rid=""CR19"">19</xref>] (2020). A scoping review is characterized by identifying, mapping, and summarizing the knowledge on",0_0,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"mapping, and summarizing the knowledge on a topic of interest and indicating aspects yet to be addressed [<xref ref-type=""bibr"" rid=""CR20"">20</xref>–<xref ref-type=""bibr"" rid=""CR22"">22</xref>]. Although this method has an exploratory approach, a scoping review also presents some characteristics of a systematic review, such as protocol and transparency, systematization, and replicability in its data search and extraction processes [<xref ref-type=""bibr"" rid=""CR19"">19</xref>, <xref ref-type=""bibr""",0_1,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"rid=""CR19"">19</xref>, <xref ref-type=""bibr"" rid=""CR20"">20</xref>, <xref ref-type=""bibr"" rid=""CR23"">23</xref>]. This scoping review is part of a larger project that is focused on the impact of phenylketonuria and its treatment in the lives of patients and their caregivers (Project PSIKUS – Impact of Phenylketonuria (PKU) and its Treatment in the Lives of Patients and Their Caregivers. Research and Ethics Committee number CAAE: 62035822.5.0000.5327). The search resulted in 3.249 records. After removing",0_2,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"search resulted in 3.249 records. After removing duplicates, it was reduced to 1.752. Next, titles and abstracts were screened, and 1.505 were excluded for failing to meet the inclusion criteria. In the next stage, after the full-text screening, 218 articles were excluded. Twenty-nine articles were included in the final review. The selection process is illustrated in Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>.",0_3,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"<fig id=""Fig1""><label>Fig. 1</label><caption><p>PRISMA flowchart of the selection process of included studies</p></caption><graphic http://www.w3.org/1999/xlink href=""13023_2024_3422_Fig1_HTML"" id=""d33e494""></graphic></fig>",0_4,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Among the 29 studies included for analysis in the present scoping review, 13 countries, 1.472 phenylketonuric patients, and 1.192 caregivers were included. Twenty-six studies were cross-sectional [<xref ref-type=""bibr"" rid=""CR8"">8</xref>, <xref ref-type=""bibr"" rid=""CR27"">27</xref>–<xref ref-type=""bibr"" rid=""CR51"">51</xref>], and three longitudinal studies [<xref ref-type=""bibr"" rid=""CR52"">52</xref>–<xref ref-type=""bibr"" rid=""CR54"">54</xref>] lasted four months to one year. The countries with the highest",0_5,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"to one year. The countries with the highest number of studies were Germany (<italic toggle=""yes"">n</italic> = 6), the Netherlands (<italic toggle=""yes"">n</italic> = 4), Iran (<italic toggle=""yes"">n</italic> = 4), the United Kingdom (<italic toggle=""yes"">n</italic> = 2), Italy (<italic toggle=""yes"">n</italic> = 2), Greece (<italic toggle=""yes"">n</italic> = 2) and Australia (<italic toggle=""yes"">n</italic> = 2). Studies were also conducted in Brazil, Hungary, Poland, Spain, Tunisia, and Turkey, with one",0_6,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Poland, Spain, Tunisia, and Turkey, with one occurrence each. European countries accounted for 65.5% (<italic toggle=""yes"">n</italic> = 19) of the publications. Three studies were multicenter studies [<xref ref-type=""bibr"" rid=""CR28"">28</xref>, <xref ref-type=""bibr"" rid=""CR34"">34</xref>, <xref ref-type=""bibr"" rid=""CR41"">41</xref>]. The number of publications ranged from 2002 to 2022, with the highest concentration occurring from 2011 to 2021 (<italic toggle=""yes"">n</italic> = 24). Eighteen out of 29",0_7,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"toggle=""yes"">n</italic> = 24). Eighteen out of 29 included studies (62%) assessed the quality of life of patients with PKU exclusively; in 10 (34,4%) studies, only the quality of life of caregivers of PKU patients was evaluated; and in one study, both the patient and the caregiver were assessed [<xref ref-type=""bibr"" rid=""CR28"">28</xref>]. In all studies whose samples included adult participants (patients or caregivers), self-reported measures were used to assess quality of life. On the other hand, in the",0_8,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"assess quality of life. On the other hand, in the studies that evaluated the quality of life of pediatric patients, most used both self-report and proxy report measures (i.e., when caregivers are used as informants) [<xref ref-type=""bibr"" rid=""CR27"">27</xref>, <xref ref-type=""bibr"" rid=""CR28"">28</xref>, <xref ref-type=""bibr"" rid=""CR33"">33</xref>, <xref ref-type=""bibr"" rid=""CR36"">36</xref>, <xref ref-type=""bibr"" rid=""CR40"">40</xref>, <xref ref-type=""bibr"" rid=""CR42"">42</xref>, <xref ref-type=""bibr""",0_9,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"rid=""CR42"">42</xref>, <xref ref-type=""bibr"" rid=""CR49"">49</xref>]. In cases where the patient was not old enough to answer the self-report questionnaires, the parent version was used as the only measure of the child’s QoL [<xref ref-type=""bibr"" rid=""CR44"">44</xref>]. The quality of life of children or adolescents was evaluated only by self-reports in three studies [<xref ref-type=""bibr"" rid=""CR29"">29</xref>, <xref ref-type=""bibr"" rid=""CR32"">32</xref>, <xref ref-type=""bibr"" rid=""CR50"">50</xref>] and",0_10,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"<xref ref-type=""bibr"" rid=""CR50"">50</xref>] and exclusively by proxy reports in one study [<xref ref-type=""bibr"" rid=""CR44"">44</xref>]. In three studies, control groups were used, consisting of relatives not affected by PKU, acquaintances/friends, and/or unrelated healthy individuals. For summary information on the included studies on patients’ quality of life, please refer to Table <xref rid=""Tab1"" ref-type=""table"">1</xref>, and for information on caregivers’ quality of life, please consult Table <xref",0_11,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"quality of life, please consult Table <xref rid=""Tab2"" ref-type=""table"">2</xref>.",0_12,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"<table-wrap id=""Tab1""><label>Table 1</label><caption><p>Data charting of the included studies with phenylketonuria patients</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th align=""left"">Authors, year, country</th><th align=""left"">Research design</th><th align=""left"">Sample size<break></break>(Mean age in years)<break></break>% Sex</th><th align=""left"">Control group</th><th align=""left"">PKU type<break></break>Diagnosis*</th><th align=""left"">Medical treatment</th><th",0_13,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left"">Medical treatment</th><th align=""left"">Instrument</th><th align=""left"">Main results</th></tr></thead><tbody><tr><td align=""left"">Aitkenhead et al., 2021 [<xref ref-type=""bibr"" rid=""CR8"">8</xref>], UK</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>149 adult patients</p><p>(32.38 ± 9.04)</p><p>55% females</p></td><td align=""left"">74 patients’ healthy relative</td><td align=""left""><p>NR</p><p>All early-treated</p></td><td align=""left"">49% classified themselves as on",0_14,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left"">49% classified themselves as on dietary treatment, 30% as off-treatment, and 11.6% as partially adherent (restricted Phe or supplementation)</td><td align=""left"">SF-36</td><td align=""left"">The authors detected no significant differences in QoL between PKU patients and the control group. They identified QoL differences between self-report dietary adherence subgroups: partially-adherent patients obtained lower scores on physical and mental QoL when compared to totally adherent and non-adherent",0_15,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"compared to totally adherent and non-adherent groups.</td></tr><tr><td align=""left"">Alptekin et al., 2018 [<xref ref-type=""bibr"" rid=""CR50"">50</xref>], Turkey</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>63 children to adult patients</p><p>(15.7 ± 6.4)</p><p>65.1% females</p></td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>According to the authors, they invited individuals diagnosed with PKU without regard to any criteria.</p></td><td align=""left"">Of all patients",0_16,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left"">Of all patients treated with AAM supplementation, 95.3% were combined with a restricted diet, and 17.4% were combined with pharmacological treatment (BH4).</td><td align=""left"">PKU-QOL</td><td align=""left"">Children reported worse scores in most domains, considering the four modules of the PKU-QoL, compared to adolescents and adults with PKU. On the other hand, some domains seem to affect the three groups with the same intensity, such as “tiredness,” “emotional,” and “social impact of PKU,”",0_17,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"“emotional,” and “social impact of PKU,” “anxiety-blood Phe levels,” “taste-supplements,” and some domains related to the dietary protein restriction module.</td></tr><tr><td align=""left"">Barta et al., 2020 [<xref ref-type=""bibr"" rid=""CR35"">35</xref>], Hungary</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>88 adult patients (median age = 31, IQR = 25–40)</p><p>52% females</p></td><td align=""left"">N/A</td><td align=""left""><p>75% Classical; 25% non-classical</p><p>All",0_18,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Classical; 25% non-classical</p><p>All early-treated</p></td><td align=""left"">Phe restricted diet with supplementation of AAM</td><td align=""left"">PKU-QOL</td><td align=""left""><p>Most patients rated their overall health status as “good” or better. Domains scores indicating moderate impact were: “Tiredness,” “Anxiety – Phe levels during pregnancy,” “Emotional impact of PKU,” “Taste – supplements,” “Guilt if poor adherence to supplements,” and “Guilt if poor dietary protein restriction not followed.” No",0_19,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"dietary protein restriction not followed.” No domain had scores indicating a severe impact.</p><p>In patients with Classical PKU, all QoL domains were positively correlated with Phe levels, indicating that patients with good metabolic control in the short or long term had a lower impact on QoL. Patients with classical PKU reported a larger financial burden impact than Non-Classical patients.</p></td></tr><tr><td align=""left"">Bik-Multanowski et al. 2008 [<xref ref-type=""bibr"" rid=""CR52"">52</xref>],",0_20,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"[<xref ref-type=""bibr"" rid=""CR52"">52</xref>], Poland</td><td align=""left"">Quantitative, prospective trial</td><td align=""left""><p>53 adult patients</p><p>(24.0)</p><p>53% males</p></td><td align=""left"">N/A</td><td align=""left""><p>Classical</p><p>All early-treated</p></td><td align=""left"">Patients resumed a strict low-phenylalanine diet after enrolment in the program.</td><td align=""left"">Psychological General Well-Being Index</td><td align=""left""><p>Before reintroducing the restricted diet, positive",0_21,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"reintroducing the restricted diet, positive well-being was observed in 55% of participants.</p><p>Twenty-nine patients managed to maintain the diet for at least three months, and only ten continued in the study for up to nine months.</p><p>The authors observed improvement in QoL after three months in most participants with severe or moderate baseline discomfort.</p></td></tr><tr><td align=""left"">Bosch et al., 2007 [<xref ref-type=""bibr"" rid=""CR48"">48</xref>], Netherlands</td><td align=""left"">Quantitative,",0_22,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Netherlands</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>32 adult patients</p><p>(24.6 ± 2.6)</p><p>69% females</p></td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>All early-treated</p></td><td align=""left"">Phe restricted diet with supplementation of AAM</td><td align=""left""><p>RAND-36 Health Survey</p><p>The cognitive scale of the TAAQOL</p></td><td align=""left"">The authors found no differences between PKU patients and normative data.</td></tr><tr><td",0_23,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"PKU patients and normative data.</td></tr><tr><td align=""left"">Bosch et al., 2015 [<xref ref-type=""bibr"" rid=""CR28"">28</xref>], multicenter</td><td align=""left"">Quantitative, cross-sectional.</td><td align=""left""><p>306 children to adult patients</p><p>(NR)</p><p>54% females</p></td><td align=""left"">N/A</td><td align=""left""><p>68% Classical; 32% Mild</p><p>NR</p></td><td align=""left"">Phe restricted diet and/or supplementation of AAM and/or pharmacological treatment (BH4)</td><td align=""left""><p>CHQ-PF 28",0_24,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"treatment (BH4)</td><td align=""left""><p>CHQ-PF 28 PedsQL</p><p>PKU-QOL</p><p>SF-36</p></td><td align=""left""><p>The scores of the generic measures of QoL in children and adolescents were similar to the general population; considering the scores of adults with PKU, the physical domains were higher, and the mental domains were lower when compared to the normative data.</p><p>Considering the scores of the PKU-specific questionnaire, patients with more severe protein restriction reported a greater impact of the",0_25,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"restriction reported a greater impact of the disease on daily life, and BH4 treatment was associated with better scores in all ages.</p></td></tr><tr><td align=""left"">Cazzorla et al., 2014 [<xref ref-type=""bibr"" rid=""CR40"">40</xref>], Italy</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>43 children to adult patients</p><p>(17.1 ± 9.0)</p><p>53% female</p><p>Caregivers (of 6–16 years old patients, <italic toggle=""yes"">proxy report</italic>).</p></td><td align=""left"">N/A</td><td",0_26,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left"">N/A</td><td align=""left""><p>51% Mild; 49% Classical</p><p>All early-treated</p></td><td align=""left""><p>Classic PKU: Phe restricted diet.</p><p>Mild PKU: 36% treated with BH4 and low protein foods, 36% with BH4 and Phe restricted diet and AAM, and 27% treated only with BH4</p></td><td align=""left"">PedsQL WHOQOL-100</td><td align=""left""><p>The authors found no significant differences in QOL between PKU patients (or parent reports) and normative data.</p><p>Compared to patients with classic PKU,",0_27,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"to patients with classic PKU, higher QOL scores were observed in patients with mild PKU on BH4 treatment.</p><p>Compared to employed or unemployed adults, better QOL was observed in students and adults with higher education.</p></td></tr><tr><td align=""left"">Cotugno et al., 2011 [<xref ref-type=""bibr"" rid=""CR27"">27</xref>], Italy</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>41 patients and their caregivers – <italic toggle=""yes"">self</italic> and <italic toggle=""yes"">proxy",0_28,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"and <italic toggle=""yes"">proxy report</italic></p><p>(10.7 ± 6)</p><p>61% males</p></td><td align=""left"">N/A</td><td align=""left""><p>73% Classical; 27% Mild</p><p>All early-treated</p></td><td align=""left"">Low Phe diet, Phe-free protein substitutes, long-chain polyunsaturated fatty acids and vitamins.</td><td align=""left""><p>CHQ</p><p>CHQ-PF 50</p><p>SF-36</p></td><td align=""left""><p>The study found that children and adolescents with PKU had significantly lower QoL scores than healthy populations,",0_29,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"lower QoL scores than healthy populations, particularly in the physical and psychological summary scores. There was a significant correlation between adherence to the prescribed diet and QoL in specific domains, such as Global Health and Family Activities.</p><p>Adolescents and young adults showed a different pattern, with generally better QoL scores than younger children, although adherence to diet was consistent across age groups.</p><p>The study highlighted that children of mothers with higher education",0_30,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"that children of mothers with higher education levels tended to have better adherence and slightly better QoL outcomes.</p></td></tr><tr><td align=""left"">Das et al., 2013 [<xref ref-type=""bibr"" rid=""CR29"">29</xref>], Germany</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>51 adult/adolescent patients</p><p>(26.6 ± 6.6)</p><p>62.7% females</p></td><td align=""left"">N/A</td><td align=""left""><p>100% Classical</p><p>All early-treated</p></td><td align=""left"">Four dietary groups: 42%",0_31,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left"">Four dietary groups: 42% of patients followed a protein-restricted diet supplemented with amino acid mixtures (AAM) [PKU recommended], 8% of patients followed a vegan diet supplemented with AAM; 14% of patients followed a vegan diet without taking AAM; 36% of patients reported eating a normal diet (Presumed normal eating habits).</td><td align=""left"">Alltagsleben (AL) questionnaire</td><td align=""left"">No differences were found between PKU patients and the general population in the scores of",0_32,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"and the general population in the scores of the subscales of the QoL assessment. No significant differences were found in quality of life or mood among the four diet conditions, indicating that patients who followed strict dietary recommendations did not feel worse than those with a more relaxed diet.</td></tr><tr><td align=""left"">Demirdas et al., 2013 [<xref ref-type=""bibr"" rid=""CR33"">33</xref>], Netherlands</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>69 children to adult",0_33,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left""><p>69 children to adult patients</p><p>(18.4 ± 10.2)</p><p>52% females</p><p>Mothers – <italic toggle=""yes"">proxy report</italic> (patients 4–7 years of age)</p></td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>All early-treated</p></td><td align=""left"">Phe restricted diet with supplementation of AAM</td><td align=""left""><p>PedsQL</p><p>TAAQOL</p><p>DISABKIDS chronic generic module.</p></td><td align=""left""><p>Children and adolescents with PKU reported higher HRQoL scores than the",0_34,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"with PKU reported higher HRQoL scores than the general population, and adults reported similar scores.</p><p>PKU Children showed no differences in HRQoL scores before and after the administration of the BH4.</p></td></tr><tr><td align=""left"">Gassió et al., 2003 [<xref ref-type=""bibr"" rid=""CR30"">30</xref>], Spain</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>15 patients</p><p>(27.5)</p><p>66% females</p></td><td align=""left"">N/A</td><td align=""left""><p>100% Classical</p><p>53.3%",0_35,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left""><p>100% Classical</p><p>53.3% late diagnosis</p></td><td align=""left"">Patients resumed treatment after a period of dietary discontinuation or initiated the restricted diet after a late diagnosis.</td><td align=""left"">Ad hoc questionnaire</td><td align=""left"">60% of patients felt that their quality of life improved after resuming or starting a phenylalanine-restricted diet compared to when they were off the diet. 53% of patients reported feeling calmer, quieter, and less easily upset, while 40%",0_36,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"calmer, quieter, and less easily upset, while 40% noted being more alert and better able to maintain attention while on the diet. 33% of patients felt happier, and 27% reported feeling more energetic and vital. 20% of patients felt less impulsive and aggressive and noted they were less argumentative than before diet resumption. 53% of patients described their health as very good and 47% as good, with 40% reporting that their current health on the diet was better than their health when off the",0_37,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"diet was better than their health when off the diet.</td></tr><tr><td align=""left"">Hatami et al., 2015 [<xref ref-type=""bibr"" rid=""CR51"">51</xref>], Iran</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>82 patients</p><p>(41% were younger than 20 years old; 49% were between 20–29 years old; 10% were 30 years or older)</p><p>58% females</p></td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>All late diagnosis</p></td><td align=""left"">NR</td><td",0_38,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"diagnosis</p></td><td align=""left"">NR</td><td align=""left"">WHOQOL-BREF</td><td align=""left"">The patients were late-diagnosed phenylketonuria (PKU), generally experiencing a low quality of life. Patients over 40 years old had significantly lower mental health compared to other age groups. The patient’s educational level notably influenced the quality of life, with those receiving higher education experiencing a better quality of life. There were no significant differences in QOL between male and female",0_39,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"differences in QOL between male and female patients. The social and environmental aspects of QOL were particularly low among the patients.</td></tr><tr><td align=""left"">Hujibregts et al., 2018 [<xref ref-type=""bibr"" rid=""CR49"">49</xref>], Netherlands</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>90 children to adult patients</p><p>(21 ± 10.1)</p><p>58.8% females</p></td><td align=""left"">109 healthy controls</td><td align=""left""><p>NR</p><p>All early-treated</p></td><td",0_40,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"early-treated</p></td><td align=""left"">Dietary treatment: 30% receive BH4 treatment.</td><td align=""left""><p>TAAQOL</p><p>TACQOL-PF TACQOL-CF</p></td><td align=""left""><p>Except for the lack of autonomy reported by parents, children with PKU showed an HRQL similar to the control group. Among adults with PKU, more differences were found compared to the control group: patients showed lower scores regarding cognition, depressive moods, and anger.</p><p>Negative correlations were found between QoL domains and",0_41,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"correlations were found between QoL domains and lifetime and concurrent Phe levels.</p></td></tr><tr><td align=""left"">Klimek et al., 2020 [<xref ref-type=""bibr"" rid=""CR34"">34</xref>], Germany</td><td align=""left"">Quantitative, cross-sectional.</td><td align=""left""><p>144 adult patients</p><p>(33 ± 8.5)</p><p>66% females</p></td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>All early-treated</p></td><td align=""left""><p>82% Phe restricted diet 84% Amino acid moisture</p><p>18% not keep any dietary",0_42,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"acid moisture</p><p>18% not keep any dietary regimen</p><p>10% neve take AAM</p></td><td align=""left"">Ad hoc questionnaire</td><td align=""left""><p>91% of early-treated adult PKU patients considered their quality of life good, and 83% rated their health as at least good.</p><p>70% of the patients reported feeling better when adhering to a diet than when they did not. Despite the strict dietary regimen, most patients felt the diet’s restrictions on their daily life were low.</p></td></tr><tr><td",0_43,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"their daily life were low.</p></td></tr><tr><td align=""left"">Landolt et al., 2002 [<xref ref-type=""bibr"" rid=""CR44"">44</xref>], Germany</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>37 pediatric patients and their caregivers - <italic toggle=""yes"">proxy report</italic></p><p>(10.9 ± 9.9)</p><p>51.8% males</p></td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>All early-treated</p></td><td align=""left"">Phe restricted diet with supplementation of AAM</td><td",0_44,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"diet with supplementation of AAM</td><td align=""left"">TACQOL-PF</td><td align=""left""><p>Only in the “Positive Emotion” domain, PKU patients showed lower scores compared to healthy children, according to parent-report.</p><p>QOL was associated with Phe level during the first year of life.</p></td></tr><tr><td align=""left"">Palermo et al., 2020 [<xref ref-type=""bibr"" rid=""CR31"">31</xref>], UK</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>36 adult",0_45,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"cross-sectional</td><td align=""left""><p>36 adult patients</p><p>(27.4 ± 8.3)</p><p>75% females</p></td><td align=""left"">40 healthy people</td><td align=""left""><p>100% Classical</p><p>All early-treated</p></td><td align=""left"">Six patients were on an unrestricted diet, and 30 were on a low-protein diet.</td><td align=""left"">SF-36</td><td align=""left""><p>No differences were found in mental and physical health-related QoL scales between patients with PKU and the control group.</p><p>Better cognitive",0_46,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"PKU and the control group.</p><p>Better cognitive functioning was associated with better physical QoL, and better physical QoL was associated with lower Phe levels and reduced Phe fluctuations across life.</p></td></tr><tr><td align=""left"">Simon et al., 2008 [<xref ref-type=""bibr"" rid=""CR32"">32</xref>], Germany</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>67 adolescent or adult patients (median age = 25)</p><p>66% females</p></td><td align=""left"">N/A</td><td",0_47,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"females</p></td><td align=""left"">N/A</td><td align=""left""><p>100% Classical</p><p>All early-treated</p></td><td align=""left"">NR</td><td align=""left"">Profile of Quality of Life in the Chronically Ill Questionnaire</td><td align=""left""><p>No differences in QoL scores were found between patients and the control group.</p><p>Women with PKU reported significantly lower levels of positive mood when compared to men with PKU.</p></td></tr><tr><td align=""left"">Thimm et al., 2013 [<xref ref-type=""bibr""",0_48,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"et al., 2013 [<xref ref-type=""bibr"" rid=""CR36"">36</xref>], Germany</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>50 pediatric patients and their caregivers – <italic toggle=""yes"">self and proxy report</italic> (Median age = 9.9)</p><p>64% females</p></td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>All early-treated</p></td><td align=""left"">Phe restricted diet with supplementation of AAM</td><td align=""left"">KINDL-R questionnaire</td><td align=""left"">No differences in",0_49,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left"">No differences in the total self- and parent-reported QoL score were found between PKU patients and healthy peers. Only the everyday functioning dimension showed a difference in parent-reported QoL, and parents rated PKU patients lower. A positive correlation between everyday functioning dimension and metabolic control was found.</td></tr><tr><td align=""left"">Vieira Neto et al., 2018 [<xref ref-type=""bibr"" rid=""CR42"">42</xref>], Brazil</td><td align=""left"">Quantitative, cross-sectional</td><td",0_50,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"cross-sectional</td><td align=""left""><p>51 pediatric patients and their caregivers - <italic toggle=""yes"">self and proxy report</italic></p><p>(NR)</p><p>56.8% males</p></td><td align=""left"">N/A</td><td align=""left""><p>64% Classical; 33% mild or moderate; 3% no information</p><p>All early-treated</p></td><td align=""left"">Phe restricted diet with supplementation of AAM</td><td align=""left"">PedsQL</td><td align=""left"">The self-reports of pediatric PKU patients’ QoL and parent reports were lower compared to a",0_51,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"QoL and parent reports were lower compared to a normative sample. A correlation between treatment adherence and quality of life was not observed.</td></tr></tbody></table><table-wrap-foot><p>Notes: <italic toggle=""yes"">CHQ</italic> = Child Health Questionnaire; <italic toggle=""yes"">CHQ-PF 28</italic> = Child Health Questionnaire 28 items - Parent Form; <italic toggle=""yes"">CHQ-PF 50</italic> = Child Health Questionnaire 50 items - Parent form; <italic toggle=""yes"">PedsQL</italic> = Pediatric Quality of",0_52,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Quality of Life Inventory; <italic toggle=""yes"">PKU-QOL</italic> = Phenylketonuria - Quality of Life questionnaire; <italic toggle=""yes"">TAAQOL</italic> = TNO-AZL Adult Quality of Life questionnaire; <italic toggle=""yes"">TACQOL-CF</italic> = TNO-AZL Child Quality of Life Questionnaire - Child form; <italic toggle=""yes"">TACQOL-PF</italic> = TNO-AZL Child Quality of Life Questionnaire - Parent form; <italic toggle=""yes"">SF-36</italic> = 36-Item Short Form Health Survey; <italic",0_53,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Short Form Health Survey; <italic toggle=""yes"">WHOQOL-100</italic> = World Health Organization Quality of Life − 100; <italic toggle=""yes"">WHOQOL-BREF</italic> = World Health Organization Quality of Life 26 items</p><p>AAM = amino acid mixture</p><p>N/A = Not applicable</p><p>NR = Not reported</p><p>*Early or late diagnosis as informed by the authors</p></table-wrap-foot></table-wrap>",0_54,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"<table-wrap id=""Tab2""><label>Table 2</label><caption><p>Data extraction of the included studies with caregivers/parents of patients with PKU</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th align=""left"">Authors, year, Country</th><th align=""left"">Research design</th><th align=""left"">Sample size (mean age in years)<break></break>% Sex</th><th align=""left"">Patient’s mean age in years.<break></break>%Sex</th><th align=""left"">Control group</th><th align=""left"">Patient’s PKU",0_55,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"group</th><th align=""left"">Patient’s PKU type<break></break>Diagnosis*</th><th align=""left"">Patient’s medical treatment</th><th align=""left"">Instrument</th><th align=""left"">Main results</th></tr></thead><tbody><tr><td align=""left"">Ben Abdelaziz et al., 2020 [<xref ref-type=""bibr"" rid=""CR43"">43</xref>], Tunisia</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>65 caregivers (No mean age reported)</p><p>62% female</p></td><td align=""left""><p>8.9 ± 6.2</p><p>NR</p></td><td",0_56,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left""><p>8.9 ± 6.2</p><p>NR</p></td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>Late diagnosis</p></td><td align=""left"">Phe restricted diet</td><td align=""left"">SF-36</td><td align=""left"">Income and sex were factors associated with worse QoL, i.e., being female and living with less than one minimum wage. Higher education was associated with better QoL, and fathers showed higher QoL than mothers. Parenting an autistic child was also associated with worse QoL levels.</td></tr><tr><td",0_57,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"with worse QoL levels.</td></tr><tr><td align=""left"">Bosch et al., 2015 [<xref ref-type=""bibr"" rid=""CR28"">28</xref>], multicenter</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>253 caregivers (41.6 ± 6.5)</p><p>72% female</p></td><td align=""left""><p>NR</p><p>54% females.</p></td><td align=""left"">N/A</td><td align=""left""><p>68% Classical; 32% Mild</p><p>NR</p></td><td align=""left"">Phe restricted diet and/or supplementation of AAM and/or pharmacological therapy (BH4)</td><td",0_58,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"AAM and/or pharmacological therapy (BH4)</td><td align=""left""><p>CHQ-PF 28</p><p>PKU-QOL</p></td><td align=""left"">Parents’ QoL scores were comparable to normative data, except for a lower score on the emotional parental impact domain, indicating a higher emotional impact than the general population.</td></tr><tr><td align=""left"">Etemad et al., 2020 [<xref ref-type=""bibr"" rid=""CR37"">37</xref>], Iran</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>240 caregivers",0_59,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left""><p>240 caregivers (36.8 ± 7.8)</p><p>55% female</p></td><td align=""left""><p>8.7 ± 8.1</p><p>55% male</p></td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>52.8% early-treated</p></td><td align=""left"">NR</td><td align=""left"">WHOQOL-BREF</td><td align=""left"">Parents of children with PKU reported low levels of QoL. Demographic factors associated with two or more QoL domains: parents’ age, parents’ education, child’s age, and household income.</td></tr><tr><td align=""left"">Fidika et al.,",0_60,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left"">Fidika et al., 2013 [<xref ref-type=""bibr"" rid=""CR41"">41</xref>], Germany</td><td align=""left"">Quantitative, cross-sectional.</td><td align=""left""><p>89 caregivers (39 ± 6.9)</p><p>85% female</p></td><td align=""left"">9 ± 5.2 51.7% female</td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>All early-treated</p></td><td align=""left"">NR</td><td align=""left"">The Ulm Quality of life Inventory for Parents of chronically ill children</td><td align=""left"">Most parents reported a positive",0_61,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left"">Most parents reported a positive appraisal of their quality of life. Lower QoL was found in parents of preschool-aged children compared to parents of school-aged children and adolescents. Age of children and parents, perceived social support, parental coping, and family stress were predictors of QoL.</td></tr><tr><td align=""left"">Iakovou and Schulpis 2019 [<xref ref-type=""bibr"" rid=""CR53"">53</xref>], Greece</td><td align=""left"">Quantitative, intervention</td><td align=""left""><p>42",0_62,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"intervention</td><td align=""left""><p>42 caregivers</p><p>(26.8)</p><p>100% female</p></td><td align=""left"">NR</td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>NR</p></td><td align=""left"">NR</td><td align=""left"">Ad hoc questionnaire</td><td align=""left"">Mothers of children with PKU and those with a college education were the most likely to benefit from psychological support compared to the primary and high school groups.</td></tr><tr><td align=""left"">Iakovou et al., 2019 [<xref ref-type=""bibr""",0_63,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"et al., 2019 [<xref ref-type=""bibr"" rid=""CR47"">47</xref>], Greece</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>110 caregivers (25.7)</p><p>100% female</p></td><td align=""left"">NR</td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>NR</p></td><td align=""left"">NR</td><td align=""left"">Ad hoc questionnaire</td><td align=""left"">Mothers who completed only elementary school and resided in a city with higher population density reported higher levels of damage to QoL. In",0_64,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"reported higher levels of damage to QoL. In addition, mothers with a university degree reported the lowest level of social discrimination, and those who resided in a small town reported the highest levels.</td></tr><tr><td align=""left"">Irannejad et al., 2018 [<xref ref-type=""bibr"" rid=""CR46"">46</xref>], Iran</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>124 caregivers (39.6 ± 10.6)</p><p>50% female</p></td><td align=""left""><p>64.1% were younger than ten years old.</p><p>57.6%",0_65,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"were younger than ten years old.</p><p>57.6% male</p></td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>78.8%</p><p>Late diagnosis</p></td><td align=""left"">NR</td><td align=""left"">SF-36</td><td align=""left"">Parents of children with PKU reported lower levels of QoL compared to average levels. A negative association was found between stress level and QoL.</td></tr><tr><td align=""left"">Mahmoudi-Gharaei et al., 2011 [<xref ref-type=""bibr"" rid=""CR45"">45</xref>], Iran</td><td align=""left"">Quantitative,",0_66,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Iran</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>49 caregivers</p><p>(35.6 ± 8.8)</p><p>59.2% female</p></td><td align=""left"">9.8 ± 6.6. 51% female</td><td align=""left"">N/A</td><td align=""left""><p>NR</p><p>The mean age of PKU diagnosis was 4.7 years ± 3.7</p></td><td align=""left"">NR</td><td align=""left"">WHOQOL-BREF</td><td align=""left"">Compared to the general population, lower levels of quality of life were found in caregivers of children with PKU. Not being employed and",0_67,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"of children with PKU. Not being employed and levels of depression and anxiety were factors associated with these parents’ quality of life.</td></tr><tr><td align=""left"">Mitchell et al. 2021 [<xref ref-type=""bibr"" rid=""CR54"">54</xref>], Australia</td><td align=""left"">Quantitative, longitudinal, non-randomized trial</td><td align=""left""><p>17 caregivers</p><p>(37.7 ± 5.4)</p><p>100% female</p></td><td align=""left"">6.2 ± 3.2 58.8% female</td><td align=""left"">N/A</td><td align=""left""><p>47%",0_68,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left"">N/A</td><td align=""left""><p>47% Classical</p><p>NR</p></td><td align=""left"">Phe restricted diet with supplementation of AAM</td><td align=""left"">PKU-QOL</td><td align=""left"">No significant differences were observed in caregivers’ QoL scores after the intervention.</td></tr><tr><td align=""left"">Morawska et al., 2020 [<xref ref-type=""bibr"" rid=""CR39"">39</xref>], Australia</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>18 caregivers</p><p>(38.6 ± 5.9)</p><p>100%",0_69,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"caregivers</p><p>(38.6 ± 5.9)</p><p>100% female</p></td><td align=""left""><p>6.89 ± 3.68</p><p>66.7% female</p></td><td align=""left"">N/A</td><td align=""left""><p>44.4% Classical; 27.8% Mild; 27.8% Hiper-Phe</p><p>All early-treated</p></td><td align=""left"">Phe restricted diet with supplementation of AAM</td><td align=""left"">PKU-QOL</td><td align=""left"">The highest reported impact was related to parental guilt due to treatment adherence levels and perceived anxiety in the child when performing the blood test.",0_70,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"in the child when performing the blood test. Several factors related to the mother and child were associated with QoL domains, such as emotional maladjustment, behavioral difficulties, parental stress, dysfunctional parent-child interaction, challenging child, and hyperactivity. Higher lifetime phe levels also showed an association with some domains of QoL.</td></tr><tr><td align=""left"">ten Hoedt et al., 2011 [<xref ref-type=""bibr"" rid=""CR38"">38</xref>], Netherlands</td><td align=""left"">Quantitative,",0_71,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Netherlands</td><td align=""left"">Quantitative, cross-sectional</td><td align=""left""><p>116 caregivers (40.7 ± 6.3)</p><p>56.9% female</p></td><td align=""left"">8.7 ± 5.0 NR</td><td align=""left""><p>69 caregivers of children with galactosemia; 108 caregivers of children with other metabolic disorders</p><p>430 caregivers of healthy children</p></td><td align=""left"">NR / NR</td><td align=""left"">NR</td><td align=""left"">TAAQOL</td><td align=""left"">Parents of healthy children, children with PKU, or children with",0_72,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"children, children with PKU, or children with galactosemia showed no differences in QoL. In addition, parents of children with PKU reported better QoL than those with other metabolic diseases. In parents of children with PKU, having older children and more emotional support were associated with better HRQoL, whereas loss of friendship was associated with worse HRQoL.</td></tr></tbody></table><table-wrap-foot><p>Notes: <italic toggle=""yes"">CHQ-PF 28</italic> = Child Health Questionnaire 28 items - Parent",0_73,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Health Questionnaire 28 items - Parent Form; <italic toggle=""yes"">PKU-QOL</italic> = Phenylketonuria - Quality of Life questionnaire; <italic toggle=""yes"">TAAQOL</italic> = TNO-AZL Adult Quality of Life questionnaire; <italic toggle=""yes"">SF-36</italic> = 36-Item Short Form Health Survey; <italic toggle=""yes"">WHOQOL-BREF</italic> = World Health Organization Quality of Life 26 items</p><p>AAM = Amino acid mixture</p><p>N/A = Not applicable</p><p>NR = Not reported</p><p>*Early or late diagnosis, as informed",0_74,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"or late diagnosis, as informed by the authors</p></table-wrap-foot></table-wrap>",0_75,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Different assessment tools were used in the studies to assess the QoL of patients with PKU and their parents. The most common ones are listed in Table <xref rid=""Tab3"" ref-type=""table"">3</xref>.",0_76,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"<table-wrap id=""Tab3""><label>Table 3</label><caption><p>Most frequently used tools in quality-of-life assessment</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th align=""left"">Instrument</th><th align=""left"">Type of measure (generic vs. disease-specific)</th><th align=""left"">Studies with Patients</th><th align=""left"">Studies with Parents/caregivers</th></tr></thead><tbody><tr><td align=""left"">Phenylketonuria - Quality of Life (PKU-QoL)</td><td align=""left"">disease-specific</td><td",0_77,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"align=""left"">disease-specific</td><td align=""left"">28, 35, 50</td><td align=""left"">28, 39, 54</td></tr><tr><td align=""left"">Medical Outcomes Short-Form Health Survey (SF-36)</td><td align=""left"">generic</td><td align=""left"">8, 27, 28, 31</td><td align=""left"">43, 46</td></tr><tr><td align=""left"">Pediatric Quality of Life Inventory (PedsQL)</td><td align=""left"">generic</td><td align=""left"">28, 33, 40, 42</td><td align=""left"">-</td></tr><tr><td align=""left"">TNO-AZL Questionnaire for Adult’s Health-Related",0_78,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Questionnaire for Adult’s Health-Related Quality of Life (TAAQOL)</td><td align=""left"">generic</td><td align=""left"">33, 48, 49</td><td align=""left"">38</td></tr><tr><td align=""left"">The World Health Organization Quality of Life Questionnaire (WHOQOL-100 and WHOQOL-BREF)</td><td align=""left"">generic</td><td align=""left"">40, 51</td><td align=""left"">37, 45</td></tr><tr><td align=""left"">Child Health Questionnaire - Children and Parent Form (CHQ; CHQ-PF 50)</td><td align=""left"">generic</td><td",0_79,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"CHQ-PF 50)</td><td align=""left"">generic</td><td align=""left"">27</td><td align=""left"">27, 28</td></tr><tr><td align=""left"">TNO-AZL Questionnaires for Children’s Health-Related Quality of Life - Children and Parent Form (TACQOL-CF; TACQOL-CP)</td><td align=""left"">generic</td><td align=""left"">44, 49</td><td align=""left"">-</td></tr></tbody></table></table-wrap>",0_80,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Two studies with patients [<xref ref-type=""bibr"" rid=""CR30"">30</xref>, <xref ref-type=""bibr"" rid=""CR34"">34</xref>] and two studies with parents [<xref ref-type=""bibr"" rid=""CR47"">47</xref>, <xref ref-type=""bibr"" rid=""CR53"">53</xref>] applied questionnaires developed especially for their research. Readers can find the names of the instruments mentioned in only one study in Tables <xref rid=""Tab1"" ref-type=""table"">1</xref> and <xref rid=""Tab2"" ref-type=""table"">2</xref>. For many years, research conducted",0_81,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"For many years, research conducted with the PKU population has focused on investigating the neurological and cognitive damage common among these patients. However, interest in exploring the quality-of-life impacts associated with the disease has been growing exponentially, with 82.7% of such studies with patients and their caregivers dating between 2011 and 2021. Different ways of accessing QoL were used, with 14 instruments used in patient samples and six with caregivers. Four studies used ad hoc",0_82,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"and six with caregivers. Four studies used ad hoc questionnaires. Most articles adopted generic questionnaires (69%); the generic instruments used varied across studies, making it difficult to summarize the results since the concepts evaluated are diverse, and some domains are not equivalent across the questionnaires. Only five studies used an instrument developed for the PKU population and their caregivers. This may be related to the fact that the final version of the first disease-specific questionnaire",0_83,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"of the first disease-specific questionnaire (i.e., PKU-QoL) was only available after 2015. The PKU-QoL includes variations for different respondents (children, adolescents, adults, and parents); its structure comprises PKU symptoms; the emotional, social, and overall impact of the disease; and the impact of treatment, including questions regarding dietary protein restriction and the administration of Phe-free protein supplements [<xref ref-type=""bibr"" rid=""CR55"">55</xref>]. Whereas generic tools access",0_84,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Whereas generic tools access universally important constructs (e.g., physical functioning, social functioning, level of independence, and mental health), the PKU-QoL questionnaire addresses the specific conditions patients and caregivers face. All studies with adult patients or caregivers collected the data through self-report questionnaires. In contrast, most studies with pediatric patients used both self-reported and proxy-reported measures. Notably, in these cases, the use of both forms of reporting is",0_85,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"cases, the use of both forms of reporting is prioritized since health decisions made by parents are influenced by their perceptions of the child’s quality of life [<xref ref-type=""bibr"" rid=""CR14"">14</xref>]. Most studies did not observe significant harm to the QoL of adult patients. This could be related to the rigidity of PKU treatment, which is lessened as the patient approaches adulthood, with more flexibility in the diet [<xref ref-type=""bibr"" rid=""CR28"">28</xref>], or, on the other hand, may be the",0_86,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"or, on the other hand, may be the result of the use of questionnaires that are not sensitive to the specifics of this population, such as special diet management and supplement administration. Generic QoL questionnaires are not designed to assess the inherent characteristics of a specific condition and may not be able to detect small changes in the QoL of particular diseases [<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. A moderate negative impact of PKU and its treatment was identified among adults in",0_87,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"and its treatment was identified among adults in studies that assessed QoL through a disease-specific measure of PKU-QoL [<xref ref-type=""bibr"" rid=""CR35"">35</xref>]. Despite the heterogeneity of the quality-of-life dimensions that compose the generic assessment tools, some similarities could be observed: damage to the emotional/psychological [<xref ref-type=""bibr"" rid=""CR27"">27</xref>, <xref ref-type=""bibr"" rid=""CR28"">28</xref>, <xref ref-type=""bibr"" rid=""CR37"">37</xref>, <xref ref-type=""bibr""",0_88,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"rid=""CR37"">37</xref>, <xref ref-type=""bibr"" rid=""CR42"">42</xref>, <xref ref-type=""bibr"" rid=""CR44"">44</xref>, <xref ref-type=""bibr"" rid=""CR49"">49</xref>] and social [<xref ref-type=""bibr"" rid=""CR27"">27</xref>, <xref ref-type=""bibr"" rid=""CR37"">37</xref>, <xref ref-type=""bibr"" rid=""CR42"">42</xref>] dimensions of QoL were described by patients with PKU in all age groups and their parents. The negative impact on social aspects of life is frequently mentioned by PKU patients in qualitative studies [<xref",0_89,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"by PKU patients in qualitative studies [<xref ref-type=""bibr"" rid=""CR6"">6</xref>, <xref ref-type=""bibr"" rid=""CR56"">56</xref>, <xref ref-type=""bibr"" rid=""CR57"">57</xref>]. Vegni and cols [<xref ref-type=""bibr"" rid=""CR57"">57</xref>]. named PKU a “social disease” since its manifestation is not visible until the moment of eating. Socializing with peers when they enter school and later in the work setting is a concern among patients, who report feelings such as anger, shame, and fear of stigmatization in",0_90,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"as anger, shame, and fear of stigmatization in food-related situations. Not telling acquaintances about the condition, eating only at home, not going to food-sharing events and even eating forbidden foods in social situations were strategies adopted by patients to avoid misconceptions and stigma [<xref ref-type=""bibr"" rid=""CR6"">6</xref>, <xref ref-type=""bibr"" rid=""CR56"">56</xref>, <xref ref-type=""bibr"" rid=""CR57"">57</xref>]. In this sense, in addition to the possible harm of nonadherence, these patients",0_91,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"the possible harm of nonadherence, these patients may also experience social deprivation. When a disease-specific questionnaire across four versions of the PKU-QoL (children, adolescents, adults, and caregivers) is considered, the aspects most affected by the different reporters include anxiety about blood Phe levels, guilt related to poor adherence to dietary restrictions, and Phe-free amino acid mixture supplement intake [<xref ref-type=""bibr"" rid=""CR28"">28</xref>, <xref ref-type=""bibr""",0_92,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"rid=""CR28"">28</xref>, <xref ref-type=""bibr"" rid=""CR35"">35</xref>, <xref ref-type=""bibr"" rid=""CR50"">50</xref>]. This highlights the particular challenges PKU patients and their parents face, the emotional impact associated with disease and treatment management, social issues, the experience of struggles regarding uncertainty about their health in the future, the need to think about diet [<xref ref-type=""bibr"" rid=""CR58"">58</xref>] constantly, and frustrations with health care providers [<xref",0_93,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"frustrations with health care providers [<xref ref-type=""bibr"" rid=""CR59"">59</xref>], all of which are corroborated by the qualitative literature. Conversely, better scores for physical health associated with QoL were found. The authors suggest that PKU patients may value their physical health more highly because they know the consequences of the disease if treatment is not followed and that patients and their caregivers who participate in surveys tend to be younger than the reference group respondents",0_94,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"be younger than the reference group respondents [<xref ref-type=""bibr"" rid=""CR28"">28</xref>, <xref ref-type=""bibr"" rid=""CR43"">43</xref>]. Many factors were reported to be associated with total QoL or its dimensions. Sociodemographic characteristics were related to the QoL of patients and their caregivers. Among patients and caregivers, females were associated with the worst QoL. In addition to addressing cultural challenges, PKU patients also have to address concerns regarding maternal PKU [<xref",0_95,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"to address concerns regarding maternal PKU [<xref ref-type=""bibr"" rid=""CR32"">32</xref>]; anxiety about blood Phe levels during pregnancy achieved the higher median scores of all domains [<xref ref-type=""bibr"" rid=""CR28"">28</xref>, <xref ref-type=""bibr"" rid=""CR50"">50</xref>]. Compared with male patients, female patients often report more emotional problems with PKU [<xref ref-type=""bibr"" rid=""CR60"">60</xref>]. The lower quality of life for mothers seems to reflect that mothers are commonly the primary care",0_96,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"that mothers are commonly the primary care providers and are more likely to be responsible for treating children and adolescents, which can be burdensome [<xref ref-type=""bibr"" rid=""CR46"">46</xref>]. Similarly, mothers of children with other rare diseases reported greater parental stress and physical and emotional strain than fathers did [<xref ref-type=""bibr"" rid=""CR61"">61</xref>]. Patients and caregivers with higher educational levels had higher QoL. Highly educated individuals may have better",0_97,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"QoL. Highly educated individuals may have better socioeconomic conditions, and parents without academic qualifications could have more difficulty achieving good metabolic control in their child [<xref ref-type=""bibr"" rid=""CR62"">62</xref>], impairing QoL. Patient and caregiver age were also associated with QoL: younger patients or caregivers were related to more QoL impairments. Patients of pediatric age, especially children, tend to have the greatest impairment in quality of life. This finding was observed",0_98,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"in quality of life. This finding was observed in studies that used generic validated instruments and in those that adopted a disease-specific questionnaire (i.e., the PKU-QoL). One explanation is that younger children have more difficulty accepting and understanding PKU [<xref ref-type=""bibr"" rid=""CR50"">50</xref>] and learning how to address their eating patterns’ specificity and the consequent differences [<xref ref-type=""bibr"" rid=""CR57"">57</xref>]. Additionally, until the age of 12 years, good metabolic",0_99,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"until the age of 12 years, good metabolic control is required to protect the child from cognitive damage. Hence, the threshold Phe concentration in young children is lower than that in other age groups [<xref ref-type=""bibr"" rid=""CR4"">4</xref>], requiring stricter diet adherence. Moreover, in a study with patients aged between 8 and 23 years, the feeling of being different and the fear of stigmatization on occasions when food is shared were particularly emphasized by adolescents [<xref ref-type=""bibr""",0_100,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"emphasized by adolescents [<xref ref-type=""bibr"" rid=""CR56"">56</xref>]. The parents of younger patients also reported the worst QoL. Younger children need more parental care and support than older children do. In the case of phenylketonuria, the younger the patient is, the greater the need for continuous supervision and management of the diet [<xref ref-type=""bibr"" rid=""CR38"">38</xref>, <xref ref-type=""bibr"" rid=""CR41"">41</xref>]. Additionally, as time passes, parents gain more experience managing the",0_101,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"passes, parents gain more experience managing the disease, which may be associated with improved QoL among older parents [<xref ref-type=""bibr"" rid=""CR37"">37</xref>]. The findings of this scoping review suggest that variables associated with the disease play crucial roles in a patient’s QoL. Treatment adherence (measured by blood Phe levels), time on treatment, and tolerance to phenylalanine were significant factors. These findings indicate that, in addition to protection from neurocognitive damage,",0_102,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"to protection from neurocognitive damage, treatment adherence can be a protective factor against impairments in quality of life. Similar findings were reported among patients with other metabolic diseases (e.g., diabetes) [<xref ref-type=""bibr"" rid=""CR63"">63</xref>]. For PKU, early-treated diet-adherent subjects had fewer medical problems, such as eczema, asthma, and headache, than did patients who discontinued their diet early [<xref ref-type=""bibr"" rid=""CR64"">64</xref>], which can be detrimental to their",0_103,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"which can be detrimental to their quality of life. Many negative correlations between elevated phenylalanine levels and quality of life domains reinforce the importance of treatment maintenance. Aitkenhead et al. [<xref ref-type=""bibr"" rid=""CR8"">8</xref>] reported that partially adherent patients had poorer QoL than did those in the fully compliant and fully non-compliant groups and explained that partially adherent patients seem to have more struggles with dietary management. Adults and parents of",0_104,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"with dietary management. Adults and parents of children had difficulty with dietary management, which required significant effort, and many parents even changed their way of working or stopped working to care for patients [<xref ref-type=""bibr"" rid=""CR59"">59</xref>]. To summarize, dietary treatment is a factor that significantly influences patients’ quality of life, with those diagnosed with classic PKU tending to have a more significant burden because the severity of the disease determines the allowed",0_105,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"severity of the disease determines the allowed daily amount of Phe intake. According to the review, psychosocial factors significantly influenced the quality of life of caregivers of phenylketonuria patients. Mental health problems, especially stress, have been described in several studies as a source of impairment of QoL. Given that high incidences of stress, anxiety, and depression are frequently reported in this population [<xref ref-type=""bibr"" rid=""CR43"">43</xref>, <xref ref-type=""bibr""",0_106,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"rid=""CR43"">43</xref>, <xref ref-type=""bibr"" rid=""CR45"">45</xref>], health care teams must be open to adopting a family-centered approach, including parents’/caregivers’ specific demands. Offering psychological support that includes stress management related to the disease may be beneficial, considering that emotional support mediates the association between perceived stress and parental QoL [<xref ref-type=""bibr"" rid=""CR38"">38</xref>]. Our search revealed a significant gap in interventions specifically",0_107,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"a significant gap in interventions specifically designed to enhance the quality of life of PKU patients. Existing interventions in this population have focused primarily on knowledge enhancement about treatment [<xref ref-type=""bibr"" rid=""CR65"">65</xref>, <xref ref-type=""bibr"" rid=""CR66"">66</xref>], as it is known to correlate with improved metabolic control [<xref ref-type=""bibr"" rid=""CR62"">62</xref>]. A comprehensive approach that combines knowledge enhancement and skills training in disease management",0_108,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"and skills training in disease management and social skills could hypothetically yield significant benefits. These aspects of a patient’s life (e.g., disease management [treatment adherence, attitudes toward diet], and social skills [social support, emotional support]) have been identified in the literature as key factors influencing quality of life. Their absence can potentially damage QOL. As a suggestion, future interventions should address training competencies related to disease management and social",0_109,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"related to disease management and social skills to prevent damage in the relational aspects of life. Quality of life is a complex construct, and it is an important outcome for patients with rare diseases such as PKU. The QoL of patients with PKU varies on the basis of patient characteristics (i.e., sex, age, education level), disease severity and type of PKU, cognitive functioning and mental health, adherence to treatment, and metabolic control (i.e., better metabolic control, higher QoL). The findings of",0_110,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"metabolic control, higher QoL). The findings of this review indicate that pediatric PKU patients are more vulnerable to QoL impairment than adult patients are (e.g., the impact is generally more pronounced in specific domains such as fatigue, emotional impact, and dietary management). Among all the patients, disease-related factors (i.e., severe dietary restrictions or poor metabolic control) had the most frequently reported associations with overall QoL and its dimensions (e.g., emotional and physical",0_111,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"and its dimensions (e.g., emotional and physical health). On the other hand, caregivers, particularly mothers, report lower QoL than normative data do, which is often influenced by factors such as stress, parenting challenges, income level, and social support. Caregivers of younger children with PKU tend to report lower QoL than do those of older children. Factors such as parental education, social support, and emotional coping significantly affect caregivers’ QoL, with higher levels of education and",0_112,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"QoL, with higher levels of education and support correlating with better QoL outcomes. The QoL of adult patients assessed by generic measures did not differ from normative data or the control group. However, differences were evident within subgroups on the basis of treatment adherence; partially adherent patients often reported lower QoL. Furthermore, measurements with disease-specific questionnaires revealed negative impacts on QoL associated with treatment in all age groups of patients and caregivers.",0_113,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"in all age groups of patients and caregivers. Therefore, future studies with the PKU population should consider combining short generic instruments and disease-specific instruments, such as the PKU-QoL, to evaluate QoL. Thus, as most of the variables related to QoL are modifiable factors (e.g., disease knowledge, cognitive skills, adherence behavior, social skills, coping with stigma, disease management, attitudes toward diet and nutritional knowledge) and can be manipulated in interventions, the PKU",0_114,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"and can be manipulated in interventions, the PKU population may benefit from future interventions focused on those factors and psychosocial support. Overall, the studies highlight the complexity of managing PKU and its impact on the QoL of both patients and their caregivers, emphasizing the importance of metabolic control, adherence to treatment, and supportive interventions to enhance QoL. Below is the link to the electronic supplementary material.",0_115,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"<supplementary-material content-type=""local-data"" id=""MOESM1""><media http://www.w3.org/1999/xlink href=""13023_2024_3422_MOESM1_ESM.docx""><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>",0_116,What is known about patients’ quality of life with Phenylketonuria and their caregivers? A scoping review,28 10 2024,,Phenylketonuria
"Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria <bold>Background/Objectives:</bold> Heavy metals are a group of metals and metalloids that have a relatively high density. They can cause toxicity even at very low levels. Trace elements are required by all living organisms to maintain their normal growth, metabolism, and development. Oral intake is the main route of exposure to both heavy metals and trace elements. Phenylketonuria (PKU) is the most common amino",1_0,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"Phenylketonuria (PKU) is the most common amino acid metabolic disorder, and the best known treatment for patients requiring treatment is a phenylalanine (Phe)-restricted diet. The objective of the present study was to evaluate the plasma heavy metal levels, sources of exposure, changes in these levels according to dietary regimen, and trace element levels and their correlations with heavy metals in PKU patients. <bold>Methods:</bold> The study was conducted between July 2022 and January 2024 on 105",1_1,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
between July 2022 and January 2024 on 105 patients aged 2–6 years diagnosed with PKU. <bold>Results:</bold> The percentage of Pb levels in individuals in the upper quartile increased by 3.47 times (95% CI = 1.07–11.29) in those who consumed canned foods and 7.29 times (95% CI = 1.21–44.03) in those who consumed spring water. The percentage of As levels in the upper tertile increased by a factor of 7.26 (95% CI = 2.09–25.28) in individuals under four years of age and 8.17 times (95% CI = 2.13–31.27) in,1_2,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"of age and 8.17 times (95% CI = 2.13–31.27) in canned food users. The odds of having blood Cd levels in the upper tertile were 0.09 (95% CI = 0.01–0.96) for those being breastfed for 6–11 months compared to 0–5 months. Zn levels were lower (93.0 vs. 83.6 µg/dL, <italic toggle=""yes"">p</italic> = 0.008) in patients on a Phe-restricted diet. <bold>Conclusions:</bold> The present study did not find a relationship between heavy metal exposure and the dietary treatment status of patients with PKU. Our findings",1_3,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"status of patients with PKU. Our findings indicate that canned food consumption is a significant contributing factor to heavy metal exposure in PKU patients. Furthermore, our findings revealed a relationship between age, perception of economic level, breastfeeding, kitchen equipment, and water usage and the levels of certain heavy metals. Exposure to environmental pollutants usually results from direct or indirect human activities, and it can cause acute or chronic health problems. These pollutants include",1_4,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"chronic health problems. These pollutants include heavy metals as well as endocrine disruptors [<xref rid=""B1-nutrients-16-03463"" ref-type=""bibr"">1</xref>]. Exposure to environmental contaminants at early ages of life is of particular concern. Environmental exposure to toxic metals and chemicals is responsible for approximately 9 million deaths each year [<xref rid=""B2-nutrients-16-03463"" ref-type=""bibr"">2</xref>]. Heavy metals are a group of metals and metalloids that occur naturally [<xref",1_5,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"metals and metalloids that occur naturally [<xref rid=""B3-nutrients-16-03463"" ref-type=""bibr"">3</xref>]. Trace elements, on the other hand, are required by all living organisms. However, they can lead to serious health effects at both deficiency and high supplementation. While trace elements like manganese (Mn), copper (Cu), zinc (Zn), and selenium (Se) are needed to maintain normal growth, metabolism, and development, heavy metals such as lead (Pb), cadmium (Cd), arsenic (As), and mercury (Hg) are four of",1_6,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"(Cd), arsenic (As), and mercury (Hg) are four of the top ten chemicals that threaten public health as reported by the World Health Organisation (WHO) [<xref rid=""B4-nutrients-16-03463"" ref-type=""bibr"">4</xref>,<xref rid=""B5-nutrients-16-03463"" ref-type=""bibr"">5</xref>]. As and Cd are categorized as “human carcinogen (Group 1)”; inorganic lead and lead compounds are classified as “probably carcinogenic to humans (Group 2A)”; methylmercury compounds are categorized as “possibly carcinogenic to humans (Group",1_7,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"as “possibly carcinogenic to humans (Group 2B)”; and metallic mercury and inorganic mercury compounds are “not classifiable to their carcinogenicity to humans (Group 3)” by the International Agency for Research on Cancer (IARC) [<xref rid=""B6-nutrients-16-03463"" ref-type=""bibr"">6</xref>,<xref rid=""B7-nutrients-16-03463"" ref-type=""bibr"">7</xref>,<xref rid=""B8-nutrients-16-03463"" ref-type=""bibr"">8</xref>,<xref rid=""B9-nutrients-16-03463"" ref-type=""bibr"">9</xref>]. Cd is classified as a “probable human",1_8,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"Cd is classified as a “probable human carcinogen (Group B)”, As as a “human carcinogen (Group A)”, elemental Hg as “not classifiable as to human carcinogenicity (Group D)”, and methylmercury and mercuric chloride as possible human carcinogens (Group C) by the US Environmental Protection Agency (US EPA) [<xref rid=""B10-nutrients-16-03463"" ref-type=""bibr"">10</xref>,<xref rid=""B11-nutrients-16-03463"" ref-type=""bibr"">11</xref>,<xref rid=""B12-nutrients-16-03463"" ref-type=""bibr"">12</xref>,<xref",1_9,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"ref-type=""bibr"">12</xref>,<xref rid=""B13-nutrients-16-03463"" ref-type=""bibr"">13</xref>]. In addition, heavy metal exposure has been reported to be associated with neurocognitive and behavioral disorders, respiratory problems, and cardiovascular diseases in children [<xref rid=""B14-nutrients-16-03463"" ref-type=""bibr"">14</xref>,<xref rid=""B15-nutrients-16-03463"" ref-type=""bibr"">15</xref>]. A number of studies conducted in various countries have documented the presence of detectable levels of heavy metals in",1_10,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"presence of detectable levels of heavy metals in soil and in a range of food products, including soil, fruit, vegetables, meat, milk, dairy products, and their canned counterparts [<xref rid=""B16-nutrients-16-03463"" ref-type=""bibr"">16</xref>,<xref rid=""B17-nutrients-16-03463"" ref-type=""bibr"">17</xref>,<xref rid=""B18-nutrients-16-03463"" ref-type=""bibr"">18</xref>,<xref rid=""B19-nutrients-16-03463"" ref-type=""bibr"">19</xref>]. Therefore, as oral intake is considered to be the main route of exposure to heavy",1_11,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"to be the main route of exposure to heavy metals as well as trace elements, the content and quality of the diet can affect both heavy metal intake and toxicity [<xref rid=""B20-nutrients-16-03463"" ref-type=""bibr"">20</xref>,<xref rid=""B21-nutrients-16-03463"" ref-type=""bibr"">21</xref>]. Phenylketonuria (PKU) is the most common amino acid metabolism disorder caused by a deficiency in the enzyme phenylalanine hydroxylase (PAH). The PAH enzyme converts phenylalanine (Phe) to tyrosine using tetrahydrobiopterin",1_12,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"(Phe) to tyrosine using tetrahydrobiopterin (BH4) as a cofactor. The PAH deficiency in untreated PKU patients leads to elevated Phe levels, which in turn causes intellectual impairment, eczematous rashes, seizures, motor function loss, and psychiatric problems [<xref rid=""B22-nutrients-16-03463"" ref-type=""bibr"">22</xref>,<xref rid=""B23-nutrients-16-03463"" ref-type=""bibr"">23</xref>]. While mild forms of PKU (blood Phe levels between 2 and 6 mg/dL) do not require treatment, patients with blood Phe levels of",1_13,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"treatment, patients with blood Phe levels of ≥6 mg/dL should be treated. The most well-established treatment, with a history of over six decades, is the Phe-restricted diet. In some patients, blood Phe levels can remain <6 mg/dL without the need for a Phe-restricted diet with sapropterin dihydrochloride therapy alone, an analog of BH4 [<xref rid=""B24-nutrients-16-03463"" ref-type=""bibr"">24</xref>,<xref rid=""B25-nutrients-16-03463"" ref-type=""bibr"">25</xref>]. Patients on a Phe-restricted diet may have very",1_14,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"Patients on a Phe-restricted diet may have very little or no protein-rich animal foods such as meat, milk, and eggs. Vegetables are an essential component of the daily diet for these patients; however, the unrestricted consumption of all vegetables is not feasible. The remainder of the daily protein requirement for the optimal growth and development of the patients on Phe-restricted (and therefore naturally protein-restricted) diets is provided by specially packaged medical Phe-free amino acid mixtures in",1_15,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"packaged medical Phe-free amino acid mixtures in powder or liquid form [<xref rid=""B23-nutrients-16-03463"" ref-type=""bibr"">23</xref>,<xref rid=""B26-nutrients-16-03463"" ref-type=""bibr"">26</xref>]. As the primary route of exposure to these heavy metals and trace elements is through the gastrointestinal system [<xref rid=""B14-nutrients-16-03463"" ref-type=""bibr"">14</xref>] and the diets of PKU patients vary according to treatment protocols, this study was designed with the aim of investigating whether the",1_16,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"with the aim of investigating whether the levels of plasma heavy metals and trace elements and their sources of exposure might differ between patients on different treatment regiments or not. The findings may provide insights into how the current PKU treatment protocols influence heavy metal and trace element exposure, potentially providing recommendations for improving these protocols in order to reduce exposure to high levels of heavy metals and trace elements.  A total of 105 patients who were diagnosed",1_17,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"A total of 105 patients who were diagnosed with the newborn screening program and continued their follow-ups with the pediatric metabolism outpatient clinic were included in the study. Of these patients, 34 (32.4%) were receiving Phe-restricted diet treatment, while 75 (67.6%) were on an unrestricted diet. The other baseline characteristics of the participants are described elsewhere [<xref rid=""B27-nutrients-16-03463"" ref-type=""bibr"">27</xref>]. The heavy metal exposure sources of the patients are given",1_18,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"metal exposure sources of the patients are given in <xref rid=""nutrients-16-03463-t001"" ref-type=""table"">Table 1</xref>. The median levels of the heavy metals were 1.62 µg/dL for Pb, 0.42 µg/dL for As, 1.45 µg/L for Cd, and 3.68 µg/L for Hg. The median levels of the trace elements were 9.74 µg/L for Mn, 130.2 µg/L for Se, 105.2 µg/dL for Cu, and 89.4 µg/dL for Zn (<xref rid=""nutrients-16-03463-t002"" ref-type=""table"">Table 2</xref>). This study is the first in the literature to evaluate the exposure of",1_19,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"in the literature to evaluate the exposure of patients with PKU to multiple heavy metals and the correlation of the heavy metals with trace elements. In a separate study conducted on the same cohort, we observed that the exposure of PKU patients to certain plasticizers varied according to their dietary status. However, in the present study, we found that the exposure of PKU patients to heavy metals did not vary according to their nutritional status or treatment regimen [<xref rid=""B27-nutrients-16-03463""",1_20,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"regimen [<xref rid=""B27-nutrients-16-03463"" ref-type=""bibr"">27</xref>]. Furthermore, the patients who were on BH4 therapy or on a Phe-restricted diet did not face an elevated risk of exposure to toxic elements due to their treatment compared to those without treatment. The Centers for Disease Control and Prevention (CDC) has set the upper limit (UL) for blood Pb levels in children 1 to 5 years of age at 3.5 µg/dL by 2021 [<xref rid=""B30-nutrients-16-03463"" ref-type=""bibr"">30</xref>]. The maximum level in",1_21,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"ref-type=""bibr"">30</xref>]. The maximum level in our study was 3.02, below the specified UL. The blood Pb levels observed in this study were comparable to those reported in healthy children in previous studies conducted in Türkiye [<xref rid=""B31-nutrients-16-03463"" ref-type=""bibr"">31</xref>,<xref rid=""B32-nutrients-16-03463"" ref-type=""bibr"">32</xref>]. The median blood As level of the patients (0.42 µg/dL) was below the UL of 1 µg/dL, given by the Agency for Toxic Substances and Disease Registry (ATSDR)",1_22,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"for Toxic Substances and Disease Registry (ATSDR) [<xref rid=""B33-nutrients-16-03463"" ref-type=""bibr"">33</xref>]. A comparison could not be made due to the absence of studies in the existing literature that assess blood As levels in Türkiye within the specified age group. The blood As levels were reported as 0.10 µg/L in children with an average age of 5 µg/L in China and 1.36 µg/L in a study evaluating 60 Peruvian children aged 3–24 months [<xref rid=""B34-nutrients-16-03463""",1_23,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"3–24 months [<xref rid=""B34-nutrients-16-03463"" ref-type=""bibr"">34</xref>,<xref rid=""B35-nutrients-16-03463"" ref-type=""bibr"">35</xref>]. According to National Health and Nutrition Examination Survey (NHANES) data, although the 95th percentile of blood Cd levels in children aged 1–5 years varies by 0.2–0.4 µg/L depending on age, ≤0.5 µg/L is generally accepted as a safe level for the blood Cd level in children [<xref rid=""B36-nutrients-16-03463"" ref-type=""bibr"">36</xref>]. In our study, we found that the",1_24,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"In our study, we found that the median blood Cd level of the patients was 1.44 µg/L, which is above this value. Bayhan et al. (2017) reported a mean blood Cd level of 0.58 µg/L in healthy individuals with a mean age of 16.8 years in Türkiye [<xref rid=""B37-nutrients-16-03463"" ref-type=""bibr"">37</xref>]. In another study conducted by Yalçın et al. (2022), the mean blood Cd level of children with a mean age of 8.2 years was 0.18 µg/L, and the mean blood Hg level was 0.16 µg/L [<xref",1_25,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"and the mean blood Hg level was 0.16 µg/L [<xref rid=""B38-nutrients-16-03463"" ref-type=""bibr"">38</xref>]. In our study, the median blood Hg value of the participants was 3.68 μg/L. According to the 2005–2006 NHANES data, the 95% p for the blood Hg levels of children aged 1–5 years was 1.43 μg/dL (14.3 μg/L), and this value increases with age [<xref rid=""B39-nutrients-16-03463"" ref-type=""bibr"">39</xref>]. The levels of heavy metals, particularly those of As and Cd, were found to be higher than those",1_26,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"of As and Cd, were found to be higher than those reported in other studies conducted in Türkiye. Nevertheless, the levels of these metals did not vary in accordance with the patients’ diagnoses, treatments, and mean Phe levels. This indicates that the elevated levels of As and Cd observed in this study are attributable to regional and individual exposure variations rather than to the underlying disease. This study is the first in the literature to examine the exposure of patients with PKU to heavy metals",1_27,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"the exposure of patients with PKU to heavy metals and the status of this exposure according to diet. The present study did not find a relationship between heavy metal exposure and the dietary treatment status of patients with PKU. Our findings indicate that canned food consumption is a significant contributing factor to the heavy metal exposure in PKU patients. Furthermore, our findings revealed a relationship between age, perception of economic level, breastfeeding, kitchen equipment, and water usage and",1_28,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"kitchen equipment, and water usage and the levels of certain toxic elements. Further research is required to gain a more comprehensive understanding of the environmental pollutant exposure of patients with PKU and to enable the implementation of effective strategies to minimize their exposure.",1_29,Heavy Metal and Trace Element Status and Dietary Determinants in Children with Phenylketonuria,12 10 2024,,Phenylketonuria
"Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase Background/Objectives: Pegvaliase, a subcutaneous therapy to treat phenylketonuria (PKU), has allowed these patients to maintain adequate phenylalanine (Phe) blood values without following a Phe-controlled diet; this brings up the challenge of promoting healthy eating while moving away from prescription diets. In our center, every patient treated",2_0,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"diets. In our center, every patient treated with Pegvaliase undergoes routine nutritional counseling aimed at promoting adherence to the Mediterranean diet (MedDiet) during regular inpatient visits. This study aims to assess adherence to MedDiet and the adequacy of the diets of patients treated with Pegvaliase regarding micro- and macronutrients. Methods: Seven patients on chronic therapy with Pegvaliase underwent a dietetic evaluation to assess the composition of their diets in terms of micro- and",2_1,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"composition of their diets in terms of micro- and macronutrients; they were also administered the Mediterranean Diet Score (MDS) questionnaire. Subcategories from MDS were extracted to evaluate the consumption of foods typically included (vegetables, olive oil, etc.) and typically excluded (red meat, etc.) in the MedDiet. To assess the adequacy of the diet, nutrient and energy levels were compared with guidelines for the Italian population. Results: MedDiet adherence in our sample was comparable to the",2_2,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"adherence in our sample was comparable to the general population; in terms of macronutrients, good adherence to the recommendations was observed, with every one of them met except for excessive simple sugar consumption. Micronutrient dietary intake was inadequate for zinc, iron, selenium, folate, thiamine, and riboflavin. Conclusions: While more work is necessary to help patients treated with Pegvaliase to progress toward healthy eating, our study suggests that nutritional counseling routinely performed",2_3,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"that nutritional counseling routinely performed during inpatient visits, typically twice a year, effectively promotes healthier eating habits than those observed in the general population. Phenylketonuria (PKU) is a rare genetic disorder caused by a deficiency in the activity of the enzyme phenylalanine hydroxylase (PAH), the enzyme responsible for converting phenylalanine (Phe) into tyrosine (Tyr) [<xref rid=""B1-nutrients-16-03348"" ref-type=""bibr"">1</xref>]. The global prevalence of the disorder is close",2_4,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"The global prevalence of the disorder is close to half a million, with various genotypes and consequent clinical phenotypes; the incidence varies in different countries, ranging from 1:4500 live births in Italy to 1:125,000 in Japan; PKU is the most common autosomal-recessive disorder of amino acid metabolism [<xref rid=""B2-nutrients-16-03348"" ref-type=""bibr"">2</xref>,<xref rid=""B3-nutrients-16-03348"" ref-type=""bibr"">3</xref>]. Left untreated, it can have irreversible impacts on people who are affected by",2_5,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"impacts on people who are affected by it; the main complications it can lead to are intellectual disability, epilepsy and behavioral disorders [<xref rid=""B1-nutrients-16-03348"" ref-type=""bibr"">1</xref>,<xref rid=""B3-nutrients-16-03348"" ref-type=""bibr"">3</xref>]. Newborn screening (NBS), performed using the dried blood spot during the first days of life [<xref rid=""B4-nutrients-16-03348"" ref-type=""bibr"">4</xref>], allows prompt diagnosis of PKU and, therefore, an immediate start of treatment before high",2_6,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"an immediate start of treatment before high blood Phe might have repercussions on long-term intellectual outcomes. The cardinal treatment of PKU is dietary, which requires patients to adhere to a diet with reduced PHE content. As Phe is an amino acid naturally present in food, patients with PKU must follow a diet with a low content of natural protein and complementary consumption of protein substitutes to achieve an adequate protein intake. A strict collaboration between the various specialists caring for",2_7,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"between the various specialists caring for the patients and metabolic dietitians is necessary to personalize the diet in order to meet individual needs, prevent other comorbidities, and minimize social difficulties [<xref rid=""B1-nutrients-16-03348"" ref-type=""bibr"">1</xref>,<xref rid=""B5-nutrients-16-03348"" ref-type=""bibr"">5</xref>]. In 2007, sapropterin dihydrochloride was approved by the Food and Drug Administration to treat patients with PKU and subsequently approved by the European Medicines Agency in",2_8,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"approved by the European Medicines Agency in Europe. It is a cofactor for PAH, and its effectiveness varies based on the genetic and clinical phenotypes of patients; in patients with PAH deficiency responsive to sapropterin supplementation, it increases tolerance to PHE content in the diet, allowing for metabolic control in patients with less strict diet management, and it should be noted that treatment with this cofactor is approved for patients of any age [<xref rid=""B6-nutrients-16-03348""",2_9,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"of any age [<xref rid=""B6-nutrients-16-03348"" ref-type=""bibr"">6</xref>]. Since 2021, Pegvaliase has been available in Italy for treating PKU in patients at least 16 years old with blood Phe levels above 600 μmol/L (10 mg/L) despite dietary prescription [<xref rid=""B7-nutrients-16-03348"" ref-type=""bibr"">7</xref>]. Pegvaliase is an injective enzyme-substitution therapy, converting Phe to ammonia and trans-cinnamic acid [<xref rid=""B8-nutrients-16-03348"" ref-type=""bibr"">8</xref>]; adequately dosed, it is",2_10,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"adequately dosed, it is effective in reducing Phe values in almost every patient, independently of the genetic mutation they might be affected by and their Phe dietary content; this allows maintenance of Phe values at target without following a diet with controlled Phe content [<xref rid=""B9-nutrients-16-03348"" ref-type=""bibr"">9</xref>]. Unequivocally, diet management in patients on Pegvaliase therapy brings up new challenges, the first being protein intake management during dose escalation and the second",2_11,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"management during dose escalation and the second one, while at a stable dose, controlling Phe levels while avoiding protein malnutrition and hypophenylalaninemia. Worldwide, various experts came together to suggest the correct dietary management for patients taking Pegvaliase, which has resulted in most patients obtaining adequate Phe blood levels with a free diet and no sign of malnutrition [<xref rid=""B10-nutrients-16-03348"" ref-type=""bibr"">10</xref>,<xref rid=""B11-nutrients-16-03348""",2_12,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"rid=""B11-nutrients-16-03348"" ref-type=""bibr"">11</xref>]. The development of new treatments and improvement of traditional ones, associated with efficient NBS, are resulting in patients growing older with better quality of life and less burden of disease, which however, brings up new challenges not necessarily related to a higher than recommended blood Phe value [<xref rid=""B12-nutrients-16-03348"" ref-type=""bibr"">12</xref>,<xref rid=""B13-nutrients-16-03348"" ref-type=""bibr"">13</xref>].  In particular,",2_13,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"ref-type=""bibr"">13</xref>].  In particular, patients affected by PKU appear to be at a higher risk of having lower bone mass density [<xref rid=""B14-nutrients-16-03348"" ref-type=""bibr"">14</xref>] and are more prone to diseases associated with poor metabolic health, such as hypertension, dyslipidemia, and obesity [<xref rid=""B15-nutrients-16-03348"" ref-type=""bibr"">15</xref>,<xref rid=""B16-nutrients-16-03348"" ref-type=""bibr"">16</xref>]. Considering modifiable risk factors for these diseases, lifestyle plays",2_14,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"risk factors for these diseases, lifestyle plays a critical role in prevention while also being crucial in their treatment in the general population [<xref rid=""B17-nutrients-16-03348"" ref-type=""bibr"">17</xref>,<xref rid=""B18-nutrients-16-03348"" ref-type=""bibr"">18</xref>]; in particular, the Mediterranean diet (MedDiet) remains a dietary model that promotes healthy aging, reduces the incidence of the most common comorbidities in Italy (i.e., hypertension, dyslipidemia, cardiovascular disease, type 2",2_15,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"dyslipidemia, cardiovascular disease, type 2 diabetes, cancer) and reduces the risk of overall mortality [<xref rid=""B19-nutrients-16-03348"" ref-type=""bibr"">19</xref>,<xref rid=""B20-nutrients-16-03348"" ref-type=""bibr"">20</xref>]. These findings, first delved into by the pioneering works of Keys et al. [<xref rid=""B21-nutrients-16-03348"" ref-type=""bibr"">21</xref>], must be taken into consideration together with modern views that diets must also be environmentally and economically sustainable while remaining",2_16,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"and economically sustainable while remaining consistent with the local traditions of Italy [<xref rid=""B22-nutrients-16-03348"" ref-type=""bibr"">22</xref>].  Managing adequate micronutrient intake has always been challenging while following a diet with controlled Phe content, with biochemical deficiencies commonly reported even when observing adequate micronutrient intake in the diet of patients affected by PKU [<xref rid=""B23-nutrients-16-03348"" ref-type=""bibr"">23</xref>,<xref rid=""B24-nutrients-16-03348""",2_17,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"rid=""B24-nutrients-16-03348"" ref-type=""bibr"">24</xref>,<xref rid=""B25-nutrients-16-03348"" ref-type=""bibr"">25</xref>]. Concerning Pegvaliase, to our knowledge, only one study has evaluated micronutrient intake in patients taking Pegvaliase, but the complete assessment was only performed when patients were starting Pegvaliase, and all but one were still regularly consuming at least one medical product; the authors reported adequate intake for every considered micronutrient but Vitamin D [<xref",2_18,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"considered micronutrient but Vitamin D [<xref rid=""B26-nutrients-16-03348"" ref-type=""bibr"">26</xref>]. In Italy, a panel of experts has already published that it is necessary to promote nutritional counseling in guiding the transition from a medically Phe-controlled diet to a regular one while introducing Pegvaliase [<xref rid=""B27-nutrients-16-03348"" ref-type=""bibr"">27</xref>]. In our center, after the induction and titration phase is concluded and Pegvaliase therapy is at the therapeutic dose, inpatient",2_19,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"therapy is at the therapeutic dose, inpatient visits are typically scheduled every six months unless specific needs arise. It should be noted that during the induction and titration phases, patients are evaluated more frequently, both by the physician and by the dietitian. In the same setting, the dietician evaluates the eating habits of the patient, and nutritional counseling takes place; this counseling is aimed at promoting a healthy diet based on the MedDiet. The main aim of this study is to evaluate",2_20,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"The main aim of this study is to evaluate how patients taking Pegvaliase who have completed both the induction and the titration phases, and who regularly undergo nutritional counseling, structure their diet, particularly concerning healthy eating and their adherence to the MedDiet. Secondly, we aim to evaluate micronutrient dietary intake in relation to age and sex-specific requirements, evaluating the potential need for more specific and structured nutritional interventions. Patients currently treated at",2_21,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"interventions. Patients currently treated at the Clinical Nutrition and Metabolism Unit, IRCCS AOUBO, Bologna, Italy, who are affected by PKU and receiving Pegvaliase therapy, who have completed the induction and titration phases of the drug, and who are on an unrestricted diet were included. In the pre-screening, patients whose food choices are made by the caregiver were excluded. Data on anthropometric measurements (height, weight, waist circumference) were collected in the morning on an empty stomach,",2_22,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"collected in the morning on an empty stomach, after urination, wearing underwear, and the BMI was calculated by dividing the weight, in kilograms, by the square of the height, in meters. Data from laboratory tests were collected regarding the main metabolic parameters (glucose, insulin, total cholesterol, HDL, triglycerides, uric acid, TSH, PTH, homocysteine), vitamins (vitamin B12, folate, vitamin D), and micronutrients (iron, ferritin, transferrin, calcium, phosphorus, zinc). The homeostatic model",2_23,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"calcium, phosphorus, zinc). The homeostatic model assessment (HOMA index) was calculated with the following formula: fasting blood glucose (mg/dL) × fasting insulin (mU/L)/405. The patients were subjected to a telephone, 7-day dietary recall conducted by a dietitian with expertise in PKU dietary treatment. During the clinical evaluation and according to clinical practice, the dietitian asks the patient to recall what they have eaten in the previous 7 days. This method of assessing diets has clear",2_24,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"7 days. This method of assessing diets has clear limitations (as do other methods): the week might not be a standard one, and the patient might not be able to recall precisely what foods or how much of them was eaten. The dietary recall data were uploaded to the program commonly used in our clinical practice, MetaDieta vers. 3.7.1.1 (METEDA S.r.l. ©, San Benedetto del Tronto AP, Italy). The analysis of the diet allowed us to calculate the following parameters for dietary content: intake of total energy in",2_25,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"for dietary content: intake of total energy in kcal; and subdivision into macronutrients (proteins, carbohydrates, lipids, and alcohol) and micronutrients (iron, calcium, phosphorus, magnesium, selenium, zinc, vitamin B12, folate riboflavin, vitamin A, niacin, thiamine). Lab parameters were collected from the analyses performed during regular clinical practice (iron, ferritin, transferrin, calcium, phosphorus, magnesium, zinc, glucose, insulin, total cholesterol, HDL, triglycerides, uric acid, TSH, vitamin",2_26,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"HDL, triglycerides, uric acid, TSH, vitamin D, PTH, homocysteine, vitamin B12, folate). Subsequently, the average daily nutritional intake of the patients was compared to the Italian guidelines, the “IV revision of Nutrients and Energy for the Italian population” (LARN) [<xref rid=""B28-nutrients-16-03348"" ref-type=""bibr"">28</xref>]. For comparison, the Population Recommended Intake (PRI) and the Reference Interval (RI) were used for minerals and vitamins, and for macronutrients, respectively. For comparing",2_27,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"for macronutrients, respectively. For comparing cholesterol intake, the Suggested Dietary Target (SDT) was used. Targets were chosen according to age and sex, and patients were grouped based on having the same SDT (e.g., females of fertile age were grouped separately for iron as their SDTs differ). Patients were also administered the MDS to assess adherence to the MedDiet; the questionnaire has been described previously by Panagiotakos et al. [<xref rid=""B29-nutrients-16-03348"" ref-type=""bibr"">29</xref>]",2_28,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"ref-type=""bibr"">29</xref>] and includes questions on non-refined cereals, fruits, vegetables, legumes, potatoes, fish, red meat, meat products, poultry, full-fat dairy products, olive oil, and alcohol. The scoring system is designed to reflect the typical dietary patterns observed in the Mediterranean region. The total score is assigned a value between 0 and 55, with higher scores reflecting greater adherence to the MedDiet. To calculate the score, the weekly consumption of foods is considered, from 0 to",2_29,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"consumption of foods is considered, from 0 to at least 5 times per week. For foods that are part of the MedDiet (non-refined cereals, fruits, vegetables, legumes, olive oil, fish, and potatoes), more frequent consumption correspond more points, up to 5 times per week for maximum points; on the other hand, for foods that are excluded from the MedDiet (red meat and products, poultry, and full-fat dairy products), higher scores correspond to lower frequency of consumption, with the highest score corresponding",2_30,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"consumption, with the highest score corresponding to not consuming those foods on a weekly basis. We also decided to evaluate the tendency to consume particular food groups; in particular, extrapolating data from the MDS, we established various subgroups, similar to the approach of Bacharaki et al. for patients with end-stage kidney disease [<xref rid=""B30-nutrients-16-03348"" ref-type=""bibr"">30</xref>]. We established the subgroup “Avoid foods”, comprising foods not traditionally found in the MedDiet",2_31,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"foods not traditionally found in the MedDiet (poultry, red meat and products, full-fat dairy products), and the group “Recommended foods”, which includes the pillars of the MedDiet (non-refined cereals, potatoes, fruits, vegetables, legumes, fish, olive oil); in addition to this, we considered the subgroup “Fruit, vegetable and legumes” (FVL). Each subgroup score was the sum of the score of the single items considered. For “Recommended foods”, the score was a value ranging from 0 to 35; for the subgroup",2_32,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"a value ranging from 0 to 35; for the subgroup “Avoid foods”, the range was from 0 to 15, and for the subgroup “FVL”, from 0 to 15. Values were expressed as percentages. A similar application of the MDS. Continuous variables were expressed as median, minimum, and maximum. Categorical variables were expressed as absolute frequency and percentages. The associations were evaluated with Spearman’s rank correlation coefficient. Statistical significance was set at <italic toggle=""yes"">p</italic> < 0.05.",2_33,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"set at <italic toggle=""yes"">p</italic> < 0.05. Statistical analysis was performed using StatView (Version 5.0.1) for Windows 92-98, SAS Institute (Lane Cove, Australia).  The data analyzed belonged to patients enrolled in the “RarEMIX-2021” observational study. This study was approved by the local Ethics Committee (reference code 796/2021/Oss/AOUBo). Of nine patients currently being treated with Pegvaliase at our center, two did not meet the criteria, as one was in the titration phase and one was unable to",2_34,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"was in the titration phase and one was unable to make independent food choices. The final sample of seven patients comprised five men and two women on Pegvaliase therapy for a median of around 30 months (891 days), ranging from 5 to 38 months (150 to 1152 days). The description of the sample is shown in <xref rid=""nutrients-16-03348-t001"" ref-type=""table"">Table 1</xref>. These were adult patients aged between 18 and 42, with a median BMI indicative of normal weight. The glycometabolic parameters were in",2_35,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"weight. The glycometabolic parameters were in the range of what is considered clinically normal; in particular, no insulin resistance was present in our patients. Blood iron and vitamin levels, thyroid function, and micronutrients were, considering the median values, in the range of normality, and there were no clinical signs of pathology. The nutritional evaluation (<xref rid=""nutrients-16-03348-t002"" ref-type=""table"">Table 2</xref>) shows the patients had a median caloric intake of 51% calories from",2_36,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"had a median caloric intake of 51% calories from carbohydrates, 16% from proteins, and 34% from lipids. Specifically, the percentage of calories provided by simple sugars was 13% of the total caloric intake, and that of saturated fats was 9%. The consumption of simple sugars and lipids exceeded the recommended guidelines. One patient had a high alcohol consumption. On average, protein consumption was 1 g/kg, which aligns with the Italian recommendations, with a significant portion being of high biological",2_37,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"a significant portion being of high biological value, as expressed by the ratio of protein coming from animal products or vegetable, ranging from 43% to 69.6%. Regarding micronutrients, we report unsatisfactory zinc, selenium, thiamine, riboflavin, and folate intake. Iron intake was found to be inadequate in the female population, considered their greater daily needs. Data concerning patients’ adherence to the MedDiet are presented in <xref rid=""nutrients-16-03348-t003"" ref-type=""table"">Table 3</xref>.",2_38,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"ref-type=""table"">Table 3</xref>.  Using the Spearman correlation test, we examined whether dietary parameters could be associated with laboratory parameters. Unfortunately, we did not find statistically and clinically significant correlations. The only significant correlation that emerged from the analysis was the positive one between age and BMI (<italic toggle=""yes"">p</italic> = 0.0358). In this study, we assessed the composition of the diet of patients affected by PKU who were being treated with",2_39,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"affected by PKU who were being treated with Pegvaliase, who had concluded the induction phase, and who were no longer prescribed low-Phe diets; we investigated their adherence to the MedDiet and how adequate their diet was in terms of nutrient intake. Concerning adherence to the MedDiet, the median adherence was 49.1%, with the highest adherence observed being 61.8% and the lowest being 34.5%. It is important to underline how MDS considers alcohol consumption; in particular, it attributes 0 points to",2_40,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"in particular, it attributes 0 points to people who do not consume any alcohol, as the questionnaire considers that people who consume moderate amounts of alcohol have the greatest adherence to MedDiet. Considering the original publication from Panagiotakos et al., the median adherence we observed was 27, in line with the average reported by them, which was 26 [<xref rid=""B29-nutrients-16-03348"" ref-type=""bibr"">29</xref>]. Considering the subcategory “recommended foods”, whose regular consumption is part",2_41,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"foods”, whose regular consumption is part of the MedDiet, the median percentage value observed was 62.9% (ranging from 42.9 to 74.3); median scores of 5 were observed for olive oil, unrefined cereals, and vegetable consumption, indicating high adherence; the median scores for fruit and fish were 3 and 2, respectively, indicating moderate regular consumption; the median scores for potatoes and legumes were both 0. Considering the value of 62.9%, consuming foods that are part of the MedDiet was a significant",2_42,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"that are part of the MedDiet was a significant positive contributor to the median percentage score of MDS, which was 49.1%. Every patient considered in the study was familiar with the low-Phe diet, as they had been previously prescribed this diet or tailored their diet accordingly, at least in childhood; potatoes and legumes are pivotal sources of natural protein that every patient had structured their diet around. This resulted in frequent consumption while following a Phe-controlled diet [<xref",2_43,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"while following a Phe-controlled diet [<xref rid=""B5-nutrients-16-03348"" ref-type=""bibr"">5</xref>]. This factor might play a role in lower consumption of these food groups by the patients after the liberalization of their diets; the same assumption can be made when evaluating the subgroup FVL, whose median value was 60%, which is in line with the category above.  On the other hand, some foods almost always excluded in Phe-controlled diets were part of the “avoid foods” subcategory. The considered sample",2_44,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"“avoid foods” subcategory. The considered sample displayed high consumption of these foods, as can be seen by the median value of 26.7%. It is not easy to speculate on the psychological impact of removing a previously established medical prohibition to consume certain foods. A previous systematic review considered patients with PKU who started sapropterin dihydrochloride therapy, allowing them to free their diet. The authors evaluated the need for nutritional education to avoid the risk of inadequate",2_45,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"education to avoid the risk of inadequate diets, but adherence to the MedDiet was not evaluated [<xref rid=""B31-nutrients-16-03348"" ref-type=""bibr"">31</xref>,<xref rid=""B32-nutrients-16-03348"" ref-type=""bibr"">32</xref>]. In general, adult patients with PKU show low adherence to a Phe-reduced diet into adulthood and to clinical follow-up in general [<xref rid=""B33-nutrients-16-03348"" ref-type=""bibr"">33</xref>]. It is logical to speculate that the nutritional counseling to adhere to a healthy diet is a",2_46,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"counseling to adhere to a healthy diet is a weaker medical veto compared to the previous requirement to follow a diet with a controlled phe content. Comparing our results with those previously reported by Cazzorla et al. in a population of adult patients with PKU not treated with Pegvaliase, the consumption of foods rich in protein not included in the MedDiet is typically high in general in this population, even without medical indications to lift the dietary restrictions [<xref",2_47,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"to lift the dietary restrictions [<xref rid=""B34-nutrients-16-03348"" ref-type=""bibr"">34</xref>]. Overall, concerning MedDiet adherence in our population, we observed that nutritional counseling according to clinical practice, typically performed twice per year during scheduled inpatient visits, effectively promoted adherence comparable to the general population in the north of Italy [<xref rid=""B35-nutrients-16-03348"" ref-type=""bibr"">35</xref>]. In general, our population presented various risk factors for",2_48,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"our population presented various risk factors for relatively lower adherence to MedDiet, in particular, being young and being from the north of Italy [<xref rid=""B36-nutrients-16-03348"" ref-type=""bibr"">36</xref>]; in addition, as was previously demonstrated, psychological factors such as family stress, which the diagnosis of PKU itself creates [<xref rid=""B37-nutrients-16-03348"" ref-type=""bibr"">37</xref>], correlate to lower adherence to the MedDiet [<xref rid=""B36-nutrients-16-03348""",2_49,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"the MedDiet [<xref rid=""B36-nutrients-16-03348"" ref-type=""bibr"">36</xref>]. The MedDiet, recognized by the United Nations Educational, Scientific and Cultural Organization (UNESCO) as an Intangible Cultural Heritage of Humanity, has conviviality as an integral part of the diet itself [<xref rid=""B38-nutrients-16-03348"" ref-type=""bibr"">38</xref>]. While our questionnaire did not evaluate this aspect of sharing meals, without Pegvaliase therapy, it would not be feasible to imagine patients with PKU freely",2_50,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"be feasible to imagine patients with PKU freely enjoying meals with people who do not have the disease and adequately manage their blood Phe levels. As nutritional counseling has proven to be effective in improving adherence to the MedDiet in the general population [<xref rid=""B39-nutrients-16-03348"" ref-type=""bibr"">39</xref>], more structured programs are necessary for patients on Pegvaliase who switch to a free diet; in particular, such programs should promote the regular consumption of “recommended",2_51,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"promote the regular consumption of “recommended foods” while reducing consumption of the “avoid foods”. Concerning how the diets of the considered sample were structured, we observed an adequate median calorie percentage coming from lipids, as well as adequacy in the median calories coming from saturated fats; the observed percentage of total lipids was close to the upper limit secondary to high consumption of extra virgin olive oil. Conversely, we noted a significant variability in the consumption of both",2_52,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"variability in the consumption of both fats and sugars. Some patients adhered to the recommended daily targets, while others significantly exceeded them. This diversity in dietary habits within the sample is an intriguing aspect of our findings. While there is some elasticity in terms of diet composition [<xref rid=""B40-nutrients-16-03348"" ref-type=""bibr"">40</xref>], the evidence that simple sugars should account for less than 10% of the daily energy intake still holds up robustly, suggesting the adequacy",2_53,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"still holds up robustly, suggesting the adequacy of this recommendation [<xref rid=""B41-nutrients-16-03348"" ref-type=""bibr"">41</xref>]. Concerning saturated fats dietary intake, even though an ever-growing body of literature is reevaluating the impact on overall health [<xref rid=""B42-nutrients-16-03348"" ref-type=""bibr"">42</xref>], as a Unit of Clinical Nutrition, we follow the various Italian guidelines that underline the need to have controlled consumption [<xref rid=""B28-nutrients-16-03348""",2_54,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"consumption [<xref rid=""B28-nutrients-16-03348"" ref-type=""bibr"">28</xref>]. Considering protein intake, the median intake of protein per kilogram was 1.0, ranging from 0.8 to 1.1. These data confirm that all the patients were able to adhere to adequate protein intake from natural sources, without either exceeding or falling below the individual needs. Comparing our findings to those reported for the diet of the general population of the north of Italy [<xref rid=""B18-nutrients-16-03348""",2_55,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"of Italy [<xref rid=""B18-nutrients-16-03348"" ref-type=""bibr"">18</xref>], considering the median values of the diet composition, our sample meets the recommended nutritional targets for all considered items more closely than the general population in the north of Italy. Considering micronutrient intake, we observed a dietary median intake lower than that recommended for zinc, selenium, folate, riboflavin, and thiamine. Comparing our data with observations by Filippini et al. on the average daily intake for",2_56,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"Filippini et al. on the average daily intake for people living in the north of Italy [<xref rid=""B43-nutrients-16-03348"" ref-type=""bibr"">43</xref>], we observed comparable intake concerning zinc. At the same time, our population displayed a significantly lower selenium intake. Selenium dietary deficiency is common worldwide and has been previously observed in Italy, even in a particular population [<xref rid=""B44-nutrients-16-03348"" ref-type=""bibr"">44</xref>]. More studies are necessary to delve into the",2_57,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"More studies are necessary to delve into the necessity of chronic supplementation. In general, even though nutritional counseling promotes adherence to the MedDiet, which should adequately meet the daily needs for macro- and micronutrients [<xref rid=""B45-nutrients-16-03348"" ref-type=""bibr"">45</xref>], more tailored and specific nutritional interventions should be performed based on specific individual needs to promote consumption of the specific food groups that might be lacking. For example, considering",2_58,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"that might be lacking. For example, considering our population, low to zero consumption of certain foods, such as nuts or shellfish, was observed; promoting consumption of these foods could help meet most of the dietary recommendations still left unmet while adhering more closely to the MedDiet. Considering the clinical and laboratory characteristics of the sample, despite the theoretical micronutrient and vitamin dietary deficiencies, the values we last observed during clinical practice were in the range",2_59,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"during clinical practice were in the range of normality for all blood parameters, which could be accounted for by the supplementation they had potentially received previously.  This study has several limitations; the first is the small number of patients we considered, which is to be expected considering PKU is a rare disease and Pegvaliase is not the only treatment. Secondly, the population was heterogeneous in terms of age, background, comorbidities, and duration of treatment with Pegvaliase. Thirdly,",2_60,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"duration of treatment with Pegvaliase. Thirdly, the diet considered in this study was evaluated only once and during summer; this might not allow us to capture the actual average diet during the whole year. This is the first study that evaluates the adherence to the MedDiet in patients with PKU being chronically treated with Pegvaliase and who undergo regular nutritional counseling; this is also the first study that evaluates the diet composition and the meeting of dietary intakes. While our study suggests",2_61,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"of dietary intakes. While our study suggests that nutritional counseling effectively promotes adherence to the pivotal principles of the MedDiet and leads to nutrition as healthy as diets observed in the general population, more work is needed to support patients in their journey toward healthy eating, addressing individual needs.",2_62,Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase,02 10 2024,,Phenylketonuria
"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status Background: Phenylketonuria (PKU) is the most common amino acid metabolism disorder. Patients with blood phenylalanine (Phe) levels of ≥6 mg/dL require treatment, and the most definitive treatment is the Phe-restricted diet. Bisphenols and phthalates are widely used endocrine-disrupting chemicals (EDCs) found in personal care products, baby bottles, and food",3_0,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"in personal care products, baby bottles, and food packaging. Methods: In this study, we evaluated the possible routes of exposure to these EDCs in patients diagnosed with PKU (n = 105, 2–6 years of age) and determined the relationship between the plasma levels of bisphenol A (BPA), bisphenol F (BPF), di-butyl phthalate (DBP), di-(2-ethylhexyl) phthalate (DEHP), mono-(2ethylhexyl) phthalate (MEHP), and dietary regimens. Participant characteristics and exposure routes were evaluated according to their",3_1,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"exposure routes were evaluated according to their dietary treatment status. Results: Thirty-four of these patients were on a Phe-restricted diet, while the remaining 71 had no dietary restrictions. DBP and DEHP levels were higher in those using plastic tablecloths (<italic toggle=""yes"">p</italic> = 0.049 and <italic toggle=""yes"">p</italic> = 0.04, respectively). In addition, plasma DBP levels were higher in those who used bottled water (<italic toggle=""yes"">p</italic> = 0.01). Being under 4 years of age,",3_2,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"= 0.01). Being under 4 years of age, using plastic food containers, and using plastic shower curtains were characteristics associated with higher MEHP levels (<italic toggle=""yes"">p</italic> = 0.027, <italic toggle=""yes"">p</italic> = 0.019, and <italic toggle=""yes"">p</italic> = 0.014, respectively). After adjustment for baseline characteristics (Model 1), the odds of having a plasma BPA level in the upper tertile were 3.34 times higher in the free-diet group (95% CI = 1.09–10.25). When we additionally",3_3,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"group (95% CI = 1.09–10.25). When we additionally adjusted for plastic exposure (Model 2), the odds ratio was found to be 18.64 (95% CI = 2.09–166.42) for BPA. In the free-diet group, the probability of having plasma DEHP levels in the upper tertile was increased by a relative risk of 3.01 (<italic toggle=""yes"">p</italic> = 0.039, 95% CI = 1.06–8.60). Conclusion: Our results indicate that exposure to bisphenols and phthalates varies with dietary treatment. The difference in sources of exposure to EDCs",3_4,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"The difference in sources of exposure to EDCs between the diet and non-diet groups indicates that diet plays an important role in EDC exposure. Phenylketonuria (PKU) is the most common amino acid metabolism disorder, caused by mutations in the phenylalanine hydroxylase (PAH) gene [<xref rid=""B1-nutrients-16-03213"" ref-type=""bibr"">1</xref>]. Although its prevalence is approximately 1:10,000 worldwide, the frequency is approximately 1:4000 in Türkiye, where consanguineous marriages are common and PKU can be",3_5,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"marriages are common and PKU can be encountered by autosomal recessive inheritance [<xref rid=""B2-nutrients-16-03213"" ref-type=""bibr"">2</xref>,<xref rid=""B3-nutrients-16-03213"" ref-type=""bibr"">3</xref>]. High levels of phenylalanine (Phe) in the blood cause toxic effects, especially in the brain, and untreated patients may have symptoms such as low IQ, cognitive retardation, emotional and psychiatric problems, eczema, autism, seizures, and motor loss [<xref rid=""B1-nutrients-16-03213""",3_6,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"and motor loss [<xref rid=""B1-nutrients-16-03213"" ref-type=""bibr"">1</xref>]. In many countries, thanks to newborn screening programs, patients are diagnosed during the neonatal period and treatment is started before the onset of symptoms [<xref rid=""B3-nutrients-16-03213"" ref-type=""bibr"">3</xref>]. In PKU patients, treatment needs are determined by blood Phe levels. In healthy individuals, blood Phe levels range from 0.8 to 1.99 mg/dL. Patients with blood Phe levels of ≥6 mg/dL require treatment, and the",3_7,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"Phe levels of ≥6 mg/dL require treatment, and the best known and most definitive treatment is the Phe-restricted diet. Sapropterin dihydrochloride, a synthetic form of tetrahydrobiopterin (BH4, cofactor of the PAH enzyme), is another treatment option, and BH4-responsive patients can continue their treatment without the need for a Phe-restricted diet [<xref rid=""B4-nutrients-16-03213"" ref-type=""bibr"">4</xref>,<xref rid=""B5-nutrients-16-03213"" ref-type=""bibr"">5</xref>,<xref rid=""B6-nutrients-16-03213""",3_8,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"rid=""B6-nutrients-16-03213"" ref-type=""bibr"">6</xref>,<xref rid=""B7-nutrients-16-03213"" ref-type=""bibr"">7</xref>]. The target of treatment is to keep Phe levels <6 mg/dL in children under 12 years of age and <10 mg/dL in those 12 years of age and older [<xref rid=""B6-nutrients-16-03213"" ref-type=""bibr"">6</xref>]. The amount of natural protein that can be taken by patients will vary depending on their level of Phe tolerance. The remainder of the protein needed for normal growth and development is provided by",3_9,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"for normal growth and development is provided by Phe free amino acid mixtures. These amino acid mixtures are offered in special packaging in powder or liquid form. Plastic packaging is usually used for liquid forms and metal packaging is used for powder forms, but in both cases there is a plastic-based coating inside the package/box [<xref rid=""B1-nutrients-16-03213"" ref-type=""bibr"">1</xref>]. Today, many environmental pollutants that result from human activities contaminate the water, soil, and air. These",3_10,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"contaminate the water, soil, and air. These chemicals, directly or indirectly, can lead to acute or chronic health problems, and exposure to these chemicals is suggested to be responsible for approximately 9 million deaths each year [<xref rid=""B8-nutrients-16-03213"" ref-type=""bibr"">8</xref>]. These pollutants include plasticizers (phthalates, bisphenols, etc.), heavy metals, and many other substances (polychlorinated biphenyls, polucyclic aromatic hydrocarbons, etc.) [<xref rid=""B9-nutrients-16-03213""",3_11,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"etc.) [<xref rid=""B9-nutrients-16-03213"" ref-type=""bibr"">9</xref>]. Phthalates, which were first used as plasticizers in the 1930s, are now widely used in consumer and personal care products [<xref rid=""B10-nutrients-16-03213"" ref-type=""bibr"">10</xref>]. Low molecular weight phthalates are often added to personal care products to preserve odor while high molecular weight phthalates are used in polyvinyl chloride (PVC) to increase flexibility. Phthalates are found in a variety of products, including",3_12,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"are found in a variety of products, including flooring, food packaging, and medical tubing. Phthalates do not covalently bind to plastic matrices and are easily separated from polymers. Humans can be exposed to these chemicals by the oral route (i.e., by food and water) [<xref rid=""B11-nutrients-16-03213"" ref-type=""bibr"">11</xref>]. Phthalates are well known for their endocrine-disrupting effects, and they are associated with metabolic syndrome, neurodevelopmental disorders, urogenital",3_13,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"neurodevelopmental disorders, urogenital changes/malformations, alterations in embryogenesis, thyroid dysfunction, obesity, diabetes, cardiovascular disease, and autoimmune and inflammatory diseases [<xref rid=""B11-nutrients-16-03213"" ref-type=""bibr"">11</xref>,<xref rid=""B12-nutrients-16-03213"" ref-type=""bibr"">12</xref>,<xref rid=""B13-nutrients-16-03213"" ref-type=""bibr"">13</xref>,<xref rid=""B14-nutrients-16-03213"" ref-type=""bibr"">14</xref>,<xref rid=""B15-nutrients-16-03213"" ref-type=""bibr"">15</xref>,<xref",3_14,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"ref-type=""bibr"">15</xref>,<xref rid=""B16-nutrients-16-03213"" ref-type=""bibr"">16</xref>,<xref rid=""B17-nutrients-16-03213"" ref-type=""bibr"">17</xref>,<xref rid=""B18-nutrients-16-03213"" ref-type=""bibr"">18</xref>,<xref rid=""B19-nutrients-16-03213"" ref-type=""bibr"">19</xref>,<xref rid=""B20-nutrients-16-03213"" ref-type=""bibr"">20</xref>,<xref rid=""B21-nutrients-16-03213"" ref-type=""bibr"">21</xref>,<xref rid=""B22-nutrients-16-03213"" ref-type=""bibr"">22</xref>]. Bisphenol A (BPA) is another of the widely exposed",3_15,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"A (BPA) is another of the widely exposed chemicals, with more than 2 million tons produced annually. It is used to harden polycarbonate plastics and epoxy resins. Polycarbonate plastics are used in baby bottles, food storage containers, water bottles and bottle caps, eyeglass lenses, CDs, DVDs, and electronic devices [<xref rid=""B23-nutrients-16-03213"" ref-type=""bibr"">23</xref>]. Studies have also shown that early BPA exposure has been linked to adverse neurodevelopmental effects, heart disease, diabetes,",3_16,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"effects, heart disease, diabetes, elevated liver enzymes, and impaired thyroid function [<xref rid=""B24-nutrients-16-03213"" ref-type=""bibr"">24</xref>,<xref rid=""B25-nutrients-16-03213"" ref-type=""bibr"">25</xref>,<xref rid=""B26-nutrients-16-03213"" ref-type=""bibr"">26</xref>,<xref rid=""B27-nutrients-16-03213"" ref-type=""bibr"">27</xref>]. BPA-containing baby bottles are banned in Europe for use by infants <3 years of age. Due to their consumption of more food according to body mass, immature detoxification",3_17,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"according to body mass, immature detoxification mechanisms, and increased susceptibility to harmful effects of endocrine-disrupting chemicals (EDCs), children are more likely to face the toxic effects of bisphenols [<xref rid=""B28-nutrients-16-03213"" ref-type=""bibr"">28</xref>]. Türkiye has prohibited the manufacture of plastics containing BPA for use in infant and toddler feeding bottles [<xref rid=""B29-nutrients-16-03213"" ref-type=""bibr"">29</xref>]. Due to increasing awareness and restrictions against",3_18,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"to increasing awareness and restrictions against BPA, bisphenol F (BPF), one of the bisphenol analogues produced by manufacturers as an alternative, has become widely used today. It can be used in almost any application where the use of BPA is restricted. Most of the materials promoted as BPA-free contain other bisphenol analogues, primarily BPF [<xref rid=""B30-nutrients-16-03213"" ref-type=""bibr"">30</xref>]. For example, the use of BPA is banned in infant formula and the interior surface coating of its",3_19,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"formula and the interior surface coating of its containers, and in the manufacture of infant and toddler feeding containers, but there is no regulation for other bisphenol analogs [<xref rid=""B30-nutrients-16-03213"" ref-type=""bibr"">30</xref>,<xref rid=""B31-nutrients-16-03213"" ref-type=""bibr"">31</xref>].  Oral exposure to EDCs is increasing every year due to the high production of these chemicals [<xref rid=""B11-nutrients-16-03213"" ref-type=""bibr"">11</xref>,<xref rid=""B32-nutrients-16-03213""",3_20,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"rid=""B32-nutrients-16-03213"" ref-type=""bibr"">32</xref>,<xref rid=""B33-nutrients-16-03213"" ref-type=""bibr"">33</xref>]. In this study, we evaluated the possible routes of exposure to phthalates and bisphenols in patients diagnosed with PKU and determined the relationship between the plasma levels of BPA, BPF, di-butyl phthalate (DBP), di-(2-ethylhexyl) phthalate (DEHP), mono-(2ethylhexyl) phthalate (MEHP), and dietary regimens. Our findings can provide valuable insights into the potential risks associated",3_21,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
insights into the potential risks associated with the specialized dietary products used in PKU patients and may lead to future regulations to minimize the exposure to harmful chemicals in this susceptible population. The study protocol was approved by the Hacettepe University Ethics Committee (GO 22/659). The study was conducted between July 2022 and January 2024 and included a total of 105 patients aged 2–6 years with diagnoses of PKU. The patients included in the study were diagnosed with PKU during the,3_22,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
in the study were diagnosed with PKU during the neonatal period through the newborn screening program and were being clinically followed at the center where the study was conducted. Written informed consent was obtained from the participating children and their families before their enrollment to the study. The patients were subject to physical examination: the anthropometric measurements (height and weight) of all participants were taken and age-related body mass index (BMI) z-scores (BAZ) were,3_23,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"body mass index (BMI) z-scores (BAZ) were calculated. The data regarding the patients’ diseases, including the age at diagnosis, Phe levels, and the treatments they were receiving, were obtained from hospital records. A total of 105 patients were included in the study, including 38 with hyperphenylalaninemia (HPA, those with blood Phe levels between 2 and 6 mg/dL without treatment at the time of diagnosis), 37 with BH4-responsive PKU, and 30 with PKU (those with a Phe-restricted diet). However, one patient",3_24,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"with a Phe-restricted diet). However, one patient with HPA did receive a Phe-restricted diet, as plasma Phe levels were above 6 mg/dL during follow-up. A total of 34 BH4-responsive PKU patients were treated with BH4 monotherapy, while 3 patients were also receiving Phe-restricted diet therapy. A total of 32.4% (n = 34) of the patients were on a Phe-restricted diet. The mean age of participants was 45.3 months, and 46.7% were male. The median age at diagnosis was 18 days, and the mean Phe level at diagnosis",3_25,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"was 18 days, and the mean Phe level at diagnosis was 6.2 mg/dL. The mean of the patients’ last three plasma PA measurements was 3.06 mg/dL, and 91.4% (n = 96) were below the treatment goal of 6 mg/dL. The percentage of mothers and fathers with >8 years of education was lower (42% and 41% for mothers and fathers, respectively). A total of 50.5% of the participants indicated that their income was sufficient to cover their expenses (<xref rid=""nutrients-16-03213-t001"" ref-type=""table"">Table 1</xref>). The",3_26,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"ref-type=""table"">Table 1</xref>). The median levels of plasticizers were 20.13 ng/mL for BPA, 6.06 ng/mL for BPF, 0.23 ng/mL for DBP, 0.48 ng/mL for DEHP, and 0.52 ng/mL for MEHP (<xref rid=""nutrients-16-03213-t002"" ref-type=""table"">Table 2</xref>). This study is the first in the literature to evaluate the exposure of PKU patients to multiple environmental EDCs. Our results suggest that the exposure of patients with PKU to EDCs varies according to their treatment regimen. Patients on a free diet have a",3_27,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"treatment regimen. Patients on a free diet have a higher odds for exposure to plasticizers compared to those on a restricted diet. It can be suggested that different dietary treatment regimens can affect plasma EDC levels. The results are discussed under two sub-titles. In conclusion, we observed that PKU patients on a free diet had higher exposure to certain plasticizers. The differences in exposure routes to environmental EDCs between groups receiving dietary treatment or not highlight the importance of",3_28,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
treatment or not highlight the importance of diet. Further research is needed to prevent PKU patients from having their growth and development risks exacerbated by environmental EDCS due to their underlying pathological condition.,3_29,"Evaluation of Exposure to Bisphenol A, Bisphenol F, and Phthalates in Patients with Phenylketonuria and Its Differences According to Dietary Status",23 9 2024,,Phenylketonuria
"Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review Phenylketonuria (PKU) is an inherited metabolic disorder that requires lifelong adherence to a low-phenylalanine (Phe) diet to prevent severe neurological complications. However, maintaining dietary adherence can be challenging for patients and their families. This systematic review aimed to comprehensively evaluate the factors affecting adherence to a low-Phe diet in patients with PKU. A systematic",4_0,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"a low-Phe diet in patients with PKU. A systematic search of multiple databases was conducted, and 49 studies were included in the final analysis. The quality of evidence was assessed using the Joanna Briggs Institute levels of evidence and the Quality Assessment with Diverse Studies tool. The review identified four main categories of factors influencing dietary adherence: family-related factors (social, psychological, behavioral, and educational), patient-specific factors (psychological, behavioral,",4_1,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"factors (psychological, behavioral, educational, and demographic), environmental factors (healthcare professional support, educational and camp-based interventions, and the COVID-19 pandemic), and therapy-related factors (protein substitute formulation, clinic visits, blood tests, and telemedicine). The findings highlight the complex interplay between elements contributing to dietary adherence in PKU patients and underscore the importance of a multifaceted approach to support patients and their families.",4_2,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"approach to support patients and their families. Future research should prioritize high-quality longitudinal and experimental studies to provide stronger evidence for the PKU community. Phenylketonuria (PKU) is an inborn error of metabolism caused by a deficiency in the enzyme phenylalanine hydroxylase (PAH), which is responsible for converting the amino acid phenylalanine (Phe) into tyrosine [<xref rid=""B1-nutrients-16-03119"" ref-type=""bibr"">1</xref>]. The resulting accumulation of Phe in the blood can",4_3,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"resulting accumulation of Phe in the blood can lead to severe intellectual disability, seizures, and other neurological problems if left untreated [<xref rid=""B2-nutrients-16-03119"" ref-type=""bibr"">2</xref>]. The primary treatment for PKU is a lifelong low-Phe diet, which involves restricting the intake of high-protein foods and supplementing patients with Phe-free or low-Phe amino acid mixtures [<xref rid=""B3-nutrients-16-03119"" ref-type=""bibr"">3</xref>]. Adherence to this strict dietary regimen is",4_4,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"Adherence to this strict dietary regimen is crucial for optimal health outcomes, but it can be challenging for patients and their families [<xref rid=""B4-nutrients-16-03119"" ref-type=""bibr"">4</xref>]. Dietary adherence in PKU is a complex behavior influenced by a multitude of factors, including individual patient characteristics, family dynamics, social support, and healthcare system factors [<xref rid=""B5-nutrients-16-03119"" ref-type=""bibr"">5</xref>]. Understanding these factors is essential for",4_5,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"Understanding these factors is essential for developing targeted interventions to improve adherence and, ultimately, health outcomes for patients with PKU. Previous studies have identified several barriers to dietary adherence, such as the restrictive nature of the diet, a lack of social support, and limited access to specialized care [<xref rid=""B6-nutrients-16-03119"" ref-type=""bibr"">6</xref>,<xref rid=""B7-nutrients-16-03119"" ref-type=""bibr"">7</xref>]. However, a comprehensive understanding of the factors",4_6,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"a comprehensive understanding of the factors influencing adherence across different age groups and settings is lacking. Systematic reviews are a valuable tool for synthesizing evidence from multiple studies and identifying gaps in the literature [<xref rid=""B8-nutrients-16-03119"" ref-type=""bibr"">8</xref>]. By systematically searching, appraising, and synthesizing the available evidence, systematic reviews can provide a more reliable and comprehensive understanding of a topic than individual studies [<xref",4_7,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"of a topic than individual studies [<xref rid=""B9-nutrients-16-03119"" ref-type=""bibr"">9</xref>]. In the context of dietary adherence in PKU, a systematic review can help us to identify the most important factors influencing adherence and inform the development of evidence-based interventions to improve adherence and health outcomes.  Previous research has identified the influence of demographic and psychosocial factors on treatment adherence in children and adolescents with PKU [<xref",4_8,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"in children and adolescents with PKU [<xref rid=""B10-nutrients-16-03119"" ref-type=""bibr"">10</xref>]. While this review provided valuable insights into the factors affecting dietary adherence in pediatric population, there is a need for a comprehensive and up-to-date systematic review on the factors affecting dietary adherence in PKU across all age groups and settings to synthesize the available evidence and identify consistent patterns across studies.    Numerous factors influence dietary adherence in PKU",4_9,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"factors influence dietary adherence in PKU patients, and they can be classified as facilitators, barriers, or mixed evidence based on their impact (<xref rid=""nutrients-16-03119-f002"" ref-type=""fig"">Figure 2</xref>).  When considering patient-specific factors, younger age, higher education level, and part-time work schedules are linked to better adherence. Conversely, reliance on parental support, an external health locus of control, the belief that treatment costs complicate diet adherence, academic",4_10,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"costs complicate diet adherence, academic difficulties, older age, unfavorable work schedules, and a higher number of perceived barriers to PKU treatment are obstacles to adherence. Family-related factors play a crucial role in promoting adherence, especially for children and adolescents. Effective parental problem-solving skills, parental employment, living with both parents, higher parental education levels, good parental psychological well-being, and better parental disease-related knowledge all",4_11,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"and better parental disease-related knowledge all contribute positively to adherence. On the other hand, adherence is hindered by poor parental mental health, single parenthood, parental unemployment, having siblings with PKU, parental divorce, and having a mother born outside the country.  Therapy-related factors such as the formulation of the protein substitute (with tablets or liquid form being preferable), more frequent visits to specialists and blood Phe tests, lower clinic Phe targets, and the",4_12,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"Phe tests, lower clinic Phe targets, and the implementation of transition programs from pediatric to adult services are associated with better adherence. Classical PKU, higher perceived barriers to treatment, and lower adherence to blood testing frequency remain challenges across all age groups. Lastly, the availability of support from health professionals, educational and camp-based interventions, and the use of telemedicine in clinics are environmental factors that facilitate adherence, while a lack of",4_13,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"that facilitate adherence, while a lack of clinic staffing resources poses a challenge. Several limitations should be acknowledged. While the dietary management of PKU has evolved significantly over time, with substantial improvements in protein substitutes and increased availability of low-protein foods, we determined that the inclusion of pre-2000 studies was scientifically justified for several reasons. Pre-2000 studies predominantly explored psychosocial, family-related, and patient-specific factors",4_14,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"family-related, and patient-specific factors influencing dietary adherence. These factors, such as family dynamics, patient attitudes, and psychological and social mechanisms underlying adherence, are less likely to be affected by changes in dietary treatment modalities over time. Therefore, insights from earlier studies on these aspects remain relevant to contemporary PKU management. Including earlier studies provides a valuable historical context, allowing for the examination of trends and persistent",4_15,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"for the examination of trends and persistent challenges in PKU management over time. We noted that pre-2000 studies contained minimal data on therapy-related factors that would be outdated by current standards. To address this, we were careful to interpret pre-2000 data within their historical context, particularly when discussing therapy-related aspects.  PKU is classified as an orphan disease, meaning that it affects a relatively small number of individuals. This inherently limits the potential",4_16,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"individuals. This inherently limits the potential recruitment pool for studies, often resulting in small sample sizes. Small cohorts can lead to a lack of statistical power to detect meaningful differences or associations. A considerable number of included studies were categorized as observational or cross-sectional studies. These studies were prone to selection bias and could not control for confounding variables as effectively as randomized controlled trials. The absence of longitudinal or follow-up data",4_17,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"The absence of longitudinal or follow-up data in cross-sectional and most observational studies limits the understanding of the long-term effects and sustainability of the outcomes reported. In observational studies without control groups, the inability to control for all potential confounding variables may lead to biased estimates of effect sizes or associations. The included studies demonstrated strengths in clearly stating their research aims, describing the study context, and selecting appropriate",4_18,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"the study context, and selecting appropriate designs; there is significant room for improvement in involving stakeholders, justifying analytic approaches, and transparently discussing study limitations. While this systematic review contributed valuable insights into PKU management, there is a clear need for more high-quality research, particularly longitudinal and experimental studies, that can provide stronger evidence for the PKU community. Future research should prioritize high-quality RCTs and",4_19,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"research should prioritize high-quality RCTs and longitudinal studies that can provide more definitive evidence regarding the efficacy of interventions. In this systematic review, we have identified a nuanced landscape of influences that span social, psychological, behavioral, educational, and environmental factors influencing dietary adherence in PKU patients across their lifespans. Family-related factors, including parental education, family dynamics, and socioeconomic status, play a significant role in",4_20,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"socioeconomic status, play a significant role in dietary adherence, particularly for children and adolescents. Higher levels of parental education correlate with better dietary control, indicating the need for targeted educational programs for caregivers. Stable family structures and problem-solving abilities further enhance adherence, pointing toward the benefit of psychological and social support services for PKU families. As patients age, the challenges to adherence evolve. Patient-specific factors,",4_21,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"to adherence evolve. Patient-specific factors, such as age and the need for support, also impact adherence, with adolescents and adults facing more significant challenges. This suggests a potential gap in transitional care from pediatric to adult services, highlighting the importance of age-appropriate interventions and support mechanisms to ensure continued adherence throughout a patient’s life. Environmental factors, such as the availability of healthcare support and educational interventions, are",4_22,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"support and educational interventions, are essential in facilitating adherence for all age groups. Camp-based programs and telemedicine have demonstrated effectiveness in improving metabolic control, emphasizing the need for accessible and engaging support infrastructures. Therapeutic factors, including treatment modalities and formulations, influence adherence across all age groups. Preferences for Phe-free amino acid tablets and liquid protein substitutes suggest that patient-centered treatment choices",4_23,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"suggest that patient-centered treatment choices can improve adherence. In conclusion, adherence to a low-Phe diet in PKU is a multifaceted behavior influenced by the interplay of family-related, patient-specific, environmental, and therapy-related factors. The impacts of these factors vary across different age groups, emphasizing the need for a personalized, age-appropriate approach to PKU management. By recognizing and addressing these diverse influences, healthcare providers can develop more effective",4_24,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"healthcare providers can develop more effective strategies to improve dietary adherence and, consequently, health outcomes for PKU patients throughout their lives.",4_25,Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review,15 9 2024,,Phenylketonuria
"Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients Background: Data suggest that metabolites, other than blood phenylalanine (Phe), better and independently predict clinical outcomes in patients with phenylketonuria (PKU). Methods: To find new biomarkers, we compared the results of untargeted lipidomics and metabolomics in treated adult PKU patients to those of matched controls. Samples (lipidomics in EDTA-plasma (22 PKU and 22 controls) and metabolomics",5_0,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"(22 PKU and 22 controls) and metabolomics in serum (35 PKU and 20 controls)) were analyzed using ultra-high-performance liquid chromatography and high-resolution mass spectrometry. Data were subjected to multivariate (PCA, OPLS-DA) and univariate (Mann–Whitney U test, <italic toggle=""yes"">p</italic> < 0.05) analyses. Results: Levels of 33 (of 20,443) lipid features and 56 (of 5885) metabolite features differed statistically between PKU patients and controls. For lipidomics, findings include higher",5_1,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"controls. For lipidomics, findings include higher glycerolipids, glycerophospholipids, and sphingolipids species. Significantly lower values were found for sterols and glycerophospholipids species. Seven features had unknown identities. Total triglyceride content was higher. Higher Phe and Phe catabolites, tryptophan derivatives, pantothenic acid, and dipeptides were observed for metabolomics. Ornithine levels were lower. Twenty-six metabolite features were not annotated. Conclusions: This study provides",5_2,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"not annotated. Conclusions: This study provides insight into the metabolic phenotype of PKU patients. Additional studies are required to establish whether the observed changes result from PKU itself, diet, and/or an unknown reason. Phenylketonuria (PKU, McKusick/OMIM# 261600) is a rare autosomal recessive disorder affecting aromatic amino acid metabolism. Worldwide, PKU has an estimated incidence of 1 in 23,930 live births [<xref rid=""B1-metabolites-14-00479"" ref-type=""bibr"">1</xref>]. The disease is",5_3,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"ref-type=""bibr"">1</xref>]. The disease is characterized by mutations in the gene encoding phenylalanine hydroxylase (PAH; EC 1.14.16.1; OMIM* 612349), an enzyme responsible for converting L-phenylalanine (Phe) into L-tyrosine (Tyr). In individuals with PKU, the activity of the enzyme PAH is significantly reduced or absent, leading to hyperphenylalaninemia (HPA), which is the accumulation of Phe in blood and brain tissue. HPA is not specific for PKU because it may also be a consequence of other hereditary",5_4,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"it may also be a consequence of other hereditary causes, like defects in the pterin metabolism, resulting in a deficiency of the PAH cosubstrate tetrahydrobiopterin (BH4) and DNAJC12 [<xref rid=""B2-metabolites-14-00479"" ref-type=""bibr"">2</xref>,<xref rid=""B3-metabolites-14-00479"" ref-type=""bibr"">3</xref>]. Depending on the residual enzyme activity, patients have a widely varying Phe tolerance. If late-treated, PKU can lead to progressive and irreversible damage to the brain, resulting in intellectual",5_5,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"damage to the brain, resulting in intellectual disability [<xref rid=""B4-metabolites-14-00479"" ref-type=""bibr"">4</xref>,<xref rid=""B5-metabolites-14-00479"" ref-type=""bibr"">5</xref>,<xref rid=""B6-metabolites-14-00479"" ref-type=""bibr"">6</xref>,<xref rid=""B7-metabolites-14-00479"" ref-type=""bibr"">7</xref>,<xref rid=""B8-metabolites-14-00479"" ref-type=""bibr"">8</xref>,<xref rid=""B9-metabolites-14-00479"" ref-type=""bibr"">9</xref>,<xref rid=""B10-metabolites-14-00479"" ref-type=""bibr"">10</xref>,<xref",5_6,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"ref-type=""bibr"">10</xref>,<xref rid=""B11-metabolites-14-00479"" ref-type=""bibr"">11</xref>,<xref rid=""B12-metabolites-14-00479"" ref-type=""bibr"">12</xref>]. Systematic measurement of Phe in dried blood spots or plasma is crucial to the diagnosis and monitoring of treatment of PKU patients [<xref rid=""B13-metabolites-14-00479"" ref-type=""bibr"">13</xref>]. Management of PKU primarily consists of a natural protein-restricted diet enriched with minerals, vitamins, and other micronutrients and/or low Phe casein",5_7,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"and other micronutrients and/or low Phe casein glycomacropeptide to keep blood Phe concentrations within an acceptable range [<xref rid=""B2-metabolites-14-00479"" ref-type=""bibr"">2</xref>,<xref rid=""B13-metabolites-14-00479"" ref-type=""bibr"">13</xref>,<xref rid=""B14-metabolites-14-00479"" ref-type=""bibr"">14</xref>,<xref rid=""B15-metabolites-14-00479"" ref-type=""bibr"">15</xref>]. Supplementation is essential for meeting nutritional needs, supporting normal growth, and preventing developmental deficiencies",5_8,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"growth, and preventing developmental deficiencies [<xref rid=""B2-metabolites-14-00479"" ref-type=""bibr"">2</xref>,<xref rid=""B13-metabolites-14-00479"" ref-type=""bibr"">13</xref>,<xref rid=""B14-metabolites-14-00479"" ref-type=""bibr"">14</xref>,<xref rid=""B15-metabolites-14-00479"" ref-type=""bibr"">15</xref>]. A subset of patients may benefit from sapropterin dihydrochloride, an orally active synthetic form of tetrahydrobiopterin that enhances the residual activity of PAH. All patients may benefit from pegvaliase,",5_9,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"of PAH. All patients may benefit from pegvaliase, which converts Phe into harmless compounds that can be excreted from the body. Both drugs lower Phe concentrations and enable patients to relax their protein restriction. However, pegvaliase is only reimbursed in a minority of countries around the world [<xref rid=""B16-metabolites-14-00479"" ref-type=""bibr"">16</xref>,<xref rid=""B17-metabolites-14-00479"" ref-type=""bibr"">17</xref>,<xref rid=""B18-metabolites-14-00479"" ref-type=""bibr"">18</xref>]. Except perhaps",5_10,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"ref-type=""bibr"">18</xref>]. Except perhaps for treatment with large neutral amino acids (LNAAs), intensive Phe monitoring is crucial but is not able to predict the clinical outcome fully [<xref rid=""B19-metabolites-14-00479"" ref-type=""bibr"">19</xref>]. For this reason, there is a need to expand the biomarker signature beyond blood Phe to better reflect neurocognitive and psychosocial function. Over the years, high-resolution mass spectrometry (HRMS) has become a powerful tool for discovering novel disease",5_11,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"a powerful tool for discovering novel disease biomarkers for diagnosis and monitoring various inborn errors of metabolism, including PKU [<xref rid=""B20-metabolites-14-00479"" ref-type=""bibr"">20</xref>,<xref rid=""B21-metabolites-14-00479"" ref-type=""bibr"">21</xref>]. This technique features high resolution and, thus, high mass accuracy, enabling comprehensive profiling of known and unknown metabolites in complex biological matrices. In the last decade, the impact of PAH deficiency on the metabolome has",5_12,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"impact of PAH deficiency on the metabolome has become evident [<xref rid=""B21-metabolites-14-00479"" ref-type=""bibr"">21</xref>,<xref rid=""B22-metabolites-14-00479"" ref-type=""bibr"">22</xref>]. The levels of Tyr and downstream metabolites are lower, while the alternative Phe degradation pathway results in higher levels of phenylpyruvate and other (neuro)toxic metabolic products. In contrast, the non-polar part of the metabolome remains rather unexplored. Guerra et al. [<xref rid=""B23-metabolites-14-00479""",5_13,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"et al. [<xref rid=""B23-metabolites-14-00479"" ref-type=""bibr"">23</xref>] emphasized the need to study the lipidome in this group of patients. Therefore, we compared the plasma lipid and serum metabolite signature of adult PKU patients with non-PKU controls. Chemicals. The following chemicals were used for lipidomics analyses: methyl tert-butyl ether UPLC-grade (MTBE; Biosolve BV, Valkenswaard, The Netherlands), methanol absolute UPLC-grade (MeOH; Biosolve BV, Valkenswaard, The Netherlands), Milli-Q (MQ;",5_14,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"BV, Valkenswaard, The Netherlands), Milli-Q (MQ; Millipore, MA, USA), chloroform (CHCl<sub>3</sub>; Merck KGaA, Darmstadt, Germany), acetonitrile (ACN; Biosolve BV, Valkenswaard, The Netherlands), 2-propanol (IPA; Biosolve BV, Valkenswaard, The Netherlands), and ammonium formate UPLC-grade (AmF; Sigma-Aldrich, Zwijndrecht, The Netherlands). The following non-physiologic or stable isotope-labeled lipid standards were purchased from Avanti Polar Lipids, Inc (Alabaster, AL, USA): LPC(17:1/0:0), PC(17:0/17:0),",5_15,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"AL, USA): LPC(17:1/0:0), PC(17:0/17:0), LPE(17:1/0:0), PE(17:0/17:0), LPG(17:0/0:0), PG(17:0/17:0), LPS(17:0/0:0), PS(17:0/17:0), CL(14:0.14:0)(14:0/14:0), CL(16:0/16:0)/(16:0/16:0), DG(16:0/16:0/0:0), and TG(17:0/17:1/17:0)d5. All lipids were dissolved in CHCl<sub>3</sub>/MeOH/MQ (60:30:4.5, <italic toggle=""yes"">v</italic>/<italic toggle=""yes"">v</italic>/<italic toggle=""yes"">v</italic>) or chloroform to a final concentration of 20 µM and stored at −20 °C (compound details are provided in <xref",5_16,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"at −20 °C (compound details are provided in <xref rid=""app1-metabolites-14-00479"" ref-type=""app"">Table S1</xref>). Chemicals used for metabolomics analyses are described elsewhere [<xref rid=""B21-metabolites-14-00479"" ref-type=""bibr"">21</xref>]. PKU samples. The PKU-COBESO study, a multicenter research project conducted in The Netherlands, focused on exploring the cognitive, behavioral, and social outcomes in relation to metabolic control in early-diagnosed and treated PKU patients [<xref",5_17,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"early-diagnosed and treated PKU patients [<xref rid=""B24-metabolites-14-00479"" ref-type=""bibr"">24</xref>,<xref rid=""B25-metabolites-14-00479"" ref-type=""bibr"">25</xref>,<xref rid=""B26-metabolites-14-00479"" ref-type=""bibr"">26</xref>,<xref rid=""B27-metabolites-14-00479"" ref-type=""bibr"">27</xref>]. The study included children and adults (age [7–42 years]). Participants were included between 2012 and 2015. Venous blood samples were taken after an overnight fast on the day of testing before the",5_18,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"overnight fast on the day of testing before the neuropsychological assessment. The EDTA- and serum samples were stored for up to 11 years at −80 °C without thawing before analysis. In the current study, individuals under the age of 18 were excluded from participation. Control samples. No blood samples were taken from the control subjects in the COBESO study. For this reason, blood samples of the control group for the current study were sourced from pre-transplant kidney donors through the TransplantLines",5_19,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"kidney donors through the TransplantLines Biobank [<xref rid=""B28-metabolites-14-00479"" ref-type=""bibr"">28</xref>]. Transplantlines is a longitudinal cohort study investigating the outcomes after transplantation in patients in the UMCG. We consider this control group to be a good representative of the general population, with the sole selection criteria as kidney donors that they have two kidneys and a normal kidney function. We opted to use control samples from this cohort study rather than obtaining new",5_20,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"from this cohort study rather than obtaining new samples from healthy individuals to partially account for any potential impacts of extended frozen storage. The EDTA- and serum samples from the TransplantLines Biobank, which were gathered between 2016 and 2020, have been preserved at −80 °C before their analysis. For the statistical analysis, samples were matched by age and gender. In lipidomics, 22 PKU samples (median age: 33, age range: 21–43, gender ratio: 14M/8F) were compared with 22 control samples",5_21,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"14M/8F) were compared with 22 control samples (median age: 34.5, age range: 24-43, gender ratio: 14M/8F). In metabolomics, 20 PKU serum samples (median age: 33, age range: 21–43, gender ratio: 12M/8F) were compared with 20 control samples (median age: 34.5, age range: 24–43, gender ratio: 12M/8F). In total, 15 metabolomics samples could not be matched with a suitable control; these were measured but were not included in the statistical analysis.  Early-diagnosed and treated patients suffering from PKU can",5_22,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"and treated patients suffering from PKU can exhibit cognitive and/or behavioral abnormalities despite intensive treatment monitoring of Phe levels. Although blood Phe concentrations correlate with neurocognitive and behavioral outcomes, blood Phe only partly explains these outcomes [<xref rid=""B49-metabolites-14-00479"" ref-type=""bibr"">49</xref>]. This reinforces the hypothesis that other metabolites beyond Phe are involved in the pathogenesis of PKU. Identification of novel metabolites that better explain",5_23,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"of novel metabolites that better explain the pathophysiology underlying PKU disease could provide markers that are of diagnostic, prognostic, and/or therapeutic value. In this study, we conducted untargeted lipidomic and metabolomic analysis using high-resolution mass spectrometry platforms in a population of treated PKU patients and non-PKU controls. The PKU patients were part of the COBESO study, whose neurocognitive functioning was assessed. In this work, we were able to show that the plasma lipid and",5_24,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"we were able to show that the plasma lipid and serum metabolite signature of PKU patients is different from healthy controls. In the analysis of the metabolomics data, Phe, Phe catabolites (phenylpyruvate, phenyllactate, phenylacetate, hydroxyphenylacetic acid), Phe-conjugates (Phe-Hex, Lac-Phe, Phenylacetylglutamine) and Phe-containing dipeptides (Glu-Phe, Leu-Phe, Gly-Phe) were significantly elevated in the PKU population. The results are consistent with our previously conducted targeted analysis of this",5_25,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"previously conducted targeted analysis of this metabolomics dataset using a different bioinformatics workflow, which searched specifically for 11 previously described PKU biomarkers, including Phe, N-lactoyl-Phe, Glu-Phe, Phe-Hexose, Glu-Glu-Phe, Phe-Phe, Phe-Leu, N-acetyl-Phe, phenyllactate, phenylacetate, and phenylpyruvate [<xref rid=""B49-metabolites-14-00479"" ref-type=""bibr"">49</xref>]. Phenylacetylglutamine and Gly-Phe were not included previously, and also have not been described as altered in plasma",5_26,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"also have not been described as altered in plasma before. However, a higher level of phenylacetylglutamine has been reported as a urinary marker for non-treated PKU patients [<xref rid=""B50-metabolites-14-00479"" ref-type=""bibr"">50</xref>,<xref rid=""B51-metabolites-14-00479"" ref-type=""bibr"">51</xref>,<xref rid=""B52-metabolites-14-00479"" ref-type=""bibr"">52</xref>]. Most Phe and Phe derivatives show a significant strong positive correlation with concurrent Phe levels. These components may seem less",5_27,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"Phe levels. These components may seem less interesting as new biomarkers because the increases in the Phe-containing metabolites are inherent to elevated Phe levels in the blood and probably the intake of balanced amino acid supplements. However, Wegberg et al. [<xref rid=""B49-metabolites-14-00479"" ref-type=""bibr"">49</xref>] demonstrated that N-lactoyl-Phe outperformed Phe as a predictor of working memory and mental health outcomes. These findings suggest that N-lactoyl-Phe may be a better biomarker to",5_28,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"that N-lactoyl-Phe may be a better biomarker to reflect neurocognitive outcomes than Phe. Additionally, phenylacetylglutamine is produced from phenylacetic acid and Phe, which may competitively inhibit L-amino acid decarboxylase, thereby decreasing neurotransmitter levels [<xref rid=""B53-metabolites-14-00479"" ref-type=""bibr"">53</xref>]. Regarding Phe-containing dipeptides, limited information exists about their general physiological significance or their clinical and pathophysiological relevance for PKU.",5_29,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"and pathophysiological relevance for PKU. The level of pantothenic acid, also referred to as vitamin B5, was reported to be higher in the PKU population. This micronutrient is a precursor of coenzyme-A (CoA) and the acyl carrier protein. It is involved in cellular energy production and the synthesis of carbohydrates, proteins, and fats. Further, it is involved in the biosynthesis of essential lipids, steroids, hormones, neurotransmitters, and porphyrin, and the formation of red blood cells, sex, and",5_30,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"and the formation of red blood cells, sex, and stress-related hormones. Stroup et al. [<xref rid=""B54-metabolites-14-00479"" ref-type=""bibr"">54</xref>] reported that without supplementation, PKU patients are at risk of inadequate intake of pantothenic acid. Recently, Bokayeva et al. [<xref rid=""B55-metabolites-14-00479"" ref-type=""bibr"">55</xref>] pointed out the lack of publications describing vitamin status, including vitamin B5, in PKU patients and the effect on clinical outcomes. We speculate that the",5_31,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"on clinical outcomes. We speculate that the higher level of vitamin B5 in our study is most likely a result of its presence in supplements. Interestingly, multiple Trp derivatives were found to be significantly higher in the serum of PKU patients, including indole-3-lactic acid (I3LA), indole-3-carboxaldehyde (I3A), and N1-methyl-2-pyridone-5-carboxamide (2PY). Moreover, N1-methyl-4-pyridone-3-carboxamide (4PY) and indole-3-propionic acid (IPA) levels were higher in PKU patients and almost reached",5_32,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"were higher in PKU patients and almost reached statistical significance (adjusted <italic toggle=""yes"">p</italic>-value = 0.05). Trp is an essential amino acid, meaning that it is obtained from the diet or protein catabolism but not synthesized endogenously. Trp itself is a precursor for various biologically active metabolites, including the neurotransmitter serotonin. The gut mucosa’s enterochromaffin cells (ECs) are primarily responsible for the body’s serotonin synthesis. Serotonin is released by",5_33,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"serotonin synthesis. Serotonin is released by activated endothelial cells (ECs) into the interstitium of the lamina propria, where it binds intrinsic sensory neurons’ nerve endings [<xref rid=""B53-metabolites-14-00479"" ref-type=""bibr"">53</xref>]. Being part of the microbiota–gut–brain axis, Trp and its metabolites could be of interest for clinical outcomes in PKU. Trp is metabolized along four pathways, including serotonin (serotonin and melatonin), tryptamine (tryptamine), indole (indolepyruvic acid), and",5_34,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"(tryptamine), indole (indolepyruvic acid), and kynurenine (niacin) pathways. The majority (~90%) of Trp is metabolized through the kynurenine pathway. The metabolites that were found to be elevated in our PKU patients are downstream catabolites of the kynurenine (2PY, 4PY) and indole (I3LA, I3A, IPA) pathways (see also <xref rid=""metabolites-14-00479-f006"" ref-type=""fig"">Figure 6</xref>). Higher levels of 2PY and 4PY have been described before in urine samples of early-treated PKU patients [<xref",5_35,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"samples of early-treated PKU patients [<xref rid=""B56-metabolites-14-00479"" ref-type=""bibr"">56</xref>]. The reason for this relation and the clinical relevance is uncertain. Both compounds are considered to be uremic toxins based on the fact that their concentrations increase with decreased kidney function and based on their ability to inhibit poly(ADP-ribose) polymerase-1 (PARP1). This enzyme is involved in cellular response to DNA damage [<xref rid=""B57-metabolites-14-00479""",5_36,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"DNA damage [<xref rid=""B57-metabolites-14-00479"" ref-type=""bibr"">57</xref>,<xref rid=""B58-metabolites-14-00479"" ref-type=""bibr"">58</xref>,<xref rid=""B59-metabolites-14-00479"" ref-type=""bibr"">59</xref>,<xref rid=""B60-metabolites-14-00479"" ref-type=""bibr"">60</xref>]. Both compounds are, however, end products of Trp catabolism (kynurenine pathway) via the degradation of nicotinamide-adenine dinucleotide (NAD). In theory, higher levels might merely reflect an increased Trp and/or niacin status or a rerouting",5_37,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"increased Trp and/or niacin status or a rerouting of Trp metabolism in the kynurenine pathway. The niacin status of PKU patients is not well described. The implications of this finding need further research. Several studies suggest changes in the gut bacterial microbes of PKU patients who have undergone treatment compared to individuals without PKU. In more detail, PKU patients exhibited a higher number of Trp-consuming bacteria in the colon [<xref rid=""B61-metabolites-14-00479""",5_38,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"the colon [<xref rid=""B61-metabolites-14-00479"" ref-type=""bibr"">61</xref>,<xref rid=""B62-metabolites-14-00479"" ref-type=""bibr"">62</xref>]. Alterations in bacteria consuming Trp might affect serotonin synthesis in the brain since it modulates the Trp availability in the circulation. Only I3A has been detected before in the urine of patients with untreated PKU. While more research is needed, these findings support those described by Parolisi et al. [<xref rid=""B63-metabolites-14-00479""",5_39,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"et al. [<xref rid=""B63-metabolites-14-00479"" ref-type=""bibr"">63</xref>,<xref rid=""B64-metabolites-14-00479"" ref-type=""bibr"">64</xref>], highlighting the relevance of exploring the potential effects of Trp availability through gut microbiota on cognitive and behavioral functions in PKU. We observed that PKU patients exhibit a different lipid signature compared to healthy individuals. Differences were predominantly observed between lipids belonging to the glycerophospholipid and glycerolipid classes. This",5_40,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"and glycerolipid classes. This observation confirms that closer evaluation of the lipidome in PKU patients might be interesting, as previously emphasized by Guerra et al. [<xref rid=""B65-metabolites-14-00479"" ref-type=""bibr"">65</xref>,<xref rid=""B66-metabolites-14-00479"" ref-type=""bibr"">66</xref>,<xref rid=""B67-metabolites-14-00479"" ref-type=""bibr"">67</xref>,<xref rid=""B68-metabolites-14-00479"" ref-type=""bibr"">68</xref>]. We identified a significant increase in various glycerophospholipids, including",5_41,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"in various glycerophospholipids, including (L)PE, (L)PC, and PI. Most species incorporated at least one fatty acid with an unsaturated aliphatic chain, as indicated by the total number of carbons and double bonds. None of the features were correlated with concurrent Phe, which makes them potential biomarkers of interest for PKU, reflecting either pathophysiological processes or consequences of the dietary treatment. Although we were unable to elucidate the full molecular structure of the fatty acyl",5_42,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"the full molecular structure of the fatty acyl chain(s), previous studies and data provided herein provide a level of insight. To date, alterations in plasma-free FA status, particularly in n-3 FA were observed in PKU patients treated with a Phe-restricted diet [<xref rid=""B69-metabolites-14-00479"" ref-type=""bibr"">69</xref>,<xref rid=""B70-metabolites-14-00479"" ref-type=""bibr"">70</xref>,<xref rid=""B71-metabolites-14-00479"" ref-type=""bibr"">71</xref>,<xref rid=""B72-metabolites-14-00479""",5_43,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"rid=""B72-metabolites-14-00479"" ref-type=""bibr"">72</xref>,<xref rid=""B73-metabolites-14-00479"" ref-type=""bibr"">73</xref>]. The n-3 long-chain PUFA species DHA (22:6 n-3) and eicosapentaenoic acid (EPA, 20:5n-3) were consistently demonstrated to be reduced [<xref rid=""B70-metabolites-14-00479"" ref-type=""bibr"">70</xref>,<xref rid=""B72-metabolites-14-00479"" ref-type=""bibr"">72</xref>,<xref rid=""B74-metabolites-14-00479"" ref-type=""bibr"">74</xref>,<xref rid=""B75-metabolites-14-00479"" ref-type=""bibr"">75</xref>].",5_44,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"ref-type=""bibr"">75</xref>]. These findings were attributed to dietary restrictions. PKU patients are advised to consume no or only a limited amount of animal products because of the high protein content in these products. As a result, foods rich in saturated fatty acids and long-chain PUFAs are excluded from their diet [<xref rid=""B74-metabolites-14-00479"" ref-type=""bibr"">74</xref>,<xref rid=""B76-metabolites-14-00479"" ref-type=""bibr"">76</xref>]. Some protein substitutes are enriched with DHA, but not all",5_45,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"substitutes are enriched with DHA, but not all of them. Long-chain PUFAs, particularly arachidonic acid (AA, 20:4n-6) and DHA, are crucial for normal neurological development [<xref rid=""B77-metabolites-14-00479"" ref-type=""bibr"">77</xref>,<xref rid=""B78-metabolites-14-00479"" ref-type=""bibr"">78</xref>,<xref rid=""B79-metabolites-14-00479"" ref-type=""bibr"">79</xref>,<xref rid=""B80-metabolites-14-00479"" ref-type=""bibr"">80</xref>]. Based on these findings, it is recommended to supplement EPA and DHA if these are",5_46,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"to supplement EPA and DHA if these are not already added to the protein substitute [<xref rid=""B17-metabolites-14-00479"" ref-type=""bibr"">17</xref>]. Unfortunately, dietary data were not available for this cohort. Studies show that suppletion increases the free and PL plasma levels of these FAs in PKU [<xref rid=""B81-metabolites-14-00479"" ref-type=""bibr"">81</xref>,<xref rid=""B82-metabolites-14-00479"" ref-type=""bibr"">82</xref>,<xref rid=""B83-metabolites-14-00479"" ref-type=""bibr"">83</xref>,<xref",5_47,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"ref-type=""bibr"">83</xref>,<xref rid=""B84-metabolites-14-00479"" ref-type=""bibr"">84</xref>,<xref rid=""B85-metabolites-14-00479"" ref-type=""bibr"">85</xref>]. Although there is a debate whether the difference is clinically relevant it is known to improve fine motor skills and short-term visual response in children with PKU [<xref rid=""B69-metabolites-14-00479"" ref-type=""bibr"">69</xref>,<xref rid=""B70-metabolites-14-00479"" ref-type=""bibr"">70</xref>,<xref rid=""B74-metabolites-14-00479""",5_48,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"rid=""B74-metabolites-14-00479"" ref-type=""bibr"">74</xref>,<xref rid=""B81-metabolites-14-00479"" ref-type=""bibr"">81</xref>,<xref rid=""B82-metabolites-14-00479"" ref-type=""bibr"">82</xref>,<xref rid=""B83-metabolites-14-00479"" ref-type=""bibr"">83</xref>,<xref rid=""B84-metabolites-14-00479"" ref-type=""bibr"">84</xref>,<xref rid=""B85-metabolites-14-00479"" ref-type=""bibr"">85</xref>,<xref rid=""B86-metabolites-14-00479"" ref-type=""bibr"">86</xref>,<xref rid=""B87-metabolites-14-00479"" ref-type=""bibr"">87</xref>].",5_49,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"ref-type=""bibr"">87</xref>]. Furthermore, the FA composition of PL-enriched plasma extracts has been reported in several studies. For instance, Drzymała-Czyż et al. [<xref rid=""B88-metabolites-14-00479"" ref-type=""bibr"">88</xref>] reported a reduction in FA: 20:3n-9, 18:2n-6 (LA, linoleic acid), and 22:6n-3 (DHA). In 2021, Guerra et al. [<xref rid=""B89-metabolites-14-00479"" ref-type=""bibr"">89</xref>] investigated the plasma PL and sphingolipid profile in children treated for PKU. In short, they found a",5_50,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"children treated for PKU. In short, they found a significant increase in FA 18:1n-9 (oleic acid), 14:0 (myristic acid), 18:0 (stearic acid), EPA, and DHA, while no significant changes in statistical difference were observed for FA 16:0, LA, and AA. Consistent with these findings, our detailed analysis of PL species confirmed a significant increase in PC species (32:0, 32:1, 34:1, 36:5, 38:7, 40:6, and 42:6) and PI species (36:4 and 38:3). Altogether, changes in FA status due to the PKU diet may explain the",5_51,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"in FA status due to the PKU diet may explain the observed alterations in the PL profile of PKU patients. Additional measurements to fully elucidate the structure of the FA chains are essential to give further meaning to these findings. The total triglyceride (TTG) concentration was significantly elevated in PKU patients. This only captures a fraction of the total lipid content and provides limited detailed information about the level of individual species. To the best of our knowledge, this is the first",5_52,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"To the best of our knowledge, this is the first study that described detailed information about TG alterations. In addition, we observed a significant increase in various TG (45:5, 50:1, 50:2, 56:7, and 58:7) containing saturated and unsaturated fatty acyl chains. To date, some perturbations in lipoprotein components of PKU individuals have been described in plasma and serum. However, the results are contradictory. To demonstrate, four studies report a reduction in TC, LDL-C, and/or HDL-C [<xref",5_53,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"a reduction in TC, LDL-C, and/or HDL-C [<xref rid=""B90-metabolites-14-00479"" ref-type=""bibr"">90</xref>,<xref rid=""B91-metabolites-14-00479"" ref-type=""bibr"">91</xref>,<xref rid=""B92-metabolites-14-00479"" ref-type=""bibr"">92</xref>,<xref rid=""B93-metabolites-14-00479"" ref-type=""bibr"">93</xref>]. However, Azabdaftari et al. [<xref rid=""B94-metabolites-14-00479"" ref-type=""bibr"">94</xref>] reported an increase in TC content in serum. Similarly, VLDL-C has been found to be higher [<xref",5_54,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"VLDL-C has been found to be higher [<xref rid=""B90-metabolites-14-00479"" ref-type=""bibr"">90</xref>,<xref rid=""B95-metabolites-14-00479"" ref-type=""bibr"">95</xref>] but also reduced [<xref rid=""B92-metabolites-14-00479"" ref-type=""bibr"">92</xref>,<xref rid=""B94-metabolites-14-00479"" ref-type=""bibr"">94</xref>]. Studies in both plasma and serum show that total TG levels increase in children and older PKU patients [<xref rid=""B90-metabolites-14-00479"" ref-type=""bibr"">90</xref>,<xref",5_55,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"ref-type=""bibr"">90</xref>,<xref rid=""B92-metabolites-14-00479"" ref-type=""bibr"">92</xref>,<xref rid=""B95-metabolites-14-00479"" ref-type=""bibr"">95</xref>,<xref rid=""B96-metabolites-14-00479"" ref-type=""bibr"">96</xref>,<xref rid=""B97-metabolites-14-00479"" ref-type=""bibr"">97</xref>]. This phenomenon was associated with increased carbohydrate intake. The implications of higher TTG levels for clinical outcomes are not fully understood. However, it is known to correlate with the accumulation of visceral fat,",5_56,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"correlate with the accumulation of visceral fat, which, in turn, is linked to a higher risk of developing type 2 diabetes and cardiovascular diseases [<xref rid=""B98-metabolites-14-00479"" ref-type=""bibr"">98</xref>,<xref rid=""B99-metabolites-14-00479"" ref-type=""bibr"">99</xref>]. This might also be relevant for PKU patients, as there are reports of obesity, dyslipidemia, hypertension, and oxidative stress in PKU patients [<xref rid=""B91-metabolites-14-00479"" ref-type=""bibr"">91</xref>,<xref",5_57,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"ref-type=""bibr"">91</xref>,<xref rid=""B100-metabolites-14-00479"" ref-type=""bibr"">100</xref>,<xref rid=""B101-metabolites-14-00479"" ref-type=""bibr"">101</xref>,<xref rid=""B102-metabolites-14-00479"" ref-type=""bibr"">102</xref>,<xref rid=""B103-metabolites-14-00479"" ref-type=""bibr"">103</xref>]. Furthermore, in the present study, we found an increase in CerPE 38:2. CerPEs are produced in small amounts and located in the plasma membrane. To date, their function remains largely unknown [<xref",5_58,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"their function remains largely unknown [<xref rid=""B104-metabolites-14-00479"" ref-type=""bibr"">104</xref>]. However, higher levels of CerPE 38:2 have been suggested to increase the risk of type 2 diabetes [<xref rid=""B105-metabolites-14-00479"" ref-type=""bibr"">105</xref>]. Additionally, we report lower levels of LPC 17:0, which is also known to be inversely correlated with type 2 diabetes [<xref rid=""B106-metabolites-14-00479"" ref-type=""bibr"">106</xref>,<xref rid=""B107-metabolites-14-00479""",5_59,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"rid=""B107-metabolites-14-00479"" ref-type=""bibr"">107</xref>]. Higher TTG and CerPE 38:2 abundance and lower levels of LPC 17:0 might suggest that this cohort of PKU patients is at increased risk of CVD and type 2 diabetes. However, the question remains whether this risk is comparable to that of non-PKU individuals. Unfortunately, no anthropometric data were available for our study cohort. The link between CVD or diabetes and the plasma lipid composition may be of interest to future research. Strengths of",5_60,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"be of interest to future research. Strengths of this study include a comprehensive metabolomic and lipidomic analysis of plasma/serum obtained in a well-defined population of PKU patients. Patients who participated in the COBESO study are well described with respect to their neuropsychological outcomes [<xref rid=""B24-metabolites-14-00479"" ref-type=""bibr"">24</xref>,<xref rid=""B25-metabolites-14-00479"" ref-type=""bibr"">25</xref>,<xref rid=""B26-metabolites-14-00479"" ref-type=""bibr"">26</xref>,<xref",5_61,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"ref-type=""bibr"">26</xref>,<xref rid=""B27-metabolites-14-00479"" ref-type=""bibr"">27</xref>]. We are, therefore, able to correlate the biomarkers to clinically relevant outcomes. We chose to comprehensively describe the analytical methods and important biomarkers for PKU in this study, whereas we aim to describe the relation with neuropsychological outcomes in a separate paper, allowing both topics to receive the attention and depth they deserve. Another advantage of our combined untargeted-omics approach is",5_62,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"of our combined untargeted-omics approach is that we found several new PKU biomarkers; in particular, the lipidome is rather unexplored. Further studies are necessary to explore the relevance of our findings. A limitation of our study is that the control and patient samples were obtained from different studies, potentially introducing variability. We would like to emphasize that this study is exploratory and acknowledge that variables such as long-term sample storage may have affected the metabolome or",5_63,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"storage may have affected the metabolome or lipid signature. It is well known that long-term storage significantly impacts the metabolome and the lipidome [<xref rid=""B108-metabolites-14-00479"" ref-type=""bibr"">108</xref>,<xref rid=""B109-metabolites-14-00479"" ref-type=""bibr"">109</xref>], including amino acids such as Phe [<xref rid=""B110-metabolites-14-00479"" ref-type=""bibr"">110</xref>,<xref rid=""B111-metabolites-14-00479"" ref-type=""bibr"">111</xref>], although the impact of storage of EDTA-plasma on the",5_64,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"the impact of storage of EDTA-plasma on the metabolome seems limited when samples are stored up to 7 years at −80 degrees Celcius [<xref rid=""B112-metabolites-14-00479"" ref-type=""bibr"">112</xref>]. Unfortunately, no long-term data on the stability of the PKU biomarkers found in our study are available in our laboratories. The impact of the difference in storage time between PKU patients and the non-PKU controls on the biomarkers is, therefore, uncertain. On the other hand, some of the biomarkers have been",5_65,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"the other hand, some of the biomarkers have been found by other groups as well, demonstrating the validity of these biomarkers. Another important aspect is that our results were obtained in a relatively small population. In combination with the other potential confounding variables, we realize that any conclusions based on this work are to be considered preliminary and should be further explored. In the future, we intend to conduct correlation analyses between the biomarkers identified in this study and",5_66,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"the biomarkers identified in this study and the previously obtained neurocognitive outcomes from the COBESO study. If these analyses reveal any interesting results, we will proceed to confirm the identity of the detected metabolomics and lipidomics features of interest. We intend to confirm the identity, preferably using standards, in addition to performing a DDA (data-dependent acquisition) experiment, allowing us to generate clean spectra and making feature annotation more reliable. Naturally, this study",5_67,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"annotation more reliable. Naturally, this study must be repeated with more recent data to verify the findings, preferably in a larger prospective study applying a quantitative analytical method, avoiding long-term storage effects. Additionally, future studies should incorporate anthropometrical and, most importantly, nutritional metrics to contextualize the metabolomic and lipidomic findings to diet. To summarize, in this study, we have shown that the lipidomic and metabolic profiles of treated adult PKU",5_68,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"and metabolic profiles of treated adult PKU patients differ from non-PKU individuals. Regarding lipidomics, total TG content was higher and alterations were found for lipid features belonging to the classes of glycerolipids, glycerophospholipids, and sphingolipids. Metabolomic results confirmed alterations in the lipidome. Furthermore, metabolomic results demonstrated that patients had higher levels of Phe and Phe catabolites, including N-lactoyl-Phe, Trp derivatives, pantothenic acid, and various",5_69,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"Trp derivatives, pantothenic acid, and various dipeptides. Future studies should focus on the identification of unknown features and correlate significantly different lipid and metabolite features with outcome parameters. Altogether, this research provides insight into the metabolomic and lipid status of treated adult PKU patients. However, the clinical and/or therapeutic relevance and validity of the biomarkers need to be determined.",5_70,Impact of Phenylketonuria on the Serum Metabolome and Plasma Lipidome: A Study in Early-Treated Patients,30 8 2024,,Phenylketonuria
"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup> Phenylketonuria (PKU) is an inborn error of amino acid metabolism that is typically identified by newborn screening. With lifelong treatment consisting of dietary management, frequent laboratory monitoring, and regular metabolic clinic visits, patients with PKU can maintain good health and metabolic control. Here, we describe the case of an 8-year-old patient with PKU",6_0,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"the case of an 8-year-old patient with PKU who has been followed by a metabolic clinic since birth. Despite responsiveness to sapropterin, this patient has had periods of poor metabolic control throughout her life due to her family's economic hardships, including limited access to transportation, housing, food, and health insurance. This case illustrates how social determinants of health may negatively affect rare disease management and potential strategies for addressing barriers to care. <list",6_1,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"strategies for addressing barriers to care. <list list-type=""simple"" id=""l0005""><list-item id=""li0005""><label>•</label><p id=""p0005"">Adverse impacts of economic hardships on metabolic control in a child with PKU.</p></list-item><list-item id=""li0010""><label>•</label><p id=""p0010"">Effects of access to transportation, housing, health insurance, and food on outcomes.</p></list-item><list-item id=""li0015""><label>•</label><p id=""p0015"">Need for clinician awareness and strategies to address SDOH barriers to",6_2,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"and strategies to address SDOH barriers to treatment.</p></list-item></list> Phenylketonuria (PKU) is an inborn error of amino acid metabolism caused by a deficiency in the enzyme phenylalanine hydroxylase (PAH; EC 1.14.16.1), which is responsible for the tetrahydrobiopterin (BH4)-dependent conversion of phenylalanine (PHE) to tyrosine (TYR). In PKU, pathogenic variants in the <italic toggle=""yes"">PAH</italic> gene (OMIM <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""261600""",6_3,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"http://www.w3.org/1999/xlink href=""261600"" id=""ir0005"">261600</ext-link>) are inherited in an autosomal recessive manner and lead to PAH deficiency, resulting in elevated blood PHE and decreased blood TYR (<xref rid=""f0005"" ref-type=""fig"">Fig. 1</xref>). Significantly delayed or absent treatment of PKU causes severe and permanent cognitive impairment [<xref rid=""bb0005"" ref-type=""bibr"">1</xref>,<xref rid=""bb0010"" ref-type=""bibr"">2</xref>].<fig id=""f0005""><label>Fig. 1</label><caption><p>Phenylalanine",6_4,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"1</label><caption><p>Phenylalanine metabolic pathway.</p><p>Normal phenylalanine (PHE) metabolism involves the conversion of PHE to tyrosine (TYR) through the BH4-dependent enzyme PAH in the liver. TYR acts as a precursor for neurotransmitters, melanin, and endogenous protein synthesis. In PKU, deficiency of the PAH enzyme leads to elevated PHE and decreased TYR. High blood PHE levels are toxic to the brain, and low blood TYR levels impair the synthesis of TYR-related end products [<xref rid=""bb0015""",6_5,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"of TYR-related end products [<xref rid=""bb0015"" ref-type=""bibr"">[3]</xref>, <xref rid=""bb0020"" ref-type=""bibr"">[4]</xref>, <xref rid=""bb0025"" ref-type=""bibr"">[5]</xref>].</p><p>BH2, dihydrobiopterin; BH4, tetrahydrobiopterin; PAH, phenylalanine hydroxylase.</p></caption><alt-text id=""al0005"">Fig. 1</alt-text><graphic http://www.w3.org/1999/xlink href=""gr1"" id=""lk0005""></graphic></fig> Early identification of PKU has been possible in the United States since the advent of newborn screening (NBS) in the 1960s",6_6,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"advent of newborn screening (NBS) in the 1960s [<xref rid=""bb0010"" ref-type=""bibr"">2</xref>]. Most affected individuals are identified and started on treatment within the first week of life. Management of PKU is challenging for patients and families since it involves a low-PHE diet, achieved by restricting natural protein through careful weighing, measuring, and tracking of food intake; the intake of medical formula to provide PHE-free protein and other essential nutrients; regular monitoring of PHE levels",6_7,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"nutrients; regular monitoring of PHE levels accompanied by detailed diet records (once or more per month); and regular follow-up with metabolic specialists and dietitians [<xref rid=""bb0030"" ref-type=""bibr"">6</xref>,<xref rid=""bb0035"" ref-type=""bibr"">7</xref>]. Metabolic stability of PKU is reflected by blood PHE and TYR levels within therapeutic ranges that help promote normal growth and cognitive development [<xref rid=""bb0010"" ref-type=""bibr"">2</xref>]. Treatment advances have enhanced the management",6_8,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"Treatment advances have enhanced the management and quality of life of individuals with PKU. First, a variety of medical formulas with increased palatability and portability aid in lifelong medical formula consumption. Next, low-protein modified foods have been developed to increase variety and provide a sense of normalcy within a protein-restricted diet [<xref rid=""bb0010"" ref-type=""bibr"">2</xref>,<xref rid=""bb0035"" ref-type=""bibr"">7</xref>]. Finally, sapropterin and pegvaliase are pharmaceutical options",6_9,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"and pegvaliase are pharmaceutical options that can significantly aid in the metabolic control of PHE levels. Sapropterin is an oral medication that supplies BH4 and may enhance PAH activity in certain PKU phenotypes, while pegvaliase is an injectable enzyme substitution therapy for adults with PKU [<xref rid=""bb0010"" ref-type=""bibr"">2</xref>,<xref rid=""bb0040"" ref-type=""bibr"">8</xref>,<xref rid=""bb0045"" ref-type=""bibr"">9</xref>]. Although it is critical to initiate treatment in infancy to protect growth",6_10,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"initiate treatment in infancy to protect growth and brain development, children and adults with PKU need to continue treatment throughout their lives to avoid neuropsychiatric problems resulting from elevated blood PHE levels. Impaired executive functioning may occur with poor metabolic control, making it even more difficult for patients to carry out all aspects of PKU management. Optimal metabolic control is essential for individuals with PKU to maintain good health and quality of life, and they often",6_11,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"good health and quality of life, and they often require the support of their health care providers, family members, and peers to achieve this goal [<xref rid=""bb0010"" ref-type=""bibr"">2</xref>,<xref rid=""bb0030"" ref-type=""bibr"">6</xref>,<xref rid=""bb0050"" ref-type=""bibr"">10</xref>,<xref rid=""bb0055"" ref-type=""bibr"">11</xref>]. Despite the continued evolution of treatment strategies, PKU remains a chronic disease requiring complex management. Patients and their families are burdened by time-intensive and",6_12,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"their families are burdened by time-intensive and costly treatments necessary to manage the condition appropriately [<xref rid=""bb0060"" ref-type=""bibr"">12</xref>]. Patients with PKU describe social isolation, relationship issues, and emotional impacts related to their treatment regimen [<xref rid=""bb0030"" ref-type=""bibr"">6</xref>]. These factors create fatigue associated with PKU management; as a result, treatment adherence tends to decline as patients get older [<xref rid=""bb0050""",6_13,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"decline as patients get older [<xref rid=""bb0050"" ref-type=""bibr"">10</xref>]. Barriers created by social determinants of health (SDOH) pose additional challenges to individuals with chronic diseases, including PKU. Food insecurity, housing instability, and financial hardships are common in the United States, and they negatively impact access to care and overall health. Poor health outcomes in people with chronic diseases may be exacerbated by SDOH-related issues [<xref rid=""bb0065""",6_14,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"by SDOH-related issues [<xref rid=""bb0065"" ref-type=""bibr"">13</xref>]. Here, we present the case of a female pediatric patient with PKU identified by NBS. Despite the patient's response to sapropterin, her metabolic control has been negatively impacted by economic factors such as food insecurity, housing instability, and inconsistent transportation. This case demonstrates how the inherent burdens of PKU management can be compounded by SDOH-related barriers.  Medical records and clinical parameters were",6_15,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"Medical records and clinical parameters were reviewed by the treating clinical team. Informed consent was obtained from our patient's mother for publication of this case. Although treatment advances continue to improve rare disease outcomes, there are disparities in care for patients who are negatively affected by SDOH [<xref rid=""bb0085"" ref-type=""bibr"">17</xref>]. PKU is a noteworthy example of a condition that has historically caused profound disability due to the absence of identification and",6_16,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"due to the absence of identification and treatment, but now it can be successfully managed with early identification and lifelong treatment. Patients with PKU who have economic challenges can have difficulties accessing care, leaving them susceptible to severe physical, cognitive, and behavioral problems that could have been prevented [<xref rid=""bb0090"" ref-type=""bibr"">18</xref>]. Access to transportation is considered a major SDOH and has been a prominent barrier to care for the patient presented in this",6_17,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"barrier to care for the patient presented in this case. Data from the National Health Interview Survey (1997–2017) revealed that in 2017, 5.8 million people in the United States postponed medical care due to lack of transportation. Those living below the poverty line and/or receiving Medicaid benefits were more likely than other demographic groups to cite transportation as a barrier to care. Although individuals who live in major metropolitan areas are more likely to have public transportation available,",6_18,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"likely to have public transportation available, transit time and finances can prevent utilization [<xref rid=""bb0095"" ref-type=""bibr"">19</xref>]. Interventions have been proposed to mitigate the impacts of transportation barriers on health care. First, screening tools can be used to identify transportation insecurity in clinical settings. These tools range from in-depth evaluations to simple yes/no questions that may be more feasible to implement in busy health care settings. While more work is needed to",6_19,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"care settings. While more work is needed to better capture these barriers, some health systems have begun utilizing screening tools [<xref rid=""bb0100"" ref-type=""bibr"">20</xref>]. Once transportation barriers are identified, evidence-based interventions can be offered, including the provision of public transit passes, transport vouchers, or travel reimbursement; arrangement of transportation services; or free shuttle services. These interventions have been found to be most beneficial to health outcomes",6_20,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"found to be most beneficial to health outcomes when combined with other interventions such as care coordination, education, and counseling. Community health workers, social workers, nurses, and other clinical staff are helpful for implementing these interventions [<xref rid=""bb0105"" ref-type=""bibr"">21</xref>]. Housing insecurity, which includes cost burden, frequent moves, and homelessness, has detrimental effects on overall health and well-being [<xref rid=""bb0110"" ref-type=""bibr"">22</xref>]. In 2021, the",6_21,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"ref-type=""bibr"">22</xref>]. In 2021, the Center for Economic and Policy Research reported that 1 in 5 US households experienced housing insecurity. Nearly 1 in 3 households with children had housing insecurity, with gaps increasing between White households and Black, Hispanic, and other households after the COVID-19 pandemic [<xref rid=""bb0115"" ref-type=""bibr"">23</xref>]. Children are disproportionately affected by housing insecurity and are at risk for poor growth, development, and health status. Families",6_22,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"growth, development, and health status. Families affected by housing insecurity frequently have challenges accessing medical care, so children with long-term health care needs such as our patient with PKU are particularly vulnerable [<xref rid=""bb0120"" ref-type=""bibr"">24</xref>]. Housing insecurity is a complex issue that requires the collaboration of government and private stakeholders; however, health care organizations are becoming increasingly involved in addressing the crisis, with payors beginning to",6_23,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"addressing the crisis, with payors beginning to invest in affordable housing initiatives [<xref rid=""bb0125"" ref-type=""bibr"">25</xref>]. Medical providers can help identify patients with housing insecurity through screening tools, and they can potentially document a diagnosis code for patients experiencing homelessness in medical records. This can be a first step to connecting at-risk patients with appropriate support systems such as social workers, counselors, and housing services [<xref rid=""bb0130""",6_24,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"and housing services [<xref rid=""bb0130"" ref-type=""bibr"">26</xref>]. Food insecurity is described as inadequate or inconsistent access to food and is an SDOH that affected 13.8 million US households in 2020 [<xref rid=""bb0135"" ref-type=""bibr"">27</xref>]. Food insecurity often occurs in tandem with housing insecurity and is independently associated with poor health, delayed development, and nutrient deficiencies in children [<xref rid=""bb0120"" ref-type=""bibr"">24</xref>]. Considering that the cornerstone of",6_25,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"Considering that the cornerstone of PKU treatment is careful adherence to a special diet, food insecurity can be a serious threat to metabolic control. While medications and medical formula for PKU are likely to be covered by insurance, costs for low-protein modified foods are typically out of pocket. It has been reported that low-protein modified foods cost 2 to 8 times more than unmodified foods, making them extremely difficult to obtain for many individuals, especially those experiencing economic",6_26,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"especially those experiencing economic hardships or food insecurity [<xref rid=""bb0090"" ref-type=""bibr"">18</xref>,<xref rid=""bb0140"" ref-type=""bibr"">28</xref>]. A 2020 pilot study found that females with PKU experience food insecurity at a rate of 2 to 4 times higher than the general US population. Compared to females with PKU who had higher food security, those experiencing food insecurity consumed more dietary PHE and less medical formula. The authors inferred that individuals with PKU who have financial",6_27,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"that individuals with PKU who have financial struggles may be unwilling or unable to spend money on their medical and dietary needs. As with other SDOH, an important step for clinicians is to screen patients and assess gaps in food access. Given that dietary evaluation of patients with PKU is a central component to metabolic clinic visits, metabolic dietitians should screen patients for food insecurity and be prepared to provide resources to those at risk. Patients and their families can be referred to",6_28,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"Patients and their families can be referred to local food banks with recommendations for low-PHE food options such as canned fruits and vegetables, fruit or vegetable juices, or certain refined grain products that can fit the PKU diet when carefully measured (eg, instant white rice or gluten-free grain items). Additionally, clinic staff can coordinate with food assistance programs such as the Supplemental Nutrition Assistance Program (SNAP) and the Special Supplemental Nutrition Program for Women, Infants,",6_29,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"Nutrition Program for Women, Infants, and Children (WIC) to ensure patients are able to receive appropriate foods for the PKU diet [<xref rid=""bb0090"" ref-type=""bibr"">18</xref>]. Finally, families managing PKU can benefit from connecting with local and national PKU advocacy groups, patient support groups, low-protein modified food manufacturers, and medical formula assistance programs. These entities can provide direct and indirect support for patients with PKU experiencing food insecurity and a variety of",6_30,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"PKU experiencing food insecurity and a variety of other issues related to PKU management. Health literacy, defined as “the degree to which individuals have the capacity to obtain, process, and understand basic health information,” is another SDOH that can present risks or benefits to patients. Low health literacy is typically associated with lower levels of education, lower economic status, and negative impacts to chronic disease management and outcomes [<xref rid=""bb0145"" ref-type=""bibr"">29</xref>]. In",6_31,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"rid=""bb0145"" ref-type=""bibr"">29</xref>]. In the case of our patient's primary caregivers, their level of education is unknown, and their health literacy is estimated as low to average. Despite this assumption, the caregivers have demonstrated understanding of PKU management principles since the patient's diagnosis. Adherence to instructions for PHE washout after the NBS visit and overall consistency with medication administration indicate that the caregivers have been able to comprehend and implement",6_32,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"have been able to comprehend and implement concepts taught to them in clinic despite various barriers. A large proportion of the US population has limited health literacy, which has a significant impact on patient outcomes [<xref rid=""bb0145"" ref-type=""bibr"">29</xref>]. As such, we recommend that metabolic teams consider health literacy when working with patients regardless of their perceived education level or economic status. Health care providers should be aware of how SDOH can affect their patients,",6_33,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"be aware of how SDOH can affect their patients, especially those with rare diseases such as PKU, given the frequency of SDOH barriers in the general population and their detrimental impacts on medical access and health outcomes (<xref rid=""f0015"" ref-type=""fig"">Fig. 3</xref>). Use of SDOH screening tools at our patient's initial clinic visit may have identified her family's barriers early and provided an opportunity for referral to appropriate resources. Outreach to the family became more difficult as time",6_34,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"to the family became more difficult as time elapsed; early intervention may have aided in keeping them connected to the clinic. Additionally, the expertise of an embedded social worker within the metabolic clinic would have been valuable to help the patient's family access transportation, housing, and other assistance programs. Currently, social workers are not embedded within our clinic, and their services are available only on a case-by-case basis. Social work consultation has been requested on multiple",6_35,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"work consultation has been requested on multiple occasions for this patient; however, missed clinic visits have prevented those consultations from occurring. Calls from social workers to the family have also been attempted but unsuccessful. Since metabolic clinicians already face time and staffing challenges, this case is a prime example of how a dedicated social worker could help address SDOH more directly while enabling dietitians, physicians, and advanced practice providers to focus on medical",6_36,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"advanced practice providers to focus on medical management [<xref rid=""bb0150"" ref-type=""bibr"">30</xref>]. While further research is needed to assess the impacts of SDOH on the management of PKU, this case illustrates the importance of awareness and persistence on the part of the metabolic team to ensure that patients with SDOH barriers have the best possible outcomes.<fig id=""f0015""><label>Fig. 3</label><caption><p>SDOH-related barriers, treatment impacts, and potential interventions for a patient with",6_37,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"and potential interventions for a patient with PKU.</p></caption><alt-text id=""al0015"">Fig. 3</alt-text><graphic http://www.w3.org/1999/xlink href=""gr3"" id=""lk0015""></graphic></fig> Informed consent was obtained from the patient's mother for this work. <funding-source id=""gts0005"">Amgen Inc.</funding-source> funded manuscript editorial support, including editorial review, author coordination, and manuscript submission. The authors confirm independence from the sponsor; the content of the article has not",6_38,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"the sponsor; the content of the article has not been influenced by the sponsor. No authors received compensation for the preparation of this manuscript outside of normal employment obligations. We the undersigned declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but",6_39,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us. We understand that the Corresponding Author is the sole contact for the Editorial process. She is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. <bold>Ashley Andrews:</bold> Writing – review & editing, Writing – original draft. <bold>Kate McMinimee:</bold> Writing –",6_40,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"draft. <bold>Kate McMinimee:</bold> Writing – review & editing, Writing – original draft. AA has participated in advisory boards and/or received honoraria from Amgen Inc., Acer Therapeutics, and Sanofi. KM has no declarations.",6_41,"Navigating social determinants of health barriers in the management of phenylketonuria<sup><xref ref-type=""fn"" rid=""d36e122"">☆</xref></sup>",03 5 2024,,Phenylketonuria
"Meta-analysis of bone mineral density in adults with phenylketonuria Phenylalanine hydroxylase (PAH) deficiency (OMIM# 261600), known commonly as phenylketonuria (PKU), is an autosomal recessive metabolic disorder caused by pathogenic variants in the gene encoding PAH. Impaired PAH function impairs conversion of the essential amino acid phenylalanine (Phe) to tyrosine [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Accumulation of Phe in the blood and the brain has toxic effects, blocking transport of other",7_0,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"has toxic effects, blocking transport of other large neutral amino acids into the brain, including tyrosine and tryptophan, via competition at the L-type amino acid transporter 1 [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Untreated PKU results in poor neurological outcomes [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Therefore, the goal of treatment is to achieve and maintain appropriate blood Phe levels. The American College of Medical Genetics guidelines",7_1,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"American College of Medical Genetics guidelines recommend a blood Phe level of 120–360 µmol/L for all patients [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]; European guidelines recommend 120–360 µmol/L for patients < 12 years of age and 120–600 µmol/L for patients ≥ 12 years of age [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Medical nutrition therapy (MNT) [<xref ref-type=""bibr"" rid=""CR3"">3</xref>] for PKU is lifelong and restricts the natural intake of protein, replacing it with a Phe-free, amino acid-based",7_2,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"replacing it with a Phe-free, amino acid-based medical food to supplement the reduced protein intake, and provide a source of energy and other nutrients. Supplements might include modified low-protein foods, Phe-free medical food beverages, Phe-free amino acid mixture, medical foods derived from glycomacropeptide, and protein substitutes [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. It is difficult for all individuals with PKU to achieve and maintain a Phe-restricted diet, particularly into adolescence and",7_3,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"diet, particularly into adolescence and adulthood [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR5"">5</xref>]. Maintaining blood Phe levels within recommended ranges, both during and after childhood is important to achieve the best long-term outcomes [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Elevated blood Phe levels may be due to low Phe tolerance (the amount of daily Phe intake that an individual can consume without increasing blood Phe levels above the recommended range),",7_4,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"blood Phe levels above the recommended range), which is linked to disease severity, and in turn, linked to mutation status and level of functional PAH. This explains how even with active management, Phe levels remain elevated in some individuals [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR6"">6</xref>]. Individuals with PKU can also present with secondary health problems; healthcare claims-based studies suggest a higher prevalence of",7_5,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"studies suggest a higher prevalence of somatic comorbidities versus the respective general population [<xref ref-type=""bibr"" rid=""CR7"">7</xref>, <xref ref-type=""bibr"" rid=""CR8"">8</xref>]. Abnormal bone status has been a concern for a long time in individuals with PKU [<xref ref-type=""bibr"" rid=""CR4"">4</xref>, <xref ref-type=""bibr"" rid=""CR9"">9</xref>]. Currently, it is unclear whether low bone mineral density (BMD) in those with PKU is a direct consequence of the disease, the result of a Phe-restricted diet",7_6,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"the disease, the result of a Phe-restricted diet [<xref ref-type=""bibr"" rid=""CR10"">10</xref>] or due to reliance on low-Phe amino acid supplementation, which can increase urinary calcium and magnesium excretion [<xref ref-type=""bibr"" rid=""CR11"">11</xref>, <xref ref-type=""bibr"" rid=""CR12"">12</xref>]. Mineral bone disease, where bone strength deteriorates, increasing the risk of osteopenia, osteoporosis, and ultimately fracture [<xref ref-type=""bibr"" rid=""CR13"">13</xref>], has been reported in individuals",7_7,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"has been reported in individuals with PKU [<xref ref-type=""bibr"" rid=""CR14"">14</xref>]. BMD contributes to bone strength and measuring BMD Z-scores is one method used to help determine an individual’s bone density status, where the individual Z-score is the number of standard deviations by which BMD differs from that expected for age and sex. The International Society for Clinical Densitometry Official Position (ISCD OP) considers a BMD Z-score ≤ -2.0 as below the expected range for age, and a BMD",7_8,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"as below the expected range for age, and a BMD Z-score > -2.0 as within the expected range for age, in females prior to menopause and males younger than 50 years of age [<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. Other BMD Z-score thresholds are also considered to be clinically informative, with a BMD Z-score of < -2.5 considered indicative of a secondary cause of osteoporosis [<xref ref-type=""bibr"" rid=""CR16"">16</xref>–<xref ref-type=""bibr"" rid=""CR18"">18</xref>] and a BMD Z-score of < -1.0 and ≥ -2.5",7_9,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"and a BMD Z-score of < -1.0 and ≥ -2.5 considered indicative of osteopenia [<xref ref-type=""bibr"" rid=""CR16"">16</xref>, <xref ref-type=""bibr"" rid=""CR18"">18</xref>, <xref ref-type=""bibr"" rid=""CR19"">19</xref>]; however, the ISCD OP states that in some populations (e.g. children and adolescents, males under the age of 50 years) osteoporosis cannot be diagnosed using BMD only [<xref ref-type=""bibr"" rid=""CR15"">15</xref>, <xref ref-type=""bibr"" rid=""CR20"">20</xref>]. A previous meta-analysis reported lower mean",7_10,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"A previous meta-analysis reported lower mean BMD Z-scores for various bones in individuals with PKU on a Phe-restricted diet versus the respective general population, but BMD Z-scores were still within the expected range for age, based on the ISCD OP definition [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. Similarly, a systematic literature review (SLR), without meta-analysis also reported lower mean BMD Z-scores in those with PKU on a Phe-restricted diet versus a reference population, but again, within the",7_11,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"a reference population, but again, within the expected range for age [<xref ref-type=""bibr"" rid=""CR21"">21</xref>]. Both studies reported BMD in mixed-age PKU populations, and so the inclusion of both children and adults limited the interpretation of BMD status by an individual’s age. This, coupled with the use of different thresholds to evaluate BMD status, means the evidence base has not reached a consensus on BMD status in individuals with PKU. A meta-analysis has been conducted to investigate BMD",7_12,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"has been conducted to investigate BMD outcome measures in adults with PKU, and to explore the impact of the Phe-restricted diet (including impact of adherence to diet, most often assessed by blood Phe level control) on BMD. This meta-analysis included studies identified in a broader SLR that was conducted to evaluate published evidence on the somatic comorbidities experienced by adults with PKU; these results have been reported separately in Whitehall et al. [<xref ref-type=""bibr"" rid=""CR22"">22</xref>].",7_13,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"al. [<xref ref-type=""bibr"" rid=""CR22"">22</xref>]. BMD was assessed in adults with PKU on a Phe-restricted diet versus a reference (non-PKU) population using reported BMD Z-scores for various bones. The prevalence of low BMD Z-scores at pre-specified thresholds was assessed in adults with PKU on a Phe-restricted diet. This meta-analysis is reported according to Meta-analysis Of Observational Studies in Epidemiology reporting guidelines [<xref ref-type=""bibr"" rid=""CR23"">23</xref>].   Adults with PKU on a",7_14,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"rid=""CR23"">23</xref>].   Adults with PKU on a Phe-restricted diet have lower mean BMD Z-scores than a non-PKU population but are still generally within what is considered the expected range for age (> -2.0). In this study, fewer than 1 in 10 adults with PKU had a BMD Z-score below the expected range for age (≤ -2.0), although more than one-third (42%) of adults with PKU had a BMD Z-score passing the threshold that is considered indicative of possible osteopenia or osteoporosis (< -1.0). Further studies are",7_15,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"or osteoporosis (< -1.0). Further studies are needed to confirm the clinical implications of a low, but within expected range, BMD Z-score, including any increased risk of fracture. The low numbers of studies evaluating BMD Z-scores in adults with PKU precludes a robust analysis of which population characteristics are most impacting BMD; the role of the Phe-restricted diet, and differences in recommended blood Phe levels, on BMD, as well as any additional impact from the disease itself.",7_16,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"<supplementary-material content-type=""local-data"" id=""MOESM1""><media http://www.w3.org/1999/xlink href=""13023_2024_3223_MOESM1_ESM.docx""><caption><p>Additional file 1.</p></caption></media></supplementary-material><supplementary-material content-type=""local-data"" id=""MOESM2""><media http://www.w3.org/1999/xlink href=""13023_2024_3223_MOESM2_ESM.docx""><caption><p>Additional file 2.</p></caption></media></supplementary-material><supplementary-material content-type=""local-data"" id=""MOESM3""><media",7_17,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"content-type=""local-data"" id=""MOESM3""><media http://www.w3.org/1999/xlink href=""13023_2024_3223_MOESM3_ESM.docx""><caption><p>Additional file 3.</p></caption></media></supplementary-material><supplementary-material content-type=""local-data"" id=""MOESM4""><media http://www.w3.org/1999/xlink href=""13023_2024_3223_MOESM4_ESM.docx""><caption><p>Additional file 4.</p></caption></media></supplementary-material><supplementary-material content-type=""local-data"" id=""MOESM5""><media http://www.w3.org/1999/xlink",7_18,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"id=""MOESM5""><media http://www.w3.org/1999/xlink href=""13023_2024_3223_MOESM5_ESM.docx""><caption><p>Additional file 5.</p></caption></media></supplementary-material>",7_19,Meta-analysis of bone mineral density in adults with phenylketonuria,12 9 2024,,Phenylketonuria
"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria Phenylketonuria (PKU), a prevalent autosomal recessive congenital aminoacidopathy, is genetically characterized by mutations in the phenylalanine hydroxylase (<italic toggle=""yes"">PAH</italic>) gene.[<xref rid=""R1"" ref-type=""bibr"">1</xref>] The global prevalence of PKU is estimated to be approximately six cases per 100,000",8_0,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"to be approximately six cases per 100,000 newborns.[<xref rid=""R2"" ref-type=""bibr"">2</xref>] In Iran, the prevalence of PKU is estimated to be around 1 in 4,698 individuals,[<xref rid=""R3"" ref-type=""bibr"">3</xref>] and it demonstrates an increasing pattern from the northern regions (0.0015%) to the southern regions (0.02%) of the country.[<xref rid=""R4"" ref-type=""bibr"">4</xref><xref rid=""R5"" ref-type=""bibr"">5</xref>] The classical form of this condition is attributed to mutations in the <italic",8_1,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"is attributed to mutations in the <italic toggle=""yes"">PAH</italic> gene, which is located on chromosome 12q23. The spectrum of <italic toggle=""yes"">PAH</italic> gene mutations varies across different ethnicities and geographic regions worldwide. <italic toggle=""yes"">PAH</italic> mutations in the Iranian population. <italic toggle=""yes"">PAH</italic> uses molecular oxygen and tetrahydrobiopterin (BH4) as cofactors to perform the conversion.[<xref rid=""R6"" ref-type=""bibr"">6</xref>] PKU may cause various",8_2,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"ref-type=""bibr"">6</xref>] PKU may cause various symptoms that can differ in severity based on factors, such as enzyme activity, age at diagnosis, and adherence to dietary restrictions. Clinical manifestation of PKU can include developmental delays, behavioral issues, cognitive impairment, microcephaly, seizures, musty odor, lighter skin and hair pigmentation, and skin disorders. Infants with PKU may experience a delay in reaching developmental milestones, such as crawling and walking.[<xref rid=""R7""",8_3,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"such as crawling and walking.[<xref rid=""R7"" ref-type=""bibr"">7</xref>] Proper management of this condition involves adhering to strict dietary restrictions and exploring gene and enzyme replacement therapies to prevent phenylalanine buildup and maintain a healthy balance of amino acids in the body.[<xref rid=""R8"" ref-type=""bibr"">8</xref>] PKU is a multifaceted condition that is classified into various categories, depending on enzyme activity, symptom severity, and treatment response. Classic PKU is the",8_4,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"and treatment response. Classic PKU is the most severe form, characterized by low or absent enzyme activity, while nonclassic PKU is milder, with some residual enzyme activity. Hyperphenylalaninemia (HPA) encompasses disorders with high phenylalanine levels, and BH4-responsive PKU is a subtype that can be treated with BH4 supplementation.[<xref rid=""R9"" ref-type=""bibr"">9</xref>] PKU is a genetic disorder with a distinctive inheritance pattern rooted in the genetic makeup of an individual’s parents. It is",8_5,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"genetic makeup of an individual’s parents. It is classified as an autosomal recessive disorder, which means that its manifestation hinges on the presence or absence of specific genetic variants in the <italic toggle=""yes"">PAH</italic> gene.[<xref rid=""R1"" ref-type=""bibr"">1</xref>] Delving into the inheritance of PKU provides essential insights into how this condition is passed down through generations. In cases where both parents are carriers (Nn), there is a 25% likelihood with each pregnancy that they",8_6,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"is a 25% likelihood with each pregnancy that they will give birth to an affected child (nn). There exists a 50% probability that the child will be a carrier (Nn), inheriting one normal and one mutated allele from the parents. Simultaneously, there is a 25% likelihood that the child will inherit two normal alleles (NN), rendering them unaffected by PKU or its carrier state.[<xref rid=""R10"" ref-type=""bibr"">10</xref>] If an individual inherits two different mutations in two alleles of the <italic",8_7,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"different mutations in two alleles of the <italic toggle=""yes"">PAH</italic> gene, one from each parent, the result is called a compound heterozygosity. In this paper, we identified a rare combination of compound heterozygosity in three families with PKU. The clinical and genomic findings were studied further using comprehensive bioinformatics approaches.   The human <italic toggle=""yes"">PAH</italic> gene is recognized as a prominent cause of hyperphenylalaninemia cases attributed to both PKU and HPA.[<xref",8_8,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"cases attributed to both PKU and HPA.[<xref rid=""R15"" ref-type=""bibr"">15</xref>] The gene, comprising 13 exons that span a length of 90 kb and located on chromosome 12, is accountable for the production of a 452 amino acid product with a molecular weight approximately equal to 52 kDa, characterized by a homotetramer structure. Each subunit of this structure consists of a regulatory domain (1–142), catalytic domain (142–410), and tetramerization domain (410–453).[<xref rid=""R6"" ref-type=""bibr"">6</xref>] The",8_9,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"rid=""R6"" ref-type=""bibr"">6</xref>] The severity of the disease is intricately linked with protein activity, which depends on the type of mutation and the reduction of enzyme activity.[<xref rid=""R16"" ref-type=""bibr"">16</xref>] <xref rid=""abr.abr_471_23-f008"" ref-type=""fig"">Figure 8</xref> shows the spectrum of <italic toggle=""yes"">PAH</italic> protein is contingent on the proper folding and stability of its catalytic domain. Any mutations that occur in this domain, particularly in its hotspot exon 6, can",8_10,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"domain, particularly in its hotspot exon 6, can lead to a decrease in enzymatic activity. It is important to note that the hotspot exon is especially susceptible to mutations that can result in functional impairment of the enzyme.[<xref rid=""R6"" ref-type=""bibr"">6</xref><xref rid=""R17"" ref-type=""bibr"">17</xref><xref rid=""R18"" ref-type=""bibr"">18</xref>] In our study, we investigated three unrelated families, each with a proband diagnosed with PKU. All three probands were found to carry compound heterozygous",8_11,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"were found to carry compound heterozygous mutations in the <italic toggle=""yes"">PAH</italic> gene, as confirmed by PCR sequencing. The identified genetic variants in these families were [c.526C>T/c.533A>G], [c.533A>G/c.1222C>T], and [c.526C>T/c.1222C>T]. Notably, all families had a history of first-cousin consanguineous marriages, suggesting a potential genetic predisposition for PKU within consanguineous unions. The clinical manifestations varied, with mild hyperphenylalaninemia observed in Family 1,",8_12,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"mild hyperphenylalaninemia observed in Family 1, moderate PKU in Family 2, and mild PKU in Family 3. These findings underscore the importance of genetic counseling and screening within consanguineous populations to better understand the genetic basis of PKU and its phenotypic diversity. PKU severity is categorized into four levels: including classic PKU, moderate PKU, mild PKU, and MHP-gray zone MHP.[<xref rid=""R19"" ref-type=""bibr"">19</xref>] The pretreatment Phe levels are categorized as follows: classic",8_13,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"Phe levels are categorized as follows: classic PKU shows Phe levels greater than 1200 μmol/L (>20 mg/dL), moderate PKU ranges from 900 to 1200 μmol/L (15–20 mg/dL), mild PKU falls between 600 and 900 μmol/L (10–15 mg/dL), and MHP-gray zone MHP ranges from 360 to 600 μmol/L (6–10 mg/dL). The Phe tolerance levels vary based on age; for classic PKU, it is less than 12 mg/kg/day, while for moderate PKU, it ranges from 12 to 18 mg/kg/day, and for mild PKU, it is greater than 18 mg/kg/day. Unfortunately, no data",8_14,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"greater than 18 mg/kg/day. Unfortunately, no data is available for Phe tolerance in the MHP-gray zone MHP category. These classifications are crucial in tailoring treatments for PKU patients, ensuring effective management of Phe levels and enhancing their overall quality of life, with normal blood Phe levels typically falling within the range of 50–110 μmol/L.[<xref rid=""R20"" ref-type=""bibr"">20</xref>] The c.1222C>T mutation, resulting in the amino acid change p.Arg408Trp, was first reported in the world",8_15,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"p.Arg408Trp, was first reported in the world by Eiken <italic toggle=""yes"">et al</italic>. in Norway.[<xref rid=""R21"" ref-type=""bibr"">21</xref>] Their study identified this mutation in 47 PKU patients from the Norwegian PKU registry. Utilizing single-strand conformation polymorphism (SSCP) analysis, the mutation was detected on six out of eight mutant haplotype 12 chromosomes while being absent on all other PKU chromosomes studied. In 1993, the c.526CT mutation, causing the p.Arg176Ter termination codon,",8_16,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"causing the p.Arg176Ter termination codon, was first identified by Guldberg <italic toggle=""yes"">et al</italic>.[<xref rid=""R22"" ref-type=""bibr"">22</xref>] They conducted a comprehensive study involving 53 Sicilian patients with persistently high blood phenylalanine levels due to <italic toggle=""yes"">PAH</italic> deficiency. Using PCR and denaturing gradient gel electrophoresis (DGGE), they analyzed genomic DNA from these patients and identified 40 distinct mutations, including 17 previously unreported",8_17,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"mutations, including 17 previously unreported <italic toggle=""yes"">PAH</italic> mutations. This study revealed the clinical diversity of hyperphenylalaninemia in Southern Europe and established valuable connections between patient phenotypes and genotypes in Sicily and neighboring regions. It significantly enhanced our knowledge of the genetic basis of <italic toggle=""yes"">PAH</italic> deficiency and its implications for clinical practice in this population. The c.533A>G mutation was also identified by",8_18,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"The c.533A>G mutation was also identified by Guldberg <italic toggle=""yes"">et al</italic>. in 1994 for the first time.[<xref rid=""R23"" ref-type=""bibr"">23</xref>] Their study focused on four families with both PKU and mild MHP cases. They identified three different mutations in the <italic toggle=""yes"">PAH</italic> gene within each family, resulting in diverse phenotypes. Unique combinations of <italic toggle=""yes"">PAH</italic> mutations explained the variation in phenotypes. The study demonstrated the",8_19,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"in phenotypes. The study demonstrated the utility of nucleic acid analysis, utilizing PCR, DGGE, and direct sequencing, for predicting outcomes in hyperphenylalaninemia infants. All these three mutations have been previously reported in the Iranian population in the homozygous genotype state.[<xref rid=""R24"" ref-type=""bibr"">24</xref><xref rid=""R25"" ref-type=""bibr"">25</xref><xref rid=""R26"" ref-type=""bibr"">26</xref>] Here, we presented these three in the form of a rare combination of compound heterozygosity.",8_20,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"of a rare combination of compound heterozygosity. By aligning sequences from various species using Clustal Omega and applying the ConSurf tool, we found that residues 178, 176, and 408 were highly conserved. Notably, their ConSurf conservation scores indicated their likely functional significance within the <italic toggle=""yes"">PAH</italic> protein. This enhances our understanding of these amino acids in the <italic toggle=""yes"">PAH</italic> protein’s evolution and function. Computational predictors of",8_21,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"and function. Computational predictors of pathogenicity labeled these three mutations as damaging, comparable to homozygous pathogenic mutations. Moreover, in terms of stability and flexibility of the <italic toggle=""yes"">PAH</italic> protein, the identified mutations were similarly destabilizers reducing the proper functioning of the protein.",8_22,"A Rare Combination of Compound Heterozygous Mutations in the <italic toggle=""yes"">PAH</italic> Gene in Three Unrelated Consanguineous Iranian Families with Classical Phenylketonuria",2024,,Phenylketonuria
"Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria Background/Objectives: Phenylketonuria is a hereditary metabolic disorder characterized by a deficiency of phenylalanine hydroxylase. The main treatment for PKU is a phenylalanine-restricted diet. The exclusion of protein rich natural foods and inclusion of low-Phe substitutes may give rise to an imbalanced diet, and the increased risk of overweight and obesity in PKU is a cause for concern. We aimed to evaluate the body",9_0,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"cause for concern. We aimed to evaluate the body composition and nutritional biochemical biomarkers in adult PKU patients who are on Phe-restricted and essential amino acid-supplemented nutrition therapy and to investigate the relationships between these parameters and patient gender, adherence to dietary therapy, and disease type, defined as mild or classic PKU. Methods: The study group comprised 37 PKU patients and 26 healthy siblings as controls. The participants were assessed based on an analysis of",9_1,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"were assessed based on an analysis of anthropometric parameters, body composition, and biochemical test results. Results: PKU patients do not have a higher incidence of overweight and obesity than healthy controls, the proportion of energy derived from carbohydrates in their diets was below the recommended level, and their total energy intake was below the recommended daily allowance. It was remarkable that patients with a treatment adherence ratio of <50% displayed a higher prevalence of overweight and",9_2,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"displayed a higher prevalence of overweight and abdominal obesity in comparison to those with a more favorable treatment adherence ratio. Conclusions: In view of the growing prevalence of overweight in the general population, PKU patients should be kept under close long-term follow-up. Particularly in the group with low treatment compliance, more caution should be taken in terms of adverse outcomes. Phenylketonuria (PKU; OMIM 261600) is a hereditary metabolic disorder characterized by a deficiency of the",9_3,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"disorder characterized by a deficiency of the enzyme phenylalanine hydroxylase, which converts the amino acid phenylalanine to tyrosine [<xref rid=""B1-nutrients-16-03355"" ref-type=""bibr"">1</xref>]. The primary treatment for PKU is a dietary regimen restricted in phenylalanine (Phe), with the supplementation of essential amino acids and micronutrients [<xref rid=""B2-nutrients-16-03355"" ref-type=""bibr"">2</xref>]. The exclusion of protein-rich natural foods and inclusion of low-Phe substitutes may give rise",9_4,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"inclusion of low-Phe substitutes may give rise to an imbalanced diet, increasing the risk of overweight and obesity; the prevalence of and propensity for excess adiposity in PKU is a cause of concern [<xref rid=""B3-nutrients-16-03355"" ref-type=""bibr"">3</xref>].  Since 1975, the global prevalence of overweight has almost tripled [<xref rid=""B4-nutrients-16-03355"" ref-type=""bibr"">4</xref>]. The World Health Organization (WHO) describes overweight and obesity as abnormal or excessive accumulation of fat.",9_5,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"as abnormal or excessive accumulation of fat. Abdominal obesity is related to dyslipidemia, hypertension, insulin resistance, and inflammation. These alterations are, in the long run, associated with non-communicable diseases such as cardiovascular diseases, non-insulin-dependent diabetes mellitus, musculoskeletal disorders, pulmonary diseases, and cancer [<xref rid=""B5-nutrients-16-03355"" ref-type=""bibr"">5</xref>,<xref rid=""B6-nutrients-16-03355"" ref-type=""bibr"">6</xref>].  A substantial body of evidence",9_6,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"A substantial body of evidence from numerous studies indicates that patients diagnosed with PKU exhibit a higher body mass index (BMI) compared to the general population [<xref rid=""B7-nutrients-16-03355"" ref-type=""bibr"">7</xref>,<xref rid=""B8-nutrients-16-03355"" ref-type=""bibr"">8</xref>,<xref rid=""B9-nutrients-16-03355"" ref-type=""bibr"">9</xref>,<xref rid=""B10-nutrients-16-03355"" ref-type=""bibr"">10</xref>]. Some studies have demonstrated that the BMI and fat mass of female patients diagnosed with PKU are",9_7,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"mass of female patients diagnosed with PKU are higher than those of control groups [<xref rid=""B1-nutrients-16-03355"" ref-type=""bibr"">1</xref>,<xref rid=""B11-nutrients-16-03355"" ref-type=""bibr"">11</xref>]. A study conducted in the United States revealed that patients with PKU in the pediatric age group were more likely to be obese or overweight [<xref rid=""B7-nutrients-16-03355"" ref-type=""bibr"">7</xref>]. In a Spanish study that evaluated patients with PKU during adolescence, it was found that their BMI",9_8,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"during adolescence, it was found that their BMI was higher than that of healthy controls [<xref rid=""B12-nutrients-16-03355"" ref-type=""bibr"">12</xref>]. A gradual increase in the frequency of overweight and obesity was observed among patients with PKU living in the same region in Brazil at two-year intervals. It has been proposed that non-adherence to nutritional therapies by patients may also be a contributing factor to the elevated risk of overweight [<xref rid=""B13-nutrients-16-03355""",9_9,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"of overweight [<xref rid=""B13-nutrients-16-03355"" ref-type=""bibr"">13</xref>]. However, the results of all studies in which anthropometric evaluations of PKU patients were performed are not consistent with one another. Mazzola and colleagues observed that 75% of the cohort of patients with PKU exhibited a normal BMI, while 22% displayed an elevated BMI [<xref rid=""B14-nutrients-16-03355"" ref-type=""bibr"">14</xref>]. Other studies have demonstrated no significant difference between patient groups and healthy",9_10,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"difference between patient groups and healthy controls in terms of BMI values [<xref rid=""B15-nutrients-16-03355"" ref-type=""bibr"">15</xref>,<xref rid=""B16-nutrients-16-03355"" ref-type=""bibr"">16</xref>,<xref rid=""B17-nutrients-16-03355"" ref-type=""bibr"">17</xref>,<xref rid=""B18-nutrients-16-03355"" ref-type=""bibr"">18</xref>,<xref rid=""B19-nutrients-16-03355"" ref-type=""bibr"">19</xref>,<xref rid=""B20-nutrients-16-03355"" ref-type=""bibr"">20</xref>,<xref rid=""B21-nutrients-16-03355"" ref-type=""bibr"">21</xref>].",9_11,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"ref-type=""bibr"">21</xref>]. Sailer et al. reported that although BMI and waist circumference z-score values were increased in the patient group compared to the control group, height z-scores were lower than in the control group [<xref rid=""B22-nutrients-16-03355"" ref-type=""bibr"">22</xref>]. While some studies did not report a negative effect on growth, other studies indicated that growth was retarded, including low height z-scores [<xref rid=""B16-nutrients-16-03355"" ref-type=""bibr"">16</xref>,<xref",9_12,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"ref-type=""bibr"">16</xref>,<xref rid=""B20-nutrients-16-03355"" ref-type=""bibr"">20</xref>,<xref rid=""B23-nutrients-16-03355"" ref-type=""bibr"">23</xref>,<xref rid=""B24-nutrients-16-03355"" ref-type=""bibr"">24</xref>]. In patients with phenylketonuria, some studies have reported higher fat mass in all patients, with a particularly pronounced effect observed in female subjects [<xref rid=""B11-nutrients-16-03355"" ref-type=""bibr"">11</xref>]. In other studies, fat mass was found to be significantly increased in male",9_13,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"was found to be significantly increased in male patients [<xref rid=""B22-nutrients-16-03355"" ref-type=""bibr"">22</xref>]. In contrast to these findings, some studies demonstrated no significant difference between the patient and control groups [<xref rid=""B14-nutrients-16-03355"" ref-type=""bibr"">14</xref>,<xref rid=""B16-nutrients-16-03355"" ref-type=""bibr"">16</xref>,<xref rid=""B18-nutrients-16-03355"" ref-type=""bibr"">18</xref>,<xref rid=""B20-nutrients-16-03355"" ref-type=""bibr"">20</xref>]. In their study on the",9_14,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"ref-type=""bibr"">20</xref>]. In their study on the nutritional composition of low-protein food products used in the dietary management of PKU, Pena and colleagues observed that the majority of these products exhibited higher energy and carbohydrate content, and that over half of them had a higher fat content than typical foods [<xref rid=""B25-nutrients-16-03355"" ref-type=""bibr"">25</xref>]. Furthermore, the quality of fat and fiber used in these products differs from that of normal foods [<xref",9_15,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"products differs from that of normal foods [<xref rid=""B26-nutrients-16-03355"" ref-type=""bibr"">26</xref>]. Excessive consumption may result in deficiencies of micronutrients and excessive energy intake due to the deficiency of micronutrient sources [<xref rid=""B22-nutrients-16-03355"" ref-type=""bibr"">22</xref>]. It is proposed that a reduction in protein intake resulting from the implementation of specific nutritional therapies in the context of amino acid metabolism disorders may precipitate the",9_16,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"acid metabolism disorders may precipitate the consumption of carbohydrate- and fat-rich foods, thereby increasing the likelihood of weight gain [<xref rid=""B22-nutrients-16-03355"" ref-type=""bibr"">22</xref>]. Furthermore, it is important to consider the differences in the absorption and bioavailability of synthetic amino acid products used in hereditary disorders of amino acid metabolism compared to natural protein sources, as this affects their suitability as protein alternatives [<xref",9_17,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"their suitability as protein alternatives [<xref rid=""B18-nutrients-16-03355"" ref-type=""bibr"">18</xref>,<xref rid=""B27-nutrients-16-03355"" ref-type=""bibr"">27</xref>]. The present study aims to evaluate the body composition and nutritional biochemical biomarkers in adult patients with PKU who are on Phe-restricted and essential amino acid-supplemented nutrition therapy and to investigate the relationships, if any, between these parameters and patient gender, adherence to dietary therapy, and disease type,",9_18,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"adherence to dietary therapy, and disease type, defined as mild or classic PKU. This single-center, cross-sectional, observational, and descriptive study was conducted in the Division of Pediatric Nutrition and Metabolism, Istanbul Faculty of Medicine, Istanbul University, between October 2023 and June 2024. The study was approved by the Istanbul Faculty of Medicine Ethics Committee (file number: 2023/1636). Patients with mild or classic PKU, aged 18 years or older, admitted to the outpatient clinic during",9_19,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"older, admitted to the outpatient clinic during the study period, and who were willing to participate in the study were selected. Written informed consent was obtained from all volunteers or their legal guardians after the study procedure was explained.  Nutritional therapies remain the primary treatment option for many inherited metabolic disorders including PKU [<xref rid=""B33-nutrients-16-03355"" ref-type=""bibr"">33</xref>]. It has long been postulated that the Phe-restricted diet consumed by patients",9_20,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"that the Phe-restricted diet consumed by patients with PKU, which necessitates the extensive use of low-protein energy-rich food products, may result in an increased consumption of energy and an imbalance in the diet [<xref rid=""B34-nutrients-16-03355"" ref-type=""bibr"">34</xref>]. This, in turn, may give rise to an increased susceptibility to abdominal obesity and metabolic syndrome in this patient population over the long-term course of dietary treatment. Consequently, studies conducted with different",9_21,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"Consequently, studies conducted with different cohorts in various countries have yielded findings that are not fully aligned with one another on this issue [<xref rid=""B21-nutrients-16-03355"" ref-type=""bibr"">21</xref>,<xref rid=""B35-nutrients-16-03355"" ref-type=""bibr"">35</xref>,<xref rid=""B36-nutrients-16-03355"" ref-type=""bibr"">36</xref>,<xref rid=""B37-nutrients-16-03355"" ref-type=""bibr"">37</xref>,<xref rid=""B38-nutrients-16-03355"" ref-type=""bibr"">38</xref>]. The principal aim of this study was to assess",9_22,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"The principal aim of this study was to assess the impact of nutritional therapy on body composition and biochemical markers in adult patients with PKU. Furthermore, we investigated the potential associations between these parameters and demographic and clinical factors, including patient gender, adherence to dietary therapy, and PKU type as mild and classic. The main findings of this study indicate that patients with PKU do not have a higher incidence of overweight and obesity than healthy controls, the",9_23,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"overweight and obesity than healthy controls, the proportion of energy derived from carbohydrates in their diets was below the recommended level, and their total energy intake was below the recommended daily allowance (RDA). Our findings further illustrated that male patients with PKU exhibited statistically significantly lower body weight than control subjects, whereas anthropometric evaluations of female patients with PKU demonstrated body compositions that were comparable to those of healthy female",9_24,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"that were comparable to those of healthy female controls. Finally, it was notable that patients with a treatment adherence ratio of <50% displayed a statistically higher prevalence of overweight and abdominal obesity in comparison to those with a more favorable treatment adherence ratio.  BMI assessments of individuals with PKU and healthy controls were not statistically different. Moreover, among PKU patients, a low BMI was more common than in healthy controls (16.2–3.8%). In addition, while the rate of",9_25,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"(16.2–3.8%). In addition, while the rate of being overweight and obese among controls was 50% in total, this rate was 32.5% in PKU patients. Although other studies have found higher rates of overweight and obesity in PKU patients compared with healthy controls, it was noteworthy that they were lower in our study group [<xref rid=""B7-nutrients-16-03355"" ref-type=""bibr"">7</xref>,<xref rid=""B8-nutrients-16-03355"" ref-type=""bibr"">8</xref>,<xref rid=""B11-nutrients-16-03355"" ref-type=""bibr"">11</xref>]. Some",9_26,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"ref-type=""bibr"">11</xref>]. Some studies have reported no changes in BMI and prevalence of overweight and obesity between patients with PKU and healthy subjects [<xref rid=""B15-nutrients-16-03355"" ref-type=""bibr"">15</xref>,<xref rid=""B18-nutrients-16-03355"" ref-type=""bibr"">18</xref>,<xref rid=""B20-nutrients-16-03355"" ref-type=""bibr"">20</xref>]. Similarly, a previous meta-analysis suggested no significant association between PKU and obesity [<xref rid=""B34-nutrients-16-03355"" ref-type=""bibr"">34</xref>].",9_27,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"ref-type=""bibr"">34</xref>].  There was no significant change in the biochemical parameters of PKU patients in accordance with metabolic syndrome and insulin resistance compared to healthy participants. Two studies reported significantly increased total cholesterol and LDL/HDL ratio and lower HDL levels in patients with PKU versus controls [<xref rid=""B11-nutrients-16-03355"" ref-type=""bibr"">11</xref>,<xref rid=""B39-nutrients-16-03355"" ref-type=""bibr"">39</xref>]. On the contrary, although there was no",9_28,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"On the contrary, although there was no statistical difference, total cholesterol and LDL cholesterol levels were lower and HDL cholesterol levels were higher in our patient group compared to the control group. Another study also revealed lower plasma levels of total cholesterol and LDL cholesterol compared to healthy controls [<xref rid=""B37-nutrients-16-03355"" ref-type=""bibr"">37</xref>]. The reason for the lack of difference in our patient group was assumed to be due to the low total amount of energy",9_29,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"to be due to the low total amount of energy consumed by the patients that was below the RDA and the mean proportion of energy derived from carbohydrate being 55.9%. We observed that our patient group did not consume a carbohydrate-rich diet compared to the other study groups, although a Phe-restricted diet may be characterized by greater carbohydrate consumption than the general population [<xref rid=""B40-nutrients-16-03355"" ref-type=""bibr"">40</xref>,<xref rid=""B41-nutrients-16-03355""",9_30,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"rid=""B41-nutrients-16-03355"" ref-type=""bibr"">41</xref>]. The mean albumin level was found to be statistically significantly higher in patients with PKU than in healthy controls. It can reasonably anticipated that, in a group receiving phenylalanine-restricted special nutritional therapy, the ratio of energy provided from carbohydrates will be higher and the ratio of energy provided from protein will be lower compared to the RDA due to this nutritional therapy. In the long term, this type of diet therapy,",9_31,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"In the long term, this type of diet therapy, which is enriched with carbohydrates and low in protein content, may have adverse effects on growth, development, and the synthesis of body proteins, decrease muscle mass, and increase fat mass and the incidence of metabolic syndrome in the patient group. However, in both the male and female patient groups, the ratio of energy derived from carbohydrates was below the levels recommended by the RDA, with the average ratio of energy derived from protein being",9_32,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"ratio of energy derived from protein being between 10 and 12.5%. It was hypothesized that this was the reason why the mean albumin level was statistically higher in the patient group. In a study by Barta et al. using multifrequency BIA, female (but not male) adult subjects with PKU had increased FM and decreased muscle mass as compared to healthy controls [<xref rid=""B36-nutrients-16-03355"" ref-type=""bibr"">36</xref>]. In contrast, Alghamdi et al. observed no statistically significant difference in body",9_33,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"no statistically significant difference in body composition in adult patients [<xref rid=""B41-nutrients-16-03355"" ref-type=""bibr"">41</xref>]. In our cohort, though not statistically significant, muscle mass was higher and fat mass was lower than controls. Despite the absence of a statistically significant difference, the WHR values observed in the patient group were also found to be lower than those observed in the control group. This was attributed to the fact that the energy intake was lower than the RDA",9_34,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"that the energy intake was lower than the RDA and the carbohydrate intake was lower than recommended. Similar to our results, the other groups reported no differences in FM evaluated by BIA in patients with PKU compared with matched or age-related controls [<xref rid=""B20-nutrients-16-03355"" ref-type=""bibr"">20</xref>,<xref rid=""B35-nutrients-16-03355"" ref-type=""bibr"">35</xref>]. Some of the studies that assessed muscle mass found that muscle mass was normal in people diagnosed with PKU [<xref",9_35,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"was normal in people diagnosed with PKU [<xref rid=""B42-nutrients-16-03355"" ref-type=""bibr"">42</xref>], while others reported a loss of muscle mass [<xref rid=""B43-nutrients-16-03355"" ref-type=""bibr"">43</xref>,<xref rid=""B44-nutrients-16-03355"" ref-type=""bibr"">44</xref>]. Female patients with PKU have a higher BMI and prevalence of overweight compared with the general population in a number of retrospective studies [<xref rid=""B7-nutrients-16-03355"" ref-type=""bibr"">7</xref>,<xref",9_36,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"ref-type=""bibr"">7</xref>,<xref rid=""B45-nutrients-16-03355"" ref-type=""bibr"">45</xref>,<xref rid=""B46-nutrients-16-03355"" ref-type=""bibr"">46</xref>]. In our patient group, anthropometric and biochemical evaluations of females with PKU were similar to those of healthy controls, whereas the mean weight of males with PKU was statistically significantly lower than that of healthy men. The proportion of overweight and obese individuals was lower in both male and female PKU groups compared to control groups of",9_37,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"female PKU groups compared to control groups of the same sex. Individuals with PKU were less prone to obesity than the control group. Among male PKU individuals, those with low BMI were more than controls. In this respect, we suggest that especially male PKU patients should be carefully evaluated in terms of nutritional deficiencies.  The mean values for height, muscle mass, and fat mass exhibited statistically significant differences between male and female patient groups. In our cohort, males were taller",9_38,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"patient groups. In our cohort, males were taller and had more muscle mass and less fat mass than females, which was expected due to gender differences. Within another PKU cohort, adolescent and adult males reported higher SMM than females [<xref rid=""B46-nutrients-16-03355"" ref-type=""bibr"">46</xref>]. No statistically significant difference was observed in waist circumference and BMI between the two genders. Consequently, it was hypothesized that there was no difference in the prevalence of abdominal",9_39,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"was no difference in the prevalence of abdominal obesity between male and female patients.  The results of our study indicate that there was no statistically significant difference between the anthropometric measurements and nutritional biochemical parameters of patients with classical PKU and those with mild PKU. However, in another study, the BMI values of patients with classical PKU were observed to be higher than those of the control group. It has been proposed that this may be due to increased energy",9_40,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"proposed that this may be due to increased energy consumption in patients with classical PKU with the intention of preventing an increase in Phe levels [<xref rid=""B34-nutrients-16-03355"" ref-type=""bibr"">34</xref>]. In our patient group, the analyses of three-day food intake records in classical PKU patients revealed no statistically significant difference from those of mild PKU patients.  In the patient cohort, the primary factor contributing to abdominal obesity was not the disease classification or the",9_41,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"obesity was not the disease classification or the gender of the patients, but compliance with treatment. In various studies, a positive correlation of mean Phe levels with BMI [<xref rid=""B1-nutrients-16-03355"" ref-type=""bibr"">1</xref>,<xref rid=""B39-nutrients-16-03355"" ref-type=""bibr"">39</xref>], as well as between mean Phe levels and the prevalence of overweight, was demonstrated, suggesting the association of good metabolic control with a reduced risk of overweight [<xref rid=""B7-nutrients-16-03355""",9_42,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"of overweight [<xref rid=""B7-nutrients-16-03355"" ref-type=""bibr"">7</xref>,<xref rid=""B21-nutrients-16-03355"" ref-type=""bibr"">21</xref>]. Conversely, two studies from Spain reported a higher prevalence of overweight and BMI in patients with good metabolic control compared with those with poor metabolic control [<xref rid=""B47-nutrients-16-03355"" ref-type=""bibr"">47</xref>,<xref rid=""B48-nutrients-16-03355"" ref-type=""bibr"">48</xref>].  Although a lifetime evaluation will provide more detailed information",9_43,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"evaluation will provide more detailed information regarding the impact of dietary treatment on anthropometric measurements, such as height, weight, BMI, WHR, and waist circumference, evaluating the two-year treatment adherence may also be informative in reaching similar conclusions. No statistically significant differences were observed between the three-day food consumption records of the two groups with different treatment adherence ratios. Nevertheless, the quantity of natural protein intake per",9_44,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"the quantity of natural protein intake per kilogram, total protein consumed per kilogram, and protein intake per calorie were observed to be higher in the cohort exhibiting better treatment compliance, although there was no statistically significant difference. The ratio of total energy consumed to the RDA was similar in both groups. This indicates that an elevated protein intake per calorie in the cohort with enhanced treatment efficacy may diminish the propensity for obesity. The quality and quantity of",9_45,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"for obesity. The quality and quantity of natural protein are important factors in determining SMM. Evans et al. showed in a small cohort of children with PKU that natural protein intake above 0.5 g/kg/day was associated with enhanced body composition [<xref rid=""B18-nutrients-16-03355"" ref-type=""bibr"">18</xref>]. Furthermore, Huemer et al. reported that natural protein intake correlated with SMM [<xref rid=""B19-nutrients-16-03355"" ref-type=""bibr"">19</xref>]. In a study by Rocha et al., no significant",9_46,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"In a study by Rocha et al., no significant difference was detected in the median intake of natural protein and protein substitutes between individuals with overweight/obesity and others with PKU [<xref rid=""B49-nutrients-16-03355"" ref-type=""bibr"">49</xref>]. The present study did not evaluate the physical activity levels of the participants. Additionally, the food consumption of the patients was evaluated on a cross-sectional basis. The potential for patients to alter their dietary habits during the",9_47,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"patients to alter their dietary habits during the assessment periods of food consumption, coupled with the fact that the cross-sectional evaluation does not reflect long-term dietary habits, may have precluded the identification of differences in food intake between patient groups. Furthermore, the analysis of patients’ three-day food intake records based on self-reported data may not accurately reflect their actual dietary intake as patients tend to report dietary intakes that align with the prescribed",9_48,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"dietary intakes that align with the prescribed recommendations rather than their actual intake. Pugliese et al. have pointed out that there is considerable heterogeneity in the outcomes reported in the PKU literature [<xref rid=""B50-nutrients-16-03355"" ref-type=""bibr"">50</xref>]. The reasons for this are multifaceted. The assessment and management of patients with PKU is challenging, with significant differences in PKU management practices between countries [<xref rid=""B51-nutrients-16-03355""",9_49,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"countries [<xref rid=""B51-nutrients-16-03355"" ref-type=""bibr"">51</xref>]. The heterogeneity of PKU mutations has consequences for both biochemical and metabolic phenotypes, leading to variability in treatment needs. Furthermore, patients with PKU may suffer from functional and neuropsychological disabilities which impact their adherence to dietary treatments. Caution should be exercised in interpreting the results of studies that employ different criteria for classifying overweight and obese individuals.",9_50,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"for classifying overweight and obese individuals. In addition, the assessment of vitamin, mineral, and trace element intakes, together with analysis of energy, carbohydrate, and fat ratios in dietary intake, may be useful in explaining the differences in the prevalence of obesity and metabolic syndrome in patients. The present study revealed that long-term, Phe-restricted nutrition therapy did not cause any adverse biochemical changes in body composition in our cohort. In view of the growing prevalence of",9_51,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"our cohort. In view of the growing prevalence of overweight in the general population, patients with PKU should be kept under close long-term follow-up. Body composition profiling plays a pivotal role in nutritional evaluation and in understanding the efficacy of nutritional therapy. This is crucial for the prevention of overweight and obesity, as well as the associated comorbidities. Particularly in the group with low treatment compliance, more caution should be paid in terms of adverse outcomes. To",9_52,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"should be paid in terms of adverse outcomes. To properly address problems and to assist in guiding the clinical practice of health professionals, future studies must employ improved methodology.",9_53,Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria,02 10 2024,,Phenylketonuria
"Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity In phenylketonuria (PKU), natural protein intake is thought to increase with age, particularly during childhood and adolescence. Longitudinal dietary intake data are scarce and lifelong phenylalanine tolerance remains unknown. Nine centres managing PKU in Europe and Turkey participated in a retrospective study. Data were collected from dietetic records between 2012 and 2018 on",10_0,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"from dietetic records between 2012 and 2018 on phenylalanine (Phe), natural protein, and protein substitute intake. A total of 1323 patients (age range: 1–57 y; 51% male) participated. Dietary intake data were available on 1163 (88%) patients. Patient numbers ranged from 59 to 320 in each centre. A total of 625 (47%) had classical PKU (cPKU), <italic toggle=""yes"">n</italic> = 357 (27%) had mild PKU (mPKU), <italic toggle=""yes"">n</italic> = 325 (25%) had hyperphenylalaninemia (HPA), and <italic",10_1,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"had hyperphenylalaninemia (HPA), and <italic toggle=""yes"">n</italic> = 16 (1%) were unknown. The mean percentage of blood Phe levels within target ranged from 65 ± 54% to 88 ± 49%. When intake was expressed as g/day, the mean Phe/natural protein and protein equivalent from protein substitute gradually increased during childhood, reaching a peak in adolescence, and then remained consistent during adulthood. When intake was expressed per kg body weight (g/kg/day), there was a decline in Phe/natural protein,",10_2,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"there was a decline in Phe/natural protein, protein equivalent from protein substitute, and total protein with increasing age. Overall, the mean daily intake (kg/day) was as follows: Phe, 904 mg ± 761 (22 ± 23 mg/kg/day), natural protein 19 g ± 16 (0.5 g/kg/day ± 0.5), protein equivalent from protein substitute 39 g ± 22 (1.1 g/kg/day ± 0.6), and total protein 59 g ± 21 (1.7 g/kg/day ± 0.6). Natural protein tolerance was similar between males and females. Patients with mPKU tolerated around 50% less",10_3,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"Patients with mPKU tolerated around 50% less Phe/natural protein than HPA, but 50% more than cPKU. Higher intakes of natural protein were observed in Southern Europe, with a higher prevalence of HPA and mPKU compared with patients from Northern European centres. Natural protein intake doubled with sapropterin usage. In sapropterin-responsive patients, 31% no longer used protein substitutes. Close monitoring and optimisation of protein intake prescriptions are needed, along with future guidelines",10_4,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"are needed, along with future guidelines specifically for different age groups and severities. Phenylketonuria (PKU) is an inherited metabolic disorder of phenylalanine (Phe) metabolism. The gene producing phenylalanine hydroxylase (PAH) fails to be expressed, leading to impaired Phe metabolism and its conversion to tyrosine. PAH activity also requires the pterin co-substrate tetrahydrobiopterin (BH4) for activity [<xref rid=""B1-nutrients-16-02909"" ref-type=""bibr"">1</xref>]. PKU is a neurological disorder,",10_5,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"PKU is a neurological disorder, with Phe accumulating in the brain tissue and biological fluids and leading to neurocognitive and neuropsychiatric sequelae, if untreated. In most countries, it is diagnosed by newborn screening and is treated when blood Phe levels are consistently >360 µmol/L [<xref rid=""B2-nutrients-16-02909"" ref-type=""bibr"">2</xref>]. The degree of PAH loss of function determines the PKU phenotype and correlates with the severity of the disorder [<xref rid=""B3-nutrients-16-02909""",10_6,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"the disorder [<xref rid=""B3-nutrients-16-02909"" ref-type=""bibr"">3</xref>]. Classical PKU (cPKU) is a result of complete or near-complete deficiency of PAH activity and is the most frequent type of PKU globally [<xref rid=""B4-nutrients-16-02909"" ref-type=""bibr"">4</xref>]. The most common variants of PAH in the BIOPKU database [<xref rid=""B5-nutrients-16-02909"" ref-type=""bibr"">5</xref>] are c.1222C>T (p.Arg408Trp) and c.1066-11G>A (p.Gln355_Tyr356insGlyLeuGln); these are severe variants that essentially",10_7,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"these are severe variants that essentially abolish PAH activity. Other variants with varying effects on the activity of PAH may be classified as mild PKU (mPKU) and hyperphenylalaninemia (HPA) associated with residual enzyme activity, and thereby a higher enzyme activity [<xref rid=""B5-nutrients-16-02909"" ref-type=""bibr"">5</xref>]. The severity of PAH deficiency is increasingly analysed by the genotype predictive value [<xref rid=""B3-nutrients-16-02909"" ref-type=""bibr"">3</xref>]. If the diagnostic Phe",10_8,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"ref-type=""bibr"">3</xref>]. If the diagnostic Phe levels prior to treatment commencement is used, then HPA is defined by a pre-treatment blood Phe level of 361–600 μmol/L, mPKU > 600–1200 μmol/L, and cPKU > 1200 μmol/L [<xref rid=""B3-nutrients-16-02909"" ref-type=""bibr"">3</xref>]. The traditional treatment of PKU is a Phe-restricted diet, supplemented with a Phe-free/low Phe protein substitute, special low protein foods (SLPFs), foods low in protein (containing protein ≤ 0.5 g/100 g), and fruits and",10_9,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"protein ≤ 0.5 g/100 g), and fruits and vegetables containing Phe ≤ 75 mg/100 g [<xref rid=""B6-nutrients-16-02909"" ref-type=""bibr"">6</xref>]. The treatment aim in Europe is to maintain a blood Phe between 120 and 360 µmol/L in children up to the age of 12 years, and between 120 and 600 µmol/L aged ≥12 years [<xref rid=""B2-nutrients-16-02909"" ref-type=""bibr"">2</xref>]. In the USA, it is recommended that blood Phe should be ≤360 µmol/L throughout life [<xref rid=""B7-nutrients-16-02909""",10_10,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"life [<xref rid=""B7-nutrients-16-02909"" ref-type=""bibr"">7</xref>], this is still above the physiological range (<120 µmol/L) [<xref rid=""B8-nutrients-16-02909"" ref-type=""bibr"">8</xref>]. In PKU, although normal growth and nutritional status can be attained, clinical problems such as inattention, poor memory and executive function deficits, anxiety, and social and emotional problems commonly occur [<xref rid=""B9-nutrients-16-02909"" ref-type=""bibr"">9</xref>]. Dietary Phe is an indispensable amino acid, and",10_11,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"Dietary Phe is an indispensable amino acid, and some is essential for protein synthesis, tissue growth, and maintenance requirements [<xref rid=""B10-nutrients-16-02909"" ref-type=""bibr"">10</xref>,<xref rid=""B11-nutrients-16-02909"" ref-type=""bibr"">11</xref>,<xref rid=""B12-nutrients-16-02909"" ref-type=""bibr"">12</xref>]. In PKU, this is referred to as the “natural Phe/protein tolerance” and the amount of Phe allocated is individually determined for each patient [<xref rid=""B13-nutrients-16-02909""",10_12,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"each patient [<xref rid=""B13-nutrients-16-02909"" ref-type=""bibr"">13</xref>,<xref rid=""B14-nutrients-16-02909"" ref-type=""bibr"">14</xref>]. Phe tolerance is defined as the maximum amount of Phe/natural protein intake that will maintain blood Phe levels within the therapeutic target range [<xref rid=""B13-nutrients-16-02909"" ref-type=""bibr"">13</xref>]. It is important that the maximum Phe tolerance is attained so that the iatrogenic consequence of overtreatment is avoided [<xref rid=""B2-nutrients-16-02909""",10_13,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"is avoided [<xref rid=""B2-nutrients-16-02909"" ref-type=""bibr"">2</xref>]. Phe tolerance is pragmatically decided by titrating Phe/natural protein intake until blood Phe levels are consistently maintained within the target range. Generally, if blood Phe levels are above or below the target range, the Phe intake is lowered or increased accordingly. In newly diagnosed infants with PKU, it can take time to establish the maximum Phe tolerance, and may even remain underestimated, particularly if blood Phe",10_14,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"remain underestimated, particularly if blood Phe consistently remains within target and a challenge with extra Phe intake is not considered [<xref rid=""B15-nutrients-16-02909"" ref-type=""bibr"">15</xref>]. Phe tolerance is commonly associated with the severity of PKU, with studies commonly describing patients with cPKU with an overall tolerance of ≤500 mg/day of Phe (equivalent to ≤10 g/d of natural protein) at various ages during life [<xref rid=""B2-nutrients-16-02909"" ref-type=""bibr"">2</xref>]. In addition",10_15,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"ref-type=""bibr"">2</xref>]. In addition to the severity of PKU, factors such as inadequate energy intake or illness can cause catabolism, increasing blood Phe levels, and can negatively impact on the amount of natural protein tolerated, while extra protein substitute may enhance Phe tolerance to some extent [<xref rid=""B16-nutrients-16-02909"" ref-type=""bibr"">16</xref>]. Dietary Phe tolerance is expected to improve in a subset of individuals with PAH deficiency in response to treatment with oral sapropterin",10_16,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"in response to treatment with oral sapropterin dihydrochloride, a synthetic form of the natural BH4 cofactor [<xref rid=""B17-nutrients-16-02909"" ref-type=""bibr"">17</xref>,<xref rid=""B18-nutrients-16-02909"" ref-type=""bibr"">18</xref>]. These individuals have PAH genotypes associated with some residual PAH enzyme activity, and patients with cPKU are excluded. Sapropterin is considered to have a chaperone function that stabilises and activates the variant PAH protein [<xref rid=""B19-nutrients-16-02909""",10_17,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"PAH protein [<xref rid=""B19-nutrients-16-02909"" ref-type=""bibr"">19</xref>,<xref rid=""B20-nutrients-16-02909"" ref-type=""bibr"">20</xref>]. Only 20–40% of PAH-deficient patients are sapropterin-responsive [<xref rid=""B21-nutrients-16-02909"" ref-type=""bibr"">21</xref>,<xref rid=""B22-nutrients-16-02909"" ref-type=""bibr"">22</xref>,<xref rid=""B23-nutrients-16-02909"" ref-type=""bibr"">23</xref>], and, in most, partial dietary Phe restriction is still necessary [<xref rid=""B24-nutrients-16-02909""",10_18,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"necessary [<xref rid=""B24-nutrients-16-02909"" ref-type=""bibr"">24</xref>], although long-term Phe tolerance is rarely described. An alternative pharmaceutical treatment for patients > 16 year of age with PKU is Pegvaliase [<xref rid=""B25-nutrients-16-02909"" ref-type=""bibr"">25</xref>]. This enzyme substitution therapy recombinantly produces PEGylated Phe ammonia lyase (PAL) [<xref rid=""B26-nutrients-16-02909"" ref-type=""bibr"">26</xref>]. It is derived from <italic toggle=""yes"">cyanobacterium Anabaena",10_19,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"from <italic toggle=""yes"">cyanobacterium Anabaena variabilis</italic> and converts circulating Phe to trans-cinnamic acid and clinically non relevant amounts of ammonia [<xref rid=""B27-nutrients-16-02909"" ref-type=""bibr"">27</xref>]. It lowers blood Phe and enables many patients to have an unrestricted diet while maintaining blood Phe levels in the target therapeutic range or even at physiological levels. However, this treatment is administered by daily subcutaneous injection and is associated with",10_20,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"subcutaneous injection and is associated with immune-mediated hypersensitivity reactions [<xref rid=""B28-nutrients-16-02909"" ref-type=""bibr"">28</xref>]. The number of countries with access to Pegvaliase is still very limited, while the global numbers of patients benefiting from this treatment is unknown [<xref rid=""B29-nutrients-16-02909"" ref-type=""bibr"">29</xref>,<xref rid=""B30-nutrients-16-02909"" ref-type=""bibr"">30</xref>]. Very little has been published about the changes in lifelong dietary Phe",10_21,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"about the changes in lifelong dietary Phe tolerance in PKU, particularly across the different severities [<xref rid=""B13-nutrients-16-02909"" ref-type=""bibr"">13</xref>]. Although studies commonly report the Phe/natural protein intake as part of their secondary outcomes, most studies are cross-sectional, provide limited dietary intake data, and often describe childhood Phe intake only [<xref rid=""B13-nutrients-16-02909"" ref-type=""bibr"">13</xref>]. Due to insufficiency of evidence in individual studies, a",10_22,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"of evidence in individual studies, a recent systematic review and meta-analysis provided a better understanding of lifelong Phe/natural tolerance [<xref rid=""B13-nutrients-16-02909"" ref-type=""bibr"">13</xref>]. Data from 37 articles were analysed, including 2464 patients with PKU. A meta-analysis of 18 studies showed that Phe and natural protein tolerance slightly increased from birth until 10 years with an average Phe intake of <500 mg/day (range: 267–460) and natural protein intake of <13 g/day (range:",10_23,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"and natural protein intake of <13 g/day (range: 5–13). With the onset of pubertal growth spurt, there was an additional increase in Phe tolerance of +250 mg/day (+5 g/day of natural protein), allowing a Phe intake of ≈710 mg/day (18 g/day of natural protein) [<xref rid=""B13-nutrients-16-02909"" ref-type=""bibr"">13</xref>]. At the end of adolescence, natural protein tolerance reached its highest peak, with an average daily tolerance of 32 g/day, remaining consistent through adulthood (1160–1810 mg/day Phe).",10_24,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"through adulthood (1160–1810 mg/day Phe). However, historically, variable target blood Phe levels were used by different centres worldwide, small study sample sizes (particularly for adults), incomplete and diverse data on PKU severity, and inadequate or unclear reporting of dietary Phe/natural protein intake complicated the results, and this reinforced the need to carefully interpret the results [<xref rid=""B13-nutrients-16-02909"" ref-type=""bibr"">13</xref>]. Accurately estimating Phe/natural protein",10_25,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"Accurately estimating Phe/natural protein tolerance in PKU is challenging [<xref rid=""B31-nutrients-16-02909"" ref-type=""bibr"">31</xref>]. Different PKU centres use dissimilar protocols for controlling the amount of daily Phe/natural protein consumed. Some calculate all the Phe/natural protein intake from all foods, whereas others permit the unlimited use of fruit and vegetables (except potatoes) containing Phe ≤ 75 mg/100 g as it does not have a negative impact on blood Phe control [<xref",10_26,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"a negative impact on blood Phe control [<xref rid=""B32-nutrients-16-02909"" ref-type=""bibr"">32</xref>,<xref rid=""B33-nutrients-16-02909"" ref-type=""bibr"">33</xref>,<xref rid=""B34-nutrients-16-02909"" ref-type=""bibr"">34</xref>]. This may partly explain the heterogeneity between study results investigating the dietary intakes. Additionally, foods containing protein ≤ 0.5 g/100 g are allowed without measurement in certain countries. Some countries may use an exchange system for allocating Phe intake and it has",10_27,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"system for allocating Phe intake and it has been shown that different dietary systems for allocating Phe achieve similar blood Phe control [<xref rid=""B35-nutrients-16-02909"" ref-type=""bibr"">35</xref>]. In countries that recommend an exchange system, variable definitions to define one exchange are used (e.g., 20 mg, 25 mg, 50 mg Phe), and there is a disparity between the amount of Phe that is prescribed compared with the actual amount eaten. In a recent study from the UK, using a 1 g protein exchange",10_28,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"study from the UK, using a 1 g protein exchange system (equivalent to around 50 mg Phe), patients consumed 40% more natural protein (+4 g/day) than prescribed without deterioration in blood Phe control [<xref rid=""B36-nutrients-16-02909"" ref-type=""bibr"">36</xref>]. In addition, a higher recommended blood Phe target range may permit more dietary Phe/natural protein. Overall, there are no studies assessing lifetime Phe/natural protein tolerance in patients with PKU. Similarly, no studies account for the",10_29,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"with PKU. Similarly, no studies account for the different variable factors influencing Phe/natural protein tolerance. To date, only one systematic review (including studies mostly from Europe, <italic toggle=""yes"">n</italic> = 30/37 studies) has described the changes in Phe/natural protein tolerance throughout a lifetime, but there were a number of limitations (e.g., different ways of presenting dietary intake analysis, and different target levels used to define good metabolic control) [<xref",10_30,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"used to define good metabolic control) [<xref rid=""B13-nutrients-16-02909"" ref-type=""bibr"">13</xref>]. Our aim was to assess dietary intake in a large cohort of patients with PKU from Europe and Turkey.   This was an observational, longitudinal and retrospective study in a large patient cohort (<italic toggle=""yes"">n</italic> = 1323) from eight European centres and one Turkish centre with PKU describing intakes of Phe, natural protein, and protein equivalent from protein substitutes in different age",10_31,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"from protein substitutes in different age groups, gender, and PKU severity. Although in PKU, a Phe-restricted diet has been prescribed for over seven decades, little is known about Phe tolerance throughout life and many studies only report dietary intake data as their secondary outcome. When expressed as mg/day and g/day, the mean Phe, natural, and protein equivalent intake from protein substitute gradually increased with age, reaching a peak in adolescence (between 13 and 18 years of age), and then",10_32,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"(between 13 and 18 years of age), and then remained consistent during adulthood. When intake data were expressed as per kg body weight (g/kg/day), there was a decline in Phe/natural protein, protein equivalent from protein substitute, and total protein with increasing age. Natural protein tolerance was comparable between males and females. Patients with mPKU tolerated around 50% less Phe/natural protein compared with HPA, and cPKU patients only tolerated 50% of the Phe/natural protein intake of mPKU",10_33,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"50% of the Phe/natural protein intake of mPKU patients. Higher intakes of natural protein were observed in Southern Europe, with a higher prevalence of HPA and mPKU compared with patients from Northern European centres. Natural protein intake doubled with sapropterin usage in BH4-responsive patients, with 31% no longer using protein substitutes. It is well established that patients with cPKU tolerate ≤500 mg/day of Phe (≤10 g/day), which is usually derived from fruit, vegetable, and cereal sources, but",10_34,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"from fruit, vegetable, and cereal sources, but little information has been published about the Phe tolerance of patients with mPKU and HPA [<xref rid=""B37-nutrients-16-02909"" ref-type=""bibr"">37</xref>]. In our study, we found that mean lifetime natural protein intake was 48 g/day in HPA and 26 g/day in mPKU compared with a mean intake of 13 g/day in cPKU. The difference in Phe/natural protein tolerance between the classical and milder forms showed a similar trend in all age groups, such that the tolerance",10_35,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"trend in all age groups, such that the tolerance in mPKU and HPA patients was approximately 1.5 up to 4 times higher than in cPKU. Age was another factor affecting Phe/natural tolerance. In this longitudinal study, daily Phe/natural protein intake increased with age, similar to what was described in a recent systematic review and meta-analysis [<xref rid=""B13-nutrients-16-02909"" ref-type=""bibr"">13</xref>]. However, the lack of data on Phe/natural protein tolerance in patients > 40 years of age was one of",10_36,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"in patients > 40 years of age was one of the limitations of the meta-analysis. Our data for cPKU were comparable to van Spronsen et al. [<xref rid=""B38-nutrients-16-02909"" ref-type=""bibr"">38</xref>], who described patients tolerating between 35 and 45 mg/kg of Phe in the first year of life (a mean of 38 mg/kg/day in our study), decreasing to 14 mg/kg at the age of 10 y (also a mean of 14 mg/kg in our study). We further provided data on Phe tolerance in a relatively large sample of adults (<italic",10_37,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"in a relatively large sample of adults (<italic toggle=""yes"">n</italic> = 442), which varied between 7 and 18 mg/kg/day. These study findings assist in patient guidance about expected natural protein tolerance at different life stages and help manage their expectations. Attaining the maximum natural protein tolerance is essential to optimize growth and body composition, and aid dietary adherence, ultimately easing the burden of dietary care and costs of overtreatment. It also enables a personalized",10_38,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"of overtreatment. It also enables a personalized approach to dietary care. In clinical practice, the same dietary method is commonly applied to all patients irrespective of PKU severity, but, potentially, a more flexible approach can be adopted for mPKU. In a cohort of 99 patients with PKU, Gomes et al. [<xref rid=""B39-nutrients-16-02909"" ref-type=""bibr"">39</xref>] showed that patients with mPKU were able to eat more and varied animal protein sources and had a higher natural protein/protein equivalent from",10_39,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"a higher natural protein/protein equivalent from protein substitute ratio in comparison with cPKU. Patients with mPKU should be able to eat a wider range of foods, possibly without calculation of Phe/natural protein, particularly from fruits and vegetables, whose Phe content is more than 75 mg/100 g. Caregivers of patients with mPKU could be encouraged to eat higher biological quality protein food sources such as milk, cheese, yoghurt, and eggs from weaning age. This will help increase the dietary quality",10_40,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"age. This will help increase the dietary quality and variety, and potentially help reduce longer term food neophobia and aversive eating patterns in some patients, which are issues commonly reported in patients with PKU [<xref rid=""B40-nutrients-16-02909"" ref-type=""bibr"">40</xref>]. It is also expected that patients with mPKU should be able to tolerate GMP-based protein substitutes without calculation of their Phe content. Understanding the expected Phe tolerance of patients, particularly with HPA and",10_41,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"tolerance of patients, particularly with HPA and mPKU, may avoid overtreatment. Over restriction of natural protein is a potential concern in PKU, with Phe tolerance potentially remaining unchallenged if blood Phe remains comfortably within target range. Studies from Centre E demonstrated that 65% of the patients, mainly with HPA or mPKU, were able to increase their natural protein intake by a median of 12 g/day when they were challenged with extra protein prior to sapropterin responsiveness testing [<xref",10_42,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"to sapropterin responsiveness testing [<xref rid=""B15-nutrients-16-02909"" ref-type=""bibr"">15</xref>,<xref rid=""B39-nutrients-16-02909"" ref-type=""bibr"">39</xref>]. Two studies observed that small cohorts of adult patients with PKU also tolerated more protein than prescribed by their clinics [<xref rid=""B41-nutrients-16-02909"" ref-type=""bibr"">41</xref>,<xref rid=""B42-nutrients-16-02909"" ref-type=""bibr"">42</xref>]. Creating a predictive mathematical model for natural protein tolerance in PKU would be a",10_43,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"for natural protein tolerance in PKU would be a particularly valuable tool and help with patient care decision making. Harnessing the data collected in this study, any historical information and new research data for such predictive analytics could give guidance on likely lifelong Phe tolerance according to PKU genotype, age, sex, and treatment course. This is similar to the function of the BIOPKU database [<xref rid=""B5-nutrients-16-02909"" ref-type=""bibr"">5</xref>] that predicts sapropterin response based",10_44,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"that predicts sapropterin response based on variant analysis and is commonly used and highly regarded by the PKU community. Different systems were used by the PKU centres to allocate Phe intake and that may have influenced the amount of Phe intake prescribed in this study. In accordance with the European PKU guidelines, Centres B, C, E, and H gave fruit and vegetables containing Phe < 76 mg/100 g (except potatoes) in unmeasured amounts, and they attained an overall blood Phe control within target close to",10_45,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"overall blood Phe control within target close to 80% or more (except for Centre H with 71% in target range). Many centres using stricter dietary management practices did not achieve higher percentages of blood Phe levels within target range, showing that calculating and measuring the Phe content of all foods does not necessarily improve metabolic control. Various studies [<xref rid=""B36-nutrients-16-02909"" ref-type=""bibr"">36</xref>,<xref rid=""B43-nutrients-16-02909"" ref-type=""bibr"">43</xref>] have",10_46,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"ref-type=""bibr"">43</xref>] have previously demonstrated that patients consumed extra Phe (40 and 50%, respectively) when consuming fruit and vegetables containing Phe < 76 mg/100 g without limit but without deterioration in metabolic control [<xref rid=""B32-nutrients-16-02909"" ref-type=""bibr"">32</xref>,<xref rid=""B33-nutrients-16-02909"" ref-type=""bibr"">33</xref>,<xref rid=""B34-nutrients-16-02909"" ref-type=""bibr"">34</xref>]. In our study, the overall mean protein equivalent prescription from protein",10_47,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"mean protein equivalent prescription from protein substitute in patients with PKU from nine centres was 39 g/day (1.1 g/kg/day), which constitutes nearly 66% of mean total protein intake (59 g/day; 1.7 g/kg/day). The optimal protein requirements in PKU are unknown. Compared with the WHO/FAO/UNU 2007 safe levels of protein intake [<xref rid=""B44-nutrients-16-02909"" ref-type=""bibr"">44</xref>], infants and children with PKU in our study were prescribed more than twice the safe level of intake, whilst the mean",10_48,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"twice the safe level of intake, whilst the mean prescribed total protein intakes of adolescents and adults were approximately 1.2 to 1.5 times the recommended safe intake due to low utilization of protein equivalent from protein substitute. Centres from Northern and Eastern Europe prescribed more protein equivalent from protein substitutes compared with centres from Central and Southern Europe. Similar findings have been reported by Aguiar et al. (2015) [<xref rid=""B45-nutrients-16-02909""",10_49,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"et al. (2015) [<xref rid=""B45-nutrients-16-02909"" ref-type=""bibr"">45</xref>]. The amount of protein equivalent intake from protein substitutes was affected by the age, severity, and the type of treatment but not by gender. Patients with cPKU were prescribed approximately 1.5 times more protein equivalent from protein substitutes than mPKU patients, and cPKU patients were particularly reliant on protein substitute to provide most of their protein intake, with a protein equivalent from protein substitute to",10_50,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"a protein equivalent from protein substitute to natural protein ratio of 1:0.3 compared with a ratio of 1:0.8 in g/kg/day in mPKU patients. In contrast, patients with HPA had a minimal intake of protein equivalent from protein substitutes, which was usually around 0.1–0.3 g/kg/day. The total protein intake we report is in line with the recommendations by the European guidelines (140% of FAO/WHO/UNU safe levels of protein intake) [<xref rid=""B2-nutrients-16-02909"" ref-type=""bibr"">2</xref>]; however, 50",10_51,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"ref-type=""bibr"">2</xref>]; however, 50 patients in our cohort were prescribed less than the safe levels of protein intake. More than 50% of those patients were from Centre A, where access to treatment was limited, particularly to protein substitutes, which may have impacted the amount of total protein prescribed. Another important factor that may impact the interpretation of protein adequacy was that 48% of these patients were overweight. It is suggested in the literature that protein intake must be",10_52,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"in the literature that protein intake must be prescribed according to ideal weight rather than actual weight when considering overweight and obesity. However, the classification of overweight also has its limitations, as patients with a high percentage of muscle mass may have a high BMI [<xref rid=""B46-nutrients-16-02909"" ref-type=""bibr"">46</xref>]. Consideration should be given to measuring body composition (e.g., percentage of lean mass) when determining and recommending protein requirements [<xref",10_53,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"and recommending protein requirements [<xref rid=""B47-nutrients-16-02909"" ref-type=""bibr"">47</xref>]. The European [<xref rid=""B2-nutrients-16-02909"" ref-type=""bibr"">2</xref>], USA [<xref rid=""B7-nutrients-16-02909"" ref-type=""bibr"">7</xref>] and Australian guidelines [<xref rid=""B48-nutrients-16-02909"" ref-type=""bibr"">48</xref>] advise additional protein substitute (≈120–140% of RDA) to compensate for the inefficiency of protein utilization of amino acids in addition to the pharmacological impact of",10_54,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"in addition to the pharmacological impact of protein substitute lowering blood Phe levels. They suggest that the same percentage increase in protein equivalent is necessary for both children and adults, and recommendations do not discuss how requirements may change with the severity of PKU. It is expected that patients with mPKU will require less protein equivalent than cPKU, due to a higher natural protein tolerance, therefore there is less concern about inefficient protein utilization. Furthermore, in",10_55,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"inefficient protein utilization. Furthermore, in adulthood, different life stages need protein requirement adjustments, particularly for pregnancy, lactation, and potentially the elderly. There is particular concern that protein requirements may be underestimated in the elderly, who may be at risk of sarcopenia [<xref rid=""B16-nutrients-16-02909"" ref-type=""bibr"">16</xref>,<xref rid=""B49-nutrients-16-02909"" ref-type=""bibr"">49</xref>]. Generally, we have limited data about the protein status and body",10_56,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"limited data about the protein status and body composition of adults with PKU, particularly if they have had a lifetime of low natural protein intake mainly sourced from plant protein. Further careful examination of total protein intake and requirements is needed. In this study, all centres used Phe-free L-AA as a source of protein substitute, with four centres prescribing some patients GMP-based protein substitutes to provide all or part of their protein equivalent requirement. In our patient cohort,",10_57,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"equivalent requirement. In our patient cohort, <italic toggle=""yes"">n</italic> = 61 adults were taking LNAA from Centres A, E, G, and I that may have contributed to a higher amount of natural protein consumed as they followed a less restricted protein intake. Ahring et al. advocate that LNAA should provide only 25–30% of total daily protein requirements, with the rest of the protein requirements met by natural protein [<xref rid=""B50-nutrients-16-02909"" ref-type=""bibr"">50</xref>]. In general, LNAA are not",10_58,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"In general, LNAA are not recommended by the European PKU guidelines due to a lack of efficacy in human studies [<xref rid=""B2-nutrients-16-02909"" ref-type=""bibr"">2</xref>], despite a long history of patient usage. It is suggested that higher amounts of LNAA compete with Phe at the blood–brain barrier, decreasing the uptake of Phe into the brain. Van Vliet et al., in a mice study, found that brain Phe concentrations were similar using LNAA with and without a Phe-restricted diet [<xref",10_59,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"with and without a Phe-restricted diet [<xref rid=""B51-nutrients-16-02909"" ref-type=""bibr"">51</xref>]. More data are needed regarding the quality of dietary intake and neurocognitive outcome when prescribing LNAA. As reported in several previous studies, we observed that mean Phe intake doubled with BH4-responsive patients treated with sapropterin dihydrochloride. Although the total protein intake did not change, similar to the data reported by Ilgaz et al. [<xref rid=""B24-nutrients-16-02909""",10_60,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"Ilgaz et al. [<xref rid=""B24-nutrients-16-02909"" ref-type=""bibr"">24</xref>], the protein equivalent intake from protein substitute decreased. In the systematic review of Ilgaz et al., 51% of patients were able to discontinue protein substitute, compared with only 31% in our study. Overall, our study reported that only 17% of the patient cohort were prescribed sapropterin, partly explained by limited or no access to this treatment by two of our centres. Our results are similar to other studies. In a single",10_61,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"results are similar to other studies. In a single centre study, with 2-year follow-up data, Phe intake increased from 421 mg to 1470 mg on sapropterin [<xref rid=""B52-nutrients-16-02909"" ref-type=""bibr"">52</xref>]. The USA PKUDOS registry showed that, after 6 years of sapropterin therapy, Phe tolerance increased from 1000 mg/day to 1539 mg/day while lowering blood Phe levels [<xref rid=""B53-nutrients-16-02909"" ref-type=""bibr"">53</xref>]. Gama et al. have also shown, in a 6-month study, that natural protein",10_62,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"shown, in a 6-month study, that natural protein intake increased from 11 g/day to 30 g/day in BH4-responsive patients, while maintaining blood Phe levels within range [<xref rid=""B54-nutrients-16-02909"" ref-type=""bibr"">54</xref>]. More long-term Phe tolerance data are required with sapropterin usage. From these data, some wide-ranging conclusions could be drawn. In general, natural protein intake (g/day) increased during childhood, reaching its highest amount during adolescence. cPKU patients only",10_63,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"amount during adolescence. cPKU patients only tolerated 50% of the natural protein of patients with mPKU. Natural protein intake doubled with sapropterin treatment. More data are required to examine protein intake throughout adulthood, including aging. Future PKU guidelines should address protein requirements based on specific characteristics that can impact requirements, e.g., age, PKU severity, body composition accounting for overweight and obesity, and pharmaceutical treatments.",10_64,Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity,31 8 2024,,Phenylketonuria
"Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data  <list list-type=""simple"" id=""l0005""><list-item id=""li0005""><label>•</label><p id=""p0005"">Large study on health economic impact of PKU in France with French SNDS database.</p></list-item><list-item id=""li0010""><label>•</label><p id=""p0010"">Patients with PKU had 7.7 times higher costs compared with non-PKU controls.</p></list-item><list-item id=""li0015""><label>•</label><p",11_0,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"id=""li0015""><label>•</label><p id=""p0015"">Impact was most evident in early-diagnosed PKU with drug costs as main driver.</p></list-item><list-item id=""li0020""><label>•</label><p id=""p0020"">Costs of patients with late-diagnosed PKU were driven by inpatient care costs.</p></list-item><list-item id=""li0025""><label>•</label><p id=""p0025"">Mortality was higher for patients with PKU.</p></list-item></list> Phenylketonuria (PKU) is a rare inherited metabolic disorder. It is characterized by a deficiency in the",11_1,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"It is characterized by a deficiency in the enzyme phenylalanine hydroxylase (PAH) which leads to an accumulation of the essential amino acid phenylalanine (Phe) to potentially toxic levels in the blood and brain [<xref rid=""bb0005"" ref-type=""bibr"">1</xref>]. Different phenotypes of PAH deficiency from mild hyperphenylalaninemia to classic PKU (severe PAH deficiency) exist depending on residual PAH activity [<xref rid=""bb0010"" ref-type=""bibr"">2</xref>]. At the time of this study, patients were classified",11_2,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"the time of this study, patients were classified into classic PKU (>1200 μmol/L), mild PKU (600–1200 μmol/L), and mild hyperphenylalaninemia (120–600 μmol/L) according to untreated plasma Phe [<xref rid=""bb0015"" ref-type=""bibr"">3</xref>]. The incidence of PKU varies worldwide. In Europe, approximately 1 in 8000 newborns is diagnosed with PAH deficiency [<xref rid=""bb0020"" ref-type=""bibr"">4</xref>] and 1 in 12,500 newborns is diagnosed with PKU [<xref rid=""bb0025"" ref-type=""bibr"">5</xref>]. The mean",11_3,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"rid=""bb0025"" ref-type=""bibr"">5</xref>]. The mean incidence in France from 1972 until 2016 was approximately 1:10,000 newborns for PAH deficiency (including classic PKU, mild PKU and mild hyperphenylalaninemia) and 1:16,500 newborns for classic and mild PKU [<xref rid=""bb0030"" ref-type=""bibr"">6</xref>]. If left untreated, PKU results in severe irreversible intellectual disability, growth failure, hypopigmentation, motor deficits, ataxia, and seizures [<xref rid=""bb0010"" ref-type=""bibr"">2</xref>,<xref",11_4,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"rid=""bb0010"" ref-type=""bibr"">2</xref>,<xref rid=""bb0035"" ref-type=""bibr"">7</xref>]. Therefore, early diagnosis is crucial and treatment with a low-Phe diet is recommended for all patients with untreated blood Phe concentrations over 360 μmol/L before the age of 12 years and over 600 μmol/L after the age of 12 years to prevent irreversible impairments in children and minimize morbidity in adolescents and adults [<xref rid=""bb0005"" ref-type=""bibr"">1</xref>,<xref rid=""bb0035"" ref-type=""bibr"">7</xref>,<xref",11_5,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"rid=""bb0035"" ref-type=""bibr"">7</xref>,<xref rid=""bb0040"" ref-type=""bibr"">8</xref>]. Adjuvant treatment with sapropterin can benefit a subset of patients with residual PAH activity who show sufficient response to the BH4 (tetrahydrobiopterin) testing protocol [<xref rid=""bb0005"" ref-type=""bibr"">1</xref>]. Enzyme substitution therapy with phenylalanine ammonia lyase provides an alternative treatment option to a low-Phe diet for adults but was not available in France at the time of the study [<xref",11_6,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"in France at the time of the study [<xref rid=""bb0035"" ref-type=""bibr"">7</xref>,<xref rid=""bb0045"" ref-type=""bibr"">9</xref>]. Newborn screening (NBS) for PKU facilitates early diagnosis and management of PKU and helps to improve patients' prognosis [<xref rid=""bb0050"" ref-type=""bibr"">10</xref>]. In France, a nationwide NBS for PKU was implemented in 1972 [<xref rid=""bb0030"" ref-type=""bibr"">6</xref>]. Even though the combination of NBS and available treatment options enables the prevention of most severe",11_7,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"options enables the prevention of most severe manifestations of PKU, patients with PKU were shown to have increased rates of age-related comorbidities like osteoporosis, hypertension, dyslipidemias, diabetes, and ischemic heart disease as well as increased rates of depression and obesity [<xref rid=""bb0055"" ref-type=""bibr"">[11]</xref>, <xref rid=""bb0060"" ref-type=""bibr"">[12]</xref>, <xref rid=""bb0065"" ref-type=""bibr"">[13]</xref>, <xref rid=""bb0070"" ref-type=""bibr"">[14]</xref>, <xref rid=""bb0075""",11_8,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"ref-type=""bibr"">[14]</xref>, <xref rid=""bb0075"" ref-type=""bibr"">[15]</xref>]. Accordingly, the health economic impact of PKU was shown to be substantial considering not only PKU-specific but all received healthcare [<xref rid=""bb0060"" ref-type=""bibr"">12</xref>,<xref rid=""bb0080"" ref-type=""bibr"">16</xref>]. The aim of this study was to gain insights into the health economic impact of patients with PKU in France using the French health insurance database SNDS (Système National des Données de Santé).   This",11_9,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"(Système National des Données de Santé).   This large study of PKU patients in France analyzed the French health insurance claims database SNDS covering >98% of the French population. The results indicate that PKU has a substantial health economic impact in France. Compared with an age-, sex-, and region-matched control group without PKU from the general French population, patients with PKU had 7.7 times higher mean healthcare costs than controls in 2018. Costs for outpatient pharmaceutical treatment were",11_10,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"for outpatient pharmaceutical treatment were the main cost driver and contributed 80% of the overall mean cost difference between patients with PKU and matched controls. More than half of the pharmaceutical costs (52%) incurred by patients with PKU was attributable to medical foods including dietary amino acid supplements, although only 39% of patients were treated with them. The increased health economic impact was most evident in patients with early-diagnosed PKU. They had 13.2 times higher healthcare",11_11,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"PKU. They had 13.2 times higher healthcare costs in 2018 than matched controls, especially due to outpatient pharmaceutical costs that contributed 89% of the overall mean cost difference between patients and controls. Again, more than half of the pharmaceutical costs (54%) were attributable to medical foods including dietary amino acid supplements, but only 48% of patients with early-diagnosed PKU received them. Sapropterin contributed 35% of the pharmaceutical costs, meaning that PKU-specific treatments",11_12,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"costs, meaning that PKU-specific treatments explained nearly 90% of the pharmaceutical costs of patients with early-diagnosed PKU. Patients with late-diagnosed PKU had 2.7 times higher healthcare costs than matched controls in 2018. As opposed to early-diagnosed patients, the main cost driver for late-diagnosed patients were costs for inpatient care which contributed 56% of the overall mean cost difference. Another notable finding is that only 3% of patients with late-diagnosed PKU received medical foods",11_13,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"with late-diagnosed PKU received medical foods including dietary amino acid supplements. This might be due to changes in the French recommendations of 2010, which previously allowed an enlarged diet for adult patients as long as levels of Phe remained <1200 μmol/L and were reinforced to recommend strict diet for life only in 2018. Moreover, depending on the neurological state and the severity of further PKU-related sequelae, the presciption of dietary amino acid supplements can be difficult to consider for",11_14,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"acid supplements can be difficult to consider for physicians or patients may have difficulties to be compliant with their diet. Higher healthcare costs for younger patients with PKU were also shown in an additional analysis that stratified the overall PKU cohort in patients aged <16 years and patients aged ≥16 years. Compared to their matched controls without PKU, patients aged <16 years had 19.6-fold increased healthcare costs and patients aged ≥16 years had 5.0-fold increased healthcare costs. The cost",11_15,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"had 5.0-fold increased healthcare costs. The cost increase in patients <16 years old (mean age 7.5 years), which was more pronounced than in the group of early-diagnosed patients (mean age 18.2 years), demonstrates that the health economic impact of PKU is especially high in children with PKU. In accordance with these findings, the study showed increased hospitalization and outpatient healthcare rates for patients with PKU compared with matched controls in 2018. More patients than controls were",11_16,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"in 2018. More patients than controls were hospitalized in 2018, especially among patients with late-diagnosed PKU. The increase in one-day hospitalizations could be attributed to more consultations with dieticians or bone density measurements for patients with PKU. Additionally, outpatient consultations in the hospital and paramedical care including consultations of nurses or physiotherapists were more frequent in patients with PKU, irrespective if early- or late-diagnosed, compared with matched controls",11_17,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"or late-diagnosed, compared with matched controls without PKU. Furthermore, medical devices and transportations for medical reasons were required for more patients with PKU than controls. These findings are in line with a study investigating the health economic impact of adult patients with PKU in Germany [<xref rid=""bb0080"" ref-type=""bibr"">16</xref>]. The authors found 2.3 times higher annual healthcare costs for adult patients with PKU than age- and sex-matched controls without PKU. In accordance with",11_18,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"controls without PKU. In accordance with our study, pharmaceutical costs were the main cost driver in the overall and early-diagnosed PKU cohort and inpatient costs were driving the costs in patients with late-diagnosed PKU. Additionally, as in our study, the health economic impact was particularly evident in adult patients with early-diagnosed PKU. Increased rates of hospitalizations for patients with PKU were also observed in accordance with our study. Overall, the findings from the German study [<xref",11_19,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"the findings from the German study [<xref rid=""bb0080"" ref-type=""bibr"">16</xref>] are consistent with our results, however, the mean cost differences between adult patients with PKU in Germany and matched controls were less pronounced than in our study. A U.S. study of adult patients with PKU also found 3.2 times higher healthcare costs for patients with PKU than matched controls [<xref rid=""bb0060"" ref-type=""bibr"">12</xref>]. An exploratory study in ten European specialist PKU centers [<xref rid=""bb0090""",11_20,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"specialist PKU centers [<xref rid=""bb0090"" ref-type=""bibr"">18</xref>] demonstrated that dietary amino acid supplements were the most expensive item in the dietary management of PKU. Our findings also showed that the medical foods including dietary amino acid supplements accounted for more than half of the outpatient pharmaceutical costs in patients with early-diagnosed PKU even though only a fraction of adult patients with early-diagnosed PKU received medical foods including dietary amino acid supplements.",11_21,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"foods including dietary amino acid supplements. Concerning healthcare costs, it needs to be pointed out that the excess costs shown in our study were expected due to the comparison of individuals with a severe disease and those without the disease. Showing the health economic burden related to the management of a severe genetic disease was the aim of this study. However, this study did not assess the cost-savings associated with the treatment of patients with PKU. Exploring cost-savings would be an",11_22,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"with PKU. Exploring cost-savings would be an important part of understanding and improving the management and treatment of patients with PKU and should be targeted in future research. The prevalence of PKU on December 31st, 2018 was estimated at 5.2 per 100,000 inhabitants in France in our study. In view of a reported mean incidence in France of 1:10,000 (10:100,000) newborns for PAH deficiency and 1:16,500 (6:100,000) newborns for PKU from 1972 until 2016 [<xref rid=""bb0030"" ref-type=""bibr"">6</xref>], the",11_23,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"rid=""bb0030"" ref-type=""bibr"">6</xref>], the estimation from our study is at the lower bound of reported ranges, even when considering the estimated mortality rate of 1.3% from our study. An explanation may be the possible underrepresentation of older patients with PKU in our study that is described in the following. This study has some limitations. As mentioned above, older patients with PKU in France seem to be underrepresented in our study as outlined in [<xref rid=""bb0070""",11_24,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"in our study as outlined in [<xref rid=""bb0070"" ref-type=""bibr"">14</xref>,<xref rid=""bb0075"" ref-type=""bibr"">15</xref>]. A possible reason could be that patients who are treated in nursing homes or specialized centers cannot be identified in the SNDS database as their ICD-10 codes are not documented in the SNDS database. Additionally, patients born before the implementation of nationwide NBS, and by definition older patients, may not have been diagnosed at all. Patients with PKU were identified via the",11_25,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"at all. Patients with PKU were identified via the ICD-10 codes E70.0 and E70.1 which may have led to the inclusion of individuals without PKU, because the latter code includes patients with disorders of the BH4 metabolism i.e., non-phenylketonuric hyperphenylalaninemia. As this is a very rare condition [<xref rid=""bb0095"" ref-type=""bibr"">19</xref>], the impact of the inclusion of such patients is considered to be small. Furthermore, the classification of patients with early- and late-diagnosed PKU was",11_26,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"patients with early- and late-diagnosed PKU was based on the year of birth in relation to the nationwide implementation of the NBS in France in 1972. This approach does not account for patients who were born in French regions where the NBS was introduced earlier, for patients who may have been born in other countries without NBS program, or for patients born before NBS but with older siblings with diagnosed PKU (who were therefore diagnosed at birth and became early-diagnosed patients). Finally, the SNDS",11_27,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"early-diagnosed patients). Finally, the SNDS database does not provide information about the level of education, income and socio-professional category of the insured. Additionally, as all administrative claims databases, the SNDS database only contains information about care that was actually reimbursed, and neither self-treatment nor the use of prescribed medications that are not reimbursed can be measured. Likewise, it is not possible to evaluate the compliance of patients, since, for example,",11_28,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"the compliance of patients, since, for example, pharmaceuticals that are prescribed but not filled by the patients are not documented in the SNDS. Moreover, the SNDS database does not contain any clinical information such as laboratory test or medical imaging results. This retrospective observational study using the French health insurance claims database SNDS demonstrated that PKU is associated with a high health economic burden in France. Considering all healthcare cost domains, patients with PKU created",11_29,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"cost domains, patients with PKU created 7.7 times higher mean healthcare costs in 2018 than age-, sex-, and region-matched controls without PKU. The health economic impact was most evident in patients with early-diagnosed PKU who had 13.2 times higher costs than matched controls. Costs for outpatient pharmaceutical treatment were revealed to be the main cost driver, with more than half of the pharmaceutical costs being attributable to medical foods including dietary amino acid supplements. For",11_30,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"including dietary amino acid supplements. For late-diagnosed and by definition older patients with PKU, the excess costs compared with matched controls were mostly driven by costs for inpatient care. The excess costs would likely be even higher if treatment compliance and follow-up of elderly patients improved. The health economic impact of PKU is reflected by increased hospitalization and outpatient healthcare rates of patients with PKU. Indirect costs for the society such as lack of employment or",11_31,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"for the society such as lack of employment or disability allowances, which could not be covered within this study in total, might further contribute to the increased health economic impact. Future research should investigate if the increased healthcare costs of patients with early-diagnosed PKU will lead to a reduced burden of disease when these patients reach an advanced age. This work was supported by BioMarin Europe Ltd. JBA, FM, and SC received expert honoraria from BioMarin. SB is a full-time employee",11_32,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"from BioMarin. SB is a full-time employee of CEMKA acting as a contractor of Xcenda GmbH for the execution of this study. CD has received consulting fees from BioMarin and Sanofi Genzyme. CJ, KMS, and JT are full-time employees of Xcenda GmbH acting as a contractor for BioMarin Europe Ltd. during the conduct of the study and writing of the manuscript. <bold>Jean-Baptiste Arnoux:</bold> Writing – review & editing, Validation, Methodology. <bold>Claire Douillard:</bold> Writing – review & editing,",11_33,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"Douillard:</bold> Writing – review & editing, Validation, Methodology. <bold>Francois Maillot:</bold> Writing – review & editing, Validation, Methodology. <bold>Stéphane Bouée:</bold> Writing – review & editing, Validation, Methodology, Formal analysis. <bold>Christian Jacob:</bold> Writing – review & editing, Writing – original draft, Validation, Methodology. <bold>Kim Maren Schneider:</bold> Writing – review & editing, Writing – original draft, Validation, Methodology. <bold>Julia Theil:</bold> Writing –",11_34,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"Methodology. <bold>Julia Theil:</bold> Writing – review & editing, Writing – original draft, Validation, Methodology. <bold>Sybil Charrière:</bold> Writing – review & editing, Validation, Methodology. None.",11_35,Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data,20 8 2024,,Phenylketonuria
"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU) Phenylketonuria (PKU) is a rare, metabolic disorder, caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH) that catalyses the hydroxylation of phenylalanine (Phe) to tyrosine. The non-functioning PAH enzyme causes accumulation of Phe in the blood and body tissues and if left untreated, it compromises early development, and results in severe injury to the central nervous system, manifested by",12_0,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"to the central nervous system, manifested by severe neurological and cognitive impairment. The management aim is to lower and maintain blood Phe concentrations within a strict target therapeutic range and treatment should commence within the first two weeks of life [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. The outcome of PKU has improved with early and lifelong management. The primary treatment for PKU is a stringent Phe restricted diet supplemented with a low Phe/Phe free protein substitute and special",12_1,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"a low Phe/Phe free protein substitute and special low protein foods. Pharmaceutical treatments may be used in combination with a Phe restricted diet. These include: sapropterin dihydrochloride and pegvaliase (Palynziq<sup>®</sup>). Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), a natural cofactor for the enzyme PAH. This drug can activate residual PAH enzyme, but as it relies upon the presence of functional PAH, it is only effective in around 30% of patients. Pegvaliase is derived from",12_2,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"30% of patients. Pegvaliase is derived from phenylalanine ammonia lyase, an enzyme that catalyzes the degradation of Phe to ammonia and trans-cinnamic acid. It is licensed for patients aged ≥ 16 years with inadequate blood Phe control (> 600 µmol/L) [<xref ref-type=""bibr"" rid=""CR2"">2</xref>] but it is not available in the UK. Despite the success of newborn screening, individuals with early-treated PKU do remain at risk of lower intellectual functioning together with impairments in executive function,",12_3,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"together with impairments in executive function, processing speed, sustained attention, fine motor control, learning capacity, and educational performance, particularly if under-treated [<xref ref-type=""bibr"" rid=""CR3"">3</xref>–<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. Early and continuously treated individuals may not attain their full neurodevelopmental potential and studies often report increased social, behavioural, and/or emotional problems compared with the general population [<xref ref-type=""bibr""",12_4,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"the general population [<xref ref-type=""bibr"" rid=""CR9"">9</xref>–<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. Dietary Phe restriction may be associated with nutritional imbalance and dietary adherence is challenging. Use of adjunct drug therapy is not without risk and requires careful supervision. Patients may also be at increased risk of co-morbidities such as obesity, metabolic syndrome and disordered eating [<xref ref-type=""bibr"" rid=""CR17"">17</xref>–<xref ref-type=""bibr"" rid=""CR22"">22</xref>]. During",12_5,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"ref-type=""bibr"" rid=""CR22"">22</xref>]. During pregnancy, sub-optimal blood Phe control may increase the risk of maternal PKU syndrome, leading to microcephaly, intellectual disability, growth retardation and congenital heart defects in the infant [<xref ref-type=""bibr"" rid=""CR23"">23</xref>–<xref ref-type=""bibr"" rid=""CR31"">31</xref>]. Therefore, regular and rigorous follow-up is recommended as patients remain vulnerable to mental health disorders, deficits in neurocognitive functioning [<xref",12_6,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"deficits in neurocognitive functioning [<xref ref-type=""bibr"" rid=""CR1"">1</xref>] and maternal PKU syndrome. Part of the ongoing care and monitoring of PKU involves regular attendance at outpatient clinics, where patients are commonly reviewed by a specialist PKU team of clinicians, dietitians and nurses. Clinic visits may be supplemented with home visits by a dietitian or nursing team and patient in-person events such as family conferences, cooking /educational schools or social functions. Blood Phe",12_7,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"schools or social functions. Blood Phe levels (from blood spots taken at home and returned to the hospital) are regularly monitored. Target blood Phe levels between 120 and 360 µmol/L for patients ≤ 12 years, pregnancy and pre-conception and between 120 and 600 µmol/L for patients older than 12 years are indicators of good metabolic control [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Nutritional monitoring is important to ensure satisfactory growth and development and there are no nutritional imbalances",12_8,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"and there are no nutritional imbalances [<xref ref-type=""bibr"" rid=""CR32"">32</xref>]. Adherence to dietary treatment commonly decreases during adolescence and extra observation may be necessary [<xref ref-type=""bibr"" rid=""CR33"">33</xref>]. In 2020, with the onset of the COVID-19 pandemic [<xref ref-type=""bibr"" rid=""CR34"">34</xref>], clinic reviews for PKU were rapidly transferred to remote video/telephone (virtual) clinics to enable continuity of care [<xref ref-type=""bibr"" rid=""CR35"">35</xref>]. This",12_9,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"ref-type=""bibr"" rid=""CR35"">35</xref>]. This allowed healthcare professionals (HCPs) to make assessments, collect some of the required monitoring data, and educate caregivers and patients [<xref ref-type=""bibr"" rid=""CR36"">36</xref>]. Recent evidence has shown virtual clinic care to be safe and effective, providing a convenient and efficient service at a low cost, reducing journeys by road and travel costs [<xref ref-type=""bibr"" rid=""CR37"">37</xref>]. Virtual care results in fewer missed days off work or",12_10,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"care results in fewer missed days off work or school, patients are consulted in their own homes, and they may perceive their HCPs to be more accessible. It has even been associated with improved blood Phe control in PKU [<xref ref-type=""bibr"" rid=""CR38"">38</xref>], by enhancing motivation associated with increased access to care [<xref ref-type=""bibr"" rid=""CR39"">39</xref>]. However, the quality of services provided virtually is variable and can impact the effectiveness of condition management and",12_11,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"the effectiveness of condition management and subsequently reduce patient satisfaction [<xref ref-type=""bibr"" rid=""CR40"">40</xref>]. Some hospitals have invested inadequately in additional patient communication technologies, patients may have unsatisfactory access to suitable equipment and factors such as poor internet connectivity are a common hindrance to successful virtual care [<xref ref-type=""bibr"" rid=""CR36"">36</xref>, <xref ref-type=""bibr"" rid=""CR41"">41</xref>–<xref ref-type=""bibr""",12_12,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"rid=""CR41"">41</xref>–<xref ref-type=""bibr"" rid=""CR44"">44</xref>]. A systematic review by Yi et al. [<xref ref-type=""bibr"" rid=""CR45"">45</xref>] highlights the barriers of using telemedicine in older adults and patients with cognitive impairment. In PKU, patients require neurological examination, venous blood samples and anthropometric assessments some of which can only be done during in-person clinics [<xref ref-type=""bibr"" rid=""CR46"">46</xref>, <xref ref-type=""bibr"" rid=""CR47"">47</xref>] or utilising",12_13,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"rid=""CR47"">47</xref>] or utilising local laboratories [<xref ref-type=""bibr"" rid=""CR36"">36</xref>]. Some health professionals report difficulties in assessing patient/caregiver body language or building patient rapport with online consultations [<xref ref-type=""bibr"" rid=""CR36"">36</xref>]. Some countries may lack a telemedicine infrastructure [<xref ref-type=""bibr"" rid=""CR39"">39</xref>]. In the UK, prior to the COVID-19 pandemic, outpatient services in PKU had changed little over time. Outpatient",12_14,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"in PKU had changed little over time. Outpatient non-attendance rates may be higher in the socially disadvantaged, those with poor blood Phe control, and patients who travel long distances to attend specialist PKU clinics. The UK’s National Information Board suggested that a different kind of health service was needed, instructing that the traditional outpatient consultation will become increasingly obsolete [<xref ref-type=""bibr"" rid=""CR48"">48</xref>]. Generally, prior to the COVID-19 pandemic, there was a",12_15,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"prior to the COVID-19 pandemic, there was a policy drive by the UK National Health Service (NHS) to harness the potential of digital technologies to improve care models and redesign care pathways in a way that improved the accessibility and efficiency of services and maximize the potential for patient self-management [<xref ref-type=""bibr"" rid=""CR49"">49</xref>]. It was always understood that just installing computers without training the workforce would not allow the system and its people to achieve the",12_16,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"allow the system and its people to achieve the new technologies optimal potential [<xref ref-type=""bibr"" rid=""CR50"">50</xref>]. Following the pandemic, the NHS were determined to ensure that ‘virtual’ care remained a routine part of care provision [<xref ref-type=""bibr"" rid=""CR51"">51</xref>]. Therefore, in PKU, it is not surprising that since the pandemic, video and telephone clinics have remained part of routine care. Despite this trend, there is a paucity of scientific studies appraising the use of",12_17,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"of scientific studies appraising the use of virtual clinics in PKU. It is therefore important to understand the patient/caregiver experience and how they view the quality of care when delivered by video clinics and /or telephone calls. This study was designed to assess the current perspective of patients with PKU and their caregivers about video/telephone clinics compared with conventional in-person clinics. An online survey (<italic toggle=""yes"">Jisc Online Surveys</italic>, 4 Portwall Lane, Bristol BS1",12_18,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"Surveys</italic>, 4 Portwall Lane, Bristol BS1 6NB, UK; <ext-link ext-link-type=""uri"" http://www.w3.org/1999/xlink href=""https://www.onlinesurveys.ac.uk"">https://www.onlinesurveys.ac.uk</ext-link><italic toggle=""yes"">)</italic> accessed via the UK National Society for PKU (NSPKU) website was promoted on social media sites for PKU in order to collect cross-sectional data. The unvalidated questionnaire was designed by a master’s degree student (HM) and edited by experienced inherited metabolic disease (IMD)",12_19,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"by experienced inherited metabolic disease (IMD) clinical and research dietitians (AP and AM). Online questionnaires were used in order to reach a wider PKU community across the UK [<xref ref-type=""bibr"" rid=""CR52"">52</xref>]. The questionnaire was pilot tested in the user group prior to study commencement to check for clarity and was then available for completion online from May to September 2021.  For patients with PKU, clinic review is an intrinsic part of continuing care by their health professional",12_20,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"of continuing care by their health professional providers. This study explored the views and experiences of individuals with PKU and their parents/carers when attending either in-person, video or telephone clinics. Although there is increasing pressure to embrace video and telephone clinics because of their ease of use, low cost, and the increased access to care, patient satisfaction with the type of service provision should remain a priority. Video and telephone clinics must provide the same, or ideally",12_21,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"clinics must provide the same, or ideally an improved level of care, to be considered a suitable option by service users. In this survey, most respondents expressed a desire for in-person clinics to continue, but considered the adoption of a hybrid approach with either video or telephone clinics was appropriate. As well as ensuring that clinical care standards are maintained, the type of clinic attended ought to be influenced by individual circumstances and experiences, indicating a need for flexibility",12_22,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"experiences, indicating a need for flexibility regarding the type of clinic review. Most respondents reported attending in-person clinics at the hospital with a PKU metabolic team prior to the COVID-19 pandemic, so they had knowledge of the benefits and drawbacks of this model of care. The respondents allocated a higher “usefulness” rating to in-person clinics; they considered that in-depth patient issues were better managed. For in-person clinics, patients were more likely to be reviewed by a medical",12_23,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"were more likely to be reviewed by a medical doctor (80%, compared with 64% in video clinics and 50% by telephone review). In particular, caregivers considered that in their child’s clinic review, it was essential that they received a clinical examination, observation and monitoring. Assessing child development is more challenging by video or telephone review and caregivers found in-person clinics better for discussing any developmental concerns. They also felt that in-person clinics were central to their",12_24,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"felt that in-person clinics were central to their child’s PKU education and motivation. It was considered important that children received information about PKU and its treatment directly from the HCPs, as they listened more intently and regarded their condition more seriously. Some PKU teams also ran separate education and cooking sessions for the children within the clinic. They also had the opportunity to meet other children with PKU at the hospital. Adults with PKU found direct contact with their HCPs",12_25,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"with PKU found direct contact with their HCPs motivational and it helped them maintain or improve their treatment plan. Caregivers and patients reported that they found it easier to talk to HCPs in-person compared with video and telephone clinics. They said they were able to consider more aspects of PKU care. Respondents described the importance of the rapport and relationship they had built with HCPs over many years. When this had been established, their in-person clinic consultation experience felt",12_26,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"in-person clinic consultation experience felt comfortable, more amiable and they expressed more confidence in their HCPs. They were less satisfied when they saw different or junior medical doctors in clinics or if the HCPs demonstrated little understanding or empathy about the issues they faced. A minority of respondents commented that clinics were repetitive, and they gained little by attending in-person clinics. They felt that their condition was stable and there was rarely any change to their management",12_27,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"there was rarely any change to their management plan. In the in-person clinics, 41% of respondents described that there were commonly three or more people present in the doctors’ consultation room including a nurse, trainee doctors as well as medical consultants, but in video or telephone clinics patients were more likely to be reviewed by the medical doctor and dietitian only. Although most respondents tolerated high numbers of professionals in the same room, 21% were overwhelmed, felt awkward and",12_28,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"same room, 21% were overwhelmed, felt awkward and self-conscious, particularly if some HCPs just observed the review, with no apparent contribution. Some said that it felt judgmental when discussing blood Phe control in a room full of people. Others reported that it was not helpful to have a room full of HCPs in transition clinics for teenagers, when they were expected to speak up for themselves without caregivers present. Sensitive issues were discussed in less than 30% of all clinics (in-person, video",12_29,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"in less than 30% of all clinics (in-person, video and telephone) and topics such as women’s reproductive health and social issues such as drugs and alcohol were even less likely to be covered by telephone clinics. Although it is important for trainee HCPs to observe clinic interactions, there should be a limit defining the number of professionals who are present in one clinic room, with the priority on ensuring that patients/caregivers are comfortable and feel able to talk about sensitive and difficult",12_30,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"feel able to talk about sensitive and difficult matters. All patients/caregivers should be given the opportunity to consent to observers attending their clinic review. Many respondents reported that they saw their dietitian in a separate room from the medical doctor for in-person clinics. They found this acceptable, as they were usually given more time to review dietary management and ask questions, as necessary. They appreciated that the dietitian was able to explain or reinforce information given by the",12_31,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"to explain or reinforce information given by the medical doctor. They particularly valued information on the suitability of new dietary products and protein substitutes although some parents commented that they had gained the same information earlier via social media. They welcomed receiving samples of special low protein foods and protein substitutes within clinics. Some patients said they prepared thoroughly before in-person clinics, writing down any questions or concerns. Although many respondents said",12_32,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"or concerns. Although many respondents said their in-person consultations were relaxed and informal, some respondents had anxiety about their clinic appointments. They worried about the travel to the hospital, any negative opinion that may be expressed by the health professionals, and the behaviour of their child in clinic, particularly when children were reluctant attendees. Some caregivers reported their children were fearful about clinic visits, particularly about venous blood tests. Equally,",12_33,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"particularly about venous blood tests. Equally, respondents expressed anxieties associated with video consultations. Some respondents said they suffered with social anxiety, and they found any kind of appointment stressful. Some did not relax because of home distractions e.g., demands of other children, doorbells or telephones ringing. Others felt embarrassed about their children’s lack of co-operation and engagement with video appointments and their failure to be seen or communicate on camera. Some",12_34,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"failure to be seen or communicate on camera. Some respondents stated that confidentiality was a problem with video/telephone reviews at home, as they had difficulty finding space to have a private conversation without others listening. Around 25% of respondents said they could not see or hear all HCPs on the video reviews and 18% said they could not hear the conversation by telephone review. Patients for whom English was not their first language were disadvantaged by telephone clinics. They were unable to",12_35,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"by telephone clinics. They were unable to see nonverbal cues that may help understanding during in-person consultations. Some caregivers said that only one parent was involved with a telephone review (commonly the parent who spoke English) and information was not always shared with both parents. Undoubtedly in-person clinic appointments caused considerable time pressures due to travel, with 2 to 4 h round trips being common. This has been reported by others [<xref ref-type=""bibr"" rid=""CR36"">36</xref>,",12_36,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"[<xref ref-type=""bibr"" rid=""CR36"">36</xref>, <xref ref-type=""bibr"" rid=""CR38"">38</xref>]. This was affected by the locations of the specialised clinics, and there is an expectation from service providers that patients are prepared to travel [<xref ref-type=""bibr"" rid=""CR54"">54</xref>]. Consequently, this caused a financial burden because of petrol and parking costs, and expenditure on public transport. With video clinics/telephone calls, the time burden of travelling to the hospital, the need to take time",12_37,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"travelling to the hospital, the need to take time off work, and to organise childcare were eliminated. Management of school time was better as some schools are increasingly reluctant to give children time off for hospital appointments in term time. Some adults used their holiday entitlement to attend in-person clinics. However, some respondents who preferred in-person reviews said that appointments were infrequent, and they did not mind being inconvenienced or financially ‘out of pocket’ as they considered",12_38,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"or financially ‘out of pocket’ as they considered ‘in-person’ consultations essential. Although video and telephone clinics overall rated highly, almost 50% of the respondents preferred in-person clinics only, and almost 50% a hybrid of video/telephone and in-person clinics. Very few respondents suggested that video/telephone clinics should replace in-person clinics completely. Virtual clinics served a purpose during the COVID-19 pandemic [<xref ref-type=""bibr"" rid=""CR35"">35</xref>, <xref ref-type=""bibr""",12_39,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"rid=""CR35"">35</xref>, <xref ref-type=""bibr"" rid=""CR36"">36</xref>] but were considered a temporary measure. However, in an Italian study, caregivers or younger patients with PKU were more likely to utilise video clinics due to greater uncertainties in their management, particularly if recently diagnosed, or if there were concerns about growth or metabolic control [<xref ref-type=""bibr"" rid=""CR55"">55</xref>]. There is also evidence that some adult patients with previously poor in-person clinic attendance",12_40,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"with previously poor in-person clinic attendance were more likely to attend video clinics as it integrated better with work life [<xref ref-type=""bibr"" rid=""CR55"">55</xref>]. In our study, video/telephone consultations appeared to work best when respondents already had a good working relationship with their health professional team and felt comfortable in their presence [<xref ref-type=""bibr"" rid=""CR56"">56</xref>]. Respondents considered it was difficult to have in-depth conversations in video/telephone",12_41,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"to have in-depth conversations in video/telephone clinics, and information was missed, leaving some respondents feeling quite vulnerable. They said that telephone calls were information gathering for the benefit of the HCPs, but they had less opportunity to be heard and engaged in their own care. Physical examinations could not occur, and reliable measures of assessing height and weight were difficult. Some patients considered that their physical symptoms may be missed or even misunderstood. Caregivers",12_42,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"may be missed or even misunderstood. Caregivers reported that their children were less likely to engage online and some even said their children had become ‘<italic toggle=""yes"">removed from their condition</italic>’ when they had no direct contact with professionals. Sometimes video calls were stopped and the review transferred to a telephone call due to technical issues. Some respondents ran out of phone credit part way through a review, and this led to some appointments being rescheduled. Overall,",12_43,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"to some appointments being rescheduled. Overall, technical problems included lack of sound, poor sound quality, and loss of picture on videos. For some families, poor broadband access may limit their ability to effectively engage with video clinics, for multifactorial reasons including geographical location and socio-economic status [<xref ref-type=""bibr"" rid=""CR57"">57</xref>]. Consultation times were shorter with video/telephone clinics. Almost 70% of in-person clinics lasted 30 min or more compared with",12_44,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"clinics lasted 30 min or more compared with only 37% of video calls and 18% of telephone calls. In fact, almost 50% of telephone reviews were no longer than 15 min. Many felt the length of time of in-person clinics was about right. They would usually see more than one professional (medical doctor and dietitian, or medical doctor, dietitian and nurse) and time spent with the different professionals would justify the time and expense in travelling to the clinic. With telephone calls, there was inadequate",12_45,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"With telephone calls, there was inadequate time for respondents to discuss the management plan or ask questions. Some found the telephone reviews so quick that they would forget what they needed to talk about. Consultations that were rushed gave the impression that health professionals were uncaring. Although healthcare organizations are encouraged to embrace telehealth (video and audio technology), patient experience is a key quality indicator of healthcare. Whilst spending fewer resources on in-person",12_46,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"Whilst spending fewer resources on in-person clinics can be beneficial in terms of heavy demand and capacity [<xref ref-type=""bibr"" rid=""CR54"">54</xref>], it can also pose a risk to patients who may not receive the necessary support and have full opportunity to discuss all their issues [<xref ref-type=""bibr"" rid=""CR58"">58</xref>]. Other studies conducted by the NHS [<xref ref-type=""bibr"" rid=""CR59"">59</xref>] have also found that patients prefer in-person clinics. Many patients consider that in",12_47,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"in-person clinics. Many patients consider that in video/telephone clinics, a full assessment of clinical problems or symptoms is not taken, and these clinics do not address their needs [<xref ref-type=""bibr"" rid=""CR60"">60</xref>, <xref ref-type=""bibr"" rid=""CR61"">61</xref>]. Long term outcomes associated with video/telephone clinics require careful study. Although they have valuable potential, it must be carefully considered how they can be successfully incorporated into the patient care pathway for PKU.",12_48,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"into the patient care pathway for PKU. Overall, patient/parent experience in PKU clinics can be improved, using a hybrid approach of both in-person and video clinics. To ensure that patients gain maximum value from long and expensive journeys to clinics, frequency of in-person clinics could be reduced but the quality of the review could be enhanced by including comprehensive clinical assessments, psycho-social support, monitoring of well-being, allocated time for patient education and even include elements",12_49,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"for patient education and even include elements that encourage patient social interaction. Patients and parents need to develop confidence in their HCPs, and care by a consistent and experienced healthcare team over time is a key component. Transition clinics need consideration in order to find a way of engaging teenagers so that they feel comfortable and in control during a review and not overwhelmed or intimated by the number of HCPs present. They need to be listened to, trusted and taken seriously and",12_50,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"be listened to, trusted and taken seriously and facilitated to feel more connected with their condition. All virtual clinics should be compliant with national and organisational data protection and telehealth regulations [<xref ref-type=""bibr"" rid=""CR62"">62</xref>]. It is important that video/telephone clinics are structured with a clear plan of their aims and expected outcomes. Patients/caregivers should be given plenty of opportunity to outline their health status, progress, concerns, and treatment needs",12_51,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"status, progress, concerns, and treatment needs as part of their ongoing management plan. To facilitate effective communication, translation services should be used when necessary. Privacy of the patient should be maintained with other people unable to hear or see the interview. If there are any safeguarding concerns, video consultations should be replaced by in-person clinics [<xref ref-type=""bibr"" rid=""CR63"">63</xref>]. If patients cannot use video technology, then telephone (if appropriate) or in-person",12_52,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"then telephone (if appropriate) or in-person clinics should be offered. Video and telephone clinics should not be seen as a ‘tick box exercise’. In summary, this study demonstrates that the patient with PKU and their parent/caregivers’ experience of video and telephone reviews does not surpass that of in-person clinics, despite the time and travel inconvenience involved. They see in-person appointments as an essential component of their individual or child’s clinical management. However, there are",12_53,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"child’s clinical management. However, there are advantages to video and telephone reviews and a combination of in-person, video and telephone consultations should be considered. It is likely that offering a choice of different types of clinic review to meet individual needs will lead to improved attendance, adherence and self-efficacy in long term management. Specialist PKU professionals should respond flexibly and adapt to provide broader consultation options to improve the experience for patients with",12_54,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
to improve the experience for patients with PKU. The challenge is now to combine and embrace the benefits of all clinic review systems so that they become engrained into routine care pathway systems.,12_55,"Patient and carer perceptions of video, telephone and in-person clinics for Phenylketonuria (PKU)",20 8 2024,,Phenylketonuria
"Nutrient Status and Intakes of Adults with Phenylketonuria A phenylalanine-restricted diet, supplemented with protein substitutes (PSs), remains the cornerstone of phenylketonuria (PKU) management. However, adherence is challenging in adulthood, and data on the nutritional status of early and continuously treated adults with PKU (ETAwPKU) are scarce. A total of 34 ETAwPKU (16 females; mean ± SD, age: 28 ± 9 years, phenylalanine concentration: 847 ± 285 µmol/L) and 34 age- and sex-matched control subjects",13_0,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"and 34 age- and sex-matched control subjects were compared regarding their blood nutrient status, self-reported dietary intake, and cognitive wellbeing. Though diet adherence varied, all ETAwPKU were taking a PS. No significant differences were found for blood DHA, calcium, ferritin, transferrin, and zinc concentrations. However, selenium and ubiquinone concentrations were 16% and 29% lower in ETAwPKU, respectively (<italic toggle=""yes"">p</italic> < 0.01 and <0.0001). Vitamin concentrations (D, B12, B6,",13_1,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"and <0.0001). Vitamin concentrations (D, B12, B6, and folic acid) were significantly higher in ETAwPKU except for alpha-tocopherol. Amino acid (AA) concentrations differed between ETAwPKU and controls: they were significantly lower for 12 AAs and higher for phenylalanine and glycine. ETAwPKU had a significantly higher intake of most minerals and vitamins, except for niacin and phosphorus (no difference). Depending on the nutrient, PSs represented 52–100% of patients’ daily intake and 19% of total daily",13_2,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"of patients’ daily intake and 19% of total daily energy intake. Compared with controls, ETAwPKU scored significantly lower in three of the four subscales of the cognitive wellbeing questionnaire. Overall, the blood DHA and micronutrient status of ETAwPKU was adequate, except for selenium, with higher intakes than controls for most micronutrients. Patients relied heavily on PSs to meet the recommended intakes for protein, DHA, and micronutrients. The potential clinical impact of differences found in AA",13_3,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"clinical impact of differences found in AA status should be further studied. Phenylketonuria (PKU) is a rare inherited metabolic disorder, where phenylalanine (Phe) is not appropriately converted into tyrosine, due to a deficiency of the enzyme Phe hydroxylase. As a result, Phe accumulates in the blood and other tissues. If PKU is left untreated, the excessive Phe concentrations in the brain can cause devastating neurocognitive deficits [<xref rid=""B1-nutrients-16-02724"" ref-type=""bibr"">1</xref>,<xref",13_4,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"ref-type=""bibr"">1</xref>,<xref rid=""B2-nutrients-16-02724"" ref-type=""bibr"">2</xref>]. This can be successfully prevented by early treatment, which has been made possible in many parts of the world thanks to newborn screening [<xref rid=""B3-nutrients-16-02724"" ref-type=""bibr"">3</xref>,<xref rid=""B4-nutrients-16-02724"" ref-type=""bibr"">4</xref>,<xref rid=""B5-nutrients-16-02724"" ref-type=""bibr"">5</xref>]. PKU treatment aims to maintain Phe concentrations in the therapeutic target range (i.e., <360 µmol/L for",13_5,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"therapeutic target range (i.e., <360 µmol/L for life according to US guidelines [<xref rid=""B5-nutrients-16-02724"" ref-type=""bibr"">5</xref>] or <360 µmol/L for children < 12 years and <600 µmol/L thereafter according to European guidelines [<xref rid=""B4-nutrients-16-02724"" ref-type=""bibr"">4</xref>]). For the majority of patients, such metabolic control is achieved through a strict, lifelong, low-protein diet, which prevents excessive Phe intake. This restrictive diet needs supplementation with a Phe-free",13_6,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"diet needs supplementation with a Phe-free or low-Phe protein substitute, i.e., a protein replacement formula, which usually contains additional tyrosine, micronutrients, essential fatty acids, and long-chain polyunsaturated fatty acids, to ensure that infants and children with PKU can meet their nutrient requirements for growth and development [<xref rid=""B6-nutrients-16-02724"" ref-type=""bibr"">6</xref>]. In adulthood, protein substitutes continue to play a key role in maintaining a healthy nutritional",13_7,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"a key role in maintaining a healthy nutritional status. Although successful, dietary management of PKU represents a heavy burden for patients as well as their families, and it is well known that diet adherence deteriorates in teenagers and adults, leading to Phe concentrations commonly above 600 µmol/L [<xref rid=""B7-nutrients-16-02724"" ref-type=""bibr"">7</xref>,<xref rid=""B8-nutrients-16-02724"" ref-type=""bibr"">8</xref>]. Non-adherence to protein substitute prescriptions further puts patients at risk of",13_8,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"prescriptions further puts patients at risk of nutritional inadequacies [<xref rid=""B9-nutrients-16-02724"" ref-type=""bibr"">9</xref>,<xref rid=""B10-nutrients-16-02724"" ref-type=""bibr"">10</xref>]. Additional factors can affect the nutrient status of patients with PKU, such as the bioavailability of different nutrient sources, differences in compositions of protein substitutes available to patients, different management approaches between metabolic centers, or even access to a multidisciplinary team [<xref",13_9,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"or even access to a multidisciplinary team [<xref rid=""B4-nutrients-16-02724"" ref-type=""bibr"">4</xref>]. Surprisingly little has been published on the nutrient status of adults with PKU. A relatively recent systematic review and meta-analysis [<xref rid=""B11-nutrients-16-02724"" ref-type=""bibr"">11</xref>] found significantly lower levels of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and cholesterol in patients with PKU compared to healthy controls [<xref rid=""B11-nutrients-16-02724""",13_10,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"controls [<xref rid=""B11-nutrients-16-02724"" ref-type=""bibr"">11</xref>]. No significant differences were observed for vitamins B12, E, and D or zinc, calcium, iron, and magnesium. However, children and adults could not be analyzed separately, and some studies were quite old (<2001), i.e., likely did not reflect later improvements in protein substitute compositions. Furthermore, interpretation for some nutrients (e.g., selenium) was challenging due to the considerable heterogeneity between studies, and for",13_11,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"heterogeneity between studies, and for others (e.g., vitamin B6, uridine), data were lacking [<xref rid=""B11-nutrients-16-02724"" ref-type=""bibr"">11</xref>]. When comparing adults with PKU who continued to take their protein substitutes regularly with irregular users, Hochuli et al. [<xref rid=""B9-nutrients-16-02724"" ref-type=""bibr"">9</xref>] found that non-adherent adults had lower intakes of protein and certain micronutrients, some falling below recommended intakes, as well as lower blood vitamin B12 and",13_12,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"intakes, as well as lower blood vitamin B12 and tyrosine levels, and trends toward lower concentrations of branched-chain amino acids. Reported values were typically in the range considered normal by the hospital’s laboratory (albeit at the lower end). This study lacked a control group (i.e., adults without PKU). Additional quantitative insights regarding the nutrient status and intakes of adults with PKU are needed to improve dietary management. Therefore, the main objective of this study was to compare",13_13,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"the main objective of this study was to compare blood micro- and macronutrient concentrations of early and continuously treated adults with PKU, taking at least one dose of protein substitute per day, with age- and sex-matched control subjects without PKU. Furthermore, we compared the nutritional intakes as well as measures of cognitive wellbeing between both groups.  A total of 36 patients with PKU and 35 matched control subjects were recruited into the study between April 2019 and April 2022. One patient",13_14,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"between April 2019 and April 2022. One patient who had not fasted was excluded from the study. Furthermore, one other patient was excluded from the per-protocol analyses due to the usage of branched-chain amino acid and multivitamin supplements, which violated the study protocol. The baseline characteristics of the analyzed cohorts are provided in <xref rid=""nutrients-16-02724-t001"" ref-type=""table"">Table 1</xref>. In short, the PKU and non-PKU groups were well-matched in terms of age, sex, and BMI. All",13_15,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"well-matched in terms of age, sex, and BMI. All but one patient had classical PKU. Patients’ average blood Phe concentrations from the previous year were highly variable (median: 648.9 µmol/L, range 241.0–1479.0 µmol/L), while historical compliance with the low-Phe diet was typical of an adult clinic setting (e.g., 26% somewhat compliant and 70% frequently/always compliant according to their metabolic team). At the time of the study, two-thirds of the patients were considered compliant with the",13_16,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"the patients were considered compliant with the Phe-restricted diet. This study evaluated the nutrient status and intakes of adults with PKU, who have been on diet therapy since infancy. Our patient sample was typical of an adult PKU clinic. The metabolic control was highly variable, as was the daily Phe intake, which is not surprising for a cohort of adult patients with varying baseline Phe tolerances, lifestyles, and degrees of adherence to dietary prescriptions. We found that, compared with controls,",13_17,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"We found that, compared with controls, adults with PKU had higher blood concentrations of folic acid and vitamins D, B6, and B12, whereas they had lower concentrations of vitamin E, selenium, ubiquinone, EPA, several amino acids, uridine, as well as creatinine, and homocysteine. Though statistically significant, the difference in magnesium concentration was minimal and likely not clinically relevant. Furthermore, no significant differences were found between groups for blood DHA, calcium, ferritin,",13_18,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"between groups for blood DHA, calcium, ferritin, transferrin, and zinc concentrations. Despite the Phe-restricted diet, nutrient intakes were adequate for the majority of patients, with most of the protein, DHA, and micronutrient intakes provided by protein substitutes. Of note, substantially fewer controls were able to meet EFSA’s DRIs for micronutrients. To date, only a handful of studies with a control group have focused specifically on adult patients on diet monotherapy. Lage et al. [<xref",13_19,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"patients on diet monotherapy. Lage et al. [<xref rid=""B14-nutrients-16-02724"" ref-type=""bibr"">14</xref>] found significantly lower plasma DHA and EPA concentrations in a group of 22 adults with PKU, compared with matched controls; however, the protein substitutes used by patients did not contain any long-chain polyunsaturated fatty acids (LCPUFA). DHA and EPA are key structural components of neuronal membranes, which, in addition, contribute to the maintenance of normal blood pressure, normal blood",13_20,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"of normal blood pressure, normal blood triglyceride levels, normal cardiac function, as well as normal vision [<xref rid=""B15-nutrients-16-02724"" ref-type=""bibr"">15</xref>,<xref rid=""B16-nutrients-16-02724"" ref-type=""bibr"">16</xref>]. However, the main food source for these LCPUFAs is oily fish, which is excluded in the Phe-restricted diet. Although this might be compensated by the consumption of vegetable fats rich in precursor omega-3 fatty acids, such as α-linolenic acid (ALA), endogenous synthesis of",13_21,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"α-linolenic acid (ALA), endogenous synthesis of DHA and EPA from ALA is limited [<xref rid=""B17-nutrients-16-02724"" ref-type=""bibr"">17</xref>,<xref rid=""B18-nutrients-16-02724"" ref-type=""bibr"">18</xref>,<xref rid=""B19-nutrients-16-02724"" ref-type=""bibr"">19</xref>]. Furthermore, in PKU, elevated concentrations of by-products of Phe metabolism are suggested to further inhibit DHA synthesis [<xref rid=""B20-nutrients-16-02724"" ref-type=""bibr"">20</xref>]. Multiple studies have highlighted a poorer LCPUFA status",13_22,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"studies have highlighted a poorer LCPUFA status in patients across various age groups [<xref rid=""B21-nutrients-16-02724"" ref-type=""bibr"">21</xref>], and thus, protein substitutes are now commonly fortified with DHA and sometimes EPA. This could explain the lack of the difference in erythrocyte omega-3 fatty acid concentrations (including DHA and EPA) reported by Htun et al. [<xref rid=""B22-nutrients-16-02724"" ref-type=""bibr"">22</xref>] between their cohort of 43 early-treated adults with PKU and controls.",13_23,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"of 43 early-treated adults with PKU and controls. In our study, most protein substitutes contained DHA, and they contributed to 100% of the total intake for patients. In contrast, almost none of the protein substitutes used were fortified with EPA, which could be why we observed lower EPA concentrations both in plasma and erythrocytes in the sensitivity analyses, which excluded one patient with surprisingly high plasma EPA concentrations. Except for selenium, patients’ micronutrient status was good in our",13_24,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"patients’ micronutrient status was good in our study. We observed higher serum folic acid and vitamin B12 concentrations in patients compared with controls, in line with Rojas-Agurto et al. [<xref rid=""B23-nutrients-16-02724"" ref-type=""bibr"">23</xref>], who studied 10 adherent adults with PKU, as well as with meta-analyses across different age groups [<xref rid=""B11-nutrients-16-02724"" ref-type=""bibr"">11</xref>,<xref rid=""B24-nutrients-16-02724"" ref-type=""bibr"">24</xref>]. Because vitamin B12 deficiency",13_25,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"Because vitamin B12 deficiency may be masked when circulating folic acid levels are elevated [<xref rid=""B25-nutrients-16-02724"" ref-type=""bibr"">25</xref>], and functional deficiency might occur even when B12 concentrations are in the normal range [<xref rid=""B26-nutrients-16-02724"" ref-type=""bibr"">26</xref>], it is important to consider more relevant biomarkers, such as total homocysteine concentrations [<xref rid=""B27-nutrients-16-02724"" ref-type=""bibr"">27</xref>]. In line with a previous report [<xref",13_26,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"In line with a previous report [<xref rid=""B23-nutrients-16-02724"" ref-type=""bibr"">23</xref>], total homocysteine concentrations were in the normal range of 5 to 12 µmol/L for almost all patients (32/34, 94%), thus suggesting that they were not B12 deficient in this study. Mixed results have been reported regarding the vitamin D status between patients and controls, with meta-analyses concluding that there was no significant difference [<xref rid=""B11-nutrients-16-02724"" ref-type=""bibr"">11</xref>,<xref",13_27,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"ref-type=""bibr"">11</xref>,<xref rid=""B24-nutrients-16-02724"" ref-type=""bibr"">24</xref>]. Like Rojas-Agurto et al. [<xref rid=""B23-nutrients-16-02724"" ref-type=""bibr"">23</xref>], we found higher vitamin D concentrations in the PKU group, with only 3/34 patients (9%) having serum levels below the recommended 50 nmol/L, against 18/34 (53%) in the control group. This is not surprising as the majority (22/34, 65%) of controls were recruited from the Netherlands in February/March, and a Dutch study reported",13_28,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"in February/March, and a Dutch study reported vitamin D deficiency in close to 60% of healthy individuals in the winter [<xref rid=""B28-nutrients-16-02724"" ref-type=""bibr"">28</xref>]. Conversely, patient recruitment spread throughout the year (including spring and summer time). Furthermore, vitamin D intake was significantly higher in the PKU group, protein substitutes being the main source (~90%) of vitamin D in patients. Nevertheless, 37% of patients (11/30) did not meet the DRI for vitamin D. Worse,",13_29,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"did not meet the DRI for vitamin D. Worse, none of the subjects in the control group met the DRI. Others have reported normal blood vitamin D concentrations in adult patients regularly taking their protein substitutes [<xref rid=""B9-nutrients-16-02724"" ref-type=""bibr"">9</xref>,<xref rid=""B14-nutrients-16-02724"" ref-type=""bibr"">14</xref>]. We observed higher whole blood pyridoxal 5′-phosphate (PLP, the active coenzyme of vitamin B6) concentrations in the PKU group compared with controls. Published data on",13_30,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"group compared with controls. Published data on vitamin B6 status in PKU are scarce. We identified only two studies, in children, reporting opposite results: Prince et al. [<xref rid=""B29-nutrients-16-02724"" ref-type=""bibr"">29</xref>] found higher plasma PLP and total vitamin B6 concentrations, whereas Schulpis et al. [<xref rid=""B30-nutrients-16-02724"" ref-type=""bibr"">30</xref>] found lower plasma PLP levels, in pediatric patients compared with controls. Prince et al. suggested that the reduced protein,",13_31,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"Prince et al. suggested that the reduced protein, high bioavailability of vitamin B6 sources in the Phe-restricted diet, and fortified protein substitutes could explain the increased circulating PLP levels. Vitamin B6 intake was significantly higher in our patients (without exceeding EFSA’s tolerable upper intake levels). Conversely, 15/35 controls (44%) had intakes below the DRI. Although significantly lower serum alpha-tocopherol (vitamin E) concentrations were observed in the PKU group compared with",13_32,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"were observed in the PKU group compared with controls (mean difference: −6 µmol/L, or a −13% difference), concentrations were all within the reference range (15–45 µmol/L), in line with another study in adults with PKU [<xref rid=""B31-nutrients-16-02724"" ref-type=""bibr"">31</xref>]. Interestingly, 15/35 (43%) of controls had values >45 µmol/L (vs. 23% in the PKU group), suggesting they were consuming many foods naturally rich in or fortified with vitamin E. In line with Montoya Parra et al. [<xref",13_33,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"E. In line with Montoya Parra et al. [<xref rid=""B11-nutrients-16-02724"" ref-type=""bibr"">11</xref>], mineral status was similar between patients and controls for calcium, ferritin, transferrin, zinc, and magnesium, whereas selenium levels were significantly lower (−16%) in the PKU group. Studies in adults with PKU regularly taking their protein substitute reported normal concentrations of iron/ferritin [<xref rid=""B9-nutrients-16-02724"" ref-type=""bibr"">9</xref>,<xref rid=""B31-nutrients-16-02724""",13_34,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"rid=""B31-nutrients-16-02724"" ref-type=""bibr"">31</xref>], as well as selenium and zinc, though levels of these two minerals were at the lower end of the normal range [<xref rid=""B9-nutrients-16-02724"" ref-type=""bibr"">9</xref>,<xref rid=""B31-nutrients-16-02724"" ref-type=""bibr"">31</xref>]. Multiple studies have described oxidative stress as a concern in patients with PKU [<xref rid=""B32-nutrients-16-02724"" ref-type=""bibr"">32</xref>]. Selenium and zinc are critical antioxidants, as is ubiquinone (also known as",13_35,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"antioxidants, as is ubiquinone (also known as coenzyme Q10), for which lower concentrations were also found in this study between the PKU and control groups, consistent with previous reports [<xref rid=""B33-nutrients-16-02724"" ref-type=""bibr"">33</xref>,<xref rid=""B34-nutrients-16-02724"" ref-type=""bibr"">34</xref>]. Adequate antioxidant status in PKU is often dictated by adherence to protein substitutes, since natural food sources are limited in the Phe-restricted diet [<xref rid=""B34-nutrients-16-02724""",13_36,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"diet [<xref rid=""B34-nutrients-16-02724"" ref-type=""bibr"">34</xref>,<xref rid=""B35-nutrients-16-02724"" ref-type=""bibr"">35</xref>,<xref rid=""B36-nutrients-16-02724"" ref-type=""bibr"">36</xref>]. In our study, we did observe lower selenium concentrations despite adequate intake, which may be due to the bioavailability of the selenium source. One study suggested that the situation may improve with glycomacropeptide (GMP)-based protein substitutes [<xref rid=""B37-nutrients-16-02724"" ref-type=""bibr"">37</xref>], as",13_37,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"ref-type=""bibr"">37</xref>], as GMP may have bioactive properties, may modulate the microbiota so that absorption might be enhanced, and/or GMP may have antioxidant properties that could spare selenium. However, further investigations are required to confirm such a hypothesis [<xref rid=""B38-nutrients-16-02724"" ref-type=""bibr"">38</xref>]. We found lower serum concentrations in the PKU group for multiple amino acids compared with the control group. Phe, along with nine other large neutral amino acids,",13_38,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"along with nine other large neutral amino acids, compete for entry into the brain via the SLC7A5 transport protein (also known as the LAT1 transporter) [<xref rid=""B39-nutrients-16-02724"" ref-type=""bibr"">39</xref>]. In our study, serum concentrations of all non-Phe large neutral amino acids except one (threonine) were significantly lower in the PKU group compared with the control group. Previously, Cannet et al. [<xref rid=""B40-nutrients-16-02724"" ref-type=""bibr"">40</xref>] did not find any significant",13_39,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"did not find any significant difference in plasma concentrations of branched-chain amino acids in a group of 22 treated adult patients with PKU compared with 14 healthy controls. Furthermore, glutamine concentrations were higher in the Cannet study, whereas we found no difference, and they reported similar glycine concentrations between groups, whereas we found higher concentrations in the PKU group in our study. Their method for measuring amino acid concentrations differed from our study. More recently,",13_40,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"differed from our study. More recently, Matuszewska et al. [<xref rid=""B41-nutrients-16-02724"" ref-type=""bibr"">41</xref>] also found alterations in serum amino acid concentrations of adult patients with PKU, e.g., lower tyrosine and higher glycine concentrations than controls. However, there appeared to be no between-group differences in concentrations of branched-chain amino acids. Further research is needed to understand whether differences in amino acid concentrations exist and to what extent they might",13_41,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"exist and to what extent they might be clinically relevant. Other studies (without a control group) reported that blood amino acid concentrations were all in the reference range in patients who adhere to their protein substitutes [<xref rid=""B9-nutrients-16-02724"" ref-type=""bibr"">9</xref>,<xref rid=""B42-nutrients-16-02724"" ref-type=""bibr"">42</xref>]. To our knowledge, we are the first to report on the uridine status in PKU. Uridine is a constituent of nucleotides and nucleic acids, and it is a precursor of",13_42,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"and nucleic acids, and it is a precursor of brain phosphatidylcholine in membranes. In addition to its pivotal role in the synthesis of these molecules, as a metabolite, uridine is also critically involved in circadian rhythms, inflammatory responses, antioxidant processes, and aging [<xref rid=""B43-nutrients-16-02724"" ref-type=""bibr"">43</xref>]. Lower plasma uridine levels have been reported in older adults with mild cognitive impairment, a pre-dementia stage [<xref rid=""B44-nutrients-16-02724""",13_43,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"stage [<xref rid=""B44-nutrients-16-02724"" ref-type=""bibr"">44</xref>]; however, the clinical relevance of the lower concentrations observed in our patients is unclear. The lower creatinine concentrations observed in our study compared with controls are in line with Cannet et al. [<xref rid=""B40-nutrients-16-02724"" ref-type=""bibr"">40</xref>] and may be related to a lower muscle mass, although this was not measured in the present study. As creatinine is a product of creatine metabolism, lower concentrations",13_44,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"of creatine metabolism, lower concentrations could also be due to low meat consumption (a major source of creatine) in the Phe-restricted diet as well as reduced de novo creatine synthesis, which necessitates arginine, and arginine concentrations were lower in patients than controls. Creatinine concentrations in the normal range were reported by Hochuli et al. [<xref rid=""B9-nutrients-16-02724"" ref-type=""bibr"">9</xref>] and Prepok et al. [<xref rid=""B45-nutrients-16-02724"" ref-type=""bibr"">45</xref>].",13_45,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"ref-type=""bibr"">45</xref>]. Although two-thirds of patients appear to have magnesium intakes above EFSA’s tolerable upper intake level (250 mg/day), this level only applies to readily dissociable magnesium salts (e.g., found in over-the-counter mineral supplements), due to their low absorption rate resulting in an osmotic laxative effect [<xref rid=""B46-nutrients-16-02724"" ref-type=""bibr"">46</xref>]. Protein substitutes are fortified with magnesium salts; however, these salts are part of a complex product",13_46,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"these salts are part of a complex product matrix including carbohydrates and fats. Furthermore, protein substitutes are usually taken around a meal. This will counteract the osmotic effect of magnesium salts in the gut [<xref rid=""B46-nutrients-16-02724"" ref-type=""bibr"">46</xref>], and therefore, patients’ intake levels in this study are unlikely to be a concern. As mentioned earlier, there was no clinically relevant difference in serum magnesium levels between the PKU and control groups, and all patients",13_47,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"the PKU and control groups, and all patients had values within the reference range (0.7 to 1.05 mmol/L). Subjective cognitive wellbeing was assessed using the FACT-Cog questionnaire, a well-established questionnaire that has been translated into different languages and tested in populations other than patients with cancer, such as students and older adults [<xref rid=""B47-nutrients-16-02724"" ref-type=""bibr"">47</xref>]. Normative data published on the healthy population compared with cancer patients in",13_48,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"population compared with cancer patients in France were in the same range as the present results [<xref rid=""B48-nutrients-16-02724"" ref-type=""bibr"">48</xref>]. Although the scores of the PKU group were significantly lower than the control group for three of the four subscales in our study, their scores were still similar to, or better than, the healthy controls from the French study. The most distinct difference was the subscale on ‘Comments from others’, which was not significantly different between the",13_49,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"which was not significantly different between the French healthy population and cancer patients, in contrast to our results comparing the PKU and control groups. PKU is an inherited metabolic disorder present from birth and requiring lifelong management, while cancer oftentimes presents later in life, which may explain this difference. We elected to use the FACT-Cog questionnaire because we wanted an easy-to-use cognitive assessment tool, to keep the burden on study participants to a minimum. However, we",13_50,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"on study participants to a minimum. However, we realize that this makes it challenging to compare our results with the PKU literature. In the largest meta-analysis to date in early-treated adults with PKU, Romani et al. [<xref rid=""B49-nutrients-16-02724"" ref-type=""bibr"">49</xref>] demonstrated that there are statistically significant cognitive impairments compared with controls, though the magnitude of the deficit varies across different cognitive functions. We support the recommendation of the authors to",13_51,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"We support the recommendation of the authors to use a PKU-specific cognitive battery to assess cognition in future studies. The National PKU Alliance neurocognitive workgroup in the US has also just published a white paper on a neurocognitive assessment platform relevant to clinical trials in PKU [<xref rid=""B50-nutrients-16-02724"" ref-type=""bibr"">50</xref>]. This study has some limitations. The overall sample size was limited (N = 34 pairs), though this is common in the field of rare diseases. The PKU and",13_52,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"common in the field of rare diseases. The PKU and control subjects were well matched for age and sex by design and, coincidentally, BMI, although not for location. While we endeavored to recruit control subjects from the same area as their counterpart with PKU, this proved too challenging in practice, and ultimately, most of the controls were recruited by an additional study site in the Netherlands. Due to the exploratory nature of this study, no corrections for multiplicity were applied in the statistical",13_53,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"for multiplicity were applied in the statistical analysis. Therefore, provided <italic toggle=""yes"">p</italic>-values should be interpreted with caution. However, although statistical analyses are helpful, as for any other study, one also ought to consider whether any differences observed are clinically meaningful. Finally, to reduce the burden on study participants, we assessed nutrient status and intake at a single time point. Additional time points would have strengthened our conclusions, though",13_54,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"would have strengthened our conclusions, though patients with PKU are known to have fairly consistent eating habits due to the many dietary restrictions. In conclusion, the nutrient status and intakes of adult patients with PKU using a protein substitute were adequate for most nutrients (DHA, micronutrients), although lower blood concentrations, compared with controls, were observed for selenium, ubiquinone, and some amino acids. The metabolic control was variable, reflecting variability in adherence with",13_55,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"reflecting variability in adherence with the Phe-restricted diet. The regular use of protein substitutes remains a point of attention in adults with PKU, as they are essential to meet DRIs.",13_56,Nutrient Status and Intakes of Adults with Phenylketonuria,15 8 2024,,Phenylketonuria
"Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria <list list-type=""simple"" id=""l0010""><list-item id=""o0010""><label>•</label><p id=""p0010"">We simulated a temporary discontinuation of the Phe-restricted diet in adults with PKU.</p></list-item><list-item id=""o0015""><label>•</label><p id=""p0015"">No effect of high Phe was found for neural activation and cerebral blood flow.</p></list-item><list-item",14_0,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"cerebral blood flow.</p></list-item><list-item id=""o0020""><label>•</label><p id=""p0020"">Reaction time but not accuracy was worse after Phe compared to placebo.</p></list-item><list-item id=""o0025""><label>•</label><p id=""p0025"">Differential effects of high Phe on neural markers and cognition are discussed.</p></list-item></list>  Phenylketonuria (PKU) is a rare inborn error of metabolism characterized by high phenylalanine (Phe) concentrations in the blood and brain due to impaired activity of the enzyme",14_1,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"and brain due to impaired activity of the enzyme phenylalanine hydroxylase (<xref rid=""b0045"" ref-type=""bibr"">Blau et al., 2010</xref>). Impaired metabolism of Phe to tyrosine results in the accumulation of Phe and has detrimental effects on the developing brain. To avoid cognitive and neurological long-term sequelae, such as severe intellectual impairments, seizures, or motor deficits, a Phe-restricted diet combined with a Phe-free amino acid supplementation should be maintained throughout childhood",14_2,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"should be maintained throughout childhood (<xref rid=""b0045"" ref-type=""bibr"">Blau et al., 2010</xref>). The introduction of newborn screening with early-initiated treatment of PKU was a big success in medicine, allowing patients to develop normally and preventing cognitive and neurological problems (<xref rid=""b0035"" ref-type=""bibr"">Berry et al., 2013</xref>). Two pharmacological treatments have been approved for the treatment of PKU – sapropterin dihydrochloride (BH<sub>4</sub>) and pegvaliase – however,",14_3,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"(BH<sub>4</sub>) and pegvaliase – however, a considerable number of adults with classical PKU do not respond to these treatments or experience side effects, leaving a Phe-restricted diet the treatment of choice (<xref rid=""b0110"" ref-type=""bibr"">Fiege and Blau, 2007</xref>, <xref rid=""b0130"" ref-type=""bibr"">Hausmann et al., 2019</xref>, <xref rid=""b0225"" ref-type=""bibr"">Sacharow et al., 2020</xref>). Adherence to dietary protein restriction is associated with challenges, and many adults report higher Phe",14_4,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"challenges, and many adults report higher Phe levels than recommended (<xref rid=""b0115"" ref-type=""bibr"">Ford et al., 2018</xref>, <xref rid=""b0175"" ref-type=""bibr"">MacDonald et al., 2010</xref>, <xref rid=""b0015"" ref-type=""bibr"">Ahring et al., 2011</xref>). Also, there is no consensus on how strict the treatment should be in adulthood, except before and during pregnancy. The European guidelines suggest a Phe concentration of <600 µmol/L, whereas the American guidelines recommend a Phe concentration of",14_5,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"guidelines recommend a Phe concentration of <360 µmol/L (<xref rid=""b0290"" ref-type=""bibr"">Van Wegberg et al., 2017</xref>, <xref rid=""b0065"" ref-type=""bibr"">Burgard et al., 2017</xref>). Consequently, it has been proposed to follow a more individual approach regarding target Phe levels for adults rather than a rigid adherence to the guidelines (<xref rid=""b0065"" ref-type=""bibr"">Burgard et al., 2017</xref>, <xref rid=""b0165"" ref-type=""bibr"">Lachmann and Langeveld, 2024</xref>). Task-based functional",14_6,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"Langeveld, 2024</xref>). Task-based functional magnetic resonance imaging (fMRI) offers a unique opportunity to study neural networks associated with the execution of a particular task (<xref rid=""b0215"" ref-type=""bibr"">Poldrack and Farah, 2015</xref>). Cross-sectional studies show that neural activation and connectivity within the fronto-parietal working memory network are slightly altered in adolescents and adults with PKU compared to controls (<xref rid=""b0075"" ref-type=""bibr"">Christ et al.,",14_7,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"(<xref rid=""b0075"" ref-type=""bibr"">Christ et al., 2010</xref>, <xref rid=""b0005"" ref-type=""bibr"">Abgottspon et al., 2022</xref>). Investigating neural activation associated with inhibition, another aspect of executive functions next to working memory (<xref rid=""b0185"" ref-type=""bibr"">Miyake et al., 2000</xref>), no or only subtle activation differences were observed in adults with early-treated classical PKU compared to healthy controls (<xref rid=""b0245"" ref-type=""bibr"">Sundermann et al., 2020</xref>).",14_8,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"ref-type=""bibr"">Sundermann et al., 2020</xref>). Only a limited number of interventional fMRI studies have been conducted in PKU. <xref rid=""b0240"" ref-type=""bibr"">Sundermann et al. (2011</xref>) administered a single oral Phe load in 17 adults with PKU and did not find any changes in neural activation associated with inhibition before and after the Phe load. Controversially, alterations in neural activation in the fronto-parietal working memory network were observed in seven children and adults only after",14_9,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"observed in seven children and adults only after successful implementation of treatment with sapropterin dihydrochloride (Kuvan®, <xref rid=""b0080"" ref-type=""bibr"">Christ et al., 2013</xref>). We showed in a sample of 29 adults with early-treated classical PKU that a four-week period of oral Phe administration did not negatively impact working memory, manual dexterity, mood, and depression (<xref rid=""b0270"" ref-type=""bibr"">Trepp et al., 2024</xref>). However, sustained attention differed following the Phe",14_10,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"sustained attention differed following the Phe intervention compared to the placebo intervention, although it is worth mentioning that the significance primarily arose from the improvement observed during the placebo intervention (<xref rid=""b0270"" ref-type=""bibr"">Trepp et al., 2024</xref>). Whether and how a four-week suspension of the Phe-restricted diet affects neural activation in the fronto-parietal working memory network remains to be investigated. In addition to fMRI, arterial spin labeling (ASL)",14_11,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"In addition to fMRI, arterial spin labeling (ASL) allows for noninvasive investigation of cerebral perfusion (<xref rid=""b0125"" ref-type=""bibr"">Haller et al., 2016</xref>). This technique uses water as an endogenous tracer, which thus enables the quantification of cerebral blood flow (CBF). ASL serves as a valuable complement to fMRI as it provides a quantitative measure for assessing CBF, while fMRI offers an indirect measure of neural activation through neurovascular coupling (<xref rid=""b0100""",14_12,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"through neurovascular coupling (<xref rid=""b0100"" ref-type=""bibr"">Detre and Wang, 2002</xref>). ASL has been employed in various clinical populations, such as dementia or stroke, to examine potential long-term alterations in CBF (<xref rid=""b0125"" ref-type=""bibr"">Haller et al., 2016</xref>, <xref rid=""b0310"" ref-type=""bibr"">Zaharchuk, 2014</xref>). It has further been used to investigate acute changes in CBF during cognitive performance, enabling the detection of regional increases and decreases in CBF",14_13,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"of regional increases and decreases in CBF (<xref rid=""b0160"" ref-type=""bibr"">Kim et al., 2006</xref>). A limited number of studies investigated cerebral perfusion in early-treated adults with PKU. Our cross-sectional study showed no significant global CBF differences between adults with PKU and controls (<xref rid=""b0230"" ref-type=""bibr"">Steiner et al., 2024</xref>). However, reduced mean CBF was observed in arterial vascular territories of the left middle cerebral artery (MCA) and the posterior cerebral",14_14,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"cerebral artery (MCA) and the posterior cerebral artery (PCA) in patients with PKU, a finding that was unrelated to cognitive performance and metabolic parameters. Results of the cross-sectional study of the present sample have previously been described (see <xref rid=""b0005"" ref-type=""bibr"">Abgottspon et al., 2022</xref>, <xref rid=""b0230"" ref-type=""bibr"">Steiner et al., 2024</xref>). The aim of the present randomized, placebo-controlled, double-blind, crossover, non-inferiority trial was to assess the",14_15,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"non-inferiority trial was to assess the effect of a short-term high Phe load − simulating a four-week discontinuation of the Phe-restricted diet − on working memory-related neural activation and resting CBF in adults with early-treated classical PKU. We hypothesized that a high Phe load compared to placebo does not modulate neural activation in the working memory network or CBF. We further aimed to investigate associations between neural markers, cognition, and metabolic parameters after the Phe and",14_16,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"and metabolic parameters after the Phe and placebo intervention. Details about the study design, participants, interventions, randomization, and blinding have been published previously (<xref rid=""b0005"" ref-type=""bibr"">Abgottspon et al., 2022</xref>, <xref rid=""b0270"" ref-type=""bibr"">Trepp et al., 2024</xref>, <xref rid=""b0230"" ref-type=""bibr"">Steiner et al., 2024</xref>, <xref rid=""b0260"" ref-type=""bibr"">Trepp et al., 2020</xref>, <xref rid=""b0195"" ref-type=""bibr"">Muri et al., 2024</xref>) and are",14_17,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"ref-type=""bibr"">Muri et al., 2024</xref>) and are summarized below.  In this double-blind, randomized, placebo-controlled, crossover, non-inferiority trial, a four-week period of oral Phe administration did not statistically significantly modulate working memory-related neural activation nor resting CBF in adults with early-treated classical PKU. Reaction time in the 1-back condition was significantly slower after the Phe intervention compared to the placebo intervention, whereas no significant effect of",14_18,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"intervention, whereas no significant effect of the intervention was found for accuracy. Relationships between neural markers, cognition, and metabolics differed following the Phe intervention compared to the placebo intervention. Our ROI and exploratory whole-brain fMRI analyses suggest that a four-week high Phe intake simulating a controlled discontinuation of the Phe-restricted diet did not affect working memory-related neural activation significantly. This is the first study showing the effect of a",14_19,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"This is the first study showing the effect of a four-week higher Phe level on fMRI outcomes. <xref rid=""b0240"" ref-type=""bibr"">Sundermann et al. (2011</xref>) implemented a Stroop task during the fMRI acquisition and observed neural activation before and after a single administration with Phe. While the single Phe dosage was about 2–3 times higher than the daily dosage in the present study, we investigated the impact of Phe during a more extended period of four weeks. However, results from <xref",14_20,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"period of four weeks. However, results from <xref rid=""b0240"" ref-type=""bibr"">Sundermann et al. (2011</xref>) and our study point in the same direction and show that neither a one-day nor a four-week suspension of the Phe-restriction diet affects neural activation in a significant matter. However, we observed non-significantly decreased neural activation in eight out of nine working memory ROIs after the Phe intervention, indicating a certain pattern of neural activity change which did not reach",14_21,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"of neural activity change which did not reach significance in our study. Whether a long-term discontinuation (e.g., one year) of Phe-restriction might impact neural activation differently, remains to be established. Similarly, no significant effect of the Phe intervention was found for CBF. Neither global CBF nor CBF in the 16 vascular territories statistically differed following the Phe or placebo intervention. Again, it is noteworthy that the mean CBF was not significantly reduced in fifteen out of",14_22,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"was not significantly reduced in fifteen out of sixteen vascular territories following the Phe intervention, suggesting a pattern of small changes in CBF after the Phe intervention. In a cross-sectional study including the present sample, <xref rid=""b0230"" ref-type=""bibr"">Steiner et al. (2024</xref>) showed reduced CBF in the left anterior and middle MCA as well as the right posterior MCA in adults with PKU compared to controls. Together with the results of the present study, this suggests that CBF",14_23,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"of the present study, this suggests that CBF alterations occur in patients with PKU when comparing them to controls cross-sectionally. However, CBF alterations are unrelated to the concurrent Phe level in our longitudinal study design. Contrary to our results, <xref rid=""b0195"" ref-type=""bibr"">Muri et al. (2024)</xref> reported extensive significant declines in cortical gray matter accompanied by elevated white matter volume assessed with structural imaging following the four-week Phe intervention. These",14_24,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"following the four-week Phe intervention. These structural alterations may represent early adjustments or modifications that have not yet been fully detected in measurable changes in neural activity or CBF. It could be hypothesized that structural and functional neural changes do not necessarily occur in parallel but could also take place sequentially. Mapping structure–function relationships is complex and is influenced by several factors (<xref rid=""b0235"" ref-type=""bibr"">Suárez et al., 2020</xref>).",14_25,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"ref-type=""bibr"">Suárez et al., 2020</xref>). Thus, structural changes observed in the study by <xref rid=""b0195"" ref-type=""bibr"">Muri et al. (2024)</xref> could precede functional changes. This further emphasizes the need for neuroimaging studies examining the impact of a high Phe load over a more extended period of time (e.g., one year). In addition, a high Phe level could indirectly influence brain structure through other mechanisms not directly detected by task-based fMRI or ASL, such as",14_26,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"detected by task-based fMRI or ASL, such as neuroinflammation, alterations in neurotransmitter levels, or white matter changes (<xref rid=""b0250"" ref-type=""bibr"">Surtees and Blau, 2000</xref>, <xref rid=""b0060"" ref-type=""bibr"">Bruinenberg et al., 2019</xref>, <xref rid=""b0020"" ref-type=""bibr"">Anderson and Leuzzi, 2010</xref>). It has been hypothesized that neuroinflammatory processes occur in PKU, but more so in patients who received treatment later in life and were thus not early-treated (<xref",14_27,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"in life and were thus not early-treated (<xref rid=""b0105"" ref-type=""bibr"">Ferreira et al., 2021</xref>). It may take longer for these effects to manifest as significant changes in neural activation or CBF. Although we did not find an effect of the Phe intervention on a neural level, we observed slower reaction times in the 1-back condition after the Phe intervention compared to the placebo. This is in line with prior research indicating that adults who have discontinued the Phe-restricted diet exhibited",14_28,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"discontinued the Phe-restricted diet exhibited slower reaction times, while stricter control of Phe levels resulted in a significant improvement in reaction times. However, reaction times were comparable between the on-diet and the control group (<xref rid=""b0090"" ref-type=""bibr"">Dawson et al., 2011</xref>). Task accuracy was comparable after the Phe intervention compared to the placebo intervention. This is in line with the findings on the primary and secondary outcomes of this trial (<xref rid=""b0270""",14_29,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"outcomes of this trial (<xref rid=""b0270"" ref-type=""bibr"">Trepp et al., 2024</xref>). No significant effect of the Phe intervention was found for various cognitive functions such as working memory, cognitive flexibility, alertness, and divided attention. However, inhibition and sustained attention – outcomes with a speed or reaction time component – differed significantly between the Phe and placebo interventions. This implies that cognitive tasks relying on intact processing speed could be vulnerable to",14_30,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"on intact processing speed could be vulnerable to elevated Phe levels, while accuracy outcomes might be less affected by increased Phe, indicating a differential effect of high Phe on cognition. Processing speed strongly relies on the integrity of the white matter (<xref rid=""b0205"" ref-type=""bibr"">Penke et al., 2010</xref>, <xref rid=""b0275"" ref-type=""bibr"">Turken et al., 2008</xref>). Cerebral white matter tracts form a complex network, allowing fast signal transmission between different brain areas",14_31,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"signal transmission between different brain areas (<xref rid=""b0205"" ref-type=""bibr"">Penke et al., 2010</xref>, <xref rid=""b0275"" ref-type=""bibr"">Turken et al., 2008</xref>). The speed of this signal transmission depends on the myelination of the white matter tracts, with higher myelination being associated with higher processing speed (<xref rid=""b0070"" ref-type=""bibr"">Chopra et al., 2018</xref>). White matter integrity can be studied using diffusion tensor imaging (DTI). This approach analyses and",14_32,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"tensor imaging (DTI). This approach analyses and visualizes the diffusion of water molecules along white matter tracts to investigate white matter integrity (<xref rid=""b0025"" ref-type=""bibr"">Assaf and Pasternak, 2008</xref>). During the past decades, PKU has predominantly been described as a disease particularly affecting white matter integrity (<xref rid=""b0020"" ref-type=""bibr"">Anderson and Leuzzi, 2010</xref>). DTI results of our earlier cross-sectional investigation, which included a similar patient",14_33,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"investigation, which included a similar patient sample, showed widespread alterations in posterior white matter tracts (<xref rid=""b0190"" ref-type=""bibr"">Muri et al., 2023</xref>). These previous findings may help elucidate why we observed an impact of the Phe intervention on cognitive performance but did not detect a corresponding effect at the neural level. Performing a working memory task requires temporarily storing and processing information at a certain speed (<xref rid=""b0030""",14_34,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"information at a certain speed (<xref rid=""b0030"" ref-type=""bibr"">Baddeley, 1983</xref>). Working memory performance is, therefore, tightly related to processing speed (<xref rid=""b0010"" ref-type=""bibr"">Ackerman et al., 2002</xref>). Thus, the observed differences in reaction time could be driven by the integrity or the volume of the white matter rather than the neural activation assessed with fMRI. We further examined associations between neural markers, cognition, and metabolic parameters following the",14_35,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"cognition, and metabolic parameters following the Phe and the placebo intervention. There was a significant association with large effect size between neural activation and 1-back accuracy after the placebo intervention, which we did not see following the Phe intervention. Also, tyrosine and tryptophan were related to cognition and neural markers following the placebo intervention but not after the Phe intervention. Both levels remained within the reference ranges following the Phe and the Placebo",14_36,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"ranges following the Phe and the Placebo intervention. It seems that exposure to high Phe somehow disrupts these associations. Whether and to what extent this is clinically relevant cannot be determined based on our data. Interestingly, tyrosine and tryptophan but not plasma Phe were associated with cognition or neural markers after the placebo intervention. This finding is comparable to the results of our cross-sectional study, where neural activation was associated with tyrosine and tryptophan rather",14_37,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"associated with tyrosine and tryptophan rather than Phe (<xref rid=""b0005"" ref-type=""bibr"">Abgottspon et al., 2022</xref>). Together with the findings from the cross-sectional study, where neural activation was related to tyrosine and tryptophan rather than Phe, this supports the notion that additional metabolic parameters play a pivotal role in the pathophysiology of PKU. Indeed, other metabolic parameters next to Phe levels, such as Phe-to-tyrosine ratio, Phe-variability, or cerebral tyrosine, have been",14_38,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"Phe-variability, or cerebral tyrosine, have been linked to cognitive performance (<xref rid=""b0295"" ref-type=""bibr"">Waisbren et al., 2016</xref>, <xref rid=""b0155"" ref-type=""bibr"">Jahja et al., 2014</xref>, <xref rid=""b0140"" ref-type=""bibr"">Hood et al., 2014</xref>, <xref rid=""b0220"" ref-type=""bibr"">Romani et al., 2019</xref>). This study further contributes to the discussion on safe Phe levels during adulthood. Our findings suggest that a high Phe exposure does not inherently have a detrimental impact on",14_39,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"does not inherently have a detrimental impact on neural markers and cognition. Instead, it reflects differential effects depending on the variable being considered. We did not find any significant impact of the four-week Phe intervention on neural activation, CBF, and task accuracy, but 1-back reaction times were slower under high Phe. The life-long Phe-restricted diet comes with economic, psychological, and social challenges. Therefore, not only PKU-related symptoms but also dietary restrictions can",14_40,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"symptoms but also dietary restrictions can affect health-related quality of life (<xref rid=""b0115"" ref-type=""bibr"">Ford et al., 2018</xref>, <xref rid=""b0175"" ref-type=""bibr"">MacDonald et al., 2010</xref>, <xref rid=""b0065"" ref-type=""bibr"">Burgard et al., 2017</xref>, <xref rid=""b0200"" ref-type=""bibr"">Olofsson et al., 2022</xref>, <xref rid=""b0040"" ref-type=""bibr"">Bhashyam et al., 2019</xref>, <xref rid=""b0180"" ref-type=""bibr"">Maissen-Abgottspon et al., 2023</xref>). <xref rid=""b0200""",14_41,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"et al., 2023</xref>). <xref rid=""b0200"" ref-type=""bibr"">Olofsson et al. (2022</xref>) suggest a trade-off between the benefits of strict dietary adherence and a more lenient diet. Strict dietary adherence might reduce PKU-related symptoms but increases dietary constraints, whereas a more lenient diet reduces the burden of the diet but takes into account possible PKU-related symptoms (<xref rid=""b0200"" ref-type=""bibr"">Olofsson et al., 2022</xref>). Considering the patients' situation and needs, an",14_42,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"Considering the patients' situation and needs, an individualized approach could be pursued instead of a target threshold (<xref rid=""b0065"" ref-type=""bibr"">Burgard et al., 2017</xref>, <xref rid=""b0165"" ref-type=""bibr"">Lachmann and Langeveld, 2024</xref>). Our results may be used to reassure patients, especially those with difficulties adhering to the Phe-restricted diet, that higher Phe during at least a limited period does not detrimentally influence their concurrent brain function in respect to the",14_43,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"their concurrent brain function in respect to the functional outcome measures used in the present study (<xref rid=""b0165"" ref-type=""bibr"">Lachmann and Langeveld, 2024</xref>). However, slight non-significant reductions in mean neural activation and CBF after a high Phe load must be acknowledged. The major strength of this study is the study design, which allows a causal conclusion to be drawn on the effect of a four-week period of oral Phe administration on neural markers and cognition. Also, the sample",14_44,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"on neural markers and cognition. Also, the sample size is relatively large when considering the rarity of the disease; however, all findings must be interpreted with consideration to the sample size. Some limitations have to be acknowledged. First, owing to the design of the four-week discontinuation of the Phe-restricted diet, conclusions about long-term effects (e.g., one year) cannot be drawn. Second, the design of our fMRI task with the 1-back condition as the baseline condition and the 3-back",14_45,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"as the baseline condition and the 3-back condition as the working memory condition did not allow us to differentiate between different <italic toggle=""yes"">n</italic>-back loads. Future studies should incorporate multiple <italic toggle=""yes"">n</italic>-back loads (1-back to 3-back with 0-back as baseline). This approach would also allow the study of functional connectivity during task performance, investigating how spatially distinct areas in a functional network cooperate while performing a task (<xref",14_46,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"network cooperate while performing a task (<xref rid=""b0145"" ref-type=""bibr"">Huettel et al., 2014</xref>, <xref rid=""b0120"" ref-type=""bibr"">Friston et al., 1997</xref>). Third, given our fMRI design, we focused on the neural basis of working memory. However, as our data suggests that cognitive domains with a processing speed component could be more sensitive to higher Phe, future task-based fMRI studies could focus on neural correlates of processing speed. Similarly, we used a combination of resting ASL",14_47,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"Similarly, we used a combination of resting ASL with task-based fMRI in our study. Integrating both neuroimaging approaches enhances the study's neuroimaging scope, providing complementary insights into task-related neural activations and cerebral perfusion dynamics at rest. Future studies could further enrich our findings by incorporating a resting-state fMRI to better understand baseline brain function and its relationship with cognitive task performance. Fourth, our study utilized a relatively",14_48,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"Fourth, our study utilized a relatively experimental setting. Further investigations with larger sample sizes, longer durations, and a stronger emphasis on patient-reported outcomes could enhance understanding of the effects of Phe variability in PKU management. During the preparation of this work, the authors used chatGPT to enhance language quality. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication. This",14_49,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"for the content of the publication. This study was supported by the the <funding-source id=""gp010"">Bangerter Rhyner Foundation</funding-source> (Switzerland), the Fondation Rolf Gaillard pour la recherche en endocrinologie, diabétologie et métabolisme (Switzerland), the Nutricia Metabolics Research Fund (Netherlands), the <funding-source id=""gp005"">Swiss Foundation for Nutrition Research, the Swiss National Science Foundation</funding-source> (grant <award-id award-type=""grant""",14_50,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"(grant <award-id award-type=""grant"" rid=""gp005"">192706</award-id> and <award-id award-type=""grant"" rid=""gp005"">184453</award-id>), the Vontobel Foundation (Switzerland), and a young investigator grant from the Inselspital Bern (CTU grant). The funding sources had no involvement in the design of the study or the collection, analysis, and interpretation of the data. <bold>Stephanie Maissen-Abgottspon:</bold> Writing – review & editing, Writing – original draft, Visualization, Project administration,",14_51,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"draft, Visualization, Project administration, Investigation, Formal analysis, Data curation. <bold>Leonie Steiner:</bold> Writing – review & editing, Software, Methodology, Formal analysis. <bold>Raphaela Muri:</bold> Writing – review & editing, Project administration, Investigation, Funding acquisition, Data curation. <bold>Dilmini Wijesinghe:</bold> Writing – review & editing, Formal analysis, Data curation. <bold>Kay Jann:</bold> Writing – review & editing, Supervision, Formal analysis, Data curation.",14_52,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"Supervision, Formal analysis, Data curation. <bold>Yosuke Morishima:</bold> Writing – review & editing, Supervision, Formal analysis, Data curation. <bold>Michel Hochuli:</bold> Writing – review & editing, Supervision, Methodology, Conceptualization. <bold>Roland Kreis:</bold> Writing – review & editing, Software, Formal analysis, Data curation. <bold>Roman Trepp:</bold> Writing – review & editing, Supervision, Methodology, Funding acquisition, Conceptualization. <bold>Regula Everts:</bold> Writing –",14_53,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"<bold>Regula Everts:</bold> Writing – review & editing, Supervision, Methodology, Investigation, Funding acquisition, Conceptualization. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.",14_54,Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria,14 8 2024,,Phenylketonuria
"Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria Phenylketonuria (PKU), as a colloquial term for phenylalanine hydroxylase (PAH) deficiency (OMIM# 261600), is an autosomal recessive inborn error of amino acid metabolism. PKU is caused by pathogenic variants in the gene encoding PAH, impairing enzyme function such that PAH cannot metabolize phenylalanine (Phe) to tyrosine normally. Phe accumulates in the blood, crossing the blood–brain barrier at high",15_0,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"blood, crossing the blood–brain barrier at high concentrations with toxic effects. Phe also competes with other large neutral amino acids for transport across the blood–brain barrier by the L-type amino acid transporter 1 (LAT1); high concentrations of Phe may block transport of other LAT1 substrates into the brain, including tyrosine and tryptophan, important for neurotransmission [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. If left untreated, PKU is associated with poor neurologic, neurocognitive, and",15_1,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"with poor neurologic, neurocognitive, and neuropsychiatric outcomes [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Recognized as exhibiting a spectrum of severity, the most severe form of PKU is often referred to as classical PKU (cPKU) and is defined as little or no PAH activity and untreated blood Phe levels typically > 1200 µmol/L at the time of diagnosis (normal blood Phe level is 50–110 µmol/L). An individual’s specific genetic variation determines the degree of",15_2,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"genetic variation determines the degree of PAH activity; variants only partially inhibiting PAH activity result in a milder form of PKU or mild hyperphenylalaninemia (HPA) [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. The goal of treating PKU is to achieve and maintain appropriate blood Phe levels recommended by the United States and European guidelines [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>]. To control blood Phe levels, individuals with PKU are placed on a",15_3,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"Phe levels, individuals with PKU are placed on a lifelong prescribed medical intervention termed medical nutrition therapy (MNT) [<xref ref-type=""bibr"" rid=""CR4"">4</xref>], which involves severely restricting the natural intake of protein and replacing it with a Phe-free, amino acid-based medical food to supplement the reduced protein intake, and provide a source of energy and other nutrients. Supplements might include modified low-protein foods and Phe-free medical food beverages, Phe-free amino acid",15_4,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"medical food beverages, Phe-free amino acid mixture, medical foods derived from glycomacropeptide, and protein substitutes [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Importantly, studies have shown that not all patients, including adolescents and adults, are able to achieve blood Phe levels within guideline-recommended target ranges [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR6"">6</xref>]. Even with active management, blood Phe levels may remain uncontrolled, especially as",15_5,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"Phe levels may remain uncontrolled, especially as patients age. An online survey conducted in the United States estimated that 67% of adults with PKU had blood Phe levels in excess of the upper limit of the American College of Medical Genetics target levels [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Patients with cPKU have the most difficulty controlling blood Phe levels with MNT, and control is considered suboptimal when compared with patients with mild PKU [<xref ref-type=""bibr"" rid=""CR6"">6</xref>].",15_6,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"PKU [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. Pharmaceutical intervention with sapropterin dihydrochloride (KUVAN®; BioMarin Pharmaceutical Inc., Novato, CA, USA), a derivative of the PAH cofactor, tetrahydrobiopterin (BH4), may be used in conjunction with a Phe-restricted diet, for individuals who are deemed responsive. For adults (or patients ≥ 16 years old outside of the United States) with uncontrolled blood Phe levels despite existing management, pegvaliase (PALYNZIQ®; BioMarin Pharmaceutical Inc.,",15_7,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"(PALYNZIQ®; BioMarin Pharmaceutical Inc., Novato, CA, USA), a PAH substitute [<xref ref-type=""bibr"" rid=""CR8"">8</xref>, <xref ref-type=""bibr"" rid=""CR9"">9</xref>], may be an option to achieve appropriate blood Phe levels, without requiring patients to maintain a Phe-restricted diet [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Lifelong treatment of PKU is recommended by guidelines [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Early intervention prevents the severe and",15_8,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"Early intervention prevents the severe and irreversible intellectual impairment caused by elevated blood Phe levels in childhood and adolescence [<xref ref-type=""bibr"" rid=""CR11"">11</xref>], but adherence to dietary restrictions is challenging, and the number of patients achieving target blood Phe levels tends to diminish with age [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Uncontrolled Phe levels are also associated with adverse neurocognitive and neuropsychiatric",15_9,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"with adverse neurocognitive and neuropsychiatric outcomes in adults [<xref ref-type=""bibr"" rid=""CR12"">12</xref>–<xref ref-type=""bibr"" rid=""CR14"">14</xref>]. Meta-analysis of cognitive function in adults with PKU has shown impairment in reasoning, visuo-spatial attention speed, sustained attention, and visuo-motor control, despite early initiation of treatment [<xref ref-type=""bibr"" rid=""CR14"">14</xref>], and meta-analysis of neuropsychiatric symptoms in adults with PKU has shown that inattention,",15_10,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"in adults with PKU has shown that inattention, hyperactivity, depression, and anxiety exceed general population estimates [<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. Neurocognitive and neuropsychiatric symptoms associated with Phe accumulation may make it more difficult for patients to adhere to dietary restriction, which in turn can lead to poor blood Phe control and worsening of symptoms [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. An emerging body of literature suggests that the impact of PKU on an",15_11,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"literature suggests that the impact of PKU on an individual’s health may extend beyond symptoms of a neurocognitive and neuropsychiatric nature. Comorbidities across various organ systems have been reported in adults with PKU, with health insurance claims-based studies suggesting a higher prevalence of somatic comorbidities compared with a general population [<xref ref-type=""bibr"" rid=""CR15"">15</xref>, <xref ref-type=""bibr"" rid=""CR16"">16</xref>]. High blood Phe levels may impact biologic mechanisms that",15_12,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"Phe levels may impact biologic mechanisms that are related to increased risk of comorbid conditions such as obesity, renal disease, metabolic dysfunction, and cardiovascular complications [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. Due to the impact on different organ systems, the etiology is complex and multifactorial [<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. Retrospective analysis of insurance claims data has enabled researchers to generate hypotheses for development of certain comorbidities based",15_13,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"for development of certain comorbidities based on their knowledge of PKU and the associated dietary management [<xref ref-type=""bibr"" rid=""CR15"">15</xref>, <xref ref-type=""bibr"" rid=""CR16"">16</xref>]. Better understanding of the etiology of somatic comorbidities associated with PKU and identification of factors other than high blood Phe that may be preventable or amenable to treatment, together with effective metabolic control, could aid in reducing the burden of illness and healthcare costs. However, the",15_14,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"of illness and healthcare costs. However, the first step is to investigate differences in somatic comorbidity burden, not only between adults with PKU and the general population but also among adults with PKU receiving different therapeutic interventions, those adherent to treatment or not, and with different disease severity. A systematic literature review (SLR) has been conducted to evaluate the published evidence on the somatic comorbidities experienced by adults with PKU. The SLR aims to further",15_15,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"by adults with PKU. The SLR aims to further characterize the physical health burden of PKU and provide insight into the impact of differences in therapeutic interventions, adherence to treatment, and differences in disease severity on the somatic comorbidity burden. The SLR is registered with the Research Registry with the unique identifying number review registry 1476 and is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Synthesis Without",15_16,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"and Meta-Analyses (PRISMA) and Synthesis Without Meta-analysis (SWiM) guidelines [<xref ref-type=""bibr"" rid=""CR18"">18</xref>, <xref ref-type=""bibr"" rid=""CR19"">19</xref>].   Individuals with PKU have a higher somatic comorbidity burden versus a non-PKU population, highlighting the unmet need for optimized approaches to blood Phe control in this population. Improved access to therapeutic interventions to maintain blood Phe levels within recommended ranges over the long term may potentially avoid the clinical",15_17,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"the long term may potentially avoid the clinical and economic implications of managing comorbidities. To build on the evidence from this review and better understand the relationship between blood Phe control, adherence to diet and comorbidity burden, more robust studies reporting consistent outcome measures are needed, especially in specific PKU populations.",15_18,Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria,12 8 2024,,Phenylketonuria
"Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report 5q Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disease caused by homozygous deletion or compound heterozygous mutations in the survival motor neuron (<italic toggle=""yes"">SMN</italic>)-1 gene (OMIM 253300, 253550, 253400) located on chromosome 5. The neonatal incidence rate of SMA in parts of East Asia is 0.51 to",16_0,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"rate of SMA in parts of East Asia is 0.51 to 0.58/10,000,<sup>[<xref rid=""R1"" ref-type=""bibr"">1</xref>,<xref rid=""R2"" ref-type=""bibr"">2</xref>]</sup> with a population carrier rate of 1/50.<sup>[<xref rid=""R3"" ref-type=""bibr"">3</xref>]</sup> Biallelic <italic toggle=""yes"">SMN1</italic> mutations cause SMN protein insufficiency and α-motor neuron apoptosis in the anterior horn of the spinal cord. Clinically, SMA is characterized by symmetrical, progressive muscle weakness and atrophy and is the most common",16_1,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"weakness and atrophy and is the most common fatal hereditary neuromuscular disease in infants and young children.<sup>[<xref rid=""R4"" ref-type=""bibr"">4</xref>]</sup> The intelligence of SMA patients is generally unaffected. Several drugs targeting restoration of SMN expression, namely, nusinersen, risdiplam, and onasemnogene abeparvovec (Zolgensma) have been approved. These drugs have changed the clinical landscape of SMA, prolonging the patient survival time and improving prognosis. Phenylketonuria (PKU,",16_2,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"and improving prognosis. Phenylketonuria (PKU, OMIM #261600) is an autosomal recessive amino acid metabolism disorder caused by compound heterozygous mutations of the phenylalanine hydroxylase (<italic toggle=""yes"">PAH</italic>) gene on chromosome 12. The incidence rate of PKU in China is 1.22 to 14.55/100,000.<sup>[<xref rid=""R5"" ref-type=""bibr"">5</xref>,<xref rid=""R6"" ref-type=""bibr"">6</xref>]</sup> PAH catalyzes conversion of phenylalanine to tyrosine. In PKU, phenylalanine hydroxylase activity is",16_3,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"In PKU, phenylalanine hydroxylase activity is completely lost or severely decreased, leading to hyperphenylalaninemia. The tyrosine concentration is also reduced, but hypotyrosinemia is not obvious as tyrosine can be obtained through diet. Common clinical manifestations of PKU include intellectual disability, fair skin, blond dry hair, eczema, pungent smelling sweat and urine, and some children may have neurological symptoms such as epilepsy and hyperactivity. Patients with PKU can be treated by long-term",16_4,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"Patients with PKU can be treated by long-term dietary restriction therapy. New therapeutic drugs and methods provide new options for patients, including tetrahydrobiopterin cofactors, recombinant phenylalanine lyase, mRNA therapy, and AAV vector gene therapy.<sup>[<xref rid=""R7"" ref-type=""bibr"">7</xref>]</sup> Currently, no case of SMA combined with PKU have been reported. Here, we retrospectively analyzed the clinical data of a child with SMA complicated by PKU to aid diagnosis and treatment of similar",16_5,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"by PKU to aid diagnosis and treatment of similar patients. Our case shows that SMA may be complicated by PKU, suggesting that various detection methods should be used to facilitate differential diagnosis of genetic diseases. This study was approved by the Research Ethics Committee of Children’s Hospital Affiliated to Shandong University (approval number QLET-IRB/P-2021090) for genomic studies of rare disorders. All the procedures performed in the work were in accordance with the Declaration of Helsinki.",16_6,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"in accordance with the Declaration of Helsinki. Informed written consent for participation in the study and for the publication of the clinical data was obtained from the child’s guardians. The male patient was 22 months old when he was admitted to the Children’s Hospital Affiliated to Shandong University (Jinan, China) due to “limb weakness for 19 months.” His motor development was normal after birth. At 2 months of age, he was able to steadily raise his head. At 3 months of age, his limb movement ability",16_7,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"At 3 months of age, his limb movement ability began to decline. He could turn over until 4 months but could not sit independently by 6 months of age; his motor function gradually deteriorated thereafter. By the time of consultation, he could not lift his head, turn over, or sit unaided. The child had visited several local hospitals after symptom onset, but a timely diagnosis was not made because of insufficient understanding of the disease. He had a history of recurrent eczema with no specific birth or",16_8,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"of recurrent eczema with no specific birth or family history. The parents were not in a consanguineous marriage, and the mother’s physical examination during pregnancy was normal. At hospital admission, the child was conscious and had weak crying, fair skin, unsteady head, decreased limb movement, grade III and II muscle strength of upper and lower limbs, respectively (determined using the Medical Research Council Scale for Muscle Strength), and hypomyotonia. Bilateral biceps, triceps, tendon, and ankle",16_9,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"Bilateral biceps, triceps, tendon, and ankle reflexes were not elicited. Cranial magnetic resonance imaging indicated no abnormalities. Electromyography was consistent with neurogenic damage. Routine blood and urine tests were normal (including creatine kinase, thereby excluding Duchenne muscular dystrophy). The further blood metabolic disease screening showed: phenylalanine concentration 870.0 μmol/L (normal range, 24.3–116 μmol/L), tyrosine 50.2 μmol/L (normal range, 25.8–195 μmol/L), and",16_10,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"50.2 μmol/L (normal range, 25.8–195 μmol/L), and phenylalanine/tyrosine ratio (Phe/Tyr) 17.3 (expected ratio, 0.1–1.5). The phenylalanine concentration and Phe/Tyr ratio were markedly higher than normal. No respiratory or feeding problems were observed. Based upon these clinical manifestations and laboratory examinations, our initial diagnoses were SMA and PKU. To further clarify the diagnoses, the child and his parents were tested for <italic toggle=""yes"">SMN1</italic> gene variants. The multiplex",16_11,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"gene variants. The multiplex ligation-dependent probe amplification (MLPA) results showed the child had homozygous deletion of exon 7 and exon 8 in <italic toggle=""yes"">SMN1</italic> with 3 copies of <italic toggle=""yes"">SMN2</italic> and his father and mother both had heterozygous deletion of exon 7 and 8 in <italic toggle=""yes"">SMN1</italic> with 2 and 3 copies of <italic toggle=""yes"">SMN2</italic>, respectively (Fig. <xref rid=""F1"" ref-type=""fig"">1</xref>). Target capture sequencing followed by Sanger",16_12,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"Target capture sequencing followed by Sanger sequencing showed that the child had c.699C > G (p.Phe233Leu) and c.721C > T (p.Arg241Cys) compound heterozygous mutations in the <italic toggle=""yes"">PAH</italic> gene. The father carried a c.699C > G (p.Phe233Leu) heterozygous mutation, while the mother had a c.721C > T (p.Arg241Cys) heterozygous mutation (Fig. <xref rid=""F2"" ref-type=""fig"">2</xref>). The effect of the c.699C > G (p.Phe233Leu) mutation site on <italic toggle=""yes"">PAH</italic> protein had not",16_13,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"<italic toggle=""yes"">PAH</italic> protein had not been previously described; therefore, we performed bioinformatic analysis of the identified <italic toggle=""yes"">PAH</italic> gene mutations. Both variants were located in a highly conserved region in different species and were evaluated in adherence to American College of Medical Genetics and Genomics standards.<sup>[<xref rid=""R8"" ref-type=""bibr"">8</xref>]</sup> Accordingly, both variants were determined to be pathogenic, as summarized in Table <xref",16_14,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"to be pathogenic, as summarized in Table <xref rid=""T1"" ref-type=""table"">1</xref>.<sup>[<xref rid=""R9"" ref-type=""bibr"">9</xref>–<xref rid=""R14"" ref-type=""bibr"">14</xref>]</sup> Based upon the child’s genetic results, a dual diagnosis of 5q-SMA and PKU was confirmed. The child had developed typical clinical manifestations of SMA and needed immediate treatment. The blood phenylalanine concentration was >360 μmol/L, necessitating dietary treatment.<sup>[<xref rid=""R15"" ref-type=""bibr"">15</xref>,<xref",16_15,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"rid=""R15"" ref-type=""bibr"">15</xref>,<xref rid=""R16"" ref-type=""bibr"">16</xref>]</sup> After the parents were fully informed of the patient’s condition, they agreed to a treatment plan of risdiplam combined with low phenylalanine formula. Before treatment, the child’s motor function was evaluated using standard SMA tests. The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND; maximum score, 64) and Hammersmith Infant Neurological Examination Part 2 (HINE-2) scores",16_16,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"Neurological Examination Part 2 (HINE-2) scores (maximum score, 26 points) were 23 and 4 points, respectively. The child was also evaluated using the Gesell assessment, scoring 100 points for the adaptive part, indicating a normal intelligence level. Reexamination after 3 months of treatment showed a 6-point increase in the CHOP INTEND score (to 29 points) and a 4-point increase in the HINE-2 score (to 8 points). After 15 months of treatment, the follow-up results showed a 23-point increase in the CHOP",16_17,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"results showed a 23-point increase in the CHOP INTEND score (to 46 points) and a 5-point increase in the HINE-2 score (to 9 points), respectively. These motor function improvements were clinically significant<sup>[<xref rid=""R17"" ref-type=""bibr"">17</xref>]</sup>; notably, the patient’s ability to lift his head had improved after treatment. Reexamination of the adaptive part of the Gesell scale maintained a score of 100 points. Retested blood phenylalanine and tyrosine concentrations were 287.2 and 36.1",16_18,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"and tyrosine concentrations were 287.2 and 36.1 μmol/L, respectively, with a Phe/Tyr ratio of 7.9. Both the phenylalanine concentration and Phe/Tyr ratio were significantly lower than baseline levels. In clinical practice, SMA usually refers to 5q-SMA, in which approximately 95% of patients have homozygous deletions of exon 7 of the <italic toggle=""yes"">SMN1</italic> gene. The remaining 5% of patients have compound heterozygous mutations, with 1 exon 7 deletion and 1 intragenic mutation on the other",16_19,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"7 deletion and 1 intragenic mutation on the other <italic toggle=""yes"">SMN1</italic> allele.<sup>[<xref rid=""R18"" ref-type=""bibr"">18</xref>]</sup> According to the age of symptom onset and maximum motor function achieved, SMA can be divided into 5 subtypes: type 0 (death typically within 1 month of birth), type I (onset before 6 months, unable to sit independently), type II (onset after 6 months, unable to stand or walk independently), type III (onset after 18 months), and type IV (onset in adulthood). The",16_20,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"18 months), and type IV (onset in adulthood). The present patient had symptom onset at 3 months of age and could not sit independently at 6 months. Therefore, he was classified as type I. In the natural course of SMA, the average event-free survival age of type I patients is only 7.3 months.<sup>[<xref rid=""R19"" ref-type=""bibr"">19</xref>]</sup> An improved prognosis is achieved with earlier treatment initiation.<sup>[<xref rid=""R20"" ref-type=""bibr"">20</xref>]</sup> After 24 months of risdiplam treatment,",16_21,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"After 24 months of risdiplam treatment, 44% of patients can achieve the motor function milestone of sitting unaided.<sup>[<xref rid=""R21"" ref-type=""bibr"">21</xref>]</sup> The common pathogenic gene of PKU is <italic toggle=""yes"">PAH</italic>, which has a total length of approximately 90 kb, containing 13 exons and encoding 451 amino acids. Nearly 800 <italic toggle=""yes"">PAH</italic> gene mutations have been reported worldwide. Without treatment, patients can develop severe intellectual and neurological",16_22,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"can develop severe intellectual and neurological impairments.<sup>[<xref rid=""R7"" ref-type=""bibr"">7</xref>]</sup> Patients receiving long-term dietary restriction therapy can avoid these problems, but if treatment compliance is poor, high phenylalanine levels can cause adverse effects on attention, mood, memory, and executive function in adolescent and adult patients.<sup>[<xref rid=""R22"" ref-type=""bibr"">22</xref>,<xref rid=""R23"" ref-type=""bibr"">23</xref>]</sup> The prognosis of PKU is related to many",16_23,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"The prognosis of PKU is related to many factors, and treatment timing is important. If treatment is started in the neonatal period, mental and physical development can reach normal levels.<sup>[<xref rid=""R15"" ref-type=""bibr"">15</xref>]</sup> Of the 2 <italic toggle=""yes"">PAH</italic> gene mutations detected in our case, c.721C > T is one of the most common mutations in the Chinese population.<sup>[<xref rid=""R6"" ref-type=""bibr"">6</xref>,<xref rid=""R23"" ref-type=""bibr"">23</xref>]</sup> This mutation",16_24,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"ref-type=""bibr"">23</xref>]</sup> This mutation results in switching of arginine to cysteine at position 241. Modeling prediction analysis showed that this mutation leads to loss (amino acid position 239) and addition (position 242) of a hydrogen bond. This rearrangement likely affects the spatial structure of the protein. The c.699C > G mutation site is rare<sup>[<xref rid=""R24"" ref-type=""bibr"">24</xref>]</sup> and results in a change of phenylalanine to leucine at position 233. Predictive analysis",16_25,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"to leucine at position 233. Predictive analysis revealed a possible effect of this mutation on enzyme binding but no change in protein structure. The patient’s blood phenylalanine concentration did not exceed 1200 μmol/L and his clinical symptoms were mild, suggesting that the c.699C > G mutation may not lead to complete loss of PAH function. Currently, more than 10,000 birth defect diseases are known, with an average of 2.8 disease-causing genes per person,<sup>[<xref rid=""R25""",16_26,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"genes per person,<sup>[<xref rid=""R25"" ref-type=""bibr"">25</xref>]</sup> which induce heavy burdens on patients, their families, and society. Because of popularization and improvements of gene detection methods, an increasing number of genetic diseases can be identified. The presence of different genetic diseases in the same individual may continue to be discovered. Therefore, for genetic diagnosis of patients with suspected genetic diseases and during prenatal consultations with families, combinations of",16_27,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"consultations with families, combinations of genetic testing methods should be chosen to detect the abnormal gene copy numbers or/and subtle mutations. For instance, if genetic diagnosis of SMA is made using only the “gold standard,” MLPA detection,<sup>[<xref rid=""R26"" ref-type=""bibr"">26</xref>]</sup> subtle mutations of the <italic toggle=""yes"">SMN1</italic> gene may be missed.<sup>[<xref rid=""R27"" ref-type=""bibr"">27</xref>]</sup> It is rare for the same individual to have multiple gene variations with",16_28,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"individual to have multiple gene variations with different disease manifestations. No case report of SMA combined with PKU was found in the CNKI full-text, Wanfang, or PubMed databases (from establishment to June 2024). We identified one report of 2 children in the same family who suffered from independent diagnoses of SMA or PKU (CNKI full-text and Wanfang)<sup>[<xref rid=""R28"" ref-type=""bibr"">28</xref>]</sup> and 2 case reports of SMA complicated with Duchenne muscular dystrophy (PubMed).<sup>[<xref",16_29,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"Duchenne muscular dystrophy (PubMed).<sup>[<xref rid=""R29"" ref-type=""bibr"">29</xref>,<xref rid=""R30"" ref-type=""bibr"">30</xref>]</sup> To our knowledge, this patient is the first reported case worldwide with a diagnosis of SMA combined with PKU, and who has received separate targeted treatments. Treatment with risdiplam and low phenylalanine formula for 3 months and 15 months showed a good effect with no serious adverse events. The study’s limitations is that: because the efficacy of the combined treatment",16_30,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"because the efficacy of the combined treatment of risdiplam and low phenylalanine formula requires a longer follow-up analysis, long-term follow-up results for the treatment are lacking in this study. In addition, it is unclear whether the 2 diseases will affect each other. This study highlights that it is necessary for comprehensive examinations including inherited metabolic diseases and utilizing different genetic analysis methods of patients with congenital defects to avoid the progressive damage caused",16_31,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"defects to avoid the progressive damage caused by the missed diagnosis of some genetic diseases with hidden onset. In addition, timely therapy initiation and intervention for genetic diseases can prevent the malignant progression of the disease. The authors thank the family for participating in the study. Funding support was provided by the Science and Technology Development Program of Jinan Municipal Health Commission (2021-2-105). The manuscript was designed by KM, DW, and FL. WH, JW, and CY collected",16_32,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"by KM, DW, and FL. WH, JW, and CY collected the clinical data and executed genetic experiments. KM, DW, and FL wrote the manuscript. All authors contributed to the article and approved the submitted version. <bold>Data curation:</bold> Wandong Hu, Zhenqiong Cui. <bold>Funding acquisition:</bold> Fangfang Liu. <bold>Investigation:</bold> Kai Ma, Wandong Hu, Jie Wang, Chunmei Yu, Zhenqiong Cui. <bold>Methodology:</bold> Kai Ma, Jie Wang, Chunmei Yu. <bold>Resources:</bold> Fangfang Liu. <bold>Writing –",16_33,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"Fangfang Liu. <bold>Writing – original draft:</bold> Dong Wang, Kai Ma, Fangfang Liu. <bold>Writing – review & editing:</bold> Dong Wang, Fangfang Liu.",16_34,Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: A case report,02 8 2024,,Phenylketonuria
"Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers <italic toggle=""yes"">Background and Objectives</italic>: Phenylketonuria (PKU) is a rare genetic disorder characterized by the inability to convert the essential amino acid phenylalanine into tyrosine. Early dietary treatment can successfully prevent complications, but controversies still exist regarding the attainment of normal growth in these patients. <italic toggle=""yes"">Materials",17_0,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"in these patients. <italic toggle=""yes"">Materials and Methods</italic>: Eighteen patients with PKU from two Romanian reference centers were compared to eighteen non-PKU controls, matched for age and gender. The comparisons used weight-for-height, weight-for-age, height/length-for-age, and body mass index-for-age z-scores from birth to three years of age. <italic toggle=""yes"">Results</italic>: The PKU study group consisted of nine boys and nine girls, with a median follow-up period of thirty-six months",17_1,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"a median follow-up period of thirty-six months (interquartile range = 9.75). While median values of all four growth metrics remained within the normal range across the entire study period, weight-for-age z-scores were significantly lower in PKU patients throughout most of the study (<italic toggle=""yes"">p</italic> < 0.001). <italic toggle=""yes"">Conclusions</italic>: The persistent lower weight-for-age z-scores of the PKU patients compared to controls indicate that ongoing monitoring and potential",17_2,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"indicate that ongoing monitoring and potential adjustments in dietary therapy may be necessary to further optimize growth outcomes. Phenylketonuria (PKU, MIM 261600) results from a deficiency in the hepatic enzyme phenylalanine hydroxylase (PAH; EC 1.14.16.1; OMIM 612349). It is a rare condition, which occurs in approximately 1 in 24,000 individuals, affecting an estimated 450,000 people globally [<xref rid=""B1-medicina-60-01185"" ref-type=""bibr"">1</xref>]. This autosomal recessive metabolic disorder is",17_3,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"This autosomal recessive metabolic disorder is characterized by the inability to convert the essential amino acid phenylalanine (Phe) into tyrosine, resulting in the accumulation of toxic metabolites [<xref rid=""B2-medicina-60-01185"" ref-type=""bibr"">2</xref>]. Many countries, including Romania, implement routine newborn screening programs for early detection of PKU [<xref rid=""B3-medicina-60-01185"" ref-type=""bibr"">3</xref>]. These screening programs facilitate the early diagnosis of PKU in infants,",17_4,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"facilitate the early diagnosis of PKU in infants, allowing for the commencement of standard care protocols, ideally within the first ten days of life [<xref rid=""B4-medicina-60-01185"" ref-type=""bibr"">4</xref>]. Still, it remains unclear how many European centers can meet this target [<xref rid=""B5-medicina-60-01185"" ref-type=""bibr"">5</xref>]. Advancements in newborn screening programs, combined with effective dietary interventions, have significantly extended the lifespan of individuals diagnosed with PKU",17_5,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"the lifespan of individuals diagnosed with PKU [<xref rid=""B6-medicina-60-01185"" ref-type=""bibr"">6</xref>]. The prevalence and severity of PKU vary across different populations. Individuals with severe PAH deficiency, known as classical PKU, exhibit untreated plasma Phe levels exceeding 1200 μmol/L. Those with a less severe phenotype, including moderate PKU and mild PKU, have untreated plasma Phe levels ranging from 600 to 1200 μmol/L. Patients with plasma Phe levels below 360 μmol/L are classified as",17_6,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"Phe levels below 360 μmol/L are classified as having mild hyperphenylalaninemia (mHPA). Target Phe levels for all these patients are 120–360 μmol/L [<xref rid=""B4-medicina-60-01185"" ref-type=""bibr"">4</xref>,<xref rid=""B7-medicina-60-01185"" ref-type=""bibr"">7</xref>,<xref rid=""B8-medicina-60-01185"" ref-type=""bibr"">8</xref>]. The goal of PKU treatment remains to prevent cognitive impairment, promote normal growth, and maintain good health and quality of life into adulthood [<xref rid=""B2-medicina-60-01185""",17_7,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"into adulthood [<xref rid=""B2-medicina-60-01185"" ref-type=""bibr"">2</xref>,<xref rid=""B9-medicina-60-01185"" ref-type=""bibr"">9</xref>]. Classical PKU treatment involves adherence to a specialized diet [<xref rid=""B10-medicina-60-01185"" ref-type=""bibr"">10</xref>], which includes stringent restriction of phenylalanine intake by limiting dietary protein, supplemented with a Phe-free formula (PFF), amino acid formula (AAF), and low-Phe glycomacropeptide (GMP), all of them providing essential amino acids,",17_8,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"all of them providing essential amino acids, vitamins, and other nutrients [<xref rid=""B11-medicina-60-01185"" ref-type=""bibr"">11</xref>,<xref rid=""B12-medicina-60-01185"" ref-type=""bibr"">12</xref>]. At approximately six months of age, a more concentrated protein substitute needs to be introduced [<xref rid=""B13-medicina-60-01185"" ref-type=""bibr"">13</xref>]. This process complements the challenge of transitioning from liquid formula to solid foods and accepting the AAF [<xref rid=""B14-medicina-60-01185""",17_9,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"the AAF [<xref rid=""B14-medicina-60-01185"" ref-type=""bibr"">14</xref>] with its intense flavor [<xref rid=""B14-medicina-60-01185"" ref-type=""bibr"">14</xref>,<xref rid=""B15-medicina-60-01185"" ref-type=""bibr"">15</xref>]. During infancy, protein substitutes provide 50–80% of the total protein requirements [<xref rid=""B5-medicina-60-01185"" ref-type=""bibr"">5</xref>,<xref rid=""B16-medicina-60-01185"" ref-type=""bibr"">16</xref>,<xref rid=""B17-medicina-60-01185"" ref-type=""bibr"">17</xref>]. Infants with classical PKU",17_10,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"Infants with classical PKU require a greater total protein intake than healthy populations due to inefficient absorption and use of amino acids from AAF sources [<xref rid=""B17-medicina-60-01185"" ref-type=""bibr"">17</xref>,<xref rid=""B18-medicina-60-01185"" ref-type=""bibr"">18</xref>]. Medical therapy mainly consists of the synthetic form of tetrahydrobiopterin (BH4), known as Sapropterin. PKU patients who respond to treatment demonstrate the capacity to increase their dietary Phe intake [<xref",17_11,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"to increase their dietary Phe intake [<xref rid=""B19-medicina-60-01185"" ref-type=""bibr"">19</xref>,<xref rid=""B20-medicina-60-01185"" ref-type=""bibr"">20</xref>,<xref rid=""B21-medicina-60-01185"" ref-type=""bibr"">21</xref>] by at least two-fold while maintaining plasma Phe levels within the normal range. Moreover, a subset of patients can maintain plasma Phe levels within the target range without any restricted diet. The transition to a more typical diet has been suggested to provide substantial benefits,",17_12,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"been suggested to provide substantial benefits, including improved nutritional status and enhanced quality of life for these patients [<xref rid=""B10-medicina-60-01185"" ref-type=""bibr"">10</xref>,<xref rid=""B22-medicina-60-01185"" ref-type=""bibr"">22</xref>]. The milder form of PKU requires no dietary restrictions [<xref rid=""B10-medicina-60-01185"" ref-type=""bibr"">10</xref>] or allows for very high tolerance [<xref rid=""B23-medicina-60-01185"" ref-type=""bibr"">23</xref>,<xref rid=""B24-medicina-60-01185""",17_13,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"rid=""B24-medicina-60-01185"" ref-type=""bibr"">24</xref>]. Managing the diet of PKU patients requires a nuanced approach, balancing the need for adequate nutrient intake to support growth and development with strict limits on intact protein to maintain optimal blood phenylalanine levels [<xref rid=""B25-medicina-60-01185"" ref-type=""bibr"">25</xref>]. The extent to which this process influences growth is still a matter of controversy, with studies across the world documenting different results. Recent reports",17_14,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"documenting different results. Recent reports have indicated no significant difference in growth and body composition between PKU patients and normal individuals [<xref rid=""B26-medicina-60-01185"" ref-type=""bibr"">26</xref>,<xref rid=""B27-medicina-60-01185"" ref-type=""bibr"">27</xref>,<xref rid=""B28-medicina-60-01185"" ref-type=""bibr"">28</xref>]. Conversely, other studies show that in the first three years of life, PKU patients have shorter length/height z-scores [<xref rid=""B12-medicina-60-01185""",17_15,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"z-scores [<xref rid=""B12-medicina-60-01185"" ref-type=""bibr"">12</xref>,<xref rid=""B29-medicina-60-01185"" ref-type=""bibr"">29</xref>,<xref rid=""B30-medicina-60-01185"" ref-type=""bibr"">30</xref>,<xref rid=""B31-medicina-60-01185"" ref-type=""bibr"">31</xref>,<xref rid=""B32-medicina-60-01185"" ref-type=""bibr"">32</xref>,<xref rid=""B33-medicina-60-01185"" ref-type=""bibr"">33</xref>,<xref rid=""B34-medicina-60-01185"" ref-type=""bibr"">34</xref>,<xref rid=""B35-medicina-60-01185"" ref-type=""bibr"">35</xref>] and a lower",17_16,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"ref-type=""bibr"">35</xref>] and a lower weight-for-age z-score, while birth weight was comparable to healthy controls [<xref rid=""B29-medicina-60-01185"" ref-type=""bibr"">29</xref>,<xref rid=""B33-medicina-60-01185"" ref-type=""bibr"">33</xref>,<xref rid=""B34-medicina-60-01185"" ref-type=""bibr"">34</xref>,<xref rid=""B35-medicina-60-01185"" ref-type=""bibr"">35</xref>]. Research on growth in mHPA patients reveals that their weight-for-age z-score, height-for-age z-score, length-for-age z-score, and",17_17,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"z-score, length-for-age z-score, and body-mass-index-for-age z-score were generally similar to the reference population [<xref rid=""B33-medicina-60-01185"" ref-type=""bibr"">33</xref>,<xref rid=""B36-medicina-60-01185"" ref-type=""bibr"">36</xref>,<xref rid=""B37-medicina-60-01185"" ref-type=""bibr"">37</xref>]. However, Thiele et al. [<xref rid=""B34-medicina-60-01185"" ref-type=""bibr"">34</xref>] observed significantly lower height-for-age z-scores in mHPA patients compared to healthy children during the first six",17_18,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"compared to healthy children during the first six years. Considering that no official information is available on growth in Romanian PKU patients, the present paper aimed to evaluate the growth trajectories of children with PKU from 2 Romanian centers over a period of 36 months.   Phenylketonuria is a genetically determined metabolic disease, where secondary prophylactic measures effectively prevent disease complications [<xref rid=""B45-medicina-60-01185"" ref-type=""bibr"">45</xref>,<xref",17_19,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"ref-type=""bibr"">45</xref>,<xref rid=""B46-medicina-60-01185"" ref-type=""bibr"">46</xref>,<xref rid=""B47-medicina-60-01185"" ref-type=""bibr"">47</xref>]. In the beginning, the only therapeutic option for children diagnosed with classical PKU was medical nutritional therapy [<xref rid=""B48-medicina-60-01185"" ref-type=""bibr"">48</xref>,<xref rid=""B49-medicina-60-01185"" ref-type=""bibr"">49</xref>]. Early initiation, within the first days after birth, of a phenylalanine-restricted diet supplemented with medical food",17_20,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"diet supplemented with medical food substantially optimized the neurological and cognitive outcomes of patients with PKU [<xref rid=""B50-medicina-60-01185"" ref-type=""bibr"">50</xref>]. Dietary management, primarily structured around control of protein consumption [<xref rid=""B24-medicina-60-01185"" ref-type=""bibr"">24</xref>], involves transitioning from natural protein sources, such as human milk and those derived from plant foods, fruits, and vegetables [<xref rid=""B51-medicina-60-01185""",17_21,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"and vegetables [<xref rid=""B51-medicina-60-01185"" ref-type=""bibr"">51</xref>], to a semi-synthetic diet, where a substantial amount of protein is derived from an amino acid mixture that lacks phenylalanine [<xref rid=""B37-medicina-60-01185"" ref-type=""bibr"">37</xref>]. Medical formulas exhibit slight variations in nutritional compositions across different countries. For instance, many European formulas lack added fat or fiber, formulas containing glycomacropeptide (GMP) often have higher carbohydrate and",17_22,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"(GMP) often have higher carbohydrate and energy content [<xref rid=""B52-medicina-60-01185"" ref-type=""bibr"">52</xref>], some amino acid mixtures include added oligosaccharides, and formulas designed for the first year of life contain more carbohydrates and fat [<xref rid=""B53-medicina-60-01185"" ref-type=""bibr"">53</xref>,<xref rid=""B54-medicina-60-01185"" ref-type=""bibr"">54</xref>]. In Romania, there are currently two options each for PFF and AAF. The PFF options have standard dilution but differ in",17_23,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"PFF options have standard dilution but differ in nutritional content: one has 466 kcal/100 g, 50.1 g of carbohydrates, 23 g of lipids, and 0.61 g of L-alanine, while the other has 508 kcal/100 g, 54 g of carbohydrates, 28 g of lipids, and 0.5 g of L-alanine. For AAF, one option provides 60 g of protein equivalent with 12 g of carbohydrates, and the other offers 74 g of protein equivalent without carbohydrates. Until recently, these formulas were only available in powdered form, whereas now they also come",17_24,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"in powdered form, whereas now they also come in single-dose packaging. In other countries, to facilitate acceptance, they are also available in granule form [<xref rid=""B55-medicina-60-01185"" ref-type=""bibr"">55</xref>]. Regarding GMP products, which were accepted in the Romanian Guideline in 2022, they are recommended for children over 3, so they have not been used during the studied period. Although the ideal timeframe for initiating dietary treatment is within 7–10 days after birth [<xref",17_25,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"treatment is within 7–10 days after birth [<xref rid=""B4-medicina-60-01185"" ref-type=""bibr"">4</xref>], delayed treatment initiation is still common in Romania, typically occurring within a few weeks and only occasionally within mere days postpartum. These delays often stem from various factors, including late dispatch of samples from maternity wards, logistical challenges in sample transportation to laboratories, and laboratory processing and reporting of elevated blood phenylalanine levels. As a result,",17_26,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"elevated blood phenylalanine levels. As a result, the authorized personnel responsible for notifying families and directing them to the nearest treatment center face significant challenges in ensuring timely intervention. However, dietary management presents a considerable challenge for patients and their caregivers, often constraining adherence [<xref rid=""B56-medicina-60-01185"" ref-type=""bibr"">56</xref>,<xref rid=""B57-medicina-60-01185"" ref-type=""bibr"">57</xref>,<xref rid=""B58-medicina-60-01185""",17_27,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"rid=""B58-medicina-60-01185"" ref-type=""bibr"">58</xref>]. Besides dietary therapy, two medical treatments are available, the most commonly used being Tetrahydrobiopterin (BH4) or Sapropterin. These oral medications act as a cofactor for the PAH protein, enhancing its activity in a subset of patients [<xref rid=""B59-medicina-60-01185"" ref-type=""bibr"">59</xref>]. They can increase dietary phenylalanine tolerance in individuals with milder forms of PKU, thereby potentially allowing for a more liberalized diet",17_28,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"potentially allowing for a more liberalized diet [<xref rid=""B10-medicina-60-01185"" ref-type=""bibr"">10</xref>]. The other treatment option is Pegvaliase [<xref rid=""B60-medicina-60-01185"" ref-type=""bibr"">60</xref>], an enzyme that catabolizes phenylalanine and is available only for patients over 16. Additionally, messenger RNA therapeutics delivered via lipid nanoparticles hold promise for treating metabolic diseases caused by protein deficiency, including phenylketonuria [<xref rid=""B61-medicina-60-01185""",17_29,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"[<xref rid=""B61-medicina-60-01185"" ref-type=""bibr"">61</xref>]. Earlier studies conducted between 1980 and 1990 in children with PKU, regardless of treatment status, displayed subnormal growth [<xref rid=""B62-medicina-60-01185"" ref-type=""bibr"">62</xref>]. As dietary management practices improved, the inadequate growth observed in treated children led to changes in dietary prescriptions. Consequently, many studies from various countries now report adequate physical growth in these children [<xref",17_30,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"adequate physical growth in these children [<xref rid=""B63-medicina-60-01185"" ref-type=""bibr"">63</xref>]. Still, the subject of optimal growth in phenylketonuria is part of an ongoing debate, with controversial findings still existing concerning the influences of PKU nutritional therapy on the physical development of these children. The reduced growth rate observed in some studies does not appear to have an endocrinological etiology, as both the somatotropic and thyrotropic axes function normally [<xref",17_31,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"and thyrotropic axes function normally [<xref rid=""B2-medicina-60-01185"" ref-type=""bibr"">2</xref>]. It is more likely influenced by therapeutic interventions and genetic predisposition [<xref rid=""B2-medicina-60-01185"" ref-type=""bibr"">2</xref>,<xref rid=""B45-medicina-60-01185"" ref-type=""bibr"">45</xref>]. Most studies have reported no correlation between Phe concentrations and PKU patients’ growth [<xref rid=""B2-medicina-60-01185"" ref-type=""bibr"">2</xref>,<xref rid=""B11-medicina-60-01185""",17_32,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"rid=""B11-medicina-60-01185"" ref-type=""bibr"">11</xref>,<xref rid=""B12-medicina-60-01185"" ref-type=""bibr"">12</xref>,<xref rid=""B31-medicina-60-01185"" ref-type=""bibr"">31</xref>,<xref rid=""B33-medicina-60-01185"" ref-type=""bibr"">33</xref>,<xref rid=""B35-medicina-60-01185"" ref-type=""bibr"">35</xref>,<xref rid=""B64-medicina-60-01185"" ref-type=""bibr"">64</xref>]. Our study’s findings aligned with this pattern, as none of the evaluated anthropometric indexes correlated with blood Phe levels. The effect of total",17_33,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"with blood Phe levels. The effect of total protein intake, natural protein, and protein substitutes has also been evaluated regarding growth, with inconsistent results [<xref rid=""B65-medicina-60-01185"" ref-type=""bibr"">65</xref>]. Suboptimal growth was revealed by earlier studies, in which total protein intake was equivalent to the RDA for the general population [<xref rid=""B30-medicina-60-01185"" ref-type=""bibr"">30</xref>,<xref rid=""B31-medicina-60-01185"" ref-type=""bibr"">31</xref>,<xref",17_34,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"ref-type=""bibr"">31</xref>,<xref rid=""B65-medicina-60-01185"" ref-type=""bibr"">65</xref>]. This prompted the European PKU guidelines to recommend a higher protein intake, advising an additional 40% of protein from phenylalanine-free amino acids beyond the WHO safe levels [<xref rid=""B40-medicina-60-01185"" ref-type=""bibr"">40</xref>] to compensate for the inefficient utilization of L-amino acids, the decreased absorption of protein fractions, and to help lower blood phenylalanine concentrations [<xref",17_35,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"lower blood phenylalanine concentrations [<xref rid=""B16-medicina-60-01185"" ref-type=""bibr"">16</xref>,<xref rid=""B66-medicina-60-01185"" ref-type=""bibr"">66</xref>,<xref rid=""B67-medicina-60-01185"" ref-type=""bibr"">67</xref>]. The increase in total protein intake was subsequently associated with satisfactory growth in most studies [<xref rid=""B19-medicina-60-01185"" ref-type=""bibr"">19</xref>,<xref rid=""B26-medicina-60-01185"" ref-type=""bibr"">26</xref>,<xref rid=""B35-medicina-60-01185""",17_36,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"rid=""B35-medicina-60-01185"" ref-type=""bibr"">35</xref>,<xref rid=""B36-medicina-60-01185"" ref-type=""bibr"">36</xref>,<xref rid=""B37-medicina-60-01185"" ref-type=""bibr"">37</xref>,<xref rid=""B68-medicina-60-01185"" ref-type=""bibr"">68</xref>,<xref rid=""B69-medicina-60-01185"" ref-type=""bibr"">69</xref>,<xref rid=""B70-medicina-60-01185"" ref-type=""bibr"">70</xref>,<xref rid=""B71-medicina-60-01185"" ref-type=""bibr"">71</xref>], with a few exceptions [<xref rid=""B2-medicina-60-01185"" ref-type=""bibr"">2</xref>,<xref",17_37,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"ref-type=""bibr"">2</xref>,<xref rid=""B31-medicina-60-01185"" ref-type=""bibr"">31</xref>,<xref rid=""B33-medicina-60-01185"" ref-type=""bibr"">33</xref>,<xref rid=""B72-medicina-60-01185"" ref-type=""bibr"">72</xref>]. In the present study, total protein intake ranged from 1.3 to 3.22 g/kg per day (mean 2.17 ± 0.36 g/kg per day), which corresponds to an average of 175.9 ± 43.1% of the recommended daily allowance, similar to the mean total protein intakes prescribed in Western Europe [<xref rid=""B34-medicina-60-01185""",17_38,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"Western Europe [<xref rid=""B34-medicina-60-01185"" ref-type=""bibr"">34</xref>,<xref rid=""B40-medicina-60-01185"" ref-type=""bibr"">40</xref>]. Children in both groups exceeded the safe levels of protein intake (mean PKU 194%, range 141–251%; mean control 188%, range 133–272%) [<xref rid=""B17-medicina-60-01185"" ref-type=""bibr"">17</xref>]. Moreover, 72% of the protein consumed by our PKU patients originated from medical food, similar to a previous study by López-Mejía et al. [<xref rid=""B73-medicina-60-01185""",17_39,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"et al. [<xref rid=""B73-medicina-60-01185"" ref-type=""bibr"">73</xref>]. Research studies have also examined how various fractions of total protein affect growth. However, they have not conclusively linked anthropometric measurements with natural protein intake [<xref rid=""B2-medicina-60-01185"" ref-type=""bibr"">2</xref>,<xref rid=""B24-medicina-60-01185"" ref-type=""bibr"">24</xref>,<xref rid=""B34-medicina-60-01185"" ref-type=""bibr"">34</xref>] or protein substitute intake [<xref rid=""B12-medicina-60-01185""",17_40,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"intake [<xref rid=""B12-medicina-60-01185"" ref-type=""bibr"">12</xref>,<xref rid=""B24-medicina-60-01185"" ref-type=""bibr"">24</xref>,<xref rid=""B33-medicina-60-01185"" ref-type=""bibr"">33</xref>]. Furthermore, evidence from the literature regarding the effects of BH4 treatment on growth has demonstrated inconsistent results [<xref rid=""B25-medicina-60-01185"" ref-type=""bibr"">25</xref>,<xref rid=""B73-medicina-60-01185"" ref-type=""bibr"">73</xref>,<xref rid=""B74-medicina-60-01185"" ref-type=""bibr"">74</xref>,<xref",17_41,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"ref-type=""bibr"">74</xref>,<xref rid=""B75-medicina-60-01185"" ref-type=""bibr"">75</xref>]. Singh et al. observed a significant increase in height z-score after two years of administering BH4 therapy [<xref rid=""B25-medicina-60-01185"" ref-type=""bibr"">25</xref>]. In contrast, Aldámiz-Echevarría et al. reported growth impairment in patients on a Phe-restricted diet alone and those on BH4 therapy [<xref rid=""B75-medicina-60-01185"" ref-type=""bibr"">75</xref>]. Similarly, Daly et al. found no difference in growth",17_42,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"Daly et al. found no difference in growth velocity between patients on BH4 therapy and those on conventional PKU treatment [<xref rid=""B76-medicina-60-01185"" ref-type=""bibr"">76</xref>]. The latter two studies had longer observation periods of five and three years, respectively. In our study, four patients (P9 and P16–18) with mHPA underwent BH-4 therapy and adhered to a liberalized diet. They displayed notably lower mean growth metrics for the entire study period than controls: WHZ −0.98 vs. −0.035, WAZ",17_43,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"period than controls: WHZ −0.98 vs. −0.035, WAZ −1.23 vs. 0.09, HAZ −0.38 vs. 0.46, and BAZ −1.1 vs. −0.08 (<italic toggle=""yes"">p</italic> < 0.001). These differences were statistically significant despite falling within the normal range. The impact of disease phenotype has been a subject of debate. Some studies have indicated normal growth regardless of PKU phenotype [<xref rid=""B37-medicina-60-01185"" ref-type=""bibr"">37</xref>], whereas others [<xref rid=""B29-medicina-60-01185""",17_44,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"whereas others [<xref rid=""B29-medicina-60-01185"" ref-type=""bibr"">29</xref>,<xref rid=""B33-medicina-60-01185"" ref-type=""bibr"">33</xref>,<xref rid=""B34-medicina-60-01185"" ref-type=""bibr"">34</xref>] have observed suboptimal growth in children with a severe phenotype. Patients with classical PKU from our study also presented with lower mean growth metrics for the entire study period compared to controls: WHZ of −0.76 (−1.49, 0.20), WAZ of −0.63 (−1.21, 0.14), HAZ of 0.11 (−1.02, 1.08), and BAZ of −1 (−1.7,",17_45,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"HAZ of 0.11 (−1.02, 1.08), and BAZ of −1 (−1.7, 0.11). These differences were all statistically significant (<italic toggle=""yes"">p</italic> < 0.001) despite falling within the normal growth range. Regarding the influence of demographic characteristics, certain studies have reported delayed catch-up growth in height and head circumference among boys [<xref rid=""B31-medicina-60-01185"" ref-type=""bibr"">31</xref>,<xref rid=""B53-medicina-60-01185"" ref-type=""bibr"">53</xref>], and a tendency toward overweight in",17_46,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"and a tendency toward overweight in females older than eight years [<xref rid=""B33-medicina-60-01185"" ref-type=""bibr"">33</xref>]. Also, studies have shown that poor adherence to treatment can result from limited access to care or inadequate social support, financial constraints, lower educational attainment, and diminished self-efficacy [<xref rid=""B77-medicina-60-01185"" ref-type=""bibr"">77</xref>]. Patients in our study showed a spectrum of caregiver educational levels (% of mothers with university",17_47,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"educational levels (% of mothers with university education) and financial resources, with all having equal access to treatment. Regarding birth anthropometrics, most studies reported normal birth weight [<xref rid=""B29-medicina-60-01185"" ref-type=""bibr"">29</xref>,<xref rid=""B33-medicina-60-01185"" ref-type=""bibr"">33</xref>,<xref rid=""B34-medicina-60-01185"" ref-type=""bibr"">34</xref>,<xref rid=""B36-medicina-60-01185"" ref-type=""bibr"">36</xref>,<xref rid=""B37-medicina-60-01185"" ref-type=""bibr"">37</xref>] and",17_48,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"ref-type=""bibr"">37</xref>] and height [<xref rid=""B32-medicina-60-01185"" ref-type=""bibr"">32</xref>,<xref rid=""B33-medicina-60-01185"" ref-type=""bibr"">33</xref>,<xref rid=""B36-medicina-60-01185"" ref-type=""bibr"">36</xref>,<xref rid=""B37-medicina-60-01185"" ref-type=""bibr"">37</xref>], likely due to the maternal liver’s metabolism of phenylalanine through phenylalanine hydroxylase [<xref rid=""B73-medicina-60-01185"" ref-type=""bibr"">73</xref>]. However, there are also reports of smaller birth height within the PKU",17_49,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"reports of smaller birth height within the PKU population [<xref rid=""B12-medicina-60-01185"" ref-type=""bibr"">12</xref>,<xref rid=""B30-medicina-60-01185"" ref-type=""bibr"">30</xref>,<xref rid=""B31-medicina-60-01185"" ref-type=""bibr"">31</xref>,<xref rid=""B34-medicina-60-01185"" ref-type=""bibr"">34</xref>]. The mean birth weight of our PKU patients was similar to those of the control group, whereas birth weight showed a borderline significant decrease (<italic toggle=""yes"">p</italic> = 0.04). This is consistent",17_50,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"= 0.04). This is consistent with the findings of Verkerk et al. [<xref rid=""B30-medicina-60-01185"" ref-type=""bibr"">30</xref>] and Dhondt et al. [<xref rid=""B32-medicina-60-01185"" ref-type=""bibr"">32</xref>]. Analyzing the growth trajectories of our two study groups, we observed that PKU patients weighed less than controls throughout the study period. Despite growth trajectories within normal ranges for most PKU patients in our study group, their weight-for-age consistently remained lower than the controls,",17_51,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"consistently remained lower than the controls, consistent with previous studies [<xref rid=""B12-medicina-60-01185"" ref-type=""bibr"">12</xref>,<xref rid=""B29-medicina-60-01185"" ref-type=""bibr"">29</xref>,<xref rid=""B33-medicina-60-01185"" ref-type=""bibr"">33</xref>,<xref rid=""B34-medicina-60-01185"" ref-type=""bibr"">34</xref>]. Overall, the percentage of eutrophic anthropometric measurements was high (76.3%), similar to previous reports [<xref rid=""B78-medicina-60-01185"" ref-type=""bibr"">78</xref>]. Although birth",17_52,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"ref-type=""bibr"">78</xref>]. Although birth height was lower in children with PKU, complete catch-up occurred and was maintained during the entire study period, with similar values recorded by both study groups. This overall normal physical development during the first years of life is in accordance with some of the previous findings [<xref rid=""B24-medicina-60-01185"" ref-type=""bibr"">24</xref>,<xref rid=""B79-medicina-60-01185"" ref-type=""bibr"">79</xref>], but not with all. Ilgaz et al. reported impaired",17_53,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"but not with all. Ilgaz et al. reported impaired growth during the first years of life [<xref rid=""B65-medicina-60-01185"" ref-type=""bibr"">65</xref>]. Also, several other studies reported shorter length/height in early childhood [<xref rid=""B29-medicina-60-01185"" ref-type=""bibr"">29</xref>,<xref rid=""B30-medicina-60-01185"" ref-type=""bibr"">30</xref>,<xref rid=""B32-medicina-60-01185"" ref-type=""bibr"">32</xref>,<xref rid=""B33-medicina-60-01185"" ref-type=""bibr"">33</xref>,<xref rid=""B34-medicina-60-01185""",17_54,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"rid=""B34-medicina-60-01185"" ref-type=""bibr"">34</xref>,<xref rid=""B35-medicina-60-01185"" ref-type=""bibr"">35</xref>]. Variations in reported growth outcomes across the studies may reflect differences in dietary protocols, rates of patient adherence to diet, access to specific products, the extent of micronutrient supplementation [<xref rid=""B79-medicina-60-01185"" ref-type=""bibr"">79</xref>], and phenotype distribution [<xref rid=""B6-medicina-60-01185"" ref-type=""bibr"">6</xref>]. The results obtained from this",17_55,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"The results obtained from this study have several important prospects for practical application and further research. Firstly, they provide a valuable reference point for healthcare providers in Romania and potentially other similar settings to assess and compare the growth trajectories of children with PKU. By demonstrating that current dietary management practices are generally effective in supporting normal growth, these findings can reassure clinicians and caregivers about the efficacy of existing",17_56,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"and caregivers about the efficacy of existing interventions. Moreover, the identification of persistent lower weight-for-age z-scores suggests specific areas where dietary therapy might be improved and can guide the development of more tailored nutritional plans aimed at addressing weight deficits, thereby enhancing overall growth outcomes. The study’s findings also underscore the need for continuous monitoring and potential adjustments in dietary practices, which could be incorporated into clinical",17_57,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"which could be incorporated into clinical guidelines and standard care protocols for PKU management. Several limitations should be acknowledged. First, the retrospective nature of the study resulted in varying degrees of data completeness. Additionally, this retrospective design introduces the possibility of selection bias, as the study only included children with phenylketonuria who attended check-ups, potentially affecting the generalizability of the findings. Self-reported data were used in a few cases,",17_58,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"Self-reported data were used in a few cases, which also could be a source of bias. Moreover, the three-year follow-up period may not capture long-term growth trends, as other studies suggest that significant weight gain can occur [<xref rid=""B73-medicina-60-01185"" ref-type=""bibr"">73</xref>,<xref rid=""B80-medicina-60-01185"" ref-type=""bibr"">80</xref>,<xref rid=""B81-medicina-60-01185"" ref-type=""bibr"">81</xref>,<xref rid=""B82-medicina-60-01185"" ref-type=""bibr"">82</xref>,<xref rid=""B83-medicina-60-01185""",17_59,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"rid=""B83-medicina-60-01185"" ref-type=""bibr"">83</xref>,<xref rid=""B84-medicina-60-01185"" ref-type=""bibr"">84</xref>], especially in girls after eight years of age [<xref rid=""B33-medicina-60-01185"" ref-type=""bibr"">33</xref>]. The small sample size further limited our ability to draw definitive conclusions, extrapolate findings, and examine the effects of genetics or socioeconomic status on the growth of these children. Additionally, our controls originated from children admitted to the hospital for routine",17_60,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"children admitted to the hospital for routine check-ups or minor ailments, with no suspected or known diagnoses that could influence growth, rather than from a general population sample. Lastly, we were unable to assess body composition or collect data on micronutrients and trace elements. Future studies should aim to include a larger and more diverse sample, along with a prospective design to better capture the long-term effects of dietary management on growth. In summary, this study provides the first",17_61,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"growth. In summary, this study provides the first insights into the growth trajectories of Romanian children with PKU during early childhood, demonstrating adequate growth across a diverse population that includes both classical PKU and mHPA, with overall good metabolic control. These findings highlighted the effectiveness of current dietary management practices in supporting normal growth in children with PKU. However, the persistent lower weight-for-age z-scores compared to controls indicated that",17_62,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"z-scores compared to controls indicated that ongoing monitoring and potential adjustments in dietary therapy may be necessary to further optimize growth outcomes. Future prospective, multicenter studies involving a larger cohort of Romanian children are warranted to validate these findings and explore additional factors influencing growth and development in this population.",17_63,Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers,22 7 2024,,Phenylketonuria
"Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice Patients with phenylketonuria (PKU) must restrict their intake of phenylalanine, which can also affect the levels of other essential and non-essential amino acids due to inadequate supply. Therefore, our objective was to assess amino acids in serum samples from 20 PKU patients and compare them with results from 51 healthy subjects. A sample analysis was conducted using liquid chromatography–tandem mass spectrometry. We",18_0,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"chromatography–tandem mass spectrometry. We obtained levels of 28 substances, including amino acids, biogenic amines, carnitine, and acetylcarnitine. Kynurenine (<italic toggle=""yes"">p</italic> = 0.000001), tyrosine (<italic toggle=""yes"">p</italic> = 0.0002), asparagine (<italic toggle=""yes"">p</italic> = 0.001), proline (<italic toggle=""yes"">p</italic> = 0.012), and the kynurenine/tryptophan ratio (<italic toggle=""yes"">p</italic> < 0.000001) were identified as features that differed between the studied",18_1,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"as features that differed between the studied groups, being significantly lower in patients with PKU. Glycine (<italic toggle=""yes"">p</italic> = 0.000012), putrescine (<italic toggle=""yes"">p</italic> = 0.0055), asymmetric dimethylarginine (<italic toggle=""yes"">p</italic> = 0.01), creatinine (<italic toggle=""yes"">p</italic> = 0.035) levels, as well as the total level of glucogenic amino acids (<italic toggle=""yes"">p</italic> = 0.0018), and the ratios of putrescine/ornithine (<italic toggle=""yes"">p</italic>",18_2,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"(<italic toggle=""yes"">p</italic> = 0.003) and citrulline/ornithine (<italic toggle=""yes"">p</italic> = 0.0043) were significantly higher in the PKU group. In conclusion, the amino acid profiles in patients with PKU differ significantly from those in healthy peers, with potential clinical implications. These findings confirm the importance of metabolic testing in clinical practice and highlight the necessity for adequate dietary monitoring and adjustment. Phenylketonuria (PKU, OMIM 261,600) is a hereditary",18_3,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"(PKU, OMIM 261,600) is a hereditary metabolic disorder caused by a single gene mutation and is inherited in an autosomal recessive manner [<xref rid=""B1-metabolites-14-00397"" ref-type=""bibr"">1</xref>]. The disease stems from a deficiency or insufficiency of the enzyme phenylalanine hydroxylase (PAH, EC 1.14.16.1), which is responsible for converting phenylalanine (Phe) into tyrosine. Most PKU cases result from mutations in the <italic toggle=""yes"">PAH</italic> gene, leading to the misfolding and",18_4,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"gene, leading to the misfolding and instability of the PAH enzyme [<xref rid=""B2-metabolites-14-00397"" ref-type=""bibr"">2</xref>]. This enzyme dysfunction causes an elevation in Phe levels in the blood and a shortage of tyrosine, leading to the toxic buildup of Phe in the brain. This metabolic process occurs within liver cells, where Phe serves as a substrate and is converted by PAH, molecular oxygen, iron, and a non-protein cofactor called tetrahydrobiopterin (BH4). The <italic toggle=""yes"">PAH</italic>",18_5,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"(BH4). The <italic toggle=""yes"">PAH</italic> gene, responsible for encoding the PAH enzyme, is located on chromosome 12 (q22–q24) [<xref rid=""B3-metabolites-14-00397"" ref-type=""bibr"">3</xref>]. To date, 3370 <italic toggle=""yes"">PAH</italic> variants have been identified, each affecting the enzyme’s activity in different ways [<xref rid=""B1-metabolites-14-00397"" ref-type=""bibr"">1</xref>,<xref rid=""B4-metabolites-14-00397"" ref-type=""bibr"">4</xref>]. PKU has a global impact, with an estimated 0.45 million",18_6,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"a global impact, with an estimated 0.45 million individuals affected, and its prevalence is roughly 1 in 23,930 live births. However, the rates of occurrence vary among different countries [<xref rid=""B5-metabolites-14-00397"" ref-type=""bibr"">5</xref>]. In Poland, PKU occurs at a frequency of 1 in 8309 individuals [<xref rid=""B6-metabolites-14-00397"" ref-type=""bibr"">6</xref>]. The observed variation in the phenotypic presentation of PKU can be attributed to a combination of genetic factors, individual",18_7,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"to a combination of genetic factors, individual predispositions, such as the blood–brain barrier, and environmental influences. Among Europeans, PKU stands as the most prevalent inborn error of metabolism. Notably, PKU played a significant role in pioneering the development of effective treatments for disorders that cause both physical and cognitive impairments [<xref rid=""B7-metabolites-14-00397"" ref-type=""bibr"">7</xref>]. The primary approach to treating PKU involves implementing a Phe-restricted diet,",18_8,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"PKU involves implementing a Phe-restricted diet, which necessitates reducing the intake of natural proteins and substituting them with a protein source that lacks Phe, consisting of a combination of amino acids. Protein substitutes supply the fundamental components for the formation of tissue proteins, and their amino acids are crucial for the creation of hormones, enzymes, and various cellular functions [<xref rid=""B8-metabolites-14-00397"" ref-type=""bibr"">8</xref>]. This therapeutic regimen should be",18_9,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"This therapeutic regimen should be overseen by a knowledgeable physician who specializes in metabolic disorders, along with a team of dietitians [<xref rid=""B6-metabolites-14-00397"" ref-type=""bibr"">6</xref>,<xref rid=""B8-metabolites-14-00397"" ref-type=""bibr"">8</xref>]. Since the foods typically consumed for protein also contain essential nutrients, it is crucial for a Phe-restricted diet to include alternative sources that provide all the necessary nutrients for healthy growth and well-being. In certain",18_10,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"for healthy growth and well-being. In certain cases, patients may also require tyrosine supplementation since it is typically scarce in the PKU diet, ensuring the sufficient production of neurotransmitters. However, the rigorous nature of the PKU diet can pose challenges for patients and their families in maintaining consistent compliance over the long term [<xref rid=""B9-metabolites-14-00397"" ref-type=""bibr"">9</xref>,<xref rid=""B10-metabolites-14-00397"" ref-type=""bibr"">10</xref>]. Furthermore, despite",18_11,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"ref-type=""bibr"">10</xref>]. Furthermore, despite adhering strictly to the diet, some individuals with PKU may still encounter neurological symptoms, emphasizing the necessity for additional treatment options [<xref rid=""B11-metabolites-14-00397"" ref-type=""bibr"">11</xref>]. A study revealed significantly higher rates of autism spectrum disorders and eating disorders among adults with PKU compared to the general population [<xref rid=""B12-metabolites-14-00397"" ref-type=""bibr"">12</xref>]. Similarly, elevated",18_12,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"ref-type=""bibr"">12</xref>]. Similarly, elevated rates of depression and anxiety were observed in the overall PKU population [<xref rid=""B13-metabolites-14-00397"" ref-type=""bibr"">13</xref>,<xref rid=""B14-metabolites-14-00397"" ref-type=""bibr"">14</xref>]. Another study demonstrated that adolescent and adult PKU patients exhibited poorer social cognition and social skills compared to control groups [<xref rid=""B11-metabolites-14-00397"" ref-type=""bibr"">11</xref>]. There was also a tendency towards lower or",18_13,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"There was also a tendency towards lower or delayed autonomy [<xref rid=""B15-metabolites-14-00397"" ref-type=""bibr"">15</xref>] and emotional difficulties associated with adhering to a PKU diet [<xref rid=""B16-metabolites-14-00397"" ref-type=""bibr"">16</xref>]. Furthermore, PKU patients often experience feelings of social isolation and limitations in social interaction [<xref rid=""B17-metabolites-14-00397"" ref-type=""bibr"">17</xref>]. Many of them also face significant neurocognitive, mental health, and general",18_14,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"neurocognitive, mental health, and general health challenges [<xref rid=""B13-metabolites-14-00397"" ref-type=""bibr"">13</xref>,<xref rid=""B15-metabolites-14-00397"" ref-type=""bibr"">15</xref>,<xref rid=""B18-metabolites-14-00397"" ref-type=""bibr"">18</xref>]. Additionally, there are reports that overweight and obesity may be more common among PKU patients when compared to their healthy peers [<xref rid=""B19-metabolites-14-00397"" ref-type=""bibr"">19</xref>,<xref rid=""B20-metabolites-14-00397""",18_15,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"rid=""B20-metabolites-14-00397"" ref-type=""bibr"">20</xref>]. Research is currently underway to develop alternative therapies for PKU, including enzyme replacement therapies and gene therapies aimed at correcting the underlying genetic mutation. Additionally, researchers are exploring the use of pharmacological agents to enhance the activity of PAH and reduce the accumulation of Phe in the brain [<xref rid=""B21-metabolites-14-00397"" ref-type=""bibr"">21</xref>,<xref rid=""B22-metabolites-14-00397""",18_16,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"rid=""B22-metabolites-14-00397"" ref-type=""bibr"">22</xref>,<xref rid=""B23-metabolites-14-00397"" ref-type=""bibr"">23</xref>]. Upon an accurate diagnosis of the disease, patients are prescribed a low Phe diet. The regular monitoring of blood Phe levels is necessary to evaluate the efficacy of the elimination diet. However, the differences between PKU patients and healthy individuals extend beyond Phe concentrations in the body. The levels of other essential and non-essential amino acids may also be affected due",18_17,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"amino acids may also be affected due to inadequate supply. Thus, the objective of this study was to quantify the concentrations of 28 amino acids in serum samples from PKU patients and compare them with results obtained from the control group. A sophisticated analytical system based on high-performance liquid chromatography–mass spectrometry was employed to achieve this. The findings from this study have the potential to enhance our understanding of the underlying mechanisms involved in PKU development.",18_18,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"mechanisms involved in PKU development. Furthermore, they may serve as a foundation for designing an even more tailored diet to address the intricate needs of PKU patients. There was a cross-sectional study [<xref rid=""B24-metabolites-14-00397"" ref-type=""bibr"">24</xref>] comprising 20 patients with classical PKU treated at the Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences. The control group consisted of 51 healthy subjects (<xref",18_19,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"group consisted of 51 healthy subjects (<xref rid=""metabolites-14-00397-t001"" ref-type=""table"">Table 1</xref>). For the purposes of the analysis, classical PKU was defined as a disease that, at diagnosis, required a low Phe diet to maintain plasma Phe levels within the target range of 2–6 mg/dL (120–360 μmol/L), and that, without diet, would result in Phe levels exceeding 20 mg/dL (1200 μmol/L) [<xref rid=""B25-metabolites-14-00397"" ref-type=""bibr"">25</xref>]. The other inclusion criteria for patients were",18_20,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"The other inclusion criteria for patients were diagnosis in the screening program and continuous treatment (Phe-restricted diet using Phe-free formula). The exclusion criteria, both for patients and healthy controls, included severe chronic or acute diseases, pregnancy, and breastfeeding. None of the patients with PKU received additional treatment (e.g., BH4 or PEG-PAL formulation). All patients were recommended to perform monthly routine checks of Phe concentrations. All blood Phe concentrations collected",18_21,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"All blood Phe concentrations collected during the 12 months preceding blood collection were evaluated in a dry blood spot; a venous blood sample (0.5 mL to clot) taken before eating in the morning following an overnight fast was checked using a fluorometric method. The Phe results were expressed as milligram per decilitre (mg/dL). The percentage of the Phe concentration within the therapeutic range was calculated for each patient according to recent recommendations [<xref rid=""B7-metabolites-14-00397""",18_22,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"[<xref rid=""B7-metabolites-14-00397"" ref-type=""bibr"">7</xref>]. The study design was compliant with the Helsinki Declaration [<xref rid=""B26-metabolites-14-00397"" ref-type=""bibr"">26</xref>] and was approved by the Bioethical Committee at the Poznan University of Medical Sciences (Poland) (approval number: 1119/18; 260/24). Written informed consent was obtained from all participants. The applied methodology resulted in the determination of serum levels of several amino acids and biogenic amines, as well as",18_23,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"amino acids and biogenic amines, as well as carnitine and acetylcarnitine. The concentrations of 28 analytes were measured within the quantification range. The univariate statistics demonstrated that the statistically significant (<italic toggle=""yes"">p</italic> < 0.05) differences between the studied groups occurred in the levels of 12 measured features. In the PKU group, levels of kynurenine, tyrosine, asparagine, proline, and the kynurenine/tryptophan ratio were significantly decreased in comparison to",18_24,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"were significantly decreased in comparison to the control group. On the contrary, glycine, putrescine, asymmetric dimethylarginine, and creatinine concentrations were significantly increased in the PKU group. Also, the total level of glucogenic amino acids and the ratios of citrulline/ornithine and putrescine/ornithine were significantly lower in the control group (<xref rid=""metabolites-14-00397-t002"" ref-type=""table"">Table 2</xref>). The results of the PLS-DA analysis indicate that the differences in",18_25,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"PLS-DA analysis indicate that the differences in concentrations of the measured features between the studied groups were strong enough to cause the grouping of the samples according to test or control group membership (<xref rid=""metabolites-14-00397-f001"" ref-type=""fig"">Figure 1</xref>). The PLS-DA analysis depicts measured features with the highest ability to the grouping of the samples. As a result of the PLS-DA analysis, it has been confirmed that the variables selected in univariate statistics as",18_26,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"variables selected in univariate statistics as discriminative between groups have, indeed, the best discriminative efficacy. <xref rid=""metabolites-14-00397-f002"" ref-type=""fig"">Figure 2</xref> shows the features listed according to their contribution to sample classification. The most differentiating variables were the kynurenine/tryptophan ratio, as well as kynurenine and glycine concentrations. The discriminative ability of the measured features that statistically significantly differentiate the studied",18_27,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"significantly differentiate the studied groups was further checked by calculating the ROC curves. The ROC curve gives a graphical presentation of the sensitivity and specificity of the studied factors. According to the results of this study, the highest AUC value (0.919) was obtained by the kynurenine/tryptophan ratio, followed by kynurenine (0.885) and glycine (0.840) concentrations (<xref rid=""metabolites-14-00397-t003"" ref-type=""table"">Table 3</xref> and <xref rid=""metabolites-14-00397-f003""",18_28,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"and <xref rid=""metabolites-14-00397-f003"" ref-type=""fig"">Figure 3</xref>). These results are consistent with the data from the PLS-DA analysis. The lowest AUC value (0.663) was calculated for creatinine. AUC values for other measured characteristics, for which no statistically significant differences between groups were shown, were lower than the AUC calculated for creatinine. The correlation heatmap was calculated using Rho Spearman’s algorithm to show the correlations between the measured features (<xref",18_29,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"correlations between the measured features (<xref rid=""metabolites-14-00397-f004"" ref-type=""fig"">Figure 4</xref>). The study revealed positive correlations between the levels of leucine, isoleucine, valine, and branched-chain amino acids. There was also a positive correlation between the concentration of glucogenic amino acids and the levels of glycine and alanine. Putrescine concentration was positively correlated with the putrescine/ornithine ratio. In addition, the ADMA/arginine and citrulline/arginine",18_30,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"the ADMA/arginine and citrulline/arginine ratios showed positive correlations with the ornithine/arginine ratio, but negative correlations with the arginine concentration. The ornithine/arginine ratio was negatively correlated with both the arginine concentration and the citrulline/ornithine ratio. In this study, we analyzed 28 metabolic features in serum samples obtained from PKU patients and healthy controls. Our findings revealed significant reductions in the levels of four substances (asparagine,",18_31,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"in the levels of four substances (asparagine, kynurenine, proline, and tyrosine) and the kynurenine/tryptophan ratio, and increased concentrations of four substances (asymmetric dimethylarginine, creatinine, glycine, and putrescine) as well as the total level of glucogenic amino acids and the ratios of citrulline/ornithine and putrescine/ornithine in the PKU group. Additionally, based on ROC curve analysis, the kynurenine/tryptophan ratio, kynurenine, glycine, and tyrosine levels showed the highest",18_32,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"glycine, and tyrosine levels showed the highest differential AUC value. These results underscore the importance of amino acid profile testing in clinical practice for patients with PKU. PKU is one of the earliest described inborn errors of metabolism. Over the years, guidelines have been developed that clearly define the diagnostic process, which is now based on determining the Phe concentration and Phe/tyrosine ratio as part of newborn screening tests. While the amino acid analysis using the HPLC method",18_33,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"the amino acid analysis using the HPLC method remains useful in diagnosing other inborn errors of metabolism, it is not the method of choice in the case of PKU due to the negative balance of potential benefits and drawbacks [<xref rid=""B7-metabolites-14-00397"" ref-type=""bibr"">7</xref>]. With the current effectiveness of disease detection protocols, scientific efforts are now focused not on improving the diagnostic process, but on improving the monitoring and treatment of patients with PKU. Advanced",18_34,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"and treatment of patients with PKU. Advanced methods, such as a detailed assessment of the amino acid profile using HPLC and techniques utilizing “-omics” discoveries, offer new possibilities for creating individualized patient management plans [<xref rid=""B31-metabolites-14-00397"" ref-type=""bibr"">31</xref>]. Although we have data defining the micronutrient status in PKU and even studies on the plasma phospholipidome of PKU analyzed using hydrophilic interaction LC-MS/MS and gas chromatography–mass",18_35,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"interaction LC-MS/MS and gas chromatography–mass spectrometry, there is still a lack of reliable scientific works defining a detailed amino acid profile in patients with PKU [<xref rid=""B5-metabolites-14-00397"" ref-type=""bibr"">5</xref>,<xref rid=""B32-metabolites-14-00397"" ref-type=""bibr"">32</xref>,<xref rid=""B33-metabolites-14-00397"" ref-type=""bibr"">33</xref>,<xref rid=""B34-metabolites-14-00397"" ref-type=""bibr"">34</xref>]. So far, a detailed amino acid profile has been evaluated as one of the parameters",18_36,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"has been evaluated as one of the parameters when introducing new protein preparations or in people with late-diagnosed disease [<xref rid=""B35-metabolites-14-00397"" ref-type=""bibr"">35</xref>,<xref rid=""B36-metabolites-14-00397"" ref-type=""bibr"">36</xref>,<xref rid=""B37-metabolites-14-00397"" ref-type=""bibr"">37</xref>]. Especially important for PKU patients is tyrosine deficiency. This large neutral amino acid in PKU patients becomes an indispensable L-amino acid as a result of insufficient endogenous supply",18_37,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"as a result of insufficient endogenous supply via PAH deficiency. Tyrosine is important not only in the production of thyroxin and melanin but also in the biosynthesis of neurotransmitters (L-dopa, dopamine, homovalinic acid). For this reason, tyrosine is supplemented in all L-amino acid formulas for PKU patients. Deficiency may indicate poorer compliance in the scope of formula intake and may result in problems with neurotransmission and, consequently, cognitive dysfunction. Lower concentrations of",18_38,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"cognitive dysfunction. Lower concentrations of proline may also indicate problems with formula admission [<xref rid=""B7-metabolites-14-00397"" ref-type=""bibr"">7</xref>]. Indeed, reduced proline levels in PKU mothers have been associated with the insufficient consumption of Phe-free formula [<xref rid=""B38-metabolites-14-00397"" ref-type=""bibr"">38</xref>]. However, to be able to state the role of tyrosine and proline, further studies are needed that consider the actual intake of Phe-free formula and determine",18_39,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"actual intake of Phe-free formula and determine whether any patients have neurological problems (including neuroimaging techniques). Moreover, the significantly lower kynurenine levels and kynurenine/tryptophan ratios in the studied group are also a matter of concern. The main precursor of kynurenine is tryptophan. Tryptophan, like tyrosine, is classified as one of the Large Neutral Amino Acids (LNAAs), which, apart from its obvious roles in the body’s protein homeostasis, reduces the toxic effects of Phe",18_40,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"homeostasis, reduces the toxic effects of Phe on the central nervous system through the ability to competitively block the transport of Phe through the blood–brain barrier [<xref rid=""B5-metabolites-14-00397"" ref-type=""bibr"">5</xref>,<xref rid=""B7-metabolites-14-00397"" ref-type=""bibr"">7</xref>,<xref rid=""B39-metabolites-14-00397"" ref-type=""bibr"">39</xref>]. Tryptophan plays a key role in the production of the neurotransmitter serotonin, melatonin, and, together with kynurenine, are precursors of niacin",18_41,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"with kynurenine, are precursors of niacin (vitamin B3). Kynurenine is associated with processes such as the body’s immune response, vasodilation in inflammatory processes, and oncogenesis. Decreased concentrations of kynurenine have been observed in patients with bipolar disorder [<xref rid=""B40-metabolites-14-00397"" ref-type=""bibr"">40</xref>,<xref rid=""B41-metabolites-14-00397"" ref-type=""bibr"">41</xref>]. Considering that in standard Phe-free mixtures, LNAAs constitute approx. 35–50% of the total number",18_42,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"constitute approx. 35–50% of the total number of L-amino acids, low concentrations of tryptophan and kynurenine may result either from the low consumption of the protein substitute by the tested patients or may indicate the need to increase LNAA’s supplementation in amino acid mixtures. However, before recommending an increase in tryptophan intake in Phe-free formulas, further studies are needed to investigate whether the intake of tryptophan is indeed low. Furthermore, it is important to note that LNAAs,",18_43,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"Furthermore, it is important to note that LNAAs, including tryptophan, compete to cross the intestinal mucosa using the same L-type amino acid transporter 1. This competition can affect the absorption efficiency of each LNAA [<xref rid=""B42-metabolites-14-00397"" ref-type=""bibr"">42</xref>]. Thus, the low concentrations of tryptophan and kynurenine observed may also be a result of this competitive absorption process. Another interesting finding is a significantly higher concentration of glycine in PKU",18_44,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"higher concentration of glycine in PKU patients. In addition to its role as a building block of proteins, glycine participates in glutathione synthesis and regulates gene expression and protein activity and configuration [<xref rid=""B43-metabolites-14-00397"" ref-type=""bibr"">43</xref>]. Zafra and Gimenez [<xref rid=""B44-metabolites-14-00397"" ref-type=""bibr"">44</xref>] highlight the important role of glycine in the process of neurotransmission. As an inhibitory neurotransmitter, particularly in the spinal",18_45,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"neurotransmitter, particularly in the spinal cord and brainstem, glycine affects reflex reactions and the processing of sensory signals through glycine receptors [<xref rid=""B45-metabolites-14-00397"" ref-type=""bibr"">45</xref>]. Glycine is also a co-agonist of glutamate in the activation of N-methyl-D-aspartate receptors, thus participating in excitatory neurotransmission [<xref rid=""B46-metabolites-14-00397"" ref-type=""bibr"">46</xref>]. Generally, glycine is considered a non-essential amino acid",18_46,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"glycine is considered a non-essential amino acid biosynthesized in metabolic pathways, mainly from serine [<xref rid=""B47-metabolites-14-00397"" ref-type=""bibr"">47</xref>]. In our study, the levels of serine in the PKU group were similar to those obtained in the control subjects. The possible causes for this discrepancy could be related to higher protein intake and non-compliance. Furthermore, in the present study, higher creatinine and asymmetric dimethylarginine levels in patients with PKU were revealed,",18_47,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"levels in patients with PKU were revealed, which could be related to renal and cardiovascular risk. Charrière et al. [<xref rid=""B48-metabolites-14-00397"" ref-type=""bibr"">48</xref>], analyzing national health insurance claims data, found a more frequent prevalence of chronic renal failure and ischemic heart disease in patients with PKU. Similar findings related to renal and cardiovascular diseases were documented earlier based on North American and German data [<xref rid=""B13-metabolites-14-00397""",18_48,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"German data [<xref rid=""B13-metabolites-14-00397"" ref-type=""bibr"">13</xref>,<xref rid=""B15-metabolites-14-00397"" ref-type=""bibr"">15</xref>]. Hennermann et al. [<xref rid=""B49-metabolites-14-00397"" ref-type=""bibr"">49</xref>] found normal creatinine and cystatin C serum concentrations in all 67 studied PKU subjects. However, the glomerular filtration rate was diminished in 19% of them and inversely correlated with lifelong protein intake. Hermida-Ameijeiras et al. [<xref rid=""B50-metabolites-14-00397""",18_49,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"et al. [<xref rid=""B50-metabolites-14-00397"" ref-type=""bibr"">50</xref>] documented that higher Phe levels were associated with an increased pulse wave velocity, which was not present in those subjects compliant with diet or under sapropterin treatment. Giret et al. [<xref rid=""B51-metabolites-14-00397"" ref-type=""bibr"">51</xref>] did not find any differences in plasma CRP levels and cytokine profiles between PKU patients and healthy controls. Kanzelmeyer et al. [<xref rid=""B52-metabolites-14-00397""",18_50,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"et al. [<xref rid=""B52-metabolites-14-00397"" ref-type=""bibr"">52</xref>] documented similar L-arginine/asymmetric dimethylarginine plasma molar ratios in PKU patients and healthy controls. Additionally, Verduci et al. [<xref rid=""B53-metabolites-14-00397"" ref-type=""bibr"">53</xref>] suggested that the cardiovascular risk of compliant PKU children is not different from that of the healthy population. However, well-designed large studies are warranted to define PKU cardiovascular risk and its factors,",18_51,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"define PKU cardiovascular risk and its factors, including a balanced diet and metabolic compliance. Our study aimed to characterize the intricate profile of metabolites using LC/MS techniques. We found significant alterations in the metabolome of PKU patients compared to healthy individuals. However, due to the small size of our study group, a limitation was the inability to interpret the results in light of adherence to dietary recommendations, assessed by average Phe levels and specific formula intake.",18_52,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"average Phe levels and specific formula intake. Further research is necessary to gather more data and comprehensively interpret and apply findings to individualize dietary management in PKU patients. In conclusion, the amino acid profiles of patients with PKU differ significantly from those of healthy peers, with potential clinical implications. These findings underscore the importance of metabolic testing in clinical practice and highlight the necessity for adequate dietary follow-up and adjustment.",18_53,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"for adequate dietary follow-up and adjustment. However, it is important to note that the sample size in this study is too small to draw definitive conclusions.",18_54,Amino Acid Profile Alterations in Phenylketonuria: Implications for Clinical Practice,21 7 2024,,Phenylketonuria
"Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants Phenylketonuria (PKU) or phenylalanine hydroxylase (<italic toggle=""yes"">PAH</italic>) deficiency is an inborn error of phenylalanine (Phe) metabolism that is caused by pathogenic variants in the <italic toggle=""yes"">PAH</italic> gene that are responsible for the conversion of Phe to tyrosine (Tyr).[<xref rid=""R1"" ref-type=""bibr"">1</xref><xref rid=""R2"" ref-type=""bibr"">2</xref>]",19_0,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"rid=""R2"" ref-type=""bibr"">2</xref>] In untreated PKU patients, blood Phe concentrations are noticeably increased, leading to the formation of phenylketone bodies that are excreted in urine. The increased Phe level will lead to a severe intellectual disability, epilepsy, and behavioral, psychiatric, and movement problems. Light pigmentation of skin, eyes, and hair, eczema, and a musty odor have also been observed in untreated patients.[<xref rid=""R3"" ref-type=""bibr"">3</xref><xref rid=""R4""",19_1,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"rid=""R3"" ref-type=""bibr"">3</xref><xref rid=""R4"" ref-type=""bibr"">4</xref><xref rid=""R5"" ref-type=""bibr"">5</xref><xref rid=""R6"" ref-type=""bibr"">6</xref>] Various incidence rates of PKU have been substantially observed among ethnicities and between different geographic regions worldwide. The highest prevalence of PKU is reported among white or East Asian populations (~1:10,000–15,000 live births).[<xref rid=""R5"" ref-type=""bibr"">5</xref>] The prevalence of PKU in European countries is varied ranging from",19_2,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"PKU in European countries is varied ranging from 1:2,700 live births in Italy to <1:100,000 live births in Finland.[<xref rid=""R1"" ref-type=""bibr"">1</xref>] The incidence rate of PKU in some regions is comparable to or even higher than what is reported in white or East Asian populations. For example, in Turkey,[<xref rid=""R6"" ref-type=""bibr"">6</xref>] and the Karachay-Cherkessia Republic of Russia,[<xref rid=""R7"" ref-type=""bibr"">7</xref>] the incidence rate is 1:4,370 and 1:850 newborns, respectively. PKU",19_3,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"is 1:4,370 and 1:850 newborns, respectively. PKU in Iran has one of the highest prevalence rates in the world with an estimate of 16.5 per 100,000 newborns.[<xref rid=""R8"" ref-type=""bibr"">8</xref>] In the Fars province of Iran, the prevalence of PKU is reported to be 1:4,698 live births.[<xref rid=""R9"" ref-type=""bibr"">9</xref><xref rid=""R10"" ref-type=""bibr"">10</xref>] PKU disease is usually caused by pathogenic variants in the <italic toggle=""yes"">PAH</italic> gene (ENSG00000171759), and in rare cases,",19_4,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"gene (ENSG00000171759), and in rare cases, failures in genes responsible for the synthesis or recycling of tetrahydrobiopterin (BH4), a cofactor for PAH enzyme, may also lead to hyperphenylalaninaemia.[<xref rid=""R11"" ref-type=""bibr"">11</xref>] The <italic toggle=""yes"">PAH</italic> gene that is located on chromosome 12 q22–q24.1 consists of 13 exons and occupies a region of about 171 kb in length.[<xref rid=""R5"" ref-type=""bibr"">5</xref>] Up to now, more than 1,100 variants of the <italic",19_5,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"to now, more than 1,100 variants of the <italic toggle=""yes"">PAH</italic> gene have been identified (the PAHvdb database (<ext-link http://www.w3.org/1999/xlink href=""http://www.biopku.org/home/pah.asp"" ext-link-type=""uri"">http://www.biopku.org/home/pah.asp</ext-link>)), most of which are recognized in exons 7, 6, 3, and 11, respectively. Missense mutations (60%), splice site variants (14%), and deletions (14%) are three common types of reported genetic variants in the PAHvdb database.[<xref rid=""R12""",19_6,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"variants in the PAHvdb database.[<xref rid=""R12"" ref-type=""bibr"">12</xref>] Mazandaran and Golestan provinces are located on the southern coastlines of the Caspian Sea with a population of around 5 million. In Golestan, Turkmens are one of the major ethnic groups, and in Mazandaran, the majority of the population has Mazandarani origin. In the first phase of the study, we investigated and published the frequency of five <italic toggle=""yes"">PAH</italic> gene mutations that were frequently reported from",19_7,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"gene mutations that were frequently reported from other parts of Iran in Mazandaran and Golestan Provinces. The investigated mutations that were identified using polymerase chain reaction – restriction fragment length polymorphism (PCR-RFLP) methods included c.106611G>A, c.782 G>A, c.754C>T, c.781C>T, and c.1200+1G>C mutations. These mutations were identified in 39.9% of the investigated alleles. The aim of the present study was to determine the pathogenic variants in all 13 exons of the <italic",19_8,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"variants in all 13 exons of the <italic toggle=""yes"">PAH</italic> gene among those patients.  Twenty-one different pathogenic variants were observed among 40 investigated patients (16 male and 24 female cases) [<xref rid=""ijpvm_50_23-t001"" ref-type=""table"">Table 1</xref>]. The pathogenic variants were identified in 68 alleles (85%). The c.106611G>A variant had the frequency among the patients, and 27.5% of the alleles carried this mutation. The c.168+5G>C, c.473G>A, and c.782G>A variants were other",19_9,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"c.473G>A, and c.782G>A variants were other frequent mutations among the investigated patients with frequencies of 7.5, 5, and 5%, respectively. The c.727C>T, c.782G>A, and c. 113_115delTCT variants were detected in three, and the c.441+5G>T and c.603T>G variants were identified in two alleles. Nine different pathogenic variants were just identified in one allele. Twenty different genotypes were observed in patients with two identified mutations [<xref rid=""ijpvm_50_23-t001"" ref-type=""table"">Table",19_10,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"rid=""ijpvm_50_23-t001"" ref-type=""table"">Table 1</xref>]. The c.106611G>A/c.106611G>A was the most frequent genotype among the patients (22.5%), especially in Golestan Province (33.3%). Eight cases carried two different mutations, and in two cases, the mutation was detected just in one allele. In the present study, three novel pathogenic variants were observed among the investigated patients including c.773T>G (NM_001354304.2), c.878T>C (NM_001354304.2), and c.1245del (NM_001354304.2) variants that were",19_11,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"and c.1245del (NM_001354304.2) variants that were located on exons 7, 8, and 12, respectively. The identified variants have not been reported before. The c.773T>G variant was identified in combination with the c.969+5G>A variant, while c.878 T>C, and c.1245del variants were detected in a homozygous state [<xref rid=""ijpvm_50_23-f001"" ref-type=""fig"">Figure 1</xref>]. All of the new variants were categorized as pathogenic based on InterVar online tool analysis. The <italic toggle=""yes"">PAH</italic> gene that",19_12,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"The <italic toggle=""yes"">PAH</italic> gene that was mapped to chromosome 12 (12q22–q24.2) is 90 kb in length and contains 13 exons.[<xref rid=""R3"" ref-type=""bibr"">3</xref>] PKU is genetically heterogeneous, and more than 1,100 PAH variants have been reported in patients with PKU worldwide.[<xref rid=""R15"" ref-type=""bibr"">15</xref>] These PAH variants are presented in the locus-specific databases PAHvdb and BioPKU (<ext-link http://www.w3.org/1999/xlink href=""http://www.biopku.org""",19_13,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"href=""http://www.biopku.org"" ext-link-type=""uri"">http://www.biopku.org</ext-link>). In the present study, we have reported the pathogenic variants of the <italic toggle=""yes"">PAH</italic> gene among patients with classic PKU in the north of Iran in which 21 different mutations including three novel pathogenic variants were identified. Since one or more specific mutations may be common in each population, the identification of such mutations at the country level may be an effective factor in the design of",19_14,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"level may be an effective factor in the design of national PKU screening programs. Moreover, the introduction of new pathogenic variants in the <italic toggle=""yes"">PAH</italic> gene provides valuable data regarding the understanding of the pathogenesis of the disease and can be helpful for prenatal diagnosis programs. In the present study, the spectrum and frequency of <italic toggle=""yes"">PAH</italic> gene mutations were investigated in the north of Iran, and three novel pathogenic variants in the",19_15,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"Iran, and three novel pathogenic variants in the <italic toggle=""yes"">PAH</italic> gene were introduced. Alibakhshi <italic toggle=""yes"">et al.</italic>,[<xref rid=""R16"" ref-type=""bibr"">16</xref>] in a systematic review study, analyzed the results of 21 articles with a sample size of 1,547 Iranian PKU patients, published between 2003 and 2020. Based on the results of that study, a total of 129 different PAH gene mutations were identified in Iranian PKU patients. They have reported that c.1066-11G>A",19_16,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"patients. They have reported that c.1066-11G>A (19.23%), c.782G>A (7.63%), c.842C>T (6.24%), c.168+5G>C(5.75%), c.727C>T (3.59%), c.969+5G>A (2.84%), c.526C>T (2.42%), c.1089delG (2.13%), c.1199+1G>C (2.07%), and c.143T>C (2.04%) are the most common mutations in Iran. The spectrum and frequency of mutations reported in that study were closer to those identified in Mediterranean countries. The results of the present study were also similar to the previous studies in Iran. Based on the BIOPKU database, the",19_17,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"in Iran. Based on the BIOPKU database, the c.1066-11G>A variant with a frequency of 6.8% is the second most frequent mutation among all reported mutations.[<xref rid=""R11"" ref-type=""bibr"">11</xref>] This variant is a major cause of PKU in the Mediterranean region and the Middle East. It is also the most frequent variant (21.11%) among PKU patients in Iran, except in western provinces, where c.969+5 G>A is the most frequent variant and c.1066-11G>A is the fourth common mutation (6.67%).[<xref rid=""R16""",19_18,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"fourth common mutation (6.67%).[<xref rid=""R16"" ref-type=""bibr"">16</xref>] In the present study like in other parts of the country the c. 1066-11G>A variant is the most common mutation (27.5%) and in Golestan province with high Turkmen settlements its frequency is 38.9% which is the highest frequency of this variant in Iran and the Middle East that may be related to genetic drift, founder effect, and consanguinity. Iran has a very heterogeneous population, and a variety of different ethnic groups live in",19_19,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"and a variety of different ethnic groups live in different parts of the country. Hence, PAH gene mutations in Iranian PKU patients are very heterogeneous. In the present study, 21 different mutations were identified; three of them (c. 1245 del, c. 878 T>C, and c.773T>G) have not been reported so far. Nemati <italic toggle=""yes"">et al</italic>.[<xref rid=""R17"" ref-type=""bibr"">17</xref>] have also reported 15 different variants containing the c.913G>T and c.1330C>A novel variants in Gilan province, which is",19_20,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"novel variants in Gilan province, which is also located in the north of Iran.[<xref rid=""R17"" ref-type=""bibr"">17</xref>] This variety of mutations and identification of new variants, especially in the north of Iran is indicative of the heterogeneity of the population in the region.",19_21,Mutation Analysis of PAH Gene in Phenylketonuria Patients from the North of Iran: Identification of Three Novel Pathogenic Variants,2024,,Phenylketonuria
"Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study The long-term efficacy and use of phenylalanine-free infant amino acid formula (PFIF) is understudied. This retrospective, longitudinal study evaluated PFIF (PKU Start: Vitaflo International) in children with phenylketonuria, collecting data on metabolic control, growth, dietary intake, and symptoms and the child’s experience with PFIF. Twenty-five children (12 males, 48%) with a median age of 3.6 years (2.0–6.2 years)",20_0,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"with a median age of 3.6 years (2.0–6.2 years) were included. During 24 months follow-up, children maintained normal growth and satisfactory metabolic control. The protein intake from protein substitutes increased from 2.7 at 6 months to 2.8 g/kg/day at 24 months, while natural protein decreased from 0.6 to 0.4 g/kg/day. By 24 months, most children (n = 16, 64%) had stopped PFIF, while nine (36%) continued with a median intake of 450 mL/day (Q1:300 mL, Q3: 560 mL). Children who continued PFIF after 24",20_1,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"Q3: 560 mL). Children who continued PFIF after 24 months of age had higher energy and fat intakes with higher weight/BMI z-scores compared with those who stopped earlier (<italic toggle=""yes"">p</italic> < 0.05). Constipation was reported in 44% of infants but improved with age. Initial difficulty with PFIF acceptance was reported in 20% of infants but also improved with time. Prolonged use of PFIF in pre-school children may contribute to poor feeding patterns and overweight; thus, replacing the majority of",20_2,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"and overweight; thus, replacing the majority of the protein equivalent provided by PFIF with a weaning protein substitute by 12 months and discontinuing PFIF before 2 years is recommended. Phenylketonuria (PKU, OMIM 261600) is an inherited autosomal recessive disorder of amino acid metabolism caused by a deficiency of phenylalanine hydroxylase (PAH). This enzyme together with its essential cofactor, tetrahydrobiopterin, converts the amino acid phenylalanine into tyrosine [<xref rid=""B1-nutrients-16-02204""",20_3,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"into tyrosine [<xref rid=""B1-nutrients-16-02204"" ref-type=""bibr"">1</xref>]. Without the functional PAH enzyme, phenylalanine accumulates in the blood, tissues, and brain and if untreated, causes severe neurological impairment with intellectual disability [<xref rid=""B1-nutrients-16-02204"" ref-type=""bibr"">1</xref>,<xref rid=""B2-nutrients-16-02204"" ref-type=""bibr"">2</xref>,<xref rid=""B3-nutrients-16-02204"" ref-type=""bibr"">3</xref>]. The global prevalence of PKU is 1 in 23,930 live births, ranging from 1 in",20_4,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"PKU is 1 in 23,930 live births, ranging from 1 in 4500 in Italy to 1 in 125,000 in Japan, with the prevalence in the UK being 1 in 10,000 [<xref rid=""B4-nutrients-16-02204"" ref-type=""bibr"">4</xref>]. Early detection through newborn screening is essential to safeguard a healthy outcome. Any infant with a blood phenylalanine level above 360 µmol/L should commence a phenylalanine restrictive diet immediately, preferably within the first 10 days of life [<xref rid=""B1-nutrients-16-02204""",20_5,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"days of life [<xref rid=""B1-nutrients-16-02204"" ref-type=""bibr"">1</xref>]. Dietary management in infancy comprises the administration of a phenylalanine-free infant amino acid formula (PFIF) together with controlled but limited amounts of breastmilk or standard infant formula that will provide essential phenylalanine requirements [<xref rid=""B1-nutrients-16-02204"" ref-type=""bibr"">1</xref>]. In PKU, phenylalanine requirements start at around 55 mg/kg/day in infants aged 0–3 months, decreasing to 27",20_6,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"in infants aged 0–3 months, decreasing to 27 mg/kg/day by 12 months, and children with classic PKU may only tolerate 200–500 mg/day of phenylalanine. However, these requirements are influenced by many factors including the severity of the disorder, energy intake, and the dosage and distribution of PFIF intake [<xref rid=""B1-nutrients-16-02204"" ref-type=""bibr"">1</xref>]. The infant’s first year is a critical time of rapid growth and development, supported by a high rate of protein synthesis. The nutritional",20_7,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"a high rate of protein synthesis. The nutritional composition of PFIF is comparable to human milk. It contains macro and micronutrients, electrolytes, and trace elements, but is based on phenylalanine-free amino acids, and the amounts of non-phenylalanine essential and conditionally essential amino acids should at least be comparable to human milk [<xref rid=""B5-nutrients-16-02204"" ref-type=""bibr"">5</xref>]. It contains long-chain fatty acids (arachidonic and docosahexaenoic) and may contain novel",20_8,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"and docosahexaenoic) and may contain novel ingredients such as prebiotics. The osmolarity of PFIF is similar to breastmilk [<xref rid=""B6-nutrients-16-02204"" ref-type=""bibr"">6</xref>]. PFIF must comply with the relevant worldwide regulations to ensure its safety and quality, and all raw materials used must be approved for infants [<xref rid=""B7-nutrients-16-02204"" ref-type=""bibr"">7</xref>,<xref rid=""B8-nutrients-16-02204"" ref-type=""bibr"">8</xref>]. Its nutritional composition should ensure appropriate",20_9,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"nutritional composition should ensure appropriate growth, optimal development, and promote healthy metabolic programming [<xref rid=""B6-nutrients-16-02204"" ref-type=""bibr"">6</xref>], be readily digestible, and well tolerated. The production of PFIF requires rigorous chemical processes and sophisticated purification techniques, affecting the cost of the end product [<xref rid=""B9-nutrients-16-02204"" ref-type=""bibr"">9</xref>,<xref rid=""B10-nutrients-16-02204"" ref-type=""bibr"">10</xref>,<xref",20_10,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"ref-type=""bibr"">10</xref>,<xref rid=""B11-nutrients-16-02204"" ref-type=""bibr"">11</xref>,<xref rid=""B12-nutrients-16-02204"" ref-type=""bibr"">12</xref>,<xref rid=""B13-nutrients-16-02204"" ref-type=""bibr"">13</xref>]. Although PFIF has evolved over the years [<xref rid=""B14-nutrients-16-02204"" ref-type=""bibr"">14</xref>,<xref rid=""B15-nutrients-16-02204"" ref-type=""bibr"">15</xref>], there are limited data on its efficacy and safety, particularly regarding long-term outcomes. We recently published a longitudinal,",20_11,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"outcomes. We recently published a longitudinal, prospective, open, multi-center study [<xref rid=""B16-nutrients-16-02204"" ref-type=""bibr"">16</xref>] evaluating the acceptability, tolerability, growth, and metabolic control of a PFIF in infants with PKU over a 12-month duration. The PFIF was well tolerated, infant growth was normal, and good metabolic control was maintained, but only a small number of subjects were studied. It was concluded that further research was necessary, investigating a greater number",20_12,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"was necessary, investigating a greater number of infants. This current study addresses the gap in long-term safety and efficacy data for PFIF by evaluating a larger cohort of infants over an extended period, contributing to the current literature on PFIF. Therefore, in this retrospective study, we evaluated the growth, metabolic control, and dietary intake of a larger group of infants with PKU who had been given a PFIF and treated in one PKU center from 2017 to 2023.   All specialist infant formula should",20_13,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"to 2023.   All specialist infant formula should be systematically evaluated to ensure its safety, tolerance, and acceptance. Although our recent study [<xref rid=""B16-nutrients-16-02204"" ref-type=""bibr"">16</xref>] in infants with PKU provided preliminary evidence on these aspects of this PFIF, its limited duration and small sample size highlighted the need for further comprehensive evaluations in a larger cohort of infants. To address this gap, the present study provides long-term retrospective data on",20_14,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"study provides long-term retrospective data on metabolic control, growth, dietary intake, symptoms, and experience of using a specialized formula in a cohort of 25 infants from diagnosis until 2 years of age. Following diagnosis, all infants received PFIF and the majority tolerated it well. Even though some had initial difficulties with acceptance, this improved with age. Introduced from around 15 to 24 weeks, semi-solid weaning phenylalanine-free protein substitute gradually replaced PFIF. By the age of 2",20_15,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"gradually replaced PFIF. By the age of 2 years, the majority of children (n = 16, 64%) had stopped their PFIF intake. Nonetheless, 9 (36%) continued to receive PFIF after the age of 2 years, with a median daily intake of 450 mL at 2 years. This group (children who discontinued PFIF after 2 years of age [n = 9, 36%]) had a significantly higher energy intake, when expressed as a percentage of estimated average requirement (%EAR), and fat intake at 24 months of age, along with significantly higher weight and",20_16,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"age, along with significantly higher weight and BMI-for-age z-scores from the age of 1 year onwards (<italic toggle=""yes"">p</italic> < 0.05), which was a concern. There were no significant differences in the length-for-age z-score and protein intake (natural and protein equivalent from protein substitutes) between the two groups. Children maintained satisfactory blood phenylalanine control, and growth remained within normal parameters throughout the study period. The prolonged use of PFIF and delayed",20_17,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"period. The prolonged use of PFIF and delayed transition from bottle to cup has been previously reported in children with PKU [<xref rid=""B24-nutrients-16-02204"" ref-type=""bibr"">24</xref>]. Similarly, a group of children in this study (n = 9, 36%) continued to receive PFIF beyond 2 years of age, despite ongoing advice from dietitians to discontinue its use. MacDonald et al. [<xref rid=""B25-nutrients-16-02204"" ref-type=""bibr"">25</xref>] has recommended limiting PFIF intake (<600 mL/day) in later infancy and",20_18,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"PFIF intake (<600 mL/day) in later infancy and replacing it mainly with a weaning protein substitute by 12 months of age. Continuing bottle use later than the age of 18–24 months has been associated with a higher risk of overweight and obesity between 3 and 5 years of age [<xref rid=""B26-nutrients-16-02204"" ref-type=""bibr"">26</xref>,<xref rid=""B27-nutrients-16-02204"" ref-type=""bibr"">27</xref>]. Ensuring the timely discontinuation of PFIF is essential to prevent excessive energy and fat intake, help avoid",20_19,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"excessive energy and fat intake, help avoid feeding problems with solid foods, and prevent potential long-term growth issues. In addition, the gradual reduction and timely discontinuation of PFIF is important to lessen satiety, encourage hunger for solid foods, and help support age-appropriate progression with protein substitutes and food textures [<xref rid=""B24-nutrients-16-02204"" ref-type=""bibr"">24</xref>,<xref rid=""B25-nutrients-16-02204"" ref-type=""bibr"">25</xref>]. Social factors, such as maternal",20_20,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"Social factors, such as maternal age, education, employment status, family structure (single-mother vs. two-parent households), and household income, influence infant feeding practices [<xref rid=""B28-nutrients-16-02204"" ref-type=""bibr"">28</xref>,<xref rid=""B29-nutrients-16-02204"" ref-type=""bibr"">29</xref>]. In our study, children from two-parent families or with mothers accomplishing higher education after secondary/high school were more likely to discontinue PFIF before 2 years of age, demonstrating the",20_21,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"PFIF before 2 years of age, demonstrating the impact of family structure and maternal education. Prolonged bottle use offers satiety and is easier and more convenient than preparing complex, time-consuming low-protein meals. However, if the discontinuation of PFIF is delayed, it may hinder the development of healthy eating behaviors and limit the dietary diversity offered to young children. It is important for parents and healthcare professionals to plan and facilitate the timely and gradual transition",20_22,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"and facilitate the timely and gradual transition from PFIF to age-appropriate protein substitutes. Healthcare professionals should also consider the demographic and socioeconomic factors influencing infant feeding practices to tailor effective guidance on PFIF discontinuation and transitioning to the next steps. The extended use of night feeds was a concern. Although night feeds may offer a potential benefit by suppressing blood phenylalanine levels and improving morning metabolic control, there are many",20_23,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"morning metabolic control, there are many disadvantages associated with this practice. Several studies have reported that patients with PKU experience poor dental and periodontal conditions, along with a higher prevalence of dental caries compared to healthy controls [<xref rid=""B30-nutrients-16-02204"" ref-type=""bibr"">30</xref>,<xref rid=""B31-nutrients-16-02204"" ref-type=""bibr"">31</xref>,<xref rid=""B32-nutrients-16-02204"" ref-type=""bibr"">32</xref>,<xref rid=""B33-nutrients-16-02204""",20_24,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"rid=""B33-nutrients-16-02204"" ref-type=""bibr"">33</xref>]. Predisposing factors contributing to dental problems in PKU include inadequate oral hygiene, high carbohydrate intakes, frequent snacking habits, irregular dental check-ups, and the relatively lower priority placed on dental health due to the demands of managing the disorder [<xref rid=""B31-nutrients-16-02204"" ref-type=""bibr"">31</xref>]. Prolonged bottle use after 12 months of age is also an important risk factor [<xref rid=""B34-nutrients-16-02204""",20_25,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"risk factor [<xref rid=""B34-nutrients-16-02204"" ref-type=""bibr"">34</xref>,<xref rid=""B35-nutrients-16-02204"" ref-type=""bibr"">35</xref>]. Notably, all children who had known dental problems in our study (n = 5) were those who received PFIF after 2 years of age with night feeds later than 12 months, suggesting an important relationship. It is recommended to introduce a cup at 6 months and complete the transition from bottle to cup by 12 to 18 months [<xref rid=""B36-nutrients-16-02204""",20_26,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"to 18 months [<xref rid=""B36-nutrients-16-02204"" ref-type=""bibr"">36</xref>]. Additionally, infants should not sleep with a bottle [<xref rid=""B37-nutrients-16-02204"" ref-type=""bibr"">37</xref>]. Another interesting finding was the prevalence of constipation symptoms during the first 6 months of life (44%), which improved with time, with only one patient experiencing constipation long term. Constipation is more common in formula-fed infants compared to breast-fed infants [<xref rid=""B38-nutrients-16-02204""",20_27,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"infants [<xref rid=""B38-nutrients-16-02204"" ref-type=""bibr"">38</xref>,<xref rid=""B39-nutrients-16-02204"" ref-type=""bibr"">39</xref>,<xref rid=""B40-nutrients-16-02204"" ref-type=""bibr"">40</xref>,<xref rid=""B41-nutrients-16-02204"" ref-type=""bibr"">41</xref>]. This finding may be attributed to differences in the lipid structure between breastmilk and infant formulae. Mehrotra et al. [<xref rid=""B42-nutrients-16-02204"" ref-type=""bibr"">42</xref>] reported that vegetable oil-based infant formulae were mainly",20_28,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"vegetable oil-based infant formulae were mainly associated with long-chain saturated fats esterified at sn-1 (stereospecific numbering) and sn-3 positions (breastmilk has fatty acids esterified at the sn-2 position) and are associated with the formation of calcium fatty-acid soaps, which in turn contributes to constipation. In healthy infants, several studies [<xref rid=""B43-nutrients-16-02204"" ref-type=""bibr"">43</xref>,<xref rid=""B44-nutrients-16-02204"" ref-type=""bibr"">44</xref>,<xref",20_29,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"ref-type=""bibr"">44</xref>,<xref rid=""B45-nutrients-16-02204"" ref-type=""bibr"">45</xref>,<xref rid=""B46-nutrients-16-02204"" ref-type=""bibr"">46</xref>], but not all [<xref rid=""B47-nutrients-16-02204"" ref-type=""bibr"">47</xref>,<xref rid=""B48-nutrients-16-02204"" ref-type=""bibr"">48</xref>], have indicated that infants fed high sn-2 palmitate formula have softer stools, suggesting that reducing the palmitic acid content in infant formula or using synthetic triglycerides with palmitic acid primarily positioned at",20_30,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"with palmitic acid primarily positioned at the sn-2 position could potentially improve stool consistency in infants. This study provides valuable long-term follow-up data on growth, blood phenylalanine control, dietary intake, symptoms, and the experience with a PFIF in infants with PKU. However, several limitations should be acknowledged. The study design was retrospective and uncontrolled, relying on patient records, which may result in incomplete or underreported data. Generalizability to the PKU",20_31,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"underreported data. Generalizability to the PKU community is limited as the study was conducted at a single center in the UK. Anthropometric measurements were taken by different professionals, although equipment calibration followed hospital standards and professionals were trained in equipment use. Dietary intakes were collected by using 24 h food recall, which may not fully reflect the actual consumption, although the dietitians involved were experienced and familiar with patients’ dietary patterns. The",20_32,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"and familiar with patients’ dietary patterns. The use of complementary feeding and a second-stage protein substitute by some infants could have influenced the outcomes and weakened the strength of these findings. The assessment of infants’ experiences with the study formula relied on parental recollection, which introduces the potential for recall bias. The PFIF given to infants with PKU in this study was well tolerated and accepted, resulting in satisfactory blood phenylalanine control and growth.",20_33,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"blood phenylalanine control and growth. However, ongoing monitoring and support with PFIF use and ensuring timely discontinuation and transition to age-appropriate weaning protein substitutes are important for optimizing PKU dietary management. The prescription of PFIF should be mainly replaced with a second-stage weaning protein substitute by 12 months and PFIF should be discontinued before 2 years of age, particularly if non-phenylalanine nitrogen requirements are met with a second-stage protein",20_34,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"requirements are met with a second-stage protein substitute. Future long-term studies should focus on long-term growth, weight gain, and developmental feeding outcomes in a larger cohort of infants with PKU.",20_35,Phenylalanine-Free Infant Formula in Patients with Phenylketonuria: A Retrospective Study,10 7 2024,,Phenylketonuria
"Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine (Phe) metabolism, resulting from the deficient activity of phenylalanine hydroxylase that converts Phe to tyrosine in the liver, leading to elevated levels of Phe. Pegvaliase is an innovative and effective enzyme replacement therapy for reducing Phe concentration, but it has been",21_0,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"for reducing Phe concentration, but it has been associated with severe drug-induced hypersensitivity adverse events (HAEs). Limited data is available on the management of these HAEs, thus, we aimed to present a case report of a successful management strategy. The patient was a 28-year-old Caucasian male with classical PKU, who was otherwise healthy. Due to poor metabolic control, the pegvaliase treatment was initiated. The titration phase was uneventful, with transient and mild side effects, localized to",21_1,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"transient and mild side effects, localized to the injection site. After the patient was on a maintenance dose of pegvaliase and had no reactions to the drug, we discontinued the H1-antihistamine. In the following days, within minutes after receiving the pegvaliase injection, an acute hypersensitivity reaction occurred that required emergency treatment. H1-antihistamine treatment was reintroduced. Four days after the incident he received pegvaliase under medical supervision and did not experience any",21_2,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"medical supervision and did not experience any symptoms. In conclusion, cautious reintroduction of pegvaliase in a hospital setting can be safely performed after HAE due to the discontinuation of H1-antihistamines. HAEs could be successfully mitigated by scheduling daily antihistamines administration closer to the pegvaliase injection. This approach can enable PKU patients to maintain their access to an effective and quality-of-life-improving therapy. <list list-type=""simple"" id=""l0005""><list-item",21_3,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"<list list-type=""simple"" id=""l0005""><list-item id=""li0005""><label>•</label><p id=""p0005"">Pegvaliase can cause acute hypersensitivity reaction after H1-antihistamine discontinuation.</p></list-item><list-item id=""li0010""><label>•</label><p id=""p0010"">Reintroduction of pegvaliase in a hospital setting after hypersensitivity reaction can be safe.</p></list-item><list-item id=""li0015""><label>•</label><p id=""p0015"">Acute hypersensitivity reaction can be mitigated by reinstating",21_4,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"reaction can be mitigated by reinstating H1-antihistamine.</p></list-item></list> Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine (Phe) metabolism and results from variations of the gene encoding phenylalanine hydroxylase (<italic toggle=""yes"">PAH</italic>) [<xref rid=""bb0005"" ref-type=""bibr"">1</xref>]. Due to the deficient activity of PAH that converts Phe to tyrosine in the liver, PKU, when left untreated, leads to elevated levels of Phe in both the bloodstream and the",21_5,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"levels of Phe in both the bloodstream and the brain, contributing to the development of severe intellectual disability, epileptic seizures and behavioral disturbances [<xref rid=""bb0010"" ref-type=""bibr"">2</xref>]. Current standards of care consist of lifelong natural protein intake restriction [<xref rid=""bb0015"" ref-type=""bibr"">3</xref>]. Unfortunately, a significant proportion of adults and adolescents with PKU fail to maintain these dietary restrictions, resulting in elevated Phe levels [<xref",21_6,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"resulting in elevated Phe levels [<xref rid=""bb0020"" ref-type=""bibr"">4</xref>]. Pegvaliase is a PEGylated recombinant phenylalanine ammonia lyase (PAL) enzyme, which converts Phe into trans-cinnamic acid and ammonia, both of which are excreted in urine and further metabolized in the liver [<xref rid=""bb0025"" ref-type=""bibr"">5</xref>]. Pegvaliase is an innovative enzyme replacement therapy that received approval from both the Food and Drug Administration in 2018 and the European Medicines Agency in 2019",21_7,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"in 2018 and the European Medicines Agency in 2019 [<xref rid=""bb0030"" ref-type=""bibr"">6</xref>,<xref rid=""bb0035"" ref-type=""bibr"">7</xref>]. Pegvaliase is indicated for PKU patients aged 16 years and older who have uncontrolled disease (Phe levels >600 μmol/L), despite previous treatment efforts [<xref rid=""bb0040"" ref-type=""bibr"">8</xref>]. Despite the high effectiveness of pegvaliase in reducing Phe concentrations, cases of severe drug-induced hypersensitivity adverse events (HAEs) have been described",21_8,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"adverse events (HAEs) have been described [<xref rid=""bb0025"" ref-type=""bibr"">5</xref>]. In clinical trials, all subjects treated with pegvaliase developed anti-drug antibodies against the protein PAL and the PEG component, which can lead to HAE [<xref rid=""bb0045"" ref-type=""bibr"">9</xref>,<xref rid=""bb0050"" ref-type=""bibr"">10</xref>]. In this article, we present a case of pegvaliase-induced HAE with generalized urticaria and angioedema and its successful management. A 28-year-old Caucasian male with",21_9,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"management. A 28-year-old Caucasian male with classical PKU, who is otherwise healthy with no regular therapy was admitted as an outpatient to our Metabolic Department. His medical history did not include any skin, joint, or muscle conditions, nor any hypersensitivity reactions. Despite his best efforts through dietary measures, the metabolic control was poor with plasma Phe levels averaging 900 μmol/L. We started the treatment with pegvaliase. The patient started increasing the dose of pegvaliase",21_10,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"patient started increasing the dose of pegvaliase following the protocol outlined in <xref rid=""t0005"" ref-type=""table"">Table 1</xref>. He initiated therapy with a once-weekly subcutaneous injection of 2.5 mg and achieved a daily maintenance therapy of 20 mg after 9 weeks.<table-wrap position=""float"" id=""t0005""><label>Table 1</label><caption><p>The titration regimen for pegvaliase in the presented case.</p></caption><alt-text id=""al0005"">Table 1</alt-text><table frame=""hsides""",21_11,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"1</alt-text><table frame=""hsides"" rules=""groups""><thead><tr><th>Treatment stage</th><th>Dose (mg)</th><th>Frequency</th><th>Duration</th></tr></thead><tbody><tr><td rowspan=""6"">Titration</td><td>2.5</td><td>once weekly</td><td>4 weeks</td></tr><tr><td>2.5</td><td>twice weekly</td><td>1 week</td></tr><tr><td>10</td><td>once weekly</td><td>1 week</td></tr><tr><td>10</td><td>twice weekly</td><td>1 week</td></tr><tr><td>10</td><td>four times weekly</td><td>1 week</td></tr><tr><td>10</td><td>once",21_12,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"daily</td><td>1 week</td></tr><tr><td>Maintenance</td><td>20</td><td>once daily</td><td>from week 10 onwards</td></tr></tbody></table></table-wrap> At the initiation of therapy, the patient and a family member received education from the professional nurse educator on side effect management and proper use of auto-injectable epinephrine. Additionally, we recommended regular use of preventive H1-antihistamine fexofenadine and instructed relieving muscle pain with acetaminophen. The patient did not take any",21_13,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"with acetaminophen. The patient did not take any local or systemic pre-medications, such as H2-antihistamines, corticosteroids, or non-steroidal anti-inflammatory drugs The titration phase was uneventful, with transient and mild adverse effects, such as localized injection site reaction and mild arthralgia. Acetaminophen was regularly administered for approximately two months from pegvaliase initiation and was then discontinued by the patient due to the spontaneous alleviation of the adverse effects. After",21_14,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"alleviation of the adverse effects. After 33 weeks of pegvaliase treatment, the patient has remained free of side effects, we recommended discontinuation of antihistamine therapy. Five days after the discontinuation of antihistamine therapy, the patient developed an acute hypersensitivity reaction. Ten minutes after the pegvaliase injection, the patient observed swelling in his right hand, followed by an intensely pruritic rash that quickly spread across his body, along with swelling of his lips. He did",21_15,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"his body, along with swelling of his lips. He did not have any other systemic symptoms, such as coughing or wheezing, dyspnea or dizziness. The patient immediately self-administered epinephrine intramuscularly and called the emergency line. He also received intravenous hydrocortisone, clemastine and saline fluid during transport to a nearby emergency department. When the patient arrived, his vital functions were normal, and the symptoms almost completely subsided. Given the adverse event emerged only after",21_16,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"Given the adverse event emerged only after the discontinuation of the antihistamine and considering the observed improvement in the patient's quality of life during the pegvaliase treatment we considered that the potential benefits of continuing pegvaliase treatment outweighed the associated risks. The patient gave consent to continue with the treatment. Following the event, the patient resumed on fexofenadine120 mg daily. Four days later, he was admitted to the Department of Endocrinology, Diabetes and",21_17,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"to the Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, where we rechallenged the patient with pegvaliase (20 mg) under the supervision of medical professionals. We observed no symptoms after the drug application and discharged the patient on the same day. The patient continued with the same regimen of 20 mg daily. Five days later, a localized urticarial reaction occurred a few minutes after injection. This time the patient chose not to administer an",21_18,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"This time the patient chose not to administer an epinephrine injection but instead took another 120 mg tablet of fexofenadine. An hour later the symptoms completely subsided. We considered the time when the patient took antihistamine (in the morning) and pegvaliase (late in the evening) too long and instructed the patient to take the antihistamine an hour before the pegvaliase injection, after which no adverse reaction has occurred. In this case report, we presented a patient with classical PKU, who",21_19,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"we presented a patient with classical PKU, who experienced an immediate episode of generalized urticaria and angioedema after receiving a subcutaneous injection of pegvaliase. The patient underwent the titration phase experiencing only transient and mild side effects primarily localized to the injection site and HAEs occurred only when the H1-antihistamine was discontinued. Pegvaliase is a pegylated recombinant enzyme, derived from the cyanobacteria <italic toggle=""yes"">Anabaena variabilis</italic>. As its",21_20,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"toggle=""yes"">Anabaena variabilis</italic>. As its protein structure is unfamiliar to the human immune system, pegvaliase exhibits high immunogenicity [<xref rid=""bb0045"" ref-type=""bibr"">9</xref>]. However, drug-specific IgE have not been detected and anaphylaxis is rarely described [<xref rid=""bb0055"" ref-type=""bibr"">11</xref>]. In all patients included in clinical trials, at the initiation of pegvaliase treatment, elevated levels of anti-PEG antibodies and anti-PAL IgM were detected [<xref rid=""bb0050""",21_21,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"anti-PAL IgM were detected [<xref rid=""bb0050"" ref-type=""bibr"">10</xref>], driving the Type III immune complex-mediated reactions. In this type of hypersensitivity response, immune complexes trigger the classical complement pathway, leading to the production of anaphylatoxins which then activate mast cells to release histamine. Histamine induces allergic and inflammatory symptoms by interacting with H1-receptors in nearby or distant body tissues. Type III immune complex-mediated HAEs reach their peak",21_22,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"III immune complex-mediated HAEs reach their peak occurrence rate during the initial induction or titration phase of pegvaliase [<xref rid=""bb0055"" ref-type=""bibr"">11</xref>]. As therapy continues, the reduction in HAEs during maintenance therapy is thought to be due to improved affinity maturation of anti-drug antibodies (mainly anti-PAL IgG), decreased formation of immune complexes and reduced activation of the complement system over time [<xref rid=""bb0050"" ref-type=""bibr"">10</xref>]. There is a common",21_23,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"ref-type=""bibr"">10</xref>]. There is a common consensus on the clinical treatment measures for HAEs, and many patients have a desire to continue using pegvaliase, even after experiencing initial HAE episodes. As majority of HAEs are restricted to the skin and not life-threatening, the benefits of pegvaliase treatment outweigh the safety concerns. Pegvaliase effectively reduces blood Phe levels to the recommended targets, which can be challenging to maintain through diet alone [<xref rid=""bb0025""",21_24,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"maintain through diet alone [<xref rid=""bb0025"" ref-type=""bibr"">5</xref>]. To improve drug tolerability, especially during the initial treatment phase when HAEs are most frequent, specific measures can be implemented. One way to minimize the risks associated with initial treatment is by following a well-defined dosing protocol that includes starting with low initial doses and gradually titrating upwards [<xref rid=""bb0060"" ref-type=""bibr"">12</xref>]. The implementation of various risk mitigation measures",21_25,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"of various risk mitigation measures has significantly improved the safety of home treatment with pegvaliase. These measures encompass premedication with H1-antihistamines, which were considered to be most effective [<xref rid=""bb0065"" ref-type=""bibr"">13</xref>,<xref rid=""bb0070"" ref-type=""bibr"">14</xref>]. Moreover, initial pegvaliase doses should be given under healthcare professional supervision until patients and observers can confidently manage dosing and identify HAE symptoms. To treat a possible",21_26,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"and identify HAE symptoms. To treat a possible acute systemic hypersensitivity reaction (ASHR), all patients using pegvaliase should have access to auto-injectable epinephrine and should be educated about recognizing ASHR symptoms and administering epinephrine [<xref rid=""bb0075"" ref-type=""bibr"">15</xref>,<xref rid=""bb0080"" ref-type=""bibr"">16</xref>]. In cases of arthralgia episodes, patients can manage their symptoms with medications, such as acetaminophen [<xref rid=""bb0060"" ref-type=""bibr"">12</xref>].",21_27,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"[<xref rid=""bb0060"" ref-type=""bibr"">12</xref>]. To prevent injection site reactions, patients are encouraged to rotate injection sites. These reactions can be treated with topical H1-antihistamines, topical steroids, or cold compresses [<xref rid=""bb0060"" ref-type=""bibr"">12</xref>,<xref rid=""bb0085"" ref-type=""bibr"">17</xref>]. The treatment interruption following a HAE is generally less favorable than dose reduction, as it helps maintain continued antigen exposure's ‘desensitizing’ effect. Temporary dose",21_28,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"exposure's ‘desensitizing’ effect. Temporary dose reduction may be necessary, depending on the severity of the event. This could involve taking one or two steps back in the dosing regimen. This is in line with common practice in allergen immunotherapy [<xref rid=""bb0025"" ref-type=""bibr"">5</xref>]. In case of recurrent and severe HAEs, 13-step desensitization may be another approach to management in order to continue the effective treatment [<xref rid=""bb0090"" ref-type=""bibr"">18</xref>]. The pharmacokinetic",21_29,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"ref-type=""bibr"">18</xref>]. The pharmacokinetic properties of antihistamine drugs play a significant role in mitigating the HAE. In this patient's case, there had been a significant time gap, about 16 h, between pegvaliase and fexofenadine which exceeded the terminal elimination half-life of the latter [<xref rid=""bb0095"" ref-type=""bibr"">19</xref>]. The diminished antihistamine effect may have contributed to the residual skin reaction. After changing the time of fexofenadine administration to be closer to",21_30,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"of fexofenadine administration to be closer to the pegvaliase injection, the adverse reaction has not reoccurred. In conclusion, this case report supports the recommendations that in the case of HAE after discontinuing antihistamines, pegvaliase can be safely reintroduced in a hospital setting. Moreover, scheduling antihistamine administration 1–2 h before the pegvaliase injection could also play a significant role in alleviating HAEs. This approach allows PKU patients to continue pegvaliase therapy. The",21_31,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"PKU patients to continue pegvaliase therapy. The study was conducted in accordance with the Declaration of Helsinki. The study and this paper were approved by the Scientific Committee of the Department of Endocrinology, Diabetes, and Metabolic Diseases, University Medical Centre Ljubljana. Informed consent has been obtained from patient to perform this study, and to publish the results in an anonymized form. All authors participated in the investigation process and writing of the original draft. Gregoric",21_32,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"and writing of the original draft. Gregoric N. and Sikonja J. conceptualized the study. Gregoric N., Janez A. and Sikonja J. critically reviewed and edited the manuscript. Janez A. supervised the study and drafting of the manuscript. All authors have read and agreed to the published version of the manuscript. <bold>Nadan Gregoric:</bold> Writing – review & editing, Writing – original draft, Supervision, Conceptualization. <bold>Anita Tara:</bold> Writing – original draft. <bold>Rebeka Kastelic:</bold>",21_33,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"– original draft. <bold>Rebeka Kastelic:</bold> Writing – original draft. <bold>Jaka Sikonja:</bold> Writing – review & editing, Writing – original draft, Visualization, Supervision, Project administration, Conceptualization. <bold>Katarina Peklaj:</bold> Investigation. <bold>Mojca Mesojedec:</bold> Investigation. <bold>Peter Kopac:</bold> Writing – review & editing. <bold>Andrej Janez:</bold> Writing – review & editing, Supervision, Funding acquisition. There is a potential conflict of interest. The",21_34,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"There is a potential conflict of interest. The Slovenian Osteology Society, of which three of the authors are members (Sikonja J., Janez A., and Gregoric N.), has been granted funds by BioMarin Pharmaceutical, the manufacturer of pegvaliase (Palynziq), to support a clinical program for patients using Palynziq. However, BioMarin Pharmaceutical had no role in the design and conduct of this case report; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the",21_35,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Other authors declare no conflict of interest.",21_36,Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report,01 7 2024,,Phenylketonuria
"Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape? Background: In 2011, a European phenylketonuria (PKU) survey reported that the blood phenylalanine (Phe) levels were well controlled in early life but deteriorated with age. Other studies have shown similar results across the globe. Different target blood Phe levels have been used throughout the years, and, in 2017, the European PKU guidelines defined new targets for blood Phe levels.",22_0,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"defined new targets for blood Phe levels. This study aimed to evaluate blood Phe control in patients with PKU across Europe. Methods: nine centres managing PKU in Europe and Turkey participated. Data were collected retrospectively from medical and dietetic records between 2012 and 2018 on blood Phe levels, PKU severity, and medications. Results: A total of 1323 patients (age range:1–57, 51% male) participated. Patient numbers ranged from 59 to 320 in each centre. The most common phenotype was classical PKU",22_1,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"The most common phenotype was classical PKU (<italic toggle=""yes"">n</italic> = 625, 48%), followed by mild PKU (<italic toggle=""yes"">n</italic> = 357, 27%) and hyperphenylalaninemia (HPA) (<italic toggle=""yes"">n</italic> = 325, 25%). The mean percentage of blood Phe levels within the target range ranged from 65 ± 54% to 88 ± 49% for all centres. The percentage of Phe levels within the target range declined with increasing age (<2 years: 89%; 2–5 years: 84%; 6–12 years: 73%; 13–18 years: 85%; 19–30 years:",22_2,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"6–12 years: 73%; 13–18 years: 85%; 19–30 years: 64%; 31–40 years: 59%; and ≥41 years: 40%). The mean blood Phe levels were significantly lower and the percentage within the target range was significantly higher (<italic toggle=""yes"">p</italic> < 0.001) in patients with HPA (290 ± 325 μmol/L; 96 ± 24%) and mild PKU (365 ± 224 μmol/L; 77 ± 36%) compared to classical PKU (458 ± 350 μmol/L, 54 ± 46%). There was no difference between males and females in the mean blood Phe levels (<italic",22_3,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"and females in the mean blood Phe levels (<italic toggle=""yes"">p</italic> = 0.939), but the percentage of Phe levels within the target range was higher in females among school-age children (6–12 years; 83% in females vs. 78% in males; <italic toggle=""yes"">p</italic> = 0.005), adolescents (13–18 years; 62% in females vs. 59% in males; <italic toggle=""yes"">p</italic> = 0.034) and adults (31–40 years; 65% in females vs. 41% in males; <italic toggle=""yes"">p</italic> < 0.001 and >41 years; 43% in females vs.",22_4,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"< 0.001 and >41 years; 43% in females vs. 28% in males; <italic toggle=""yes"">p</italic> < 0.001). Patients treated with sapropterin (<italic toggle=""yes"">n</italic> = 222) had statistically significantly lower Phe levels compared to diet-only-treated patients (mean 391 ± 334 μmol/L; percentage within target 84 ± 39% vs. 406 ± 334 μmol/L; 73 ± 41%; <italic toggle=""yes"">p</italic> < 0.001), although a blood Phe mean difference of 15 µmol/L may not be clinically relevant. An increased frequency of blood Phe",22_5,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"relevant. An increased frequency of blood Phe monitoring was associated with better metabolic control (<italic toggle=""yes"">p</italic> < 0.05). The mean blood Phe (% Phe levels within target) from blood Phe samples collected weekly was 271 ± 204 μmol/L, (81 ± 33%); for once every 2 weeks, it was 376 ± 262 μmol/L, (78 ± 42%); for once every 4 weeks, it was 426 ± 282 μmol/L, (71 ± 50%); and less than monthly samples, it was 534 ± 468 μmol/L, (70 ± 58%). Conclusions: Overall, blood Phe control deteriorated",22_6,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"Overall, blood Phe control deteriorated with age. A higher frequency of blood sampling was associated with better blood Phe control with less variability. The severity of PKU and the available treatments and resources may impact the blood Phe control achieved by each treatment centre. Phenylketonuria (PKU, OMIM 261600), an inborn error of metabolism, is defined by the dysfunction of phenylalanine hydroxylase (PAH) caused by a defect in the PAH gene. This encodes the hepatic enzyme PAH, which, under",22_7,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"This encodes the hepatic enzyme PAH, which, under standard conditions, catalyses the conversion of the amino acid phenylalanine (Phe) into tyrosine (Tyr), using tetrahydrobiopterin (BH<sub>4</sub>) as a co-substrate. In PKU, if untreated or if therapy is delayed, the toxic accumulation of Phe in the blood, tissue, brain and cerebrospinal fluid is likely to cause severe neurocognitive impairment [<xref rid=""B1-nutrients-16-02064"" ref-type=""bibr"">1</xref>]. Although there is genetic and phenotypical",22_8,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"Although there is genetic and phenotypical population heterogeneity, the most frequently occurring pathogenic PAH variant worldwide is c.1222C>T (p.Arg408Trp). This is particularly prevalent in Celtic and Eastern European countries and is associated with severe enzyme deficiency [<xref rid=""B1-nutrients-16-02064"" ref-type=""bibr"">1</xref>,<xref rid=""B2-nutrients-16-02064"" ref-type=""bibr"">2</xref>]. Newborn screening detects PKU, and patients treated early are expected to have normal intellectual quotients.",22_9,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"expected to have normal intellectual quotients. As the human brain is intricate and brain complexity continues to increase throughout adulthood, lifelong treatment is essential [<xref rid=""B3-nutrients-16-02064"" ref-type=""bibr"">3</xref>,<xref rid=""B4-nutrients-16-02064"" ref-type=""bibr"">4</xref>]. Blood Phe is the main biomarker used to guide disorder management in PKU. Long-term outcomes and cognition are closely related to blood Phe levels. Recently, in a small group of adults, a strong cognitive",22_10,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"in a small group of adults, a strong cognitive improvement was demonstrated when lowering and attaining a stable blood Phe close to 240 μmol/L for 3 to 6 months [<xref rid=""B5-nutrients-16-02064"" ref-type=""bibr"">5</xref>]. Poor metabolic control with elevated blood Phe is associated with cognitive decline and has a negative impact on executive functioning, processing speeds, sustained attention, memory and fine motor control [<xref rid=""B6-nutrients-16-02064"" ref-type=""bibr"">6</xref>]. Inattention may lead",22_11,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"ref-type=""bibr"">6</xref>]. Inattention may lead to careless mistakes, distraction from tasks, interruption or intruding on others and difficulties in concentrating, organising or completing tasks or following instructions [<xref rid=""B7-nutrients-16-02064"" ref-type=""bibr"">7</xref>]. High blood Phe may also cause ataxia, tremors, clumsiness, headaches, visual loss, anxiety disorders, mood swings and depression [<xref rid=""B8-nutrients-16-02064"" ref-type=""bibr"">8</xref>,<xref rid=""B9-nutrients-16-02064""",22_12,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"rid=""B9-nutrients-16-02064"" ref-type=""bibr"">9</xref>,<xref rid=""B10-nutrients-16-02064"" ref-type=""bibr"">10</xref>,<xref rid=""B11-nutrients-16-02064"" ref-type=""bibr"">11</xref>,<xref rid=""B12-nutrients-16-02064"" ref-type=""bibr"">12</xref>]. Levy et al. reported that almost 70% of adults with PKU had at least one neuropsychiatric comorbidity [<xref rid=""B13-nutrients-16-02064"" ref-type=""bibr"">13</xref>], and neurological deficits may only occur after several years of exposure to high blood Phe levels [<xref",22_13,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"years of exposure to high blood Phe levels [<xref rid=""B14-nutrients-16-02064"" ref-type=""bibr"">14</xref>]. In older patients, the risk of comorbidities is higher than in non-PKU controls [<xref rid=""B15-nutrients-16-02064"" ref-type=""bibr"">15</xref>]. Therefore, the maintenance of blood Phe within the therapeutic target ranges is essential to enable optimal neurocognitive outcomes. The European guidelines (2017) recommend a blood Phe therapeutic target range of 120 to 360 μmol/L for patients ≤12 years and",22_14,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"of 120 to 360 μmol/L for patients ≤12 years and between 120 and 600 μmol/L for patients older than 12 years. The United States and Japan’s blood Phe therapeutic target is <360 µmol/L throughout life [<xref rid=""B16-nutrients-16-02064"" ref-type=""bibr"">16</xref>,<xref rid=""B17-nutrients-16-02064"" ref-type=""bibr"">17</xref>,<xref rid=""B18-nutrients-16-02064"" ref-type=""bibr"">18</xref>,<xref rid=""B19-nutrients-16-02064"" ref-type=""bibr"">19</xref>]. Blood Phe control may be affected by many factors including the",22_15,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"may be affected by many factors including the phenotype severity, target therapeutic blood Phe levels and access to treatment(s) [<xref rid=""B18-nutrients-16-02064"" ref-type=""bibr"">18</xref>]. In PKU, since 2008, there have been considerable advancements in the range of treatments and their delivery, in addition to the introduction of transition and adult clinics. Primary management is dietary Phe restriction supplemented with low-Phe/Phe-free protein substitutes [<xref rid=""B20-nutrients-16-02064""",22_16,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"substitutes [<xref rid=""B20-nutrients-16-02064"" ref-type=""bibr"">20</xref>]. Special low-protein foods, which accompany Phe restriction, provide energy to promote growth and variety and support dietary adherence. Although the range, quality and palatability of the dietary products have improved (e.g., the introduction of glycomacropeptide as a protein substitute, the increased diversity of special low-protein foods), the global access to low-Phe/Phe-free protein substitutes and special low-protein foods is",22_17,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"substitutes and special low-protein foods is unequal between countries, potentially affecting patients’ ability to adhere to dietary Phe restriction [<xref rid=""B21-nutrients-16-02064"" ref-type=""bibr"">21</xref>]. In some countries e.g., Poland and Turkey, patients or their families/caregivers are expected to self-fund special low-protein foods at a high cost. However, even when ‘medical foods’ are available on prescription or reimbursed by insurance companies, there may be issues with administration",22_18,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"there may be issues with administration inefficiency, insufficient supplies or poor distribution systems, leading to treatment interruption. Adjunct pharmaceutical therapies like sapropterin or pegvaliase are treatment options that can improve blood Phe control but are not universally available or appropriate for all patients [<xref rid=""B2-nutrients-16-02064"" ref-type=""bibr"">2</xref>]. Sapropterin dihydrochloride (sapropterin) is a synthetic analogue of tetrahydrobiopterin, the natural co-substrate for",22_19,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"tetrahydrobiopterin, the natural co-substrate for the PAH enzyme. It has a chaperone function, stabilising the mutant PAH protein and stimulating residual PAH activity in responsive subjects [<xref rid=""B2-nutrients-16-02064"" ref-type=""bibr"">2</xref>]. Sapropterin, therefore, increases enzyme activity and thereby lowers blood Phe and improves dietary Phe tolerance, although some Phe restriction is usually required. It has also been shown to improve symptoms of inattention, hyperactivity/impulsivity and",22_20,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"of inattention, hyperactivity/impulsivity and executive functioning in children and adolescents with PKU [<xref rid=""B7-nutrients-16-02064"" ref-type=""bibr"">7</xref>]. Only around 30 to 40% of patients (with mild phenotypes) respond to sapropterin therapy, and this is defined as a ≥30% reduction in blood Phe from baseline levels [<xref rid=""B22-nutrients-16-02064"" ref-type=""bibr"">22</xref>]. Sapropterin has been approved in Europe since 2008 but has only been reimbursed in the UK since 2021. It is still",22_21,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"been reimbursed in the UK since 2021. It is still unavailable in some countries, such as Poland. Data on its long-term use are scarce. Reports from the USA show an improvement in blood Phe over 5 years with patients using sapropterin uninterruptedly [<xref rid=""B23-nutrients-16-02064"" ref-type=""bibr"">23</xref>]. However, blood Phe levels may deteriorate [<xref rid=""B24-nutrients-16-02064"" ref-type=""bibr"">24</xref>], with a high number of patients using sapropterin in the short term only, without attaining",22_22,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"in the short term only, without attaining the expected benefit [<xref rid=""B25-nutrients-16-02064"" ref-type=""bibr"">25</xref>]. For adults with PKU with uncontrolled blood Phe levels ≥ 600 µmol/L, pegvaliase, an enzyme substitution therapy, is a treatment option. It is a bacterial enzyme that converts Phe into trans-cinnamic acid and ammonia, which are metabolised by the liver and excreted in the urine, and it is given by subcutaneous injection. It is highly effective in lowering the blood Phe levels, with",22_23,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"effective in lowering the blood Phe levels, with a report from the US indicating that after 3 years of treatment (<italic toggle=""yes"">n</italic> = 153 patients), the median blood Phe levels had decreased from 1244 to only 167 μmol/L [<xref rid=""B24-nutrients-16-02064"" ref-type=""bibr"">24</xref>]. In addition, some individuals may not require any Phe restriction or supplementation with low-Phe/Phe-free protein substitutes [<xref rid=""B26-nutrients-16-02064"" ref-type=""bibr"">26</xref>]. However, it may take",22_24,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"ref-type=""bibr"">26</xref>]. However, it may take more than 2 years to work effectively, and it is associated with immune-mediated hypersensitivity reactions (commonly injection site reactions and arthralgia), especially during the early months of treatment [<xref rid=""B27-nutrients-16-02064"" ref-type=""bibr"">27</xref>]. Hypophenylalaninaemia may occur with alopecia [<xref rid=""B26-nutrients-16-02064"" ref-type=""bibr"">26</xref>,<xref rid=""B28-nutrients-16-02064"" ref-type=""bibr"">28</xref>], patient anxiety is",22_25,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"ref-type=""bibr"">28</xref>], patient anxiety is common when it is first introduced [<xref rid=""B29-nutrients-16-02064"" ref-type=""bibr"">29</xref>], and it requires significant medical supervision. Pegvaliase is approved for adults with PKU in the US (>18 years), the European Union (in 2019, >16 years), Australia, Canada and Japan, but it is expensive, limiting its availability globally [<xref rid=""B27-nutrients-16-02064"" ref-type=""bibr"">27</xref>]. With conventional dietary treatment only, it is well",22_26,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"conventional dietary treatment only, it is well established that a substantial proportion of adult patients treated early maintain blood Phe levels above the recommended target ranges. In 2002, blood Phe control in patients with PKU from four centres (three UK centres and one Australian centre) was reported over a 6-year period from 1994 to 2000 [<xref rid=""B30-nutrients-16-02064"" ref-type=""bibr"">30</xref>]. It was described that 70% of the blood Phe levels were within the target range in patients aged <10",22_27,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"were within the target range in patients aged <10 years old, but, among those aged >15 years, only 30% of the blood Phe levels were within the therapeutic target range. A survey from the USA, which enrolled 5530 patients in active follow-up (44 clinics, 52% adults), reported that more than half of the adolescents (13–17 years old) and more than 65% of the adult patients with PKU had unacceptable blood Phe control [<xref rid=""B31-nutrients-16-02064"" ref-type=""bibr"">31</xref>]. Only 33% of the blood Phe",22_28,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"Only 33% of the blood Phe levels were within the target range in patients above the age of 30 years. In a further US study, the blood Phe levels of 152 patients (aged 10–40 years, 66% with classical PKU) from two clinics [<xref rid=""B13-nutrients-16-02064"" ref-type=""bibr"">13</xref>] were consistently elevated, with a mean of 584 µmol/L over 5 years. Blood Phe control deteriorated with age. In Europe, data on blood Phe control are more contradictory. One of the largest European PKU blood Phe audits was",22_29,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"of the largest European PKU blood Phe audits was conducted in 2010, with the participation of nearly 2000 diet-treated patients with PKU from 10 centres [<xref rid=""B32-nutrients-16-02064"" ref-type=""bibr"">32</xref>]. Data were retrospectively collected over a 1-year period. Although the results were variable between centres, the percentages of blood Phe levels meeting each centre’s local and national target ranges were 88% in children aged up to 1 year, 74% for children aged 1–10 years, 89% for 11–16 years",22_30,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"for children aged 1–10 years, 89% for 11–16 years and 65% for adults (>16 years). The frequency of blood sampling declined with age. More recently, a single-centre study by Kanufre et al. [<xref rid=""B33-nutrients-16-02064"" ref-type=""bibr"">33</xref>] showed that less than 30% of patients aged ≥ 12 years on dietary treatment had blood Phe above the local target ranges (<12 years: 120–360 µmol/L; >12 years: 120–480 µmol/L). The international treatment guidelines for PKU aim to standardise treatment. The",22_31,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"for PKU aim to standardise treatment. The first European PKU guidelines, published in 2017, issued 70 recommendations about PKU management [<xref rid=""B18-nutrients-16-02064"" ref-type=""bibr"">18</xref>], including statements about target therapeutic blood Phe levels, the frequency of blood Phe monitoring, treatment management and overall care. With the changing treatment landscape and better management guidance, it is important to establish current blood Phe control across the lifespan in PKU. We aimed to",22_32,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"control across the lifespan in PKU. We aimed to collect data in nine well-established European and Turkish centres, which would indicate whether the current treatment practices have led to metabolic control in line with the first PKU guidelines. These data will provide a baseline to examine whether the European guidelines and new treatments will result in improved metabolic control.   This retrospective study collected real-world clinical data on a total of 1323 patients with PKU across nine centres in",22_33,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"of 1323 patients with PKU across nine centres in Europe over 7 years from 2012 to 2018 inclusively. When the mean blood Phe level was used as an indicator of metabolic control, in this cohort, the blood Phe achieved was found to be fully in line with the European PKU guidelines for all age groups [<xref rid=""B18-nutrients-16-02064"" ref-type=""bibr"">18</xref>]. However, when examining the percentage of blood Phe levels within the therapeutic target range, the mean percentages varied between 65 and 88% across",22_34,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"mean percentages varied between 65 and 88% across all centres for the 7-year period observed. Predictably, the blood Phe level, as well as its variability, increased with age, indicating a deterioration in metabolic control, particularly when transitioning from adolescence to adulthood. This is probably associated with an increase in natural protein and the reduced intake of low-Phe/Phe-free protein substitutes. Unsurprisingly, patients with classical PKU had higher mean blood Phe levels and a lower",22_35,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"PKU had higher mean blood Phe levels and a lower percentage of blood Phe levels within the therapeutic target range compared with patients with HPA and mPKU. Although there was no overall difference in blood Phe levels between female and male patients with PKU, a higher percentage of levels within the target range was found in female patients during school age, adolescence and adulthood, but not in young adults (19–30 years). After the age of 30 years, women had lower mean blood Phe levels when compared",22_36,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"had lower mean blood Phe levels when compared with men. Using sapropterin as an adjunct or alternative treatment to the low-Phe diet resulted in significantly lower blood Phe levels. Unlike dietary treatment alone, sapropterin helped patients to sustain acceptable metabolic control post-adolescence. We also report that a higher frequency of blood Phe monitoring improved metabolic control, and this was maintained even with increasing age. Although, in PKU, it is well established that treatment adherence",22_37,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"it is well established that treatment adherence lowers progressively with age [<xref rid=""B30-nutrients-16-02064"" ref-type=""bibr"">30</xref>,<xref rid=""B36-nutrients-16-02064"" ref-type=""bibr"">36</xref>], we observed that the percentage of blood Phe levels within the therapeutic target range was relatively high (approximately 70–90%) until the age of 18 years, which is similar to earlier studies reported from Europe and USA (<xref rid=""nutrients-16-02064-t011"" ref-type=""table"">Table 11</xref>) [<xref",22_38,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"ref-type=""table"">Table 11</xref>) [<xref rid=""B13-nutrients-16-02064"" ref-type=""bibr"">13</xref>,<xref rid=""B30-nutrients-16-02064"" ref-type=""bibr"">30</xref>,<xref rid=""B31-nutrients-16-02064"" ref-type=""bibr"">31</xref>,<xref rid=""B32-nutrients-16-02064"" ref-type=""bibr"">32</xref>,<xref rid=""B33-nutrients-16-02064"" ref-type=""bibr"">33</xref>,<xref rid=""B37-nutrients-16-02064"" ref-type=""bibr"">37</xref>,<xref rid=""B38-nutrients-16-02064"" ref-type=""bibr"">38</xref>]. However, together with other studies that have",22_39,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"However, together with other studies that have reported since the mid-2000s [<xref rid=""B13-nutrients-16-02064"" ref-type=""bibr"">13</xref>,<xref rid=""B30-nutrients-16-02064"" ref-type=""bibr"">30</xref>,<xref rid=""B31-nutrients-16-02064"" ref-type=""bibr"">31</xref>,<xref rid=""B32-nutrients-16-02064"" ref-type=""bibr"">32</xref>,<xref rid=""B33-nutrients-16-02064"" ref-type=""bibr"">33</xref>,<xref rid=""B37-nutrients-16-02064"" ref-type=""bibr"">37</xref>,<xref rid=""B38-nutrients-16-02064"" ref-type=""bibr"">38</xref>],",22_40,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"ref-type=""bibr"">38</xref>], metabolic control did not deteriorate during adolescence, based on the percentage of blood Phe levels within the therapeutic target range. This is probably associated with the relaxation of the European PKU Guidelines target ranges from the age of 12 years (upper limit: 360 μmol/L in <12 years vs. 600 μmol/L in ≥12 years), but, even so, despite the challenges of treatment and adolescence in PKU, the majority were able to maintain their blood Phe within the target range. This",22_41,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"their blood Phe within the target range. This finding is encouraging as good metabolic control has been shown to be correlated with both higher IQ and improved executive function in adolescents [<xref rid=""B39-nutrients-16-02064"" ref-type=""bibr"">39</xref>]. Most centres in this study continued to perform blood Phe monitoring during illness, including infection, and this could have contributed to the overall blood Phe control observed. However, illness is usually highest in early childhood and should not",22_42,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"usually highest in early childhood and should not explain deteriorating blood Phe control in late childhood and adults. Considering the emphasis on treatment for life, the introduction of adjunct or alternative pharmaceutical treatments and the increased number of adult care teams, overall blood Phe control in adulthood is disappointing. Using the upper target range of 600 µmol/L, which is higher than in childhood, only around 60% of our adult cohort <40 years of age were able to meet the European PKU",22_43,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"years of age were able to meet the European PKU guideline on metabolic control. This can be partly explained by the use of a higher upper target range in adults in some of the centres, such as France, Denmark and Spain, during part of the study period (pre-publication of European guidelines), and the French centre continuing to use a higher target blood Phe range following the publication of the European PKU guidelines [<xref rid=""B18-nutrients-16-02064"" ref-type=""bibr"">18</xref>]. Some centres (Turkey,",22_44,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"ref-type=""bibr"">18</xref>]. Some centres (Turkey, Portugal, Italy and Denmark) used LNAA treatments. Although not recommended by the European guidelines, LNAA competes with Phe at the blood–brain barrier, and, in PKU mice, it has been shown to reduce brain Phe and increase brain non-Phe LNAA and brain monoaminergic neurotransmitter concentrations [<xref rid=""B40-nutrients-16-02064"" ref-type=""bibr"">40</xref>]. These centres permitted a higher blood Phe target for patients prescribed LNAA. Other factors that",22_45,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"for patients prescribed LNAA. Other factors that may have contributed to the higher blood Phe levels in adults include low risk perception by adult patients [<xref rid=""B14-nutrients-16-02064"" ref-type=""bibr"">14</xref>,<xref rid=""B41-nutrients-16-02064"" ref-type=""bibr"">41</xref>], inconsistent health professional messages about the need for stringent blood Phe control [<xref rid=""B42-nutrients-16-02064"" ref-type=""bibr"">42</xref>,<xref rid=""B43-nutrients-16-02064"" ref-type=""bibr"">43</xref>], low awareness",22_46,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"ref-type=""bibr"">43</xref>], low awareness about the importance of lowering blood Phe in adulthood [<xref rid=""B42-nutrients-16-02064"" ref-type=""bibr"">42</xref>], uncomfortable or negative doctor/patient relationships [<xref rid=""B44-nutrients-16-02064"" ref-type=""bibr"">44</xref>] and a lack of access to treatment [<xref rid=""B45-nutrients-16-02064"" ref-type=""bibr"">45</xref>]. Some adult physicians remain unconvinced that adults gain a substantial clinical benefit from better metabolic control [<xref",22_47,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"benefit from better metabolic control [<xref rid=""B43-nutrients-16-02064"" ref-type=""bibr"">43</xref>], and, in some cases, patients have been advised to stop treatment [<xref rid=""B46-nutrients-16-02064"" ref-type=""bibr"">46</xref>]. Although our data showed that blood Phe control deteriorated in adult patients, this may not be a true reflection of the overall landscape in adult PKU care. Our results do not include the blood Phe control of the many adults not being actively followed up within the clinics. In",22_48,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"being actively followed up within the clinics. In our cohort, some adults with PKU were reported as lost to follow-up (<20%), but this was lower than in previous studies that have reported rates as high as 50% [<xref rid=""B31-nutrients-16-02064"" ref-type=""bibr"">31</xref>,<xref rid=""B44-nutrients-16-02064"" ref-type=""bibr"">44</xref>,<xref rid=""B47-nutrients-16-02064"" ref-type=""bibr"">47</xref>,<xref rid=""B48-nutrients-16-02064"" ref-type=""bibr"">48</xref>]. However, the actual number of patients lost to",22_49,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"However, the actual number of patients lost to follow-up was unknown in some of our centres; therefore, this figure may be underestimated and the outcomes of patients not in follow-up is undetermined. It is essential that we strive to gain lifetime knowledge about the blood Phe control of all adult patients with PKU, as it is necessary to establish the impact of blood Phe control on the brain health of early treated patients when they age beyond 60 years of age. In our cohort, patients on dietary",22_50,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"years of age. In our cohort, patients on dietary management only or with classical PKU had higher blood Phe variability. The significance of this is not clear, but Romani et al. [<xref rid=""B49-nutrients-16-02064"" ref-type=""bibr"">49</xref>] stated that Phe variation was influential, if not more important than the mean Phe, in predicting adult cognitive outcomes. Hood et al. [<xref rid=""B50-nutrients-16-02064"" ref-type=""bibr"">50</xref>] reported, in 47 school-age children with PKU, that variability in blood",22_51,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"children with PKU, that variability in blood Phe was a stronger predictor of cognitive performance than other indices of blood Phe control. In our PKU centres, clinic resources varied widely, including the availability and reimbursement of SLPFs, pharmaceutical treatments, the number of health professionals and the composition of each multidisciplinary team. In one of our centres (from Poland), which had the highest percentage of patients with classical PKU, SLPFs were not reimbursed, and adjunct drug",22_52,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"PKU, SLPFs were not reimbursed, and adjunct drug therapy was unavailable for all patient age groups. This is likely to have adversely affected patients’ ability to be able to adhere to their treatment and ultimately led to less stable blood Phe control. In the US, Jurecki et al. [<xref rid=""B31-nutrients-16-02064"" ref-type=""bibr"">31</xref>] reported that a higher staffing intensity was associated with lower blood Phe levels, particularly in 5- to 12-year-old children and young adults aged 18–29 years.",22_53,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"children and young adults aged 18–29 years. Generally, younger children (0–4 years) and women planning pregnancy receive more attention from their clinic, irrespective of resources [<xref rid=""B42-nutrients-16-02064"" ref-type=""bibr"">42</xref>]. Most centres with psychologists and support workers as part of their multidisciplinary team appeared to have better blood Phe control. However, only four centres had a psychologist and two had a support worker as part of their health professional team. Given the",22_54,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"part of their health professional team. Given the high rates of poor metabolic control in our adult PKU population, it is possible that some patients may have had neuropsychiatric symptoms or lower cognition/executive function that affected their ability to adhere to a Phe-restricted diet. Mental health issues and neurocognitive outcomes should be monitored and supported by neuropsychologists and clinical psychologists as part of routine care [<xref rid=""B18-nutrients-16-02064"" ref-type=""bibr"">18</xref>].",22_55,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"ref-type=""bibr"">18</xref>]. In addition, coordinated transition systems between paediatric and adult clinics, continuous and consistent treatment and regular attendance at clinics is associated with better blood Phe control in adult patients [<xref rid=""B51-nutrients-16-02064"" ref-type=""bibr"">51</xref>] and may prevent loss of follow-up [<xref rid=""B51-nutrients-16-02064"" ref-type=""bibr"">51</xref>,<xref rid=""B52-nutrients-16-02064"" ref-type=""bibr"">52</xref>]. In our study, centres without a structured",22_56,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"In our study, centres without a structured transition process and an adult metabolic specialist team had higher numbers of patients lost to follow-up. In addition only five of our centres had a transition service in place and three had a partial transition to an adult medical team only, similar to many other European centres. Thus, most adult patients with PKU continue to be treated by paediatricians. As treatment is self-administered and is dependent on the patient’s ability and motivation, good-quality",22_57,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"patient’s ability and motivation, good-quality follow-up and monitoring is essential and should lead to better metabolic control. However, in newly established adult clinics, physicians new to the treatment of metabolic disorders, may lead to distrust and low patient confidence. The poor metabolic control observed in adulthood continues to highlight the shortcomings of the current treatment. Alternative, practical oral therapies associated with minimal side effects are required. Sapropterin was established",22_58,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"effects are required. Sapropterin was established or introduced in 8 of 9 PKU centres during the data collection period but overall was only prescribed to 222 (17%) patients, even though 52% of the patients either had HPA or mPKU and may have potentially responded to this therapy. Hillert et al. [<xref rid=""B1-nutrients-16-02064"" ref-type=""bibr"">1</xref>] estimated, from a database of 16,092 patients with PKU from 51 countries (22% had mPKU, 16% HPA), that 43% of patients were sapropterin-responsive.",22_59,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"that 43% of patients were sapropterin-responsive. Therefore, in our cohort, sapropterin appears to have been under-prescribed. Others have reported the under-utilisation of sapropterin. In a nationwide French study examining the health status of 3549 adults with PKU, only 7% received sapropterin [<xref rid=""B15-nutrients-16-02064"" ref-type=""bibr"">15</xref>]. In our study, the variability in blood Phe levels in the sapropterin group was lower, with better mean blood levels than in the diet-only-treated",22_60,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"mean blood levels than in the diet-only-treated patients. However, this needs to interpreted with caution given that sapropterin-treated patients have a milder PAH deficiency while non-sapropterin-treated patients might include both milder and more severely PAH-deficient patients. New adjunct therapies are required that are safe and effective for all levels of severity and age groups in PKU. We studied a mixed cohort of patients with HPA, mild and classical phenotypes, and approximately half of the sample",22_61,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"phenotypes, and approximately half of the sample had mPKU or HPA. Overall, the percentage of blood Phe levels within the target range was close to 100% in HPA but decreased in mPKU, and it was only 54% in classical PKU. In general, patients with HPA/mPKU were able to maintain good metabolic control irrespective of their age, but patients with classical PKU struggled to achieve blood Phe levels within target, particularly with increasing age. In our cohort, one third of the centres (Italy, Portugal and",22_62,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"one third of the centres (Italy, Portugal and Turkey) had a high rate of HPA and mPKU, of which two centres (Italy and Portugal) had a higher percentage of levels within the target range. As patients with milder forms may need less frequent follow-up than patients with classical PKU, specific recommendations should be considered in the future to address the different needs of the diverse phenotypes within this disorder. The current study found no overall differences in blood Phe levels between males and",22_63,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"differences in blood Phe levels between males and females (<italic toggle=""yes"">p</italic> = 0.939). However, in school-age children, adolescents and older adults, females had a higher percentage of blood Phe levels within the target range. It has been suggested that the start of the menstrual cycle could impact the blood Phe levels in girls but there are no data to support this. After the age of 19 y, there was a trend towards a higher percentage of Phe levels within the target in female patients, and",22_64,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"levels within the target in female patients, and their mean blood Phe levels were clinically significantly lower when compared with male patients. There are few data in the literature showing differences between sex, but both Levy et al. [<xref rid=""B13-nutrients-16-02064"" ref-type=""bibr"">13</xref>] and Kanufre et al. [<xref rid=""B33-nutrients-16-02064"" ref-type=""bibr"">33</xref>] found a trend for lower blood Phe levels in female patients over time. This could be associated with women receiving more",22_65,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"could be associated with women receiving more attention from healthcare professionals from adolescence onwards due to the need to prevent maternal PKU syndrome. In a recent UK survey in adults with PKU, health professionals appeared less concerned about the follow-up of males than females, with clinic visits being less attentive towards male patients and their health [<xref rid=""B42-nutrients-16-02064"" ref-type=""bibr"">42</xref>]. Both males and females should have all of their needs equally met,",22_66,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"should have all of their needs equally met, irrespective of their sex. The regular monitoring of blood Phe levels is essential in the management of PKU, although the optimal frequency is unknown. The European PKU guidelines suggest less monitoring with increasing age, although this statement does not have a strong evidence base. It is rather counterintuitive to recommend this when it is known that blood Phe control deteriorates with age [<xref rid=""B18-nutrients-16-02064"" ref-type=""bibr"">18</xref>]. Our",22_67,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"ref-type=""bibr"">18</xref>]. Our data indicate that a higher frequency of monitoring of blood Phe levels is associated with better blood Phe control. These results contrast with Jureki et al. [<xref rid=""B31-nutrients-16-02064"" ref-type=""bibr"">31</xref>]. Overall, limited research is available on the benefits of frequent blood Phe sampling. It has been reported that some patients who undergo blood Phe tests infrequently may lower their Phe intake prior to testing, suggesting that their blood Phe levels may",22_68,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"suggesting that their blood Phe levels may be underestimated [<xref rid=""B53-nutrients-16-02064"" ref-type=""bibr"">53</xref>]. Adults may also doubt the necessity for regular blood Phe sampling [<xref rid=""B53-nutrients-16-02064"" ref-type=""bibr"">53</xref>], although, for the parents of children with PKU, regular blood Phe testing may provide some ‘peace of mind’. Patients who are monitored more frequently may be more motivated and their overall treatment adherence is better, leading to less variability in",22_69,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"is better, leading to less variability in their blood Phe levels, which is important for neurocognitive outcomes [<xref rid=""B49-nutrients-16-02064"" ref-type=""bibr"">49</xref>]. It may also be associated with increased engagement between the patient and health professionals. Some patients perform infrequent blood spots due to problems with blood sampling techniques; they may forget to take blood samples; or they may consider that a lack of blood samples has no effect on the treatment outcome [<xref",22_70,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"has no effect on the treatment outcome [<xref rid=""B42-nutrients-16-02064"" ref-type=""bibr"">42</xref>]. The availability of blood equipment and the frequency of blood Phe analysis (related to the speed of processing by the lab, postal delays or patients’ frequency of monitoring) may also have an important impact on blood Phe control and treatment adherence. A point-of-care (POC) device capable of measuring blood Phe levels in homes could lower the test costs, provide immediate test results and broaden the",22_71,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"provide immediate test results and broaden the accessibility of home Phe monitoring [<xref rid=""B54-nutrients-16-02064"" ref-type=""bibr"">54</xref>]. Currently, there are no approved POC devices, although there has been development over many years. However, it should be remembered that any such device cannot be expected to improve blood Phe control by itself. In PKU, overall metabolic control has not improved throughout the years, particularly in adulthood, although more frequent blood Phe sampling and",22_72,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"although more frequent blood Phe sampling and pharmaceutical adjunct therapies appear to have a positive influence on blood Phe levels. The impact of the frequency of blood sampling should be explored in more depth in future studies. Variable and changing blood Phe targets may lead to confusion about the necessity for consistent and lower blood Phe levels in adulthood. In PKU, pharmaceutical therapies are needed that will lower blood Phe levels in all patients without adding to the burden of care.",22_73,Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?,28 6 2024,,Phenylketonuria
"No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study Patients with phenylketonuria (PKU) present signs of impaired executive functioning and bone health in adolescence and adulthood, depending in part on the success of therapy in childhood. Therefore, nine children with well-treated PKU (4–7 years old, 22.2% ♀, seven with a full set of data, two included into partial analysis) and 18 age-, gender- and season-matched controls were analyzed for",23_0,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"and season-matched controls were analyzed for differences in executive functioning and bone parameters in plasma. Plasma was analyzed with commercially available kits. Cognitive performance in tonic alertness, visuo-spatial working memory, inhibitory control and task switching was assessed by a task battery presented on a touch screen. Regarding cognition, only the performance in incongruent conditions in inhibitory control was significantly better in children with PKU than in controls. No further",23_1,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"in children with PKU than in controls. No further differences in cognitive tests were detected. Furthermore, no significant difference in the bone turnover markers osteocalcin, undercarboxylated osteocalcin and CTX were detected between children with PKU and controls, while children with PKU had a significantly higher vitamin D concentration (69.44 ± 12.83 nmol/L vs. 41.87 ± 15.99 nmol/L, <italic toggle=""yes"">p</italic> < 0.001) and trended towards lower parathyroid hormone concentrations than controls",23_2,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"parathyroid hormone concentrations than controls (48.27 ± 15.16 pg/mL vs. 70.61 ± 30.53 pg/mL, <italic toggle=""yes"">p</italic> = 0.066). In this small group of well-treated preschoolers with PKU, no impairments in cognitive performance and bone turnover were observed, while vitamin D supplementation of amino acid supplements seems to be sufficient to achieve good vitamin D status. Phenylketonuria (PKU; OMIM #261600) is a congenital defect of the Phenylalanine (Phe) metabolism with an incidence of",23_3,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"(Phe) metabolism with an incidence of 19.3/100,000 newborns in 2020 in Germany [<xref rid=""B1-nutrients-16-02072"" ref-type=""bibr"">1</xref>,<xref rid=""B2-nutrients-16-02072"" ref-type=""bibr"">2</xref>]. Variants in the gene encoding phenylalanine hydroxylases lead to reduced activity of the enzyme, subsequently causing the accumulation of Phe and its metabolites in the blood and brain [<xref rid=""B1-nutrients-16-02072"" ref-type=""bibr"">1</xref>]. Classical symptoms of PKU include irreversible intellectual",23_4,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"symptoms of PKU include irreversible intellectual disability, motor deficits and developmental problems [<xref rid=""B1-nutrients-16-02072"" ref-type=""bibr"">1</xref>]. Early diagnosis and start of treatment, which entails the reduction of Phe intake from natural protein and the supplementation of amino acids, can prevent the development of most symptoms [<xref rid=""B1-nutrients-16-02072"" ref-type=""bibr"">1</xref>,<xref rid=""B3-nutrients-16-02072"" ref-type=""bibr"">3</xref>]. As consumption of natural protein",23_5,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"As consumption of natural protein needs to be reduced up until the point of the Phe blood concentrations meeting the target range, overall protein and caloric restriction is not sufficient for normal growth [<xref rid=""B3-nutrients-16-02072"" ref-type=""bibr"">3</xref>]. Therefore, foods naturally higher in protein, such as baked goods and pastas, are available as low-protein substitutes to ensure an adequate energy supply, while protein requirement is covered by Phe-free amino acid mixtures with added",23_6,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"by Phe-free amino acid mixtures with added vitamins (such as vitamin D) and minerals [<xref rid=""B3-nutrients-16-02072"" ref-type=""bibr"">3</xref>]. While a certain amount of Phe is required for healthy development, a higher intake of Phe results in the elevation of blood Phe concentration and should be limited [<xref rid=""B1-nutrients-16-02072"" ref-type=""bibr"">1</xref>,<xref rid=""B3-nutrients-16-02072"" ref-type=""bibr"">3</xref>]. Adults, therefore, tend towards a vegan-like diet, to reduce the intake of",23_7,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"a vegan-like diet, to reduce the intake of natural Phe [<xref rid=""B4-nutrients-16-02072"" ref-type=""bibr"">4</xref>]. Tetrahydrobiopterin (BH<sub>4</sub>) is the co-factor of phenylalanine hydroxylases, as well as various enzymes involved in neurotransmitter synthesis [<xref rid=""B1-nutrients-16-02072"" ref-type=""bibr"">1</xref>,<xref rid=""B5-nutrients-16-02072"" ref-type=""bibr"">5</xref>]. BH<sub>4</sub> is available as therapeutic agent for patients responding to the treatment, which enables them to increase",23_8,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"to the treatment, which enables them to increase their intake of natural protein by ≥100% and/or gain biochemical control [<xref rid=""B1-nutrients-16-02072"" ref-type=""bibr"">1</xref>]. The leading goal in the therapy of patients with PKU is the prevention of neurocognitive deficits [<xref rid=""B1-nutrients-16-02072"" ref-type=""bibr"">1</xref>]. Despite the early diagnosis, children and adults with PKU achieve a significantly lower IQ than controls, but within normal range [<xref rid=""B6-nutrients-16-02072""",23_9,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"normal range [<xref rid=""B6-nutrients-16-02072"" ref-type=""bibr"">6</xref>,<xref rid=""B7-nutrients-16-02072"" ref-type=""bibr"">7</xref>,<xref rid=""B8-nutrients-16-02072"" ref-type=""bibr"">8</xref>]. Additionally, executive functioning, e.g., working memory, sustained attention, problem solving and strategy was found to be lower in adolescents and adults with PKU, but less so in children in most but not all studies [<xref rid=""B9-nutrients-16-02072"" ref-type=""bibr"">9</xref>,<xref rid=""B10-nutrients-16-02072""",23_10,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"rid=""B10-nutrients-16-02072"" ref-type=""bibr"">10</xref>,<xref rid=""B11-nutrients-16-02072"" ref-type=""bibr"">11</xref>,<xref rid=""B12-nutrients-16-02072"" ref-type=""bibr"">12</xref>]. The effects of BH<sub>4</sub> usage and dietary control were also studied in relationship with cognitive outcomes in patients with PKU, and lead to inconsistent results [<xref rid=""B6-nutrients-16-02072"" ref-type=""bibr"">6</xref>,<xref rid=""B9-nutrients-16-02072"" ref-type=""bibr"">9</xref>,<xref rid=""B10-nutrients-16-02072""",23_11,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"rid=""B10-nutrients-16-02072"" ref-type=""bibr"">10</xref>,<xref rid=""B11-nutrients-16-02072"" ref-type=""bibr"">11</xref>,<xref rid=""B12-nutrients-16-02072"" ref-type=""bibr"">12</xref>]. A regression analysis of Phe levels early in life and attention in 57 children with PKU between 7 and 14 years of age showed a significant influence of Phe levels between ages 5 and 7 on attention control and reaction speed [<xref rid=""B13-nutrients-16-02072"" ref-type=""bibr"">13</xref>]. Additionally, lesions sustained in the white",23_12,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"Additionally, lesions sustained in the white matter of the brain were observed in patients with PKU of all ages and seem to be negatively affected by Phe concentrations earlier in life [<xref rid=""B7-nutrients-16-02072"" ref-type=""bibr"">7</xref>,<xref rid=""B8-nutrients-16-02072"" ref-type=""bibr"">8</xref>,<xref rid=""B14-nutrients-16-02072"" ref-type=""bibr"">14</xref>,<xref rid=""B15-nutrients-16-02072"" ref-type=""bibr"">15</xref>]. The ability to sustain attention, suppress impulsivity and renew and connect",23_13,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"suppress impulsivity and renew and connect information at preschool age is important for later academic achievements [<xref rid=""B16-nutrients-16-02072"" ref-type=""bibr"">16</xref>]. Accordingly, preschool age might be especially interesting in the cognitive development of children with PKU. We were especially interested in the attention and executive functioning (inhibition, working memory and task switching) of preschoolers, as these are underlying mechanisms for higher cognitive functions [<xref",23_14,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"mechanisms for higher cognitive functions [<xref rid=""B17-nutrients-16-02072"" ref-type=""bibr"">17</xref>,<xref rid=""B18-nutrients-16-02072"" ref-type=""bibr"">18</xref>,<xref rid=""B19-nutrients-16-02072"" ref-type=""bibr"">19</xref>,<xref rid=""B20-nutrients-16-02072"" ref-type=""bibr"">20</xref>]. Executive functions correlate with general intelligence but are not a measure for intelligence itself [<xref rid=""B21-nutrients-16-02072"" ref-type=""bibr"">21</xref>]. Inhibition can be tested by the Flanker Task, in which",23_15,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"can be tested by the Flanker Task, in which an interfering item surrounding the goal item slows down the reaction time [<xref rid=""B17-nutrients-16-02072"" ref-type=""bibr"">17</xref>]. Corsi Block Tapping Task can be used to measure the renewing and span of the visuo-spatial subsystem [<xref rid=""B22-nutrients-16-02072"" ref-type=""bibr"">22</xref>]. Switching between tasks requires both inhibition and working memory for accurate and speedy processing [<xref rid=""B17-nutrients-16-02072""",23_16,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"processing [<xref rid=""B17-nutrients-16-02072"" ref-type=""bibr"">17</xref>,<xref rid=""B19-nutrients-16-02072"" ref-type=""bibr"">19</xref>]. However, cognitive disturbances are not the only obstacle patients with PKU have to deal with. For instance, a lower bone mineral density (BMD) was described in several studies in children and adults with PKU [<xref rid=""B23-nutrients-16-02072"" ref-type=""bibr"">23</xref>,<xref rid=""B24-nutrients-16-02072"" ref-type=""bibr"">24</xref>,<xref rid=""B25-nutrients-16-02072""",23_17,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"rid=""B25-nutrients-16-02072"" ref-type=""bibr"">25</xref>,<xref rid=""B26-nutrients-16-02072"" ref-type=""bibr"">26</xref>,<xref rid=""B27-nutrients-16-02072"" ref-type=""bibr"">27</xref>], while some found reduced bone quality in some patients with PKU [<xref rid=""B28-nutrients-16-02072"" ref-type=""bibr"">28</xref>,<xref rid=""B29-nutrients-16-02072"" ref-type=""bibr"">29</xref>,<xref rid=""B30-nutrients-16-02072"" ref-type=""bibr"">30</xref>,<xref rid=""B31-nutrients-16-02072"" ref-type=""bibr"">31</xref>,<xref",23_18,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"ref-type=""bibr"">31</xref>,<xref rid=""B32-nutrients-16-02072"" ref-type=""bibr"">32</xref>]. A systematic review and meta-analysis of bone health in patients with PKU found a frequency of BMD Z-Score between −1 and −2.5 in 28–45% of children, and 5–13% showed BMD Z-Scores below −2.5 [<xref rid=""B27-nutrients-16-02072"" ref-type=""bibr"">27</xref>]. In European adults with PKU, mean BMD Z-Scores were significantly lower than in the reference population, but a low BMD Z-Score (≤−2) only occurred in 1.6–5.5% [<xref",23_19,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"Z-Score (≤−2) only occurred in 1.6–5.5% [<xref rid=""B25-nutrients-16-02072"" ref-type=""bibr"">25</xref>]. While low adherence to diet (and therefore a higher intake of Phe than required for low Phe blood concentration) on the one hand is associated with reduced bone quality and higher spontaneous osteoclastogenesis [<xref rid=""B24-nutrients-16-02072"" ref-type=""bibr"">24</xref>,<xref rid=""B28-nutrients-16-02072"" ref-type=""bibr"">28</xref>], dietary supplementation with amino acids on the other hand might",23_20,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"with amino acids on the other hand might negatively affect bone mineralization [<xref rid=""B23-nutrients-16-02072"" ref-type=""bibr"">23</xref>,<xref rid=""B33-nutrients-16-02072"" ref-type=""bibr"">33</xref>,<xref rid=""B34-nutrients-16-02072"" ref-type=""bibr"">34</xref>,<xref rid=""B35-nutrients-16-02072"" ref-type=""bibr"">35</xref>]. Bone accrual in childhood might influence bone health in older age. Even subclinical disturbances during early childhood could have an impact on peak bone mass, with short-term effects",23_21,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"impact on peak bone mass, with short-term effects being visible in bone turnover markers rather than in changed BMD, which only depicts bone mineral status but not the fluctuation in bone turnover [<xref rid=""B36-nutrients-16-02072"" ref-type=""bibr"">36</xref>,<xref rid=""B37-nutrients-16-02072"" ref-type=""bibr"">37</xref>,<xref rid=""B38-nutrients-16-02072"" ref-type=""bibr"">38</xref>]. On the other hand, single measurements of bone turnover markers may be limited in their ability to reflect current bone status",23_22,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"in their ability to reflect current bone status in children, but an analysis of BMD is reliant upon radiation usage and therefore not without risk [<xref rid=""B36-nutrients-16-02072"" ref-type=""bibr"">36</xref>,<xref rid=""B39-nutrients-16-02072"" ref-type=""bibr"">39</xref>]. Bone turnover is the result of bone resorption and bone formation, which are tightly interwoven with each another. To evaluate bone formation, certain markers from collagen synthesis and osteoblast activity can be used, such as osteocalcin",23_23,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"activity can be used, such as osteocalcin (OCN), alkaline phosphatases, or procollagen 1 N-Peptide [<xref rid=""B40-nutrients-16-02072"" ref-type=""bibr"">40</xref>]. Bone resorption can be measured by collagens released from bone matrix and osteoclast activity markers, such as N- or C-terminal cross-linked telopeptide of type-1 collagen (CTX) as well as Tartrate-resistant acid phosphatase type 5b activity [<xref rid=""B40-nutrients-16-02072"" ref-type=""bibr"">40</xref>]. As described, the studied impairments in",23_24,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"As described, the studied impairments in bone health and the cognition of patients with PKU are manifold and complex. Since early intervention in cognitive development and bone formation could have a positive effect on health in adulthood, the investigation of corresponding parameters in young, well-treated children with PKU is of interest. We hypothesized that even in young, well-treated children with PKU, the first signs of increased bone turnover and deficits in executive functions compared to healthy",23_25,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"in executive functions compared to healthy age-matched controls can be observed. Nine children with PKU (4–7 years old) were recruited to participate during routine check-ups and were characterized by daily Phe tolerance, which is matched to the child’s weight and changes in blood Phe concentration, as well as blood/dried blood filter cards (DBS) Phe concentrations and tyrosine concentrations in the months before, during and after study participation (<xref rid=""nutrients-16-02072-f001""",23_26,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"(<xref rid=""nutrients-16-02072-f001"" ref-type=""fig"">Figure 1</xref>A). Mean Phe and tyrosine concentrations were calculated for these 3 months from a mixture of plasma and DBS results, as DBS usually are collected regularly by the parents. All participating patients were treated with protein restriction and amino acid-supplements; therefore, no child with mild hyperphenylalaninemia was included [<xref rid=""B1-nutrients-16-02072"" ref-type=""bibr"">1</xref>]. Additionally, caregivers of children with PKU gave",23_27,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"caregivers of children with PKU gave information on supplement use, other than amino acid supplementation used in treatment. Eighteen age- and gender-matched otherwise healthy preschoolers (4–6 years old) who underwent tonsillotomy or tonsillectomy were recruited to participate as controls, during the same season as the children with PKU. Exclusion criteria were a diagnosed learning disorder or metabolic disease other than PKU, and little or no knowledge of the German language as assessed by clinic staff.",23_28,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"the German language as assessed by clinic staff. In patients with PKU, fasted blood was drawn in the morning on the same day as cognition was tested. For controls, fasted blood was drawn in the morning of the operation. Two days after the operation, digital cognitive testing was conducted at the hospital (<xref rid=""nutrients-16-02072-f001"" ref-type=""fig"">Figure 1</xref>B). Written informed consent was given by parents or legal guardians of all participants. All participating children gave spoken consent",23_29,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"All participating children gave spoken consent prior to inclusion. The study was approved by the Ethics Committees of Ruhr-University Bochum (No. 17-6311), in accordance with the Declaration of Helsinki.  Older children and adults with PKU showed bone health and executive performance deficits in previous studies [<xref rid=""B6-nutrients-16-02072"" ref-type=""bibr"">6</xref>,<xref rid=""B7-nutrients-16-02072"" ref-type=""bibr"">7</xref>,<xref rid=""B8-nutrients-16-02072"" ref-type=""bibr"">8</xref>,<xref",23_30,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"ref-type=""bibr"">8</xref>,<xref rid=""B9-nutrients-16-02072"" ref-type=""bibr"">9</xref>,<xref rid=""B10-nutrients-16-02072"" ref-type=""bibr"">10</xref>,<xref rid=""B11-nutrients-16-02072"" ref-type=""bibr"">11</xref>,<xref rid=""B12-nutrients-16-02072"" ref-type=""bibr"">12</xref>,<xref rid=""B13-nutrients-16-02072"" ref-type=""bibr"">13</xref>,<xref rid=""B14-nutrients-16-02072"" ref-type=""bibr"">14</xref>,<xref rid=""B23-nutrients-16-02072"" ref-type=""bibr"">23</xref>,<xref rid=""B24-nutrients-16-02072""",23_31,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"rid=""B24-nutrients-16-02072"" ref-type=""bibr"">24</xref>,<xref rid=""B25-nutrients-16-02072"" ref-type=""bibr"">25</xref>,<xref rid=""B26-nutrients-16-02072"" ref-type=""bibr"">26</xref>,<xref rid=""B27-nutrients-16-02072"" ref-type=""bibr"">27</xref>,<xref rid=""B28-nutrients-16-02072"" ref-type=""bibr"">28</xref>,<xref rid=""B29-nutrients-16-02072"" ref-type=""bibr"">29</xref>,<xref rid=""B30-nutrients-16-02072"" ref-type=""bibr"">30</xref>,<xref rid=""B31-nutrients-16-02072"" ref-type=""bibr"">31</xref>,<xref",23_32,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"ref-type=""bibr"">31</xref>,<xref rid=""B32-nutrients-16-02072"" ref-type=""bibr"">32</xref>,<xref rid=""B33-nutrients-16-02072"" ref-type=""bibr"">33</xref>,<xref rid=""B34-nutrients-16-02072"" ref-type=""bibr"">34</xref>,<xref rid=""B35-nutrients-16-02072"" ref-type=""bibr"">35</xref>]. Therefore, an analysis of bone turnover and executive functioning in preschool children with PKU and matched controls was conducted. Neither bone resorption and formation markers, nor most parameters of executive functioning, differed",23_33,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"parameters of executive functioning, differed between young children with well-treated PKU and age- and gender-matched controls. Most interestingly, we did find significantly higher vitamin D levels in children with PKU than in controls, even though they were recruited during the same season. None of the children with PKU exceeded the recommended blood Phe concentration of 360 µmol/L in the months before, during and after participation in the study, and two participants had mean Phe concentrations slightly",23_34,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"participants had mean Phe concentrations slightly below 120 µmol/L [<xref rid=""B1-nutrients-16-02072"" ref-type=""bibr"">1</xref>]. As the American College of Medical Genetics and Genomics stated, there is no evidence for the recommendation of blood Phe concentrations of 60–120 µmol/L, but low Phe levels are safe if adequately monitored to avoid prolonged phases of blood Phe concentrations below 30 µmol/L [<xref rid=""B3-nutrients-16-02072"" ref-type=""bibr"">3</xref>]. Therefore, all participants with PKU had",23_35,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"Therefore, all participants with PKU had good compliance and all consumed amino acid supplements. The prevention of neurocognitive deficits in patients with PKU is the leading treatment goal in the care of the metabolic disease [<xref rid=""B1-nutrients-16-02072"" ref-type=""bibr"">1</xref>]. We observed no difference in performance in the Corsi Block Tapping Task, Tonic Alertness Task and Switch Task in well-treated preschool children with PKU and healthy controls. As Townsend and Ashby suggested in 1978, and",23_36,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"As Townsend and Ashby suggested in 1978, and Bruyer and Brysnaert discussed in 2011, speed and accuracy in some cognitive testing can influence each other in a speed–accuracy trade-off [<xref rid=""B50-nutrients-16-02072"" ref-type=""bibr"">50</xref>]. Therefore, we used the inverse efficiency (IE) as discussed to evaluate Flanker Task performance [<xref rid=""B50-nutrients-16-02072"" ref-type=""bibr"">50</xref>]. The IE penalizes faster RT if this comes with a higher number of false reactions. Therefore, higher",23_37,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"number of false reactions. Therefore, higher IE indicates poorer performance in the Flanker Task [<xref rid=""B51-nutrients-16-02072"" ref-type=""bibr"">51</xref>]. We observed significantly better performance in processing the incongruent stimuli in children with PKU vs. controls. Matching our results, Paermentier et al. observed no significant difference in the spatial working memory of pre-school children with hyperphenylalaninemia and controls, but better performance in inhibitory control in pre-school",23_38,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"performance in inhibitory control in pre-school children with hyperphenylalaninemia. As they included children with moderate hyperphenylalaninemia and phenylketonuria, they were able to compare these two groups as well, and found lower performance in inhibitory control and spatial working memory in children with PKU compared to children with moderate hyperphenylalaninemia (none treated with protein restriction) [<xref rid=""B52-nutrients-16-02072"" ref-type=""bibr"">52</xref>]. As all participants in our study",23_39,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"As all participants in our study had PKU, we were not able to compare participants with classical PKU and hyperphenylalaninemia in our cohort. In the Netherlands, children with PKU were recruited to participate in a study analyzing executive functioning and its associations to Phe blood concentrations in 1997–1998 [<xref rid=""B13-nutrients-16-02072"" ref-type=""bibr"">13</xref>,<xref rid=""B53-nutrients-16-02072"" ref-type=""bibr"">53</xref>,<xref rid=""B54-nutrients-16-02072"" ref-type=""bibr"">54</xref>,<xref",23_40,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"ref-type=""bibr"">54</xref>,<xref rid=""B55-nutrients-16-02072"" ref-type=""bibr"">55</xref>]. Comparable to our results, children with Phe blood levels below 360 µmol/L did not differ from healthy controls in inhibition and attention flexibility [<xref rid=""B53-nutrients-16-02072"" ref-type=""bibr"">53</xref>,<xref rid=""B54-nutrients-16-02072"" ref-type=""bibr"">54</xref>], whereas in the baseline speed task (comparable to the attention testing we used), all patients with PKU had longer RTs than age-matched controls",23_41,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"with PKU had longer RTs than age-matched controls [<xref rid=""B13-nutrients-16-02072"" ref-type=""bibr"">13</xref>]. In 2012–2015, all patients were re-invited to participate. In this adult group of early-treated patients, a significant correlation of Phe levels during early childhood (0–12 years), as well as during adolescents (13–17 years), and executive functioning was observed. For inhibitory control (Flanker Task), a greater increase in blood Phe levels from childhood to adulthood correlated with poorer",23_42,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"childhood to adulthood correlated with poorer performance in the task, while cognitive flexibility was correlated with Phe levels in early childhood [<xref rid=""B55-nutrients-16-02072"" ref-type=""bibr"">55</xref>]. On the contrary, another study revealed a trend towards higher error rates in NoGo trials of the Go-NoGo test (reduced inhibitory control) in young adult female patients with PKU compared to healthy age-matched controls. These results did not correlate with the average Phe blood concentration",23_43,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"with the average Phe blood concentration during the first six years of the lives of these patients, but came with a relative increase in brain activity in the right middle frontal gyrus [<xref rid=""B56-nutrients-16-02072"" ref-type=""bibr"">56</xref>]. Another study showed that 29 out of 30 patients with PKU had lesions, especially in the parietal and occipital lobes [<xref rid=""B57-nutrients-16-02072"" ref-type=""bibr"">57</xref>]. Additionally, working memory, cognitive flexibility, sustained attention and",23_44,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"cognitive flexibility, sustained attention and processing speed were measured in these patients with PKU and compared to controls, describing significantly lower performance in the patients. Neither historical nor current metabolic control in those patients was associated with performance in the cognitive testing and the white matter lesions, after correcting for multiple comparisons [<xref rid=""B57-nutrients-16-02072"" ref-type=""bibr"">57</xref>]. In children with PKU, Hood et al. observed correlations of",23_45,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"with PKU, Hood et al. observed correlations of mean diffusivity of two white matter brain regions with lifetime exposure to Phe and with performance in executive functioning testing [<xref rid=""B58-nutrients-16-02072"" ref-type=""bibr"">58</xref>]. Similarly, 86 children (8–17 years old) showed significant improvement in parent-reported executive functioning after blood Phe concentration was reduced due to treatment with BH<sub>4</sub> [<xref rid=""B59-nutrients-16-02072"" ref-type=""bibr"">59</xref>]. We",23_46,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"ref-type=""bibr"">59</xref>]. We observed no difference in the performance of visuo-spatial working memory, task switching or tonic alertness, but better performance in the inhibition of incongruent stimuli in children with PKU compared to healthy controls. Since a significant difference was neither observed in processing the congruent stimuli nor in the difference of IE, further analysis of inhibitory control in young children with PKU is needed. As children included into the present study were well",23_47,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"included into the present study were well treated, with no patient exceeding the upper recommendation of Phe level for the age group, it might be possible for executive functioning to still be unaffected in these young children, which in turn does not exclude the possibility for the occurrence of damages in the brain and performance issues later in life. Because the children included into our pilot study had lower blood Phe concentrations than those in the study of Paermentier et al., their performance in",23_48,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"study of Paermentier et al., their performance in the inhibition task seems comparable to the children with moderate hyperphenylalaninemia [<xref rid=""B52-nutrients-16-02072"" ref-type=""bibr"">52</xref>]. In the IDEFICS study, children between 3 and 15 years of age from eight European countries had a mean 25-OH D serum concentration of 45.2 (±16.7) nmol/L, with 37% of children being classified as vitamin D sufficient and significant differences between countries [<xref rid=""B60-nutrients-16-02072""",23_49,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"countries [<xref rid=""B60-nutrients-16-02072"" ref-type=""bibr"">60</xref>]. Controls in our sample reached vitamin D sufficiency in 31.3% of cases, consistent with the IDEFICS observations. The 560 German children included in the IDEFICS study had a mean 25-OH D serum concentration of 36.1 (±15.1) nmol/L [<xref rid=""B60-nutrients-16-02072"" ref-type=""bibr"">60</xref>]. In 2007, data from the German KiGGS cohort study on 25-OH D in the serum of 10,115 children living in Germany were published. In the group of",23_50,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"living in Germany were published. In the group of 3–6 year olds, median serum 25-OH D was 44.1 nmol/L (p5–p95: 15.0–95.8 nmol/L) [<xref rid=""B61-nutrients-16-02072"" ref-type=""bibr"">61</xref>], which corresponds to the controls in our study. On the contrary, median serum 25-OH D in 1–2 year olds in KiGGS was the highest of all age groups at 61.9 nmol/L (p5–p95: 19.4–115.0 nmol/L) [<xref rid=""B61-nutrients-16-02072"" ref-type=""bibr"">61</xref>], matching the 25-OH D concentrations of patients with PKU in our",23_51,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"D concentrations of patients with PKU in our pilot study. It is recommended for infants in Germany to be given vitamin D supplementation until their second summer of life (e.g., up until about 1.5 years of age) [<xref rid=""B62-nutrients-16-02072"" ref-type=""bibr"">62</xref>]. Kunz et al. found clear differences in the vitamin D status in German children according to season [<xref rid=""B63-nutrients-16-02072"" ref-type=""bibr"">63</xref>]. In 967 participants between 0 and 17 years of age, vitamin D sufficiency",23_52,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"0 and 17 years of age, vitamin D sufficiency in 2013–2014 was observed to be 56%/39.7% during summer/autumn, while only 29.2% and 28.1% reached sufficiency in winter and spring [<xref rid=""B63-nutrients-16-02072"" ref-type=""bibr"">63</xref>]. Overall, children in our pilot study were mostly recruited during summer and autumn, when UV exposure and time spent outside tend to be higher. Therefore, the results presented here fit into the current literature for healthy children living in Germany. Accordingly, the",23_53,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"children living in Germany. Accordingly, the good vitamin D status of the children recruited with PKU is interesting. As vitamin D is either taken in by food sources or dietary supplements, or is produced by the skin as it is exposed to ultraviolet (UV) radiation [<xref rid=""B64-nutrients-16-02072"" ref-type=""bibr"">64</xref>], we matched patients and controls not only for age and gender, but also for recruitment season. Thus, differences in sun exposure are less likely and differences in vitamin D from",23_54,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"are less likely and differences in vitamin D from foods or supplements might account for the higher vitamin D concentrations in patients. The recommended vitamin D supplementation in infants explains the higher 25-OH D concentrations in younger children, as described in KiGGS [<xref rid=""B61-nutrients-16-02072"" ref-type=""bibr"">61</xref>] and by Geserick et al. [<xref rid=""B65-nutrients-16-02072"" ref-type=""bibr"">65</xref>]. All patients with PKU consumed amino acid supplements containing 2.5–5 µg vitamin",23_55,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"acid supplements containing 2.5–5 µg vitamin D/portion (xPHE energy, xPHE enjoy, and xPHE hello, metaX, Friedberg, Germany; PKU gel and PKU cooler, Vitaflo, Steinbach, Germany; Glytactin, Cambrook, Dali, Nicosia, Cyprus). The parents or guardians stated that the included children with PKU consumed about 2.5 to 3 portions of amino acid supplements and no further Vitamin D supplement each day, resulting in a vitamin D intake of 6.25–9 µg per day from these amino acid supplements. At the same time, healthy",23_56,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"amino acid supplements. At the same time, healthy children between 6 and 8 years of age in Germany consume on average 1.8 µg of vitamin D from food [<xref rid=""B66-nutrients-16-02072"" ref-type=""bibr"">66</xref>]. Therefore, the higher vitamin D plasma concentration in PKU patients probably results from intake of amino acid supplements. In their study on bone mineral density in patients (aged 8–20 years) Geiger et al. also did not find a patient with PKU with vitamin D deficiency [<xref",23_57,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"patient with PKU with vitamin D deficiency [<xref rid=""B30-nutrients-16-02072"" ref-type=""bibr"">30</xref>]. In contrast, Demirads et al. found that of 60 patients with PKU (aged 1–39 years), 12% were not vitamin D sufficient, with 4 using Phe-free amino acid mixtures (1 without added vitamin D) and 3 who did not adhere to a restrictive diet [<xref rid=""B32-nutrients-16-02072"" ref-type=""bibr"">32</xref>]. Next to a significantly higher 25-OH D plasma concentration in children with PKU, we found lower PTH",23_58,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"in children with PKU, we found lower PTH plasma concentrations in these children compared to controls, which did not reach significance. Several studies described a negative non-linear relationship between 25-OH D and PTH in children, with a plateau at about 75 nmol/L 25-OH D [<xref rid=""B67-nutrients-16-02072"" ref-type=""bibr"">67</xref>,<xref rid=""B68-nutrients-16-02072"" ref-type=""bibr"">68</xref>,<xref rid=""B69-nutrients-16-02072"" ref-type=""bibr"">69</xref>]. Therefore, the trend for lower PTH levels in our",23_59,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"Therefore, the trend for lower PTH levels in our patients with PKU can be a result of higher 25-OH D levels, but the lack of significance might be a result of the small group of analyzed children. Additionally, the lack of a significant correlation between PTH and 25-OH D could be a result of the non-linearity of the relationship between the two hormones, with a flattening of the curve before the plateau [<xref rid=""B67-nutrients-16-02072"" ref-type=""bibr"">67</xref>]. As no data on PTH from the IDEFICS",23_60,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"As no data on PTH from the IDEFICS observations or the KiGGS [<xref rid=""B70-nutrients-16-02072"" ref-type=""bibr"">70</xref>] on PTH in children exist, comparing controls in our study to healthy children living in Germany was not feasible. Sahin et al. [<xref rid=""B67-nutrients-16-02072"" ref-type=""bibr"">67</xref>] and Vissing Landgrebe et al. [<xref rid=""B71-nutrients-16-02072"" ref-type=""bibr"">71</xref>] measured PTH in children. Compared to both studies [<xref rid=""B67-nutrients-16-02072""",23_61,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"both studies [<xref rid=""B67-nutrients-16-02072"" ref-type=""bibr"">67</xref>,<xref rid=""B71-nutrients-16-02072"" ref-type=""bibr"">71</xref>], PTH in our controls was higher than expected, but 25-OHD was lower. The regression analysis conducted by Vissing Landgrebe et al. resulted in an increase of 1 pmol/L of PTH for each 4.6 nmol/L decrease of vitamin D in serum [<xref rid=""B71-nutrients-16-02072"" ref-type=""bibr"">71</xref>]. As the controls in our study were younger and had vitamin D concentrations of 21",23_62,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"younger and had vitamin D concentrations of 21 nmol/L lower than the participants in Vissing Landgrebe et al.’s study, higher PTH concentration might result from these differences [<xref rid=""B71-nutrients-16-02072"" ref-type=""bibr"">71</xref>]. Higher 25-OHD concentrations were also observed in Sahin et al.’s study, with children of the same age as in our study [<xref rid=""B67-nutrients-16-02072"" ref-type=""bibr"">67</xref>]. As for patients with PKU, PTH concentration in plasma was also slightly higher than",23_63,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"in plasma was also slightly higher than in the studies referred to, but still within, their standard deviation [<xref rid=""B67-nutrients-16-02072"" ref-type=""bibr"">67</xref>,<xref rid=""B71-nutrients-16-02072"" ref-type=""bibr"">71</xref>]. Bone formation and resorption are continuous processes that do not only occur during growth or bone mass accrual. In 395 7-year-old children from Portugal, no correlation of total body bone mineral content and bone formation and resorption parameters was observed after age,",23_64,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"and resorption parameters was observed after age, body size, and season were considered. Single measurements of these markers may be limited in their ability to reflect current bone status in children [<xref rid=""B39-nutrients-16-02072"" ref-type=""bibr"">39</xref>]. As a marker of bone resorption, CTX was analyzed in this pilot study. In children, CTX rises from birth to puberty, with a median CTX concentration of about 1.5 ng/mL at 6 years and a p95 of about 2.5 ng/mL [<xref rid=""B65-nutrients-16-02072""",23_65,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"2.5 ng/mL [<xref rid=""B65-nutrients-16-02072"" ref-type=""bibr"">65</xref>]. According to these reference values, the bone resorption in children included into our pilot study was within the normal range. For OCN, a bone formation marker, Geserick et al. observed high values during the first year of life [<xref rid=""B65-nutrients-16-02072"" ref-type=""bibr"">65</xref>], which subsequently fell to a nadir between 3–4 years of age and then rose again. Previously, Johansen et al., van Summeren et al. and Popko et",23_66,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"Johansen et al., van Summeren et al. and Popko et al. found uOCN and OCN serum concentrations comparable with those we found in plasma [<xref rid=""B72-nutrients-16-02072"" ref-type=""bibr"">72</xref>,<xref rid=""B73-nutrients-16-02072"" ref-type=""bibr"">73</xref>,<xref rid=""B74-nutrients-16-02072"" ref-type=""bibr"">74</xref>], whereas Tubic et al. found uOCN at a mean concentration of 7 ng/mL and OCN at a concentration of 75.6 ng/mL, and Geserick et al. described median OCN at 3–4 years of age of 74.5 ng/mL in",23_67,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"median OCN at 3–4 years of age of 74.5 ng/mL in boys and 78.1 ng/mL for girls [<xref rid=""B65-nutrients-16-02072"" ref-type=""bibr"">65</xref>,<xref rid=""B75-nutrients-16-02072"" ref-type=""bibr"">75</xref>]. While van Summeren et al. and Popko et al. used the same ELISA assays we used here [<xref rid=""B73-nutrients-16-02072"" ref-type=""bibr"">73</xref>,<xref rid=""B74-nutrients-16-02072"" ref-type=""bibr"">74</xref>], Johansen et al. used radio-immunoassay [<xref rid=""B72-nutrients-16-02072""",23_68,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"[<xref rid=""B72-nutrients-16-02072"" ref-type=""bibr"">72</xref>], Tubic et al. and Geserick et al. used an electrochemiluminescence immunoassay on Cobas instruments, which explains the contradicting results [<xref rid=""B65-nutrients-16-02072"" ref-type=""bibr"">65</xref>,<xref rid=""B75-nutrients-16-02072"" ref-type=""bibr"">75</xref>]. To our knowledge, this is the first study that analyzed uOCN in well-treated young children with PKU, which was described to have hormonal effects in mice acting on glucose",23_69,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"have hormonal effects in mice acting on glucose sensitivity and neurotransmitter production [<xref rid=""B76-nutrients-16-02072"" ref-type=""bibr"">76</xref>]. A limiting factor of this study was the small number of patients included due to its design as a pilot study. In addition, only eight patients with PKU were able to give blood, and one child with PKU was not able to participate in cognitive testing. As the drawing of blood in healthy children is problematic, children undergoing a small surgical",23_70,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"problematic, children undergoing a small surgical procedure were used as controls. To secure no influence of sedation on the test results of cognitive battery, children were tested two days after the surgery. It cannot be excluded that pain or malaise could have influenced the performance of controls. Furthermore, the small amount of blood collected did not allow for a thorough analysis of bone-related parameters. Children with PKU did not only give blood for study purposes, but also for routine check-up,",23_71,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"study purposes, but also for routine check-up, to minimize the times children had to be punctured. Moreover, the age range of 4 to 7 years is a timeframe during childhood when growth spurts occur [<xref rid=""B77-nutrients-16-02072"" ref-type=""bibr"">77</xref>] and cognition is developing rapidly [<xref rid=""B78-nutrients-16-02072"" ref-type=""bibr"">78</xref>]. Because growth spurts are difficult to predict [<xref rid=""B77-nutrients-16-02072"" ref-type=""bibr"">77</xref>], we cannot rule out that the children",23_72,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"we cannot rule out that the children included in this analysis were undergoing a spurt at the time of blood collection, which in turn might have influenced the parameters of bone formation and resorption. Parameters such as height or weight would have been helpful in interpreting the results, but were regrettably not collected. As cognitive functions are rapidly developing during early childhood [<xref rid=""B78-nutrients-16-02072"" ref-type=""bibr"">78</xref>], the tests might have been too difficult for",23_73,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"the tests might have been too difficult for younger children and/or too easy for older children. We tried to eradicate this by matching patients with controls of the same age, but since calendar age does not necessarily reflect brain maturity [<xref rid=""B78-nutrients-16-02072"" ref-type=""bibr"">78</xref>], results have to be interpreted with caution. Additionally, although based on well-established pen-and-paper tests, the battery used for cognitive testing was not validated; however, this is in part",23_74,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"was not validated; however, this is in part compensated by the direct comparison of patients with controls. Vitamin D supplementation in controls was not documented. As 25-OHD concentration in these children was comparable to children in the German KiGGS cohort study [<xref rid=""B61-nutrients-16-02072"" ref-type=""bibr"">61</xref>], it can be expected that the children did not take any vitamin D supplementation. Additionally, the usual diet in children with PKU and early-life management was not analyzed, but",23_75,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"and early-life management was not analyzed, but could have influenced data on cognition and bone formation and resorption. This data should be included in future studies. As this study was a pilot study, we are interested in further investigating bone health, cognition and the relationship between these parameters with habitual diet, physical activity and Phe concentration in older individuals. In particular, we would like to include older individuals to study a broader spectrum of parameters, as this",23_76,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"study a broader spectrum of parameters, as this allows for larger volumes of blood to be obtained and reduces the impact of developmental spurts. In conclusion, we did not find an early indication for preventable comorbidities in well-treated young children with PKU compared to healthy age-, gender- and season-matched controls. No child with PKU included was vitamin D insufficient or deficient, with no effect on bone formation or resorption markers. Additionally, no difference in executive functioning was",23_77,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"no difference in executive functioning was observed in the children with PKU compared to the controls. Nevertheless, many studies describe impairments in bone turnover and cognitive performance in older children with PKU. Continuous treatment and regular check-ups should be performed to prevent the development of these impairments and to ensure early intervention.",23_78,No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria—A Pilot Study,28 6 2024,,Phenylketonuria
"Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis Phenylketonuria (PKU) is an autosomal recessive innate error of metabolism due to a deficiency in the enzyme phenylalanine hydroxylase, produced in the liver (<xref rid=""ref1"" ref-type=""bibr"">1</xref>). This enzyme is crucial for converting phenylalanine (phe) to tyrosine (tyr), a vital component in both fetal and adult neurodevelopment (<xref rid=""ref1"" ref-type=""bibr"">1</xref>,",24_0,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"(<xref rid=""ref1"" ref-type=""bibr"">1</xref>, <xref rid=""ref2"" ref-type=""bibr"">2</xref>). The primary treatment for PKU involves a lifelong low-phe diet with phe supplementation to prevent neurotoxicity, as elevated phe levels can lead to irreversible intellectual disability and various complications, including seizures, behavioral disorders, eczema, and gait instability (<xref rid=""ref1"" ref-type=""bibr"">1–3</xref>). Nutritional assessment for PKU patients includes restrictions on animal-based foods and",24_1,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"includes restrictions on animal-based foods and limitations on other items such as sweet potatoes (<xref rid=""ref4"" ref-type=""bibr"">4</xref>). Supplementation with tyr, essential amino acids, vitamins, and minerals is essential, requiring biweekly blood phe and tyr quantification for optimal management, along with strict diet assessment and clinical evaluation by specialists (<xref rid=""ref1"" ref-type=""bibr"">1</xref>, <xref rid=""ref2"" ref-type=""bibr"">2</xref>). PKU is commonly included in newborn screening",24_2,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"PKU is commonly included in newborn screening programs. However, there is considerable diversity in the implementation of these programs across Latin America (<xref rid=""ref5"" ref-type=""bibr"">5</xref>). This lack of comprehensive screening is associated with higher infant mortality rates in the region, currently standing at 14.0 per 1,000 live births (<xref rid=""ref6"" ref-type=""bibr"">6</xref>, <xref rid=""ref7"" ref-type=""bibr"">7</xref>). Challenges include the absence of national newborn screening",24_3,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"include the absence of national newborn screening registries, hampering case contact, and geographic and economic burdens limiting program accessibility. Latin American countries face difficulties keeping pace with the rapid evolution of newborn screening techniques observed in developed nations (<xref rid=""ref5"" ref-type=""bibr"">5</xref>). A shared objective should be the prompt detection, diagnosis, treatment, and follow-up of newborn screening-related diseases, with tailored treatment guidelines",24_4,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"diseases, with tailored treatment guidelines addressing economic, social, and geographic considerations (<xref rid=""ref3"" ref-type=""bibr"">3</xref>, <xref rid=""ref6"" ref-type=""bibr"">6</xref>, <xref rid=""ref7"" ref-type=""bibr"">7</xref>). This is especially critical in countries like Ecuador, where public institutions lack specialization in the medical and nutritional treatment required for PKU patients, necessitating knowledge of nutrition by physicians and families. The diverse foods in Latin America,",24_5,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"and families. The diverse foods in Latin America, exemplified by the four regions in Ecuador such as the different types of fruits encountered in the coast region comparted to the ones in the highlands, make it challenging to establish national guidelines or databases for quantifying essential amino acids, such as phe and tyr, vital for proper PKU control. While Ecuador initiated a neonatal screening program for PKU in 2012, challenges persist in accessing healthcare systems and timely diagnosis,",24_6,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"healthcare systems and timely diagnosis, contributing to a high prevalence of intellectual disability in certain communities (<xref rid=""ref8"" ref-type=""bibr"">8</xref>). For optimum patient outcomes, PKU requires a multidisciplinary and personalized management. This literature review explores the multifaceted landscape of PKU care, particularly focusing on the Latin American context. The reviewed materials encompass a series of guides offering diverse perspectives on PKU management, emphasizing various",24_7,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"on PKU management, emphasizing various aspects such as multidisciplinary team approaches, dietary interventions, regular monitoring, and regional food variations. In addition, demonstrates the challenges as limited resources, lack of specialized professionals and patient education. We aim to contribute meaningful insights to the advancement of PKU care in the Latin American healthcare landscape (<xref rid=""ref1"" ref-type=""bibr"">1</xref>, <xref rid=""ref2"" ref-type=""bibr"">2</xref>, <xref rid=""ref6""",24_8,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"ref-type=""bibr"">2</xref>, <xref rid=""ref6"" ref-type=""bibr"">6</xref>, <xref rid=""ref7"" ref-type=""bibr"">7</xref>).  <xref rid=""tab1"" ref-type=""table"">Table 1</xref> shows each article and offers unique perspectives, contributing valuable knowledge to guide the holistic understanding and management of PKU. Managing PKU poses unique challenges requiring a comprehensive, individualized approach, with a central emphasis on a multidisciplinary healthcare team (<xref rid=""ref1"" ref-type=""bibr"">1</xref>, <xref",24_9,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"(<xref rid=""ref1"" ref-type=""bibr"">1</xref>, <xref rid=""ref2"" ref-type=""bibr"">2</xref>, <xref rid=""ref9"" ref-type=""bibr"">9</xref>, <xref rid=""ref10"" ref-type=""bibr"">10</xref>). This collaborative model ensures holistic care, addressing nutritional, psychological, social, and genetic aspects. Long-term adherence to a low-phe diet is pivotal for positive outcomes and normal growth (<xref rid=""ref1"" ref-type=""bibr"">1</xref>). Concerns about breastfeeding practices in PKU patients highlight the need for",24_10,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"practices in PKU patients highlight the need for standardized guidelines, specialized training, and support for healthcare providers and families (<xref rid=""ref9"" ref-type=""bibr"">9</xref>, <xref rid=""ref10"" ref-type=""bibr"">10</xref>, <xref rid=""ref12"" ref-type=""bibr"">12</xref>, <xref rid=""ref13"" ref-type=""bibr"">13</xref>). Meticulous monitoring and dietary adherence before conception are crucial due to elevated complication risks. Preconception dietary training is essential, promoting improved metabolic",24_11,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"is essential, promoting improved metabolic control for favorable maternal and infant outcomes (<xref rid=""ref9"" ref-type=""bibr"">9</xref>). A multidisciplinary care approach involving geneticists, obstetricians, and pediatricians is vital, emphasizing teamwork in optimizing maternal and fetal health (<xref rid=""ref1"" ref-type=""bibr"">1</xref>, <xref rid=""ref2"" ref-type=""bibr"">2</xref>, <xref rid=""ref9"" ref-type=""bibr"">9</xref>, <xref rid=""ref10"" ref-type=""bibr"">10</xref>). The challenges faced by healthcare",24_12,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"The challenges faced by healthcare providers in Latin America in managing PKU patients are various. Limited access to specialized healthcare professionals and resources is a barrier, aggravated by a scarcity of awareness and familiarity with PKU among healthcare providers (<xref rid=""ref6"" ref-type=""bibr"">6</xref>). This issue is worsened by inadequate opportunities for specialized training and continuing education, hindering the effective management of PKU patients. Laboratories capable of quantifying phe",24_13,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"patients. Laboratories capable of quantifying phe are primarily situated in major cities, resulting in inconsistent and expensive testing. The dietary management of PKU across Latin America varies, with a significant scarcity of experienced nutritional and medical professionals. A mere 45% of physicians and dietitians involved in PKU treatment have completed specialization courses, and only 9 out of 13 countries report having national guidelines for PKU management (<xref rid=""ref6""",24_14,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"guidelines for PKU management (<xref rid=""ref6"" ref-type=""bibr"">6</xref>). The absence of region-specific databases detailing the phe content of foods further complicates dietary recommendations, potentially leading to suboptimal outcomes; thus, we are supplementing a list with available food products and their quantification (<xref rid=""SM1"" ref-type=""supplementary-material"">Supplementary Table S1</xref>) (<xref rid=""ref6"" ref-type=""bibr"">6</xref>). In Ecuador specifically, the responsibility for PKU",24_15,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"Ecuador specifically, the responsibility for PKU management falls on gastroenterologists and geneticists due to the absence of a dedicated multidisciplinary team. The scarcity of metabolic dietitians forces patients, and often parents, to seek guidance from other countries like Argentina and Chile (<xref rid=""ref6"" ref-type=""bibr"">6</xref>). Access to commercial low-phe foods in Latin America, including Ecuador, is notably limited, with the exclusive option being formula, which is only available at the",24_16,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"being formula, which is only available at the public system, and there is not a private option to buy it. Furthermore, there is a lack of dietitians with experience, and a deficit in dietary education for these patients. In the public system of Ecuador, patients are monitored for phe levels twice a year, receiving results 3 months post-sample collection. This situation is exacerbated by the lack of regional databases containing phe content information for foods and the absence of specially designed",24_17,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"for foods and the absence of specially designed low-protein products and commercially available alternatives. Furthermore, there is not many options for pediatric patients with PKU in most supermarkets, this may worsen the problem in adolescent ages where they want to experiment with their environment. Moreover, there is a critical gap in comprehensive care for pregnant women with PKU in Ecuador, as there are no dedicated dietitians or a specialized healthcare team catering to this demographic. Addressing",24_18,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"team catering to this demographic. Addressing these challenges requires collaborative efforts from healthcare institutions, policymakers, and educators to enhance awareness, provide specialized training, establish robust regional databases, and facilitate international collaborations for knowledge exchange and resource availability (<xref rid=""ref14"" ref-type=""bibr"">14–17</xref>). PKU is included in the public free nationwide newborn screening program for all infants in Ecuador. A study using data from",24_19,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"all infants in Ecuador. A study using data from this screening program between 2012 and 2019 reported an incidence of PKU of approximately 1.53 per 100,000 live births (<xref rid=""ref8"" ref-type=""bibr"">8</xref>). However, the study did not provide information on false-negative cases, highlighted discrepancies in coverage due to inadequate case detection in certain provinces and does not mention a follow-up strategy for the positive cases. In our experience, despite the free and supposedly nationwide nature",24_20,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"despite the free and supposedly nationwide nature of the newborn screening program, some patients, particularly in rural areas, were not detected, and there is no plan to detect older patients (before 2012). Additionally, there is a shortage of nutritionists experienced in managing the PKU diet, even in major cities. The Ministry of Health is the sole provider of the formula but does not supply phenylalanine-free food, and patients cannot buy on stores. Countries like Argentina, Brazil, Chile, Colombia,",24_21,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"like Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Guatemala, Mexico, and Peru are improving their healthcare systems in response to the United Nations’ call to action. Our study aims to highlight the significance of these efforts, raise awareness, and advocate for effective solutions. We propose several specific measures: developing region-specific management strategies tailored to the diverse healthcare landscapes within Latin America, which account for variations in healthcare infrastructure,",24_22,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"for variations in healthcare infrastructure, access to resources, and cultural considerations to ensure PKU management protocols are effectively adapted to local contexts. We emphasize the importance of establishing standardized methods for consulting PKU patients and distributing PKU-free products, suggesting the implementation of telemedicine or online consultation services to reach patients in remote areas, alongside centralized procurement, and distribution systems to ensure equitable access to",24_23,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"systems to ensure equitable access to essential products across the region. Furthermore, we underscore the necessity of developing guidelines or algorithms based on individual patient needs, such as age, weight, dietary requirements, and PKU severity, to help healthcare providers make informed decisions on the quantity and type of products to allocate, thereby optimizing patient outcomes. Additionally, we propose establishing a South American computer network dedicated to the detection and management of",24_24,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"dedicated to the detection and management of PKU to facilitate communication and data sharing among healthcare professionals, researchers, policymakers, and patient advocacy groups, thus enhancing the efficiency of diagnosis, treatment, and follow-up care. We also advocate for the development of comprehensive follow-up programs tailored to different age groups, from infancy to pregnancy, to ensure ongoing monitoring, nutritional counseling, psychosocial support, and medical interventions as needed.",24_25,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"support, and medical interventions as needed. Finally, we highlight the importance of establishing multidisciplinary teams to manage complex PKU cases associated with other acute or chronic conditions, ensuring that patients receive comprehensive and coordinated care. In conclusion, this study highlights the urgent need for collaborative efforts between healthcare institutions, policymakers, and international organizations to bridge the gaps in PKU management in Latin America. Managing PKU in Latin America",24_26,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"in Latin America. Managing PKU in Latin America involves multifaceted approaches. Establishing and reinforcing multidisciplinary teams, including physicians, psychologists, dietitians, nurses, and genetic counselors, is essential for comprehensive care. By enhancing and fostering a supportive environment, we can make the way for improved diagnosis, effective management, and a better quality of life for individuals living with PKU in the region. Embracing the lessons from these guides, we can work towards a",24_27,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"lessons from these guides, we can work towards a future where every PKU patient receives the care and support they deserve, ultimately leading to better health and well-being. AA: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Writing – original draft, Writing – review & editing. EH: Data curation, Formal analysis, Investigation, Methodology, Resources, Writing – original draft, Writing – review & editing. AC: Data curation, Formal analysis, Investigation,",24_28,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"Data curation, Formal analysis, Investigation, Methodology, Resources, Writing – original draft, Writing – review & editing. AM: Data curation, Formal analysis, Investigation, Methodology, Resources, Writing – original draft, Writing – review & editing. BB: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Writing – original draft, Writing – review & editing. VR: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration,",24_29,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing.",24_30,Navigating phenylketonuria management to improve it in Latin America: a systematic literature review and applicability analysis,25 6 2024,,Phenylketonuria
"Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase Treatment of phenylketonuria (PKU) has evolved since the initial introduction of a phenylalanine (Phe) restricted diet. The most recent option for adults affected with PKU is treatment with an alternate enzyme, phenylalanine ammonia lyase (PAL), that metabolizes excess Phe. Proper management of all patients with PKU relies on accurate measurement of Phe levels in blood, to comply with guidance intended",25_0,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"levels in blood, to comply with guidance intended to minimize the neurological symptoms. Recently, our laboratory was notified of discrepant results for a patient with PKU who is treated with pegvaliase. Two specimens were collected at the same time but yielded unexpectedly different Phe concentrations. After exclusion of specimen mix-ups or analytical errors, we suspected that there was residual pegvaliase activity in the specimens continuing to degrade Phe after collection. To investigate this",25_1,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"degrade Phe after collection. To investigate this possibility, we performed spiking studies that showed the degradation of Phe over time at ambient temperatures. Sample preparation by protein crash appears to deactivate pegvaliase and prevents further Phe degradation. However, because pegvaliase deactivation would be required immediately following blood collection, appropriate mitigation measures must be implemented, including stringent pre-analytical requirements, alternate sample matrices such as dried",25_2,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"alternate sample matrices such as dried blood spots, or point of care testing. Until then, health care professionals need to be cautious in their interpretation of Phe levels in their patients with PKU that are treated with pegvaliase. <list list-type=""simple"" id=""l0005""><list-item id=""li0005""><label>•</label><p id=""p0005"">Pegvaliase has continued action after plasma samples are collected.</p></list-item><list-item id=""li0010""><label>•</label><p id=""p0010"">Patients with PKU taking pegvaliase may have",25_3,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"with PKU taking pegvaliase may have falsely decreased phenylalanine levels.</p></list-item><list-item id=""li0015""><label>•</label><p id=""p0015"">Phenylalanine degradation post collection is variable and unpredictable.</p></list-item></list> Phenylketonuria (PKU, OMIM #<ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""261600"" id=""ir0005"">261600</ext-link>) is an autosomal recessive deficiency of phenylalanine hydroxylase (PAH), an enzyme catalyzing the conversion of phenylalanine (Phe) to",25_4,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"the conversion of phenylalanine (Phe) to tyrosine (Tyr). In the absence of functional PAH, Phe accumulates in blood and tissues and causes irreversible neurological damage. PKU is a treatable disorder that can be readily identified by newborn screening. Early identification and implementation of a Phe-restricted diet can avoid the most severe symptoms associated with untreated PKU [<xref rid=""bb0005"" ref-type=""bibr"">1</xref>]. While early treatment for PKU relied entirely on dietary restriction, over the",25_5,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"relied entirely on dietary restriction, over the last two decades improvements have been achieved, including medications to enhance residual PAH activity [<xref rid=""bb0010"" ref-type=""bibr"">2</xref>,<xref rid=""bb0015"" ref-type=""bibr"">3</xref>], and enzyme-based treatments that metabolize Phe via alternate pathways [<xref rid=""bb0020"" ref-type=""bibr"">4</xref>,<xref rid=""bb0025"" ref-type=""bibr"">5</xref>]. Pegvaliase, is a pegylated form of phenylalanine ammonia lyase (PAL), an enzyme which converts Phe to",25_6,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"lyase (PAL), an enzyme which converts Phe to ammonia and trans-cinnamic acid. It is the first enzyme therapy for a metabolic disorder that can also be treated by dietary modification. Pegvaliase was approved for use in 2018 for the treatment of individuals 16 years of age and older with PKU who consistently have elevated blood Phe concentrations >600 μmol/L. [<xref rid=""bb0025"" ref-type=""bibr"">5</xref>,<xref rid=""bb0030"" ref-type=""bibr"">6</xref>] Management guidelines for PKU have evolved as knowledge has",25_7,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"guidelines for PKU have evolved as knowledge has increased but have consistently focused on maintaining blood Phe levels at a level which will not cause neurological damage, typically 120 to 360 μmol/L in childhood and 120 to 600 μmol/L after the age of 12 years old. The lower cutoff of 360 μmol/L is also advised leading up to and during pregnancy [<xref rid=""bb0035"" ref-type=""bibr"">7</xref>]. Dietary management for PKU is highly individualized, and patients with PKU undergo frequent testing to monitor",25_8,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"with PKU undergo frequent testing to monitor their blood Phe levels to ensure they are in the appropriate therapeutic range. Patients are monitored using either plasma or dried blood spots (DBS) [<xref rid=""bb0040"" ref-type=""bibr"">[8]</xref>, <xref rid=""bb0045"" ref-type=""bibr"">[9]</xref>, <xref rid=""bb0050"" ref-type=""bibr"">[10]</xref>]. These analyses are not typically performed in hospital laboratories, thus specimens are transported from the collection site to the performing laboratory. Much attention is",25_9,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"to the performing laboratory. Much attention is focused on the upper limit of Phe concentrations to prevent irreversible neurological symptoms, however Phe is an essential amino acid and required for proper growth and development. Accordingly, overrestriction of Phe can have negative side effects, including failure to thrive, hair loss, and skin lesions [<xref rid=""bb0055"" ref-type=""bibr"">11</xref>,<xref rid=""bb0060"" ref-type=""bibr"">12</xref>]. Here, we report on the investigation of discrepant blood Phe",25_10,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"on the investigation of discrepant blood Phe concentrations in patients treated with pegvaliase that identified a pre-analytical decrease of Phe due to the continued action of pegvaliase in specimens after collection. Our laboratory provides monitoring for patients with PKU by comprehensive amino acid profiles, as well as measurement of only Phe and Tyr in plasma and DBS. We were contacted by a physician recently to discuss discrepant results between two plasma samples collected from a patient treated with",25_11,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"samples collected from a patient treated with pegvaliase. The specimens were collected at the same time, but processed into two separate plasma tubes, one for a comprehensive amino acid profile, and one for targeted measurement of Phe and Tyr. This patient receives Phe and Tyr measurements monthly, and a comprehensive amino acid profile annually. Both assays are performed using isotope labeled internal standards and liquid chromatography – tandem mass spectrometry (LC-MS/MS). The results of the initial",25_12,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"(LC-MS/MS). The results of the initial analyses are shown in <xref rid=""t0005"" ref-type=""table"">Table 1</xref>. After we were notified of the concern, we undertook an investigation to rule out common causes of discrepant results: labels on all tubes were verified, and the specimens were re-analyzed by both methods. Results of the reanalysis are also shown in <xref rid=""t0005"" ref-type=""table"">Table 1</xref>. Stability studies performed during assay validation did not show significant loss of Phe during",25_13,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"did not show significant loss of Phe during freeze thaw cycles. At this point, we suspected either contamination by or continued action of pegvaliase after collection. Communication with the patient's physician confirmed that the patient was being treated with pegvaliase.<table-wrap position=""float"" id=""t0005""><label>Table 1</label><caption><p>Patient Phe results that raised suspicion due to discrepant results.</p></caption><alt-text id=""al0010"">Table 1</alt-text><table frame=""hsides""",25_14,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"1</alt-text><table frame=""hsides"" rules=""groups""><thead><tr><th rowspan=""2""></th><th colspan=""2"">Tube Submitted for Targeted Testing<hr></hr></th><th colspan=""2"">Tube Submitted for Comprehensive Analysis<hr></hr></th></tr><tr><th>Targeted</th><th>Comprehensive</th><th>Targeted</th><th>Comprehensive</th></tr></thead><tbody><tr><td>Initial Analysis</td><td align=""center"">2</td><td align=""center"">NP<xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref></td><td align=""center"">NP<xref rid=""tf0005""",25_15,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"align=""center"">NP<xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref></td><td align=""center"">143</td></tr><tr><td>Repeat Analysis</td><td align=""center"">11</td><td align=""center"">2</td><td align=""center"">87</td><td align=""center"">38</td></tr></tbody></table><table-wrap-foot><fn id=""tf0005""><label>⁎</label><p id=""np0005"">NP: not performed; all units μmol/L.</p></fn></table-wrap-foot></table-wrap> To investigate the hypothesis of continued pegvaliase activity ex vivo, we identified plasma samples from individuals",25_16,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"we identified plasma samples from individuals with PKU who were confirmed to be treated with pegvaliase, suspected to be treated with pegvaliase and those who were not treated with pegvaliase (children under 16 and adults on alternate treatments). Initial Phe and Tyr results were available for all patients. For adults, we focused on patients who had extremely low levels of measured Phe concentrations. These specimens were then spiked with 250 μM of aqueous Phe, and analyzed after storage at ambient",25_17,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"Phe, and analyzed after storage at ambient temperatures at 4 time points (0, 1, 4 and 6) hours. In addition an aliquot of each spiked plasma sample was frozen at −80 °C, and thawed for analysis at the 6 h time point. Quantitative analysis of amino acids was performed by LC-MS/MS. Plasma was combined with isotopically labeled internal standard. Following protein precipitation, the supernatant was diluted and subjected to hydrophilic interaction liquid chromatography (HILIC) for the separation of isomers",25_18,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"(HILIC) for the separation of isomers with MS/MS detection of the underivatized amino acids. To determine that Phe concentrations following preparation for analysis were stabilized in samples from patients with and without pegvaliase, samples were analyzed immediately and 24 h following preparation. Our routine quality control specimens were analyzed as well. The low QC was analyzed with no alterations, and the high QC sample was spiked with 250 μM Phe to verify that there was no degradation of Phe",25_19,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"to verify that there was no degradation of Phe occurring in the spiking solution over this time period. Details about the specimens included in the study are shown in <xref rid=""t0010"" ref-type=""table"">Table 2</xref>. Treatment status for all adult patients was confirmed via communication with providers. As pegvaliase is not approved for use in individuals <16 years of age, treatment status was assumed for patients 2 and 3.<table-wrap position=""float"" id=""t0010""><label>Table",25_20,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"position=""float"" id=""t0010""><label>Table 2</label><caption><p>Description of specimens included in Phe spiking study. Specimens with the same specimen ID are from the same patient.</p></caption><alt-text id=""al0015"">Table 2</alt-text><table frame=""hsides"" rules=""groups""><thead><tr><th>Study ID</th><th>Description</th><th>Pegvaliase Treatment?</th><th>Spiked with 250 μM Phe?</th><th>Age</th><th>Sex</th><th>Original Phe (μM)</th><th>Original Tyr (μM)</th></tr></thead><tbody><tr><td>1</td><td>Low",25_21,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
QC</td><td>NA</td><td>No</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>2</td><td>PKU - Infant</td><td>No</td><td>No</td><td>6 M</td><td>Male</td><td>226</td><td>36</td></tr><tr><td>3</td><td>PKU - Child</td><td>No</td><td>No</td><td>8 Y</td><td>Male</td><td>283</td><td>48</td></tr><tr><td>4</td><td>PKU - Adult</td><td>No</td><td>Yes</td><td>18 Y</td><td>Female</td><td>5</td><td>108</td></tr><tr><td>5A</td><td>PKU - Adult</td><td>Yes</td><td>Yes</td><td>41,25_22,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
- Adult</td><td>Yes</td><td>Yes</td><td>41 Y</td><td>Female</td><td>2</td><td>47</td></tr><tr><td>5B</td><td>PKU - Adult</td><td>Yes</td><td>Yes</td><td>41 Y</td><td>Female</td><td>143</td><td>42</td></tr><tr><td>6</td><td>PKU - Adult</td><td>Yes</td><td>Yes</td><td>27 Y</td><td>Female</td><td>1</td><td>34</td></tr><tr><td>7A</td><td>PKU - Adult</td><td>Yes</td><td>Yes</td><td>39 Y</td><td>Female</td><td>0</td><td>23</td></tr><tr><td>7B</td><td>PKU - Adult</td><td>Yes</td><td>Yes</td><td>39,25_23,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
- Adult</td><td>Yes</td><td>Yes</td><td>39 Y</td><td>Female</td><td>0</td><td>30</td></tr><tr><td>7C</td><td>PKU - Adult</td><td>Yes</td><td>Yes</td><td>39 Y</td><td>Female</td><td>3</td><td>44</td></tr><tr><td>8</td><td>PKU - Adult</td><td>No</td><td>Yes</td><td>62 Y</td><td>Female</td><td>7</td><td>169</td></tr><tr><td>9</td><td>PKU - Adult</td><td>Yes</td><td>Yes</td><td>33 Y</td><td>Female</td><td>1</td><td>53</td></tr><tr><td>10</td><td>High,25_24,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"QC</td><td>NA</td><td>Yes</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr></tbody></table></table-wrap> LC-MS/MS analysis showed steady decreases in Phe concentrations in specimens from patients confirmed to be treated with pegvaliase over the 6-h period of the study. Phe concentrations at ambient temperature over time are shown in <xref rid=""f0005"" ref-type=""fig"">Fig. 1</xref>. Specimens which were from untreated patients and control samples did not show a decrease in Phe concentrations over the same",25_25,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"a decrease in Phe concentrations over the same time period, beyond what was expected for normal variation in the analytical performance of the method (<10%). Tyr concentrations were stable for all patients at all time points, within expected method variation parameters (<10%). This was expected, as PAL does not break down Phe into Tyr. All samples from patients not treated with pegvaliase showed stable Phe concentrations, for both endogenous and spiked specimens. Initially, we selected adult patients with",25_26,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"Initially, we selected adult patients with Phe < 10 μmol/L, and included them in our study as suspected on receiving pegvaliase treatment. Our spiking study suggested that two patients (#4 and #8) did not have residual pegvaliase activity in their plasma specimens and follow up with their providers confirmed that they were treated conventionally and without pegvaliase.<fig id=""f0005""><label>Fig. 1</label><caption><p>Phe concentration decreases over time in plasma specimens from patients treated with",25_27,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"in plasma specimens from patients treated with pegvaliase. Specimens 5 A, 5B, 6, 7 A, 7B, 7C and 9 are collected from treated patients and show a marked decrease in Phe over time at ambient temperatures. Specimen IDs are the same as shown in <xref rid=""t0010"" ref-type=""table"">Table 2</xref>.</p></caption><alt-text id=""al0005"">Fig. 1</alt-text><graphic http://www.w3.org/1999/xlink href=""gr1"" id=""lk0005""></graphic></fig> Preliminary studies were performed to identify measures which may arrest the activity of",25_28,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"measures which may arrest the activity of pegvaliase in an already collected plasma specimen. While we do not have a large enough dataset to explore any effect related to pegvaliase dose or timing, most recommendations are to collect specimens immediately prior to a dose. However compliance is unknown, and it is unclear if this would be enough time to clear pegvaliase activity in blood. Pegvaliase, as an unadministered medication, is stable for at least 30 days at room temperature [<xref rid=""bb0065""",25_29,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"30 days at room temperature [<xref rid=""bb0065"" ref-type=""bibr"">13</xref>]. Freezing at −80 °C arrests the activity, however we still found an average decrease of 23% between the measurement at <italic toggle=""yes"">t</italic> = 0 h and the specimen stored at −80 °C analyzed at <italic toggle=""yes"">t</italic> = 6 h for patients treated with pegvaliase. This decrease most likely represents activity of pegvaliase during the freeze/thaw process and sample preparation steps. Specimens collected from patients",25_30,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"steps. Specimens collected from patients who were not treated with pegvaliase showed an average difference of only 1% over 6 h (<xref rid=""t0015"" ref-type=""table"">Table 3</xref>). Preparation of the sample by protein crash appears to stabilize the Phe concentration, as evidenced by the re-analysis of the <italic toggle=""yes"">t</italic> = 0 prepared plate at <italic toggle=""yes"">t</italic> = 24 h (<xref rid=""t0015"" ref-type=""table"">Table 3</xref>). These studies show that some mitigation of Phe loss is",25_31,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"studies show that some mitigation of Phe loss is possible, with proper collection and storage, but there is still a significant drop in the time needed for the minimal necessary amount of sample preparation. Protein crash at the moment of collection is likely not practical, due to the number of sites at which collections take place, and the additional reagent requirements.<table-wrap position=""float"" id=""t0015""><label>Table 3</label><caption><p>Additional studies showing decrease in Phe concentrations when",25_32,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"showing decrease in Phe concentrations when stored at −80 °C and stability after protein crash for sample preparation.</p></caption><alt-text id=""al0020"">Table 3</alt-text><table frame=""hsides"" rules=""groups""><thead><tr><th>Study ID</th><th>Pegvaliase Treatment?</th><th>Spiked with 250 μM Phe?</th><th>t = 0 h Phe (μM)</th><th>t = 6 h —80C storage Phe (μM)</th><th>Difference from <italic toggle=""yes"">t</italic> = 0</th><th>t = 0 h prepared sample reinjected next morning Phe (μM)</th><th>Difference from",25_33,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
next morning Phe (μM)</th><th>Difference from initial,25_34,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
injection</th></tr></thead><tbody><tr><td>1</td><td>No</td><td>No</td><td>56</td><td>NP</td><td>NP</td><td>54</td><td>−3%</td></tr><tr><td>2</td><td>No</td><td>No</td><td>236</td><td>NP</td><td>NP</td><td>238</td><td>1%</td></tr><tr><td>3</td><td>No</td><td>No</td><td>283</td><td>NP</td><td>NP</td><td>285</td><td>0%</td></tr><tr><td>4</td><td>No</td><td>Yes</td><td>269</td><td>271</td><td>1%</td><td>271</td><td>1%</td></tr><tr><td>5A</td><td>Yes</td><td>Yes</td><td>255</td><td>209</td><td>−18%</td><td>258<,25_35,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
</td><td>255</td><td>209</td><td>−18%</td><td>258</td><td>1%</td></tr><tr><td>5B</td><td>Yes</td><td>Yes</td><td>256</td><td>208</td><td>−19%</td><td>253</td><td>−1%</td></tr><tr><td>6</td><td>Yes</td><td>Yes</td><td>253</td><td>189</td><td>−25%</td><td>253</td><td>0%</td></tr><tr><td>7A</td><td>Yes</td><td>Yes</td><td>236</td><td>159</td><td>−32%</td><td>244</td><td>4%</td></tr><tr><td>7B</td><td>Yes</td><td>Yes</td><td>245</td><td>208</td><td>−15%</td><td>250</td><td>2%</td></tr><tr><td>7C</td><td>Yes</td,25_36,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
250</td><td>2%</td></tr><tr><td>7C</td><td>Yes</td><td>Yes</td><td>244</td><td>195</td><td>−20%</td><td>242</td><td>−1%</td></tr><tr><td>8</td><td>No</td><td>Yes</td><td>259</td><td>261</td><td>1%</td><td>262</td><td>1%</td></tr><tr><td>9</td><td>Yes</td><td>Yes</td><td>228</td><td>160</td><td>−30%</td><td>235</td><td>3%</td></tr><tr><td>10</td><td>No</td><td>Yes</td><td>326</td><td>341</td><td>5%</td><td>326</td><td>0%</td></tr></tbody></table><table-wrap-foot><fn><p>NP:,25_37,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"not performed.</p></fn></table-wrap-foot></table-wrap> Management of patients with PKU has always centered around maintaining blood Phe levels at appropriate levels to prevent neurological damage. Medications, such as pegvaliase, designed to reduce blood Phe are a recent addition to treatment options and are particularly beneficial to adult patients who are unable to manage blood Phe levels by other means. This report identifies a challenge to obtaining accurate Phe measurements in plasma of patients",25_38,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"accurate Phe measurements in plasma of patients treated with pegvaliase. While extended storage at ambient temperatures is generally not recommended for plasma amino acid analysis, specimens do spend some unavoidable time at ambient temperatures between collection and processing. Significant residual pegvaliase activity remains in plasma after collection, and even freezing at −80 °C does not permanently inactivate the enzyme as we found a reduction of measured Phe concentrations of approximately 20% after",25_39,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"Phe concentrations of approximately 20% after thawing frozen specimens before preparation for analysis. Accordingly, routine repeat analyses, for example due to a quality control failure, should be treated with extreme caution, and it may be necessary to obtain a new sample rather than relying on the established stability metrics determined during assay validation. Point of care (POC) approaches to PKU management have been explored, and may benefit particularly patients treated with pegvaliase [<xref",25_40,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"patients treated with pegvaliase [<xref rid=""bb0070"" ref-type=""bibr"">14</xref>,<xref rid=""bb0075"" ref-type=""bibr"">15</xref>]. Interestingly, a POC approach utilizing PAL and ammonia measurement has been proposed, although its effectiveness in the context of pegvaliase treatment has not been established [<xref rid=""bb0080"" ref-type=""bibr"">16</xref>]. We were unable to identify a single event that caused the initial discrepant results between two samples collected at the same time. Perhaps the sample with",25_41,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"at the same time. Perhaps the sample with initially lower Phe value was exposed longer to room temperature, either due to an increased time (relative to the other tube) before freezing and/or while being thawed and processed in the laboratory for testing. Additional studies are required to evaluate mitigation strategies of ex vivo pegvaliase activity and its clinical relevance. Our literature search did not identify other reports of unexpectedly low Phe concentrations in patients treated with pegvaliase",25_42,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"in patients treated with pegvaliase that were not assumed to reflect the patient's circulating Phe concentration at the time of collection. Indeed, while hypophenylalaninemia is a recognized possible effect of treatment, recent management guidelines advise dietary adjustment as a countermeasure, and do not mention the possibility of a falsely decreased result, beyond requiring two low measurements consecutively [<xref rid=""bb0085"" ref-type=""bibr"">17</xref>,<xref rid=""bb0090"" ref-type=""bibr"">18</xref>].",25_43,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"rid=""bb0090"" ref-type=""bibr"">18</xref>]. Moreover, no specific blood collection protocols are recommended that would suggest there was concern for or realization of continued action of pegvaliase in blood and plasma specimens. Reassuringly, there are no reports of improper pegvaliase dosing which can likely be attributed to the fact that treatment decisions are not based solely on Phe concentrations measured in plasma and (measured) Phe concentrations down to 31 μmol/L are considered acceptable [<xref",25_44,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"to 31 μmol/L are considered acceptable [<xref rid=""bb0095"" ref-type=""bibr"">19</xref>]. Similarly, our study was not prompted by a concern for overtreatment resulting in hypophenylalaninenia but for our laboratory's ability to measure reliable Phe concentrations in aliquots of blood from the same collection. Potential mitigation strategies are varied and will require extensive testing and experimentation. Some options are: exploiting and enhancing the stabilizing features of filter paper, chemical",25_45,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"stabilizing features of filter paper, chemical inhibitors of pegvaliase activity, or alternate analyses to include downstream metabolites such as trans-cinnamic acid to calculate a value that correlates with the blood Phe levels. In conclusion, especially unexpectedly low Phe concentrations in a patient treated with pegvaliase should be interpreted with caution, and not assumed to reflect circulating Phe. Adjustment of diet or other treatments based on extremely low Phe values may result in higher than",25_46,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"low Phe values may result in higher than intended blood Phe concentrations. Conversely, measured Phe concentrations at the upper limit of the target range should not be assumed to reflect sufficiently appropriate treatment. Moreover, the continued ex-vivo activity demonstrated by pegvaliase administered to these patients should be a consideration for other situations where amino acid metabolism may be altered by exogenous enzymes, such as emerging cancer therapies [<xref rid=""bb0100""",25_47,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"as emerging cancer therapies [<xref rid=""bb0100"" ref-type=""bibr"">20</xref>]. If monitoring the targeted metabolite is a key factor in the treatment regimen, steps should be taken to ensure that this can be done reliably, including the consideration to alternative specimen types such as blood dried on filter paper. This preliminary study is a reminder of the importance of pre-analytical variables in the accuracy of laboratory measurements, especially in the development of new therapies where associated",25_48,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"the development of new therapies where associated biomarkers of disease are used to monitor treatment. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. <bold>Coleman Turgeon:</bold> Writing – review & editing, Methodology, Investigation, Formal analysis, Conceptualization. <bold>Kari Casas:</bold> Writing – review & editing, Investigation, Conceptualization. <bold>Ryan Flanagan:</bold> Writing – review & editing, Investigation.",25_49,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"Writing – review & editing, Investigation. <bold>Amy White:</bold> Writing – review & editing, Investigation. <bold>Dawn Peck:</bold> Writing – review & editing, Investigation. <bold>Gisele Bentz Pino:</bold> Writing – review & editing, Investigation. <bold>April Studinski Jones:</bold> Writing – review & editing, Investigation. <bold>Dimitar Gavrilov:</bold> Writing – review & editing, Investigation. <bold>Devin Oglesbee:</bold> Writing – review & editing, Investigation. <bold>Matthew J. Schultz:</bold>",25_50,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"Investigation. <bold>Matthew J. Schultz:</bold> Writing – review & editing, Investigation. <bold>Silvia Tortorelli:</bold> Writing – review & editing, Investigation. <bold>Dietrich Matern:</bold> Writing – review & editing, Writing – original draft, Methodology, Investigation, Conceptualization. <bold>Patricia L. Hall:</bold> Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. The authors declare no conflict of interest",25_51,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
The authors declare no conflict of interest related to this work.,25_52,Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase,21 6 2024,,Phenylketonuria
"Neurovascular retinal impairment in early-treated adults with phenylketonuria Phenylalanine hydroxylase (PAH) deficiency, conventionally identified as Phenylketonuria (PKU), is an autosomal recessive inherited metabolic disorder marked by various mutations in the gene (<xref rid=""ref1"" ref-type=""bibr"">1</xref>). PAH serves as a catabolic enzyme responsible for converting L-phenylalanine (L-Phe) into L-tyrosine (L-Tyr), a process reliant on molecular oxygen, iron, and tetrahydrobiopterin (BH4) (<xref",26_0,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"iron, and tetrahydrobiopterin (BH4) (<xref rid=""ref2"" ref-type=""bibr"">2</xref>). Such deficiency leads to an impaired degradation of L-Phe and its metabolites, resulting in elevated levels in the blood. The hyperphenylalaninaemia and the increased Phe: Tyr ratio leads to Phe and Tyr to compete to cross the blood–brain barrier and tissues of affected individuals, resulting in an accumulation of Phe in the brain, especially in the White Matter (<xref rid=""ref3"" ref-type=""bibr"">3</xref>). The prevalence of",26_1,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"ref-type=""bibr"">3</xref>). The prevalence of PKU varies worldwide, with an incidence of 1:10,000 newborn in Europe (<xref rid=""ref4"" ref-type=""bibr"">4</xref>). As PKU has autosomal recessive inheritance, consanguineous marriage is an important risk factor; thus, high disease incidence is expectable for countries with a high rate of consanguineous marriages (<xref rid=""ref5"" ref-type=""bibr"">5</xref>). Untreated PKU can lead to a severe neurological impairment and progressive intellectual disability,",26_2,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"and progressive intellectual disability, accompanied by several additional symptoms such as eczematous rash, epilepsy, autism, seizures, and motor deficits (<xref rid=""ref6"" ref-type=""bibr"">6</xref>). The current classification of PKU distinguishes less severe forms of PAH deficiency, referred to as moderate PKU, mild PKU, mild hyperphenylalaninaemia (HPA) or benign HPA, and more severe manifestations referred to as classic PKU (<xref rid=""ref2"" ref-type=""bibr"">2</xref>). The neuropathology is determined",26_3,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"The neuropathology is determined by the increased levels of L-Phe, leading to disruptions in neuronal dendritic outgrowth and synaptic connectivity, as well as impaired cerebral glucose metabolism and neurotransmitters deficiency. The primary marker of disease progression includes white matter lesions (WMLs), which correlate with both metabolic control and the patient’s age (<xref rid=""ref2"" ref-type=""bibr"">2</xref>). To date, the mainstay of the treatment involves limiting dietary phenylalanine intake,",26_4,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"involves limiting dietary phenylalanine intake, coupled with daily supplementation of Phe-free amino acids. Indeed, the introduction of the neonatal screening allowed early intervention for this condition, with a consequent prevention of most of neuropsychological complications and an improved quality of life (<xref rid=""ref3"" ref-type=""bibr"">3</xref>). By consequence, individuals diagnosed with PKU and subjected to lifelong therapy from birth have significantly reduced the incidence of the more severe",26_5,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"reduced the incidence of the more severe impairments associated with untreated PKU. This specific group is termed early-treated PKU (ETPKU) (<xref rid=""ref7"" ref-type=""bibr"">7</xref>). In such a scenario, ocular findings include photophobia, ocular hypopigmentation, cataract and corneal opacities (<xref rid=""ref8"" ref-type=""bibr"">8</xref>), and various functional visual impairment such as a lower Best-corrected visual acuity (BCVA) and a lower contrast sensitivity (<xref rid=""ref9""",26_6,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"a lower contrast sensitivity (<xref rid=""ref9"" ref-type=""bibr"">9</xref>). The introduction of optical coherence tomography (OCT) has facilitated the identification of retinal neurodegeneration across various systemic and ocular conditions (<xref rid=""ref10"" ref-type=""bibr"">10</xref>). Specifically, earlier researchers have directed their attention towards assessing the thickness of the retinal nerve fiber layer (pRNFL) and the ganglion cell layer (GCC), proposing these measurements as potential biomarkers",26_7,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"these measurements as potential biomarkers for neurodegeneration (<xref rid=""ref11"" ref-type=""bibr"">11</xref>). Furthermore, due to the recent advancements in ophthalmic imaging techniques, notably OCTA, the ability to visualize vascular disorders has expanded to encompass various neurodegenerative conditions, including Parkinson’s disease (<xref rid=""ref12"" ref-type=""bibr"">12</xref>) (PD). Given the retina’s status as an extension of the central nervous system and shares numerous common characteristics",26_8,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"system and shares numerous common characteristics with the central nervous system’s vasculature, the potential identification of retinal structural changes through OCT and vascular alterations using OCTA in ETPKU could potentially provide insights into overarching cerebral modifications that manifest during the initial stages of the disease. Consequently, the primary objective of this study was to explore changes in pRNFL thickness and the radial peripapillary capillary (RPC) plexus in individuals with",26_9,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"capillary (RPC) plexus in individuals with ETPKU when contrasted with controls.   In this observational study, we exanimated the potential role of radial peripapillary capillary density and peripapillary retinal nerve fiber layer as markers of retinal damage in individuals with ETPKU compared to age-matched controls. Our findings align with previous research revealing a significant reduction in pRNFL thickness in ETPKU patients. Interestingly, we also observed that ETPKU patients exhibited a higher density",26_10,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"that ETPKU patients exhibited a higher density of the total RPC compared to controls, suggesting an increased vascular activity associated with the disease. ETPKU patients, thanks to neonatal screening and the early initiation of life-long phenylalanine-lowering therapy, benefit from protection against the most severe consequences of the disease (<xref rid=""ref16"" ref-type=""bibr"">16</xref>). Nevertheless, ETPKU patients have more pronounced issues in social functioning and neurocognitive problems (<xref",26_11,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"functioning and neurocognitive problems (<xref rid=""ref17"" ref-type=""bibr"">17</xref>). Recently, several researchers explored OCT and OCTA findings in ETPKU patients. For instance, Serfozo and coworkers observed significant thinning of both pRNFL and GCC in ETPKU compared to controls. This suggests that ocular microstructural abnormalities in PKU patients might be influenced by dietary control (<xref rid=""ref13"" ref-type=""bibr"">13</xref>). Subsequently, Lotz-Havla and coworkers corroborated these findings.",26_12,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"and coworkers corroborated these findings. They also noted a reduction of the inner plexiform layer (IPL) volume, and an inner nuclear layer (INL) swelling strongly correlated with the metabolic control (<xref rid=""ref18"" ref-type=""bibr"">18</xref>). These findings are partly consistent with our results, as we did not measure macular thickness, but we observed a thinning in the pRNFL thickness ETPKU patients who were solely treated with dietary control. Several studies have reported a significant",26_13,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"Several studies have reported a significant correlation between pRNFL thinning and cerebral neurodegeneration, suggesting that average pRNFL might serve as a suitable biomarker for detecting and monitoring the progression of conditions such as Parkinson’s disease (PD) (<xref rid=""ref19"" ref-type=""bibr"">19</xref>). The pattern of impairment observed in PKU, including ETPKU patients, shares similarities with other conditions characterized by dopamine imbalances and white matter damage such as PD or multiple",26_14,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"and white matter damage such as PD or multiple sclerosis (MS) (<xref rid=""ref20"" ref-type=""bibr"">20</xref>). In a recent review from Lancet, the authors stated that measurements of pRNFL and macular GCL and IPL combined could be an important tool for diagnosis, monitoring and research of MS (<xref rid=""ref20"" ref-type=""bibr"">20</xref>). Specifically, in PKU and ETPKU patients, elevated phenylalanine (Phe) levels in the brain can inhibit the activities of enzymes like tyrosine and tryptophan hydroxylases",26_15,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"enzymes like tyrosine and tryptophan hydroxylases activities, causing a reduction of dopamine (DA) and serotonin biosynthesis (<xref rid=""ref21"" ref-type=""bibr"">21</xref>). In the eye, DA is released by amacrine cells, activates dopamine receptors distributed throughout the retina, and covers multiple trophic roles related to circadian rhythmicity, cell survival, and eye growth (<xref rid=""ref22"" ref-type=""bibr"">22</xref>). Consequently, conditions of metabolic dysregulation of DA like PKU, have been",26_16,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"metabolic dysregulation of DA like PKU, have been showed to be related to a DA imbalance in the retina as well (<xref rid=""ref23"" ref-type=""bibr"">23</xref>). The exact mechanism of neurotoxicity on the retina in PKU is not clearly understood, but, according to one of the hypotheses, altered DA levels and impaired neurotransmission, are discussed to play a role in the retinal damage (<xref rid=""ref21"" ref-type=""bibr"">21</xref>). In addition to using OCT angiography, this study also evaluated the perfusion",26_17,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"this study also evaluated the perfusion of the peripapillary vascular plexus. A previous OCTA study on ETPKU individuals by Serfozo et al. revealed a decrease in parafoveal superficial capillary plexus density in ETPKU compared to controls (<xref rid=""ref24"" ref-type=""bibr"">24</xref>). However, our findings demonstrated a significant increase in RPC perfusion in ETPKU patients. Given the aforementioned common pathways of retinal damage among DA imbalance diseases, it is not surprising the increased RPC",26_18,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"diseases, it is not surprising the increased RPC density we found in ETPKU patients compared to controls (<xref rid=""ref25"" ref-type=""bibr"">25</xref>). Indeed, the RPC is a network of capillaries that has a unique anatomic organization since it runs in parallel with retinal nerve fiber layer axon bundles and plays a role in nourishing the axons of retinal ganglion cells in peripapillary area (<xref rid=""ref24"" ref-type=""bibr"">24</xref>). We speculate that the neuroinflammation and the cellular stress may",26_19,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"the neuroinflammation and the cellular stress may lead to an increased amount of vasodilatory and vasogenic mediators, resulting in enhanced blood flow to pRNFL axons. A similar mechanism has been proposed in Parkinson’s disease (<xref rid=""ref26"" ref-type=""bibr"">26</xref>). This hypothetical condition might explain the simultaneous increase in RPC density and pRNFL thinning we found. Another potential explanation may be the formation of dysfunctional capillaries similar to the string vessels of",26_20,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"capillaries similar to the string vessels of Alzheimer’s disease. The present study has limitations to consider when interpreting our findings. Our sample size was relatively small, which may limit the results generalizability. Furthermore, it’s important to acknowledge that our analysis focused solely on one phenotype of these patients (ETPKU), which may introduce a potential bias in our results. We analyzed OCTA images using spectral domain OCTA which utilizes shorter wavelength light in comparison with",26_21,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"shorter wavelength light in comparison with swept source OCT angiography. We did not measure the macular thickness and we did not compare the retinal measurements with brain parameters correlated to neurocognitive impairment. Additionally, we did not investigate the correlation between the duration of the pathology and the quantitative OCTA parameters analyzed. Future randomized prospective case–control trials are necessary to confirm our findings, as well as longitudinal studies are always recommended for",26_22,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"longitudinal studies are always recommended for establishing the validity of such biomarkers. In conclusion, our observational study provides evidence of neurovascular impairment in ETPKU patients who were solely treated with dietary control when compared to controls. Through structural OCT and OCT angiography, we observed thinning of the peripapillary nerve fibers accompanied by an increase in perfusion of the peripapillary vascular plexus. We suggest that, similar to other neurodegenerative diseases,",26_23,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"similar to other neurodegenerative diseases, increased neuroinflammation may lead to a higher production of vasodilatory mediators, resulting in an augmented vessel density in the RPC. These findings warrant further investigation as they may serve as an additional retinal biomarker in individuals with ETPKU. The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author. Ethical review and approval was not",26_24,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"author. Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was provided by the participants. RB: Writing – original draft. GB: Formal analysis, Methodology, Supervision, Writing – review & editing. MGa: Data curation, Writing – original draft. SG: Supervision, Writing – original draft. RF: Data curation, Writing – original draft. AM: Conceptualization,",26_25,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"Writing – original draft. AM: Conceptualization, Writing – original draft. MGr: Conceptualization, Writing – review & editing. MP: Data curation, Writing – original draft. PP: Conceptualization, Writing – original draft. EG: Conceptualization, Writing – review & editing. MD’a: Data curation Writing – original draft. GA: Conceptualization, Writing – review & editing. FB: Conceptualization, Writing – review & editing. PV: Supervision, Writing – review & editing.",26_26,Neurovascular retinal impairment in early-treated adults with phenylketonuria,21 6 2024,,Phenylketonuria
"Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels Phenylketonuria (PKU) (OMIM #261600) and its milder variant hyperphenylalaninemia (HPA) (OMIM #261630) are inborn errors of amino acid metabolism. These conditions result from homozygous or compound heterozygous mutations in the phenylalanine hydroxylase gene (OMIM #612349), which encodes an enzyme responsible for the conversion of phenylalanine (Phe) into tyrosine. The disruption of",27_0,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"(Phe) into tyrosine. The disruption of this enzymatic pathway leads to a notable accumulation of Phe and a corresponding decrease in tyrosine levels. This imbalance manifests in elevated Phe concentrations in the brain, inducing various neuropathological outcomes. Among these neurotoxic effects [<xref ref-type=""bibr"" rid=""CR1"">1</xref>], there is a relevant effect on the dopaminergic system [<xref ref-type=""bibr"" rid=""CR2"">2</xref>], along with an adverse impact on oligodendroglia, causing defective myelin",27_1,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"on oligodendroglia, causing defective myelin synthesis [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Blood Phe concentration is the primary reported marker of metabolic control. Although target ranges are based on plasma Phe (the upper target for adults has been set at 600 μmol/L according to the European guidelines) [<xref ref-type=""bibr"" rid=""CR1"">1</xref>], patients are routinely monitored using dried bloodspot (DBS) specimens due to the convenience of their",27_2,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"(DBS) specimens due to the convenience of their collection [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. PKU early diagnosis through newborn screening (NBS) programs and early treatment with a restricted low-protein diet together with an adapted nutritional formula, and sometimes tetrahydrobiopterin (BH4), prevents severe neurological damage and allows a good quality of life and long-term survival [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. However, despite early treatment, cognitive, psychiatric and brain",27_3,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"early treatment, cognitive, psychiatric and brain alterations have also been reported [<xref ref-type=""bibr"" rid=""CR6"">6</xref>–<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. White matter alterations associated with PKU are the most consistent neuroradiological finding. Indeed, neuropathological studies of untreated patients showed an altered myelination pattern. Magnetic resonance imaging (MRI) (T2 weighted images and FLAIR images) allows the identification of impaired myelination as high-signal intensity in",27_4,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"impaired myelination as high-signal intensity in periventricular white matter. In a review including 312 individuals with PKU aged between 0.9 and 49 years, Anderson and Leuzzi [<xref ref-type=""bibr"" rid=""CR3"">3</xref>] reported abnormal white matter in 93% of cases viewed on T2; and some years later Mastrangelo et al., also in a mixed age cohort, reported alterations in white matter mostly seen during adulthood [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. There is clear evidence that the degree of white",27_5,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"There is clear evidence that the degree of white matter (WM) abnormalities, and specifically diffusivity in WM, is influenced by metabolic control [<xref ref-type=""bibr"" rid=""CR10"">10</xref>] and thus, it could change according to diet adherence and/or clinical evolution even in treated patients [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>] due to individual sensitivity to Phe [<xref ref-type=""bibr"" rid=""CR12"">12</xref>]. Diffusion tensor imaging (DTI) is a suitable",27_6,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"Diffusion tensor imaging (DTI) is a suitable technique to identify and quantify regional white matter changes through diffusion [<xref ref-type=""bibr"" rid=""CR13"">13</xref>], with the posterior-anterior decrement in mean diffusivity (MD) being the most consistently reported finding in PKU patient samples [<xref ref-type=""bibr"" rid=""CR13"">13</xref>–<xref ref-type=""bibr"" rid=""CR23"">23</xref>]. On the other hand, studies on volumetric gray matter subcortical structure in PKU are scarce. An early study",27_7,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"structure in PKU are scarce. An early study published in 2005 performed manual volumetry of brain structures in a sample of 31 adult patients with PKU and found hippocampal reductions but no differences in the caudate, nucleus lentiformis, or thalamic structures [<xref ref-type=""bibr"" rid=""CR24"">24</xref>]. In 2006, Pérez-Dueñas et al. [<xref ref-type=""bibr"" rid=""CR25"">25</xref>] studied a sample including children and adolescents with PKU using the voxel-based morphometry (VBM) technique and reported",27_8,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"morphometry (VBM) technique and reported increased volume of the ventral striatum. Using the same neuroimaging approach but in a sample including only adults, Pilotto et al. [<xref ref-type=""bibr"" rid=""CR26"">26</xref>] reported significant gray matter reductions in the putamen and thalamus. Nevertheless, only putamen nuclei remained significant after correcting for multiple comparisons. In a small sample of 13 participants with PKU, mixing children, adolescents, and adults and performing manual volumetry",27_9,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"and adults and performing manual volumetry of basal ganglia, Bodner et al. [<xref ref-type=""bibr"" rid=""CR27"">27</xref>] reported increased volumes of putamen and a significant positive correlation between current Phe levels and putamen volume. A similar positive correlation was reported by Brown et al. [<xref ref-type=""bibr"" rid=""CR28"">28</xref>] using automatic volumetry. To summarize, these discrepant results may be explained by methodological differences and/or the inclusion of dissimilar study groups,",27_10,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"and/or the inclusion of dissimilar study groups, sometimes including patients with immature brains. Currently, only one study has focused on adult patients exclusively, and this observed reductions in the putamen volume [<xref ref-type=""bibr"" rid=""CR26"">26</xref>]. Although traditionally it was considered uncommon, recent studies are increasingly demonstrating cortical gray matter involvement in the PKU setting. Pfaendner et al. [<xref ref-type=""bibr"" rid=""CR24"">24</xref>] described global reductions of",27_11,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"described global reductions of estimated gray matter volume in adult patients with PKU, and Pérez-Dueñas et al. [<xref ref-type=""bibr"" rid=""CR25"">25</xref>] found gray matter reductions in the motor cortex and the left premotor cortex using the VBM approach. Later, Christ et al. [<xref ref-type=""bibr"" rid=""CR29"">29</xref>] obtained average gray matter volumetric measurements for each major cortical lobe and reported a decrease in parietal cortex volume in the group with PKU (19 patients with an age range",27_12,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"the group with PKU (19 patients with an age range from 9 to 33 years) compared with the control group. Subsequent subregional analysis revealed significant differences in parietal (e.g., left precuneus, dorsal supramarginal gyrus) and occipital regions (e.g., left inferior occipital gyrus, right posterior collateral sulcus). Later, Muri et al. [<xref ref-type=""bibr"" rid=""CR30"">30</xref>] reported whole brain mean cortical thickness reduction in adult patients with PKU based on residual scores obtained by",27_13,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"with PKU based on residual scores obtained by considering intracranial volume and age. However, surface area on a whole-brain level did not differ between patients and controls. At the lobar level, patients showed a significantly thinner cortex in the left and right temporal, parietal, and occipital lobar regions of interest (ROIs). Conversely, Hawks et al. [<xref ref-type=""bibr"" rid=""CR19"">19</xref>] found no significant group differences in cortical whole-brain measures (cortical gray matter volume,",27_14,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"measures (cortical gray matter volume, total surface area, and average cortical thickness). To the best of our knowledge, there are no previous studies that have demonstrated a vertex-wise cortical thickness reduction in adults with PKU. In summary, current research suggests a link between elevated Phe levels, which may indicate Phe toxicity, and anomalies in brain anatomy [<xref ref-type=""bibr"" rid=""CR10"">10</xref>] and neuropsychological functioning, mostly when referred to subcortical structures, even",27_15,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"when referred to subcortical structures, even in treated patients with PKU [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Nevertheless, most studies have been performed on children or on mixed child and adult samples. Only four structural MRI-quantified studies have included adults only [<xref ref-type=""bibr"" rid=""CR26"">26</xref>, <xref ref-type=""bibr"" rid=""CR28"">28</xref>, <xref ref-type=""bibr"" rid=""CR30"">30</xref>, <xref ref-type=""bibr"" rid=""CR31"">31</xref>]. As",27_16,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"<xref ref-type=""bibr"" rid=""CR31"">31</xref>]. As adulthood is the ideal condition in which to study structural changes associated with PKU as no significant neurodevelopmental variations are expected, we selected a relatively large sample of adults with PKU under early dietary treatment in the current study. We primarily aimed to investigate differences in cortical and subcortical gray matter and global volumetric measures in comparison to healthy controls. As a secondary objective, we tested the possible",27_17,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"As a secondary objective, we tested the possible relationship between structural alterations and metabolic and neuropsychological variables.  The sociodemographic and clinical characteristics of the participants are summarized in Table <xref rid=""Tab1"" ref-type=""table"">1</xref>. There were no between-group differences in age (U = 311.500; <italic toggle=""yes"">p</italic> = 0.228), sex (X<sup>2</sup> = 0.127; <italic toggle=""yes"">p</italic> = 0.722), parents’ education (U = 382.000; <italic",27_18,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"parents’ education (U = 382.000; <italic toggle=""yes"">p</italic> = 0.961), or BMI (t = 0.889; <italic toggle=""yes"">p</italic> = 0.189), but there were differences in years of education (U = 218.500; <italic toggle=""yes"">p</italic> = 0.006), psychiatric comorbidities (X<sup>2</sup> = 8.568; <italic toggle=""yes"">p</italic> = 0.003) and natural protein intake (U = 60.000; <italic toggle=""yes"">p</italic> =  < 0.001).",27_19,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"<table-wrap id=""Tab1""><label>Table 1</label><caption><p>Sociodemographic and clinical characteristics of the participants (HC vs PKU)</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th align=""left""></th><th align=""left""><bold>HC</bold>
<italic toggle=""yes"">n</italic> = 22</th><th align=""left""><bold>PKU/HPA</bold>",27_20,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"<italic toggle=""yes"">n</italic> = 35</th><th align=""left""><bold>Statistics</bold></th><th align=""left""><bold><italic toggle=""yes"">p-value</italic></bold></th></tr></thead><tbody><tr><td align=""left"">Age, years</td><td align=""left"">34.73 ± 8.87 (22–56)</td><td align=""left"">31.86 ± 8.30 (18–55)</td><td align=""left"">311.500<sup>U</sup></td><td align=""left"">0.228</td></tr><tr><td align=""left"">Sex, male (%)</td><td align=""left"">20 (38.46%)</td><td align=""left"">14 (41.18%)</td><td",27_21,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"(38.46%)</td><td align=""left"">14 (41.18%)</td><td align=""left"">0.127<sup>X</sup><sup>2</sup></td><td align=""left"">0.722</td></tr><tr><td align=""left"">Education, years </td><td align=""left"">17.95 ± 3.36 (9–23)</td><td align=""left"">15.29 ± 3.359 (10–24)</td><td align=""left"">218.500<sup>U</sup></td><td align=""left""><bold>0.006</bold><sup><bold>*</bold></sup></td></tr><tr><td align=""left"">Parents education, years</td><td align=""left"">10.75 ± 4.03 (4–18)</td><td align=""left"">10.40 ± 3.66 (3–19)</td><td",27_22,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">10.40 ± 3.66 (3–19)</td><td align=""left"">382.000<sup>U</sup></td><td align=""left"">0.961</td></tr><tr><td align=""left"">BMI</td><td align=""left"">24.54 ± 3.75 (18.95–33.74)</td><td align=""left"">23.72 ± 3.17 (18.25–30.38)</td><td align=""left"">0.889<sup>t</sup></td><td align=""left"">0.189</td></tr><tr><td align=""left"">IDC-Phe levels (µmol/L)</td><td align=""left"">-</td><td align=""left"">519.09 ± 248.48 (109–1000)</td><td align=""left"">-</td><td align=""left"">-</td></tr><tr><td align=""left"">Good",27_23,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">-</td></tr><tr><td align=""left"">Good control<sup>a</sup>, yes (%)</td><td align=""left"">-</td><td align=""left"">20 (57.14%)</td><td align=""left"">-</td><td align=""left"">-</td></tr><tr><td align=""left"">Synthetic BH4<sup>b</sup>, yes (%)</td><td align=""left"">-</td><td align=""left"">9 (28.12%)</td><td align=""left"">-</td><td align=""left"">-</td></tr><tr><td align=""left"" colspan=""5"">Classical PKU<sup>c</sup></td></tr><tr><td align=""left""> Early dx, yes (%)</td><td align=""left"">-</td><td align=""left"">27",27_24,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">-</td><td align=""left"">27 (77.14%)</td><td align=""left"">-</td><td align=""left"">-</td></tr><tr><td align=""left""> Late dx, yes (%)</td><td align=""left"">-</td><td align=""left"">3 (8.57%)</td><td align=""left"">-</td><td align=""left"">-</td></tr><tr><td align=""left"">HPA, yes (%)</td><td align=""left"">-</td><td align=""left"">5 (14.28%)</td><td align=""left"">-</td><td align=""left"">-</td></tr><tr><td align=""left"" colspan=""5"">Protein intake</td></tr><tr><td align=""left""> Natural protein</td><td",27_25,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left""> Natural protein</td><td align=""left"">76 ± 20.80</td><td align=""left"">32.29 ± 21.57</td><td align=""left"">60.000<sup>U</sup></td><td align=""left""><bold> < 0.001</bold><sup><bold>*</bold></sup></td></tr><tr><td align=""left""> Total protein<sup>d</sup></td><td align=""left"">76.79 ± 20.49</td><td align=""left"">89.04 ± 23.92</td><td align=""left"">254.000<sup>U</sup></td><td align=""left"">0.061</td></tr><tr><td align=""left"">Psychiatric comorbidities, yes (%)</td><td align=""left"">0 (0%)</td><td",27_26,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"yes (%)</td><td align=""left"">0 (0%)</td><td align=""left"">11 (47.83%)</td><td align=""left"">8.568<sup>X</sup><sup>2</sup></td><td align=""left""><bold>0.003</bold><sup><bold>*</bold></sup></td></tr><tr><td align=""left"">Subjective cognitive complaints, yes (%)</td><td align=""left"">14 (63.64%)</td><td align=""left"">23 (71.87%)</td><td align=""left"">0.026<sup>X</sup><sup>2</sup></td><td align=""left"">0.873</td></tr></tbody></table><table-wrap-foot><p>Values denote mean ± SD (range) or numbers",27_27,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"denote mean ± SD (range) or numbers (frequencies)</p><p>Statistical tests used: <sup>X</sup><sup>2</sup>Chi-Squared, <sup>t</sup>t-test, <sup>U</sup>Mann-Whitney</p><p><italic toggle=""yes"">Abbreviations</italic>: <italic toggle=""yes"">BMI</italic> body mass index, <italic toggle=""yes"">BRIEF-A</italic> Behavior Rating Inventory of Executive Function for Adults (Self-Report form), <italic toggle=""yes"">dx</italic> diagnosed, <italic toggle=""yes"">HC</italic> healthy controls, <italic toggle=""yes"">IDC</italic>",27_28,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"controls, <italic toggle=""yes"">IDC</italic> Index Dietary Control, <italic toggle=""yes"">PKU/HPA</italic> patients with phenylketonuria/hyperphenylalaninemia, <italic toggle=""yes"">WAIS-IV</italic> Wechsler Adult Intelligence Scale-IV</p><p><sup>*</sup>Statistical significance highlight, threshold set at <italic toggle=""yes"">p</italic> < 0.05</p><p><sup>a</sup>According to European guidelines standards (Phe values < 600 μmol/L) [<xref ref-type=""bibr"" rid=""CR36"">36</xref>]</p><p><sup>b</sup>Sapropterin",27_29,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"dihydrochloride (Kuvan®, <italic toggle=""yes"">BioMarin Pharmaceutical Inc</italic>.; Novato, California, U.S.), a synthetic form of the tetrahydrobiopterin (BH4), a cofactor for phenylalanine hydroxylase gene</p><p><sup>c</sup>Classical PKU is divided into ‘early diagnosed’ (< 3 months of age) and ‘late diagnosed’ (≥ 3 months-< 7 years) [<xref ref-type=""bibr"" rid=""CR37"">37</xref>]. Within the group of early diagnosed 26 of them were at New-born screening and one of them at 2 months of age. Late diagnosed",27_30,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"one of them at 2 months of age. Late diagnosed PKU were diagnosed at the age of 3 years old</p><p><sup>d</sup>Total protein refers to natural plus formula-derived protein</p></table-wrap-foot></table-wrap> Adult patients with PKU/HPA showed significantly lower performance than HC in the Verbal Comprehension Index (VCI) (<italic toggle=""yes"">t</italic> = 2.08; <italic toggle=""yes"">p</italic> = 0.043) and prorated Full Scale IQ (FSIQ) (<italic toggle=""yes"">t</italic> = 2.67; <italic",27_31,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"(<italic toggle=""yes"">t</italic> = 2.67; <italic toggle=""yes"">p</italic> = 0.010) from the WAIS-IV (Table <xref rid=""Tab2"" ref-type=""table"">2</xref>). Only FSIQ survived FDR correction (F = 7.107; <italic toggle=""yes"">p</italic> = 0.035).",27_32,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"<table-wrap id=""Tab2""><label>Table 2</label><caption><p>Neuropsychological performance of the participants</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th align=""left""></th><th align=""left""><bold>HC</bold> <italic toggle=""yes"">n</italic> = 22</th><th align=""left""><bold>PKU/HPA</bold>",27_33,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"<italic toggle=""yes"">n</italic> = 35</th><th align=""left""><bold>statistics</bold></th><th align=""left""><bold><italic toggle=""yes"">p-value</italic></bold></th><th align=""left""><bold><italic toggle=""yes"">pFDR</italic></bold></th></tr></thead><tbody><tr><td align=""left"">Vocabulary</td><td align=""left"">38.27 ± 5.650</td><td align=""left"">34.66 ± 7.447<sup>a</sup></td><td align=""left"">246.500<sup>U</sup></td><td align=""left"">0.063</td><td align=""left"">0.090</td></tr><tr><td align=""left"">Similarities</td><td",27_34,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">Similarities</td><td align=""left"">25.05 ± 3.848</td><td align=""left"">23.19 ± 3.831<sup>a</sup></td><td align=""left"">248.500<sup>U</sup></td><td align=""left"">0.067</td><td align=""left"">0.104</td></tr><tr><td align=""left"">VCI</td><td align=""left"">116.14 ± 15.050</td><td align=""left"">108.06 ± 13.320<sup>a</sup></td><td align=""left"">2.076<sup>t</sup></td><td align=""left""><bold>0.043</bold><sup><bold>*</bold></sup></td><td align=""left"">0.090</td></tr><tr><td align=""left"">Block design</td><td",27_35,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">Block design</td><td align=""left"">44.64 ± 8.295</td><td align=""left"">44.66 ± 11.545</td><td align=""left"">-0.007<sup>t</sup></td><td align=""left"">0.994</td><td align=""left"">0.996</td></tr><tr><td align=""left"">Matrix reasoning</td><td align=""left"">21.23 ± 2.468</td><td align=""left"">19.34 ± 4.051</td><td align=""left"">286.500<sup>U</sup></td><td align=""left"">0.103</td><td align=""left"">0.346</td></tr><tr><td align=""left"">PRI</td><td align=""left"">102.45 ± 12.439</td><td",27_36,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">102.45 ± 12.439</td><td align=""left"">96.89 ± 13.503</td><td align=""left"">1.562<sup>t</sup></td><td align=""left"">0.124</td><td align=""left"">0.422</td></tr><tr><td align=""left"">Digit</td><td align=""left"">25.14 ± 4.804</td><td align=""left"">24.74 ± 4.415</td><td align=""left"">384.000<sup>U</sup></td><td align=""left"">0.987</td><td align=""left"">0.926</td></tr><tr><td align=""left""> <italic toggle=""yes"">Forward</italic></td><td align=""left"">8.64 ± 2.128</td><td align=""left"">8.49 ± 1.652</td><td",27_37,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">8.49 ± 1.652</td><td align=""left"">385.000<sup>U</sup></td><td align=""left"">1.000</td><td align=""left"">0.926</td></tr><tr><td align=""left""> <italic toggle=""yes"">Backwards</italic></td><td align=""left"">8.95 ± 2.149</td><td align=""left"">8.74 ± 1.853</td><td align=""left"">366.000<sup>U</sup></td><td align=""left"">0.752</td><td align=""left"">0.926</td></tr><tr><td align=""left""> <italic toggle=""yes"">Sequencing</italic></td><td align=""left"">7.55 ± 1.471</td><td align=""left"">7.51 ± 1.755</td><td",27_38,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">7.51 ± 1.755</td><td align=""left"">380.500<sup>U</sup></td><td align=""left"">0.940</td><td align=""left"">0.996</td></tr><tr><td align=""left"">Arithmetic</td><td align=""left"">13.18 ± 2.373</td><td align=""left"">11.81 ± 3.267<sup>a</sup></td><td align=""left"">261.000<sup>U</sup></td><td align=""left"">0.107</td><td align=""left"">0.120</td></tr><tr><td align=""left"">Letter-number sequencing</td><td align=""left"">19.27 ± 2.529</td><td align=""left"">18.54 ± 2.267</td><td",27_39,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">18.54 ± 2.267</td><td align=""left"">295.500<sup>U</sup></td><td align=""left"">0.139</td><td align=""left"">0.480</td></tr><tr><td align=""left"">WMI</td><td align=""left"">95.32 ± 11.721</td><td align=""left"">89.63 ± 14.334</td><td align=""left"">299.500<sup>U</sup></td><td align=""left"">0.159</td><td align=""left"">0.442</td></tr><tr><td align=""left"">Symbol search</td><td align=""left"">33.23 ± 5.589</td><td align=""left"">32.34 ± 7.662</td><td align=""left"">0.503<sup>t</sup></td><td align=""left"">0.617</td><td",27_40,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">0.617</td><td align=""left"">0.909</td></tr><tr><td align=""left"">Digit-symbol coding</td><td align=""left"">78.27 ± 12.456</td><td align=""left"">70.74 ± 14.650</td><td align=""left"">1.998<sup>t</sup></td><td align=""left"">0.051</td><td align=""left"">0.346</td></tr><tr><td align=""left"">PSI</td><td align=""left"">104.77 ± 11.351</td><td align=""left"">98.17 ± 11.610</td><td align=""left"">271.500<sup>U</sup></td><td align=""left"">0.061</td><td align=""left"">0.346</td></tr><tr><td align=""left""",27_41,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">0.346</td></tr><tr><td align=""left"" colspan=""6"">Fluency tests</td></tr><tr><td align=""left""> <italic toggle=""yes"">Semantic (animals)</italic></td><td align=""left"">24.77 ± 3.963</td><td align=""left"">22.68 ± 5.470<sup>b</sup></td><td align=""left"">270.500<sup>U</sup></td><td align=""left"">0.082</td><td align=""left"">0.179</td></tr><tr><td align=""left""> <italic toggle=""yes"">Phonetic (letter P)</italic></td><td align=""left"">16.05 ± 4.134</td><td align=""left"">14.68 ± 3.470<sup>b</sup></td><td",27_42,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">14.68 ± 3.470<sup>b</sup></td><td align=""left"">311.500<sup>U</sup></td><td align=""left"">0.292</td><td align=""left"">0.179</td></tr><tr><td align=""left"" colspan=""6"">TMT</td></tr><tr><td align=""left""> <italic toggle=""yes"">Part A</italic></td><td align=""left"">28.68 ± 8.855</td><td align=""left"">31.89 ± 9.588</td><td align=""left"">312.000<sup>U</sup></td><td align=""left"">0.321</td><td align=""left"">0.480</td></tr><tr><td align=""left""> <italic toggle=""yes"">Part B</italic></td><td",27_43,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"toggle=""yes"">Part B</italic></td><td align=""left"">68.50 ± 25.194</td><td align=""left"">70.69 ± 20.786</td><td align=""left"">360.000<sup>U</sup></td><td align=""left"">0.682</td><td align=""left"">0.926</td></tr><tr><td align=""left"">FSIQ</td><td align=""left"">105.95 ± 12.167</td><td align=""left"">97.34 ± 11.307<sup>a</sup></td><td align=""left"">2.666<sup>t</sup></td><td align=""left""><bold>0.010</bold><sup><bold>*</bold></sup></td><td align=""left""><bold>0.035</bold><sup><bold>*</bold></sup></td></tr><tr><td",27_44,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"" colspan=""6"">RAVLT</td></tr><tr><td align=""left""> <italic toggle=""yes"">Total</italic></td><td align=""left"">54.09 ± 6.575</td><td align=""left"">51.00 ± 8.363</td><td align=""left"">312.500<sup>U</sup></td><td align=""left"">0.234</td><td align=""left"">0.422</td></tr><tr><td align=""left""> <italic toggle=""yes"">Recall</italic></td><td align=""left"">11.77 ± 1.688</td><td align=""left"">11.06 ± 2.555</td><td align=""left"">323.000<sup>U</sup></td><td align=""left"">0.305</td><td",27_45,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">0.305</td><td align=""left"">0.480</td></tr><tr><td align=""left"" colspan=""6"">ROCF</td></tr><tr><td align=""left""> <italic toggle=""yes"">Copy</italic></td><td align=""left"">32.909 ± 2.580</td><td align=""left"">32.771 ± 3.828</td><td align=""left"">368.500<sup>U</sup></td><td align=""left"">0.231</td><td align=""left"">0.926</td></tr><tr><td align=""left""> <italic toggle=""yes"">Immediate recall</italic></td><td align=""left"">21.818 ± 6.563</td><td align=""left"">21.471 ± 5.326</td><td",27_46,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">21.471 ± 5.326</td><td align=""left"">0.219<sup>t</sup></td><td align=""left"">0.828</td><td align=""left"">0.946</td></tr><tr><td align=""left"">BRIEF</td><td align=""left"">109.88 ± 17.885</td><td align=""left"">107.21 ± 20.898</td><td align=""left"">917.000<sup>U</sup></td><td align=""left"">0.577</td><td align=""left"">0.577</td></tr><tr><td align=""left"">BRIEF, altered (%)</td><td align=""left"">3 (13.636%)</td><td align=""left"">3 (8.571%)</td><td align=""left"">0.368<sup>X</sup><sup>2</sup></td><td",27_47,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">0.544</td><td align=""left"">0.577</td></tr></tbody></table><table-wrap-foot><p>Values denote the mean ± SD of raw scores and index of the WAIS-IV</p><p>Statistical tests used: <sup>X</sup><sup>2</sup>Chi-Squared, <sup>t</sup>t-test, <sup>U</sup>Mann-Whitney, FDR correction</p><p><italic toggle=""yes"">Abbreviations</italic>: <italic toggle=""yes"">BRIEF</italic> Behavior Rating Inventory of Executive Function for Adults, <italic toggle=""yes"">FSIQ</italic> Full Scale IQ, <italic",27_48,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"toggle=""yes"">FSIQ</italic> Full Scale IQ, <italic toggle=""yes"">HC</italic> healthy controls, <italic toggle=""yes"">PKU/HPA</italic> patients with phenylketonuria/hyperphenylalaninemia, <italic toggle=""yes"">PRI</italic> Perceptual Reasoning Index, <italic toggle=""yes"">PSI</italic> Processing Speed Index, <italic toggle=""yes"">RAVLT</italic> Rey Auditory Verbal Learning Test, <italic toggle=""yes"">ROCF</italic> Rey-Osterrieth Complex Figure, <italic toggle=""yes"">TMT</italic> Trail Making Test, <italic",27_49,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"Trail Making Test, <italic toggle=""yes"">VCI</italic> Verbal Comprehension Index, <italic toggle=""yes"">WMI</italic> Working Memory Index</p><p><sup>*</sup>Statistical significance highlight, threshold set at <italic toggle=""yes"">p</italic> < 0.05</p><p><sup>a</sup><italic toggle=""yes"">n</italic> = 32</p><p><sup>b</sup><italic toggle=""yes"">n</italic> = 34</p></table-wrap-foot></table-wrap> The PKU group showed significantly lower volumes than HC in the pallidum (U = 224.000; <italic",27_50,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"than HC in the pallidum (U = 224.000; <italic toggle=""yes"">p</italic> = 0.008), hippocampus (U = 243.000; <italic toggle=""yes"">p</italic> = 0.020), amygdala (U = 200.000; <italic toggle=""yes"">p</italic> = 0.002), brainstem (t = 3.17; <italic toggle=""yes"">p</italic> = 0.006) and total cerebral white matter (U = 175.000; <italic toggle=""yes"">p</italic> = 0.001) (Table <xref rid=""Tab3"" ref-type=""table"">3</xref>; Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>). These results remained significant after",27_51,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
These results remained significant after adjustment for age.,27_52,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"<table-wrap id=""Tab3""><label>Table 3</label><caption><p>Subcortical and global volumetric ratios of the participants</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th align=""left""></th><th align=""left""><bold>HC</bold> <italic toggle=""yes"">n</italic> = 22</th><th align=""left""><bold>PKU/HPA</bold>",27_53,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"<italic toggle=""yes"">n</italic> = 35</th><th align=""left""><bold>Statistics</bold></th><th align=""left""><bold><italic toggle=""yes"">p-value</italic></bold></th><th align=""left""><bold><italic toggle=""yes"">pFDR</italic></bold></th></tr></thead><tbody><tr><td align=""left"">Thalamus</td><td align=""left"">0.532 ± 0.056</td><td align=""left"">0.519 ± 0.045</td><td align=""left"">340.000<sup>U</sup></td><td align=""left"">0.461</td><td align=""left"">0,421</td></tr><tr><td align=""left"">Caudate</td><td",27_54,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">Caudate</td><td align=""left"">0.245 ± 0.030</td><td align=""left"">0.237 ± 0.023</td><td align=""left"">351.000<sup>U</sup></td><td align=""left"">0.577</td><td align=""left"">0,357</td></tr><tr><td align=""left"">Putamen</td><td align=""left"">0.343 ± 0.039</td><td align=""left"">0.332 ± 0.028</td><td align=""left"">1.239<sup>t</sup></td><td align=""left"">0.221</td><td align=""left"">0,327</td></tr><tr><td align=""left"">Pallidum</td><td align=""left"">0.142 ± 0.014</td><td align=""left"">0.133 ± 0.012</td><td",27_55,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">0.133 ± 0.012</td><td align=""left"">224.000<sup>U</sup></td><td align=""left""><bold>0.008</bold><sup><bold>*</bold></sup></td><td align=""left""><bold>0,031</bold><sup><bold>*</bold></sup></td></tr><tr><td align=""left"">Hippocampus</td><td align=""left"">0.293 ± 0.034</td><td align=""left"">0.273 ± 0.023</td><td align=""left"">243.000<sup>U</sup></td><td align=""left""><bold>0.020</bold><sup><bold>*</bold></sup></td><td align=""left""><bold>0,031</bold><sup><bold>*</bold></sup></td></tr><tr><td",27_56,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">Amygdala</td><td align=""left"">0.116 ± 0.012</td><td align=""left"">0.108 ± 0.009</td><td align=""left"">200.000<sup>U</sup></td><td align=""left""><bold>0.002</bold><sup><bold>*</bold></sup></td><td align=""left""><bold>0,013</bold><sup><bold>*</bold></sup></td></tr><tr><td align=""left"">Accumbens</td><td align=""left"">0.034 ± 0.006</td><td align=""left"">0.033 ± 0.004</td><td align=""left"">0.656<sup>t</sup></td><td align=""left"">0.515</td><td align=""left"">0,508</td></tr><tr><td",27_57,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">0,508</td></tr><tr><td align=""left"">Brainstem</td><td align=""left"">1.510 ± 0.172</td><td align=""left"">1.390 ± 0.116</td><td align=""left"">3.172<sup>t</sup></td><td align=""left""><bold>0.006</bold><sup><bold>*</bold></sup></td><td align=""left""><bold>0,013</bold><sup><bold>*</bold></sup></td></tr><tr><td align=""left"">Cortical gray matter</td><td align=""left"">33.363 ± 3.195</td><td align=""left"">32.097 ± 2.166</td><td align=""left"">289.000<sup>U</sup></td><td align=""left"">0.116</td><td",27_58,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">0.116</td><td align=""left"">0,685</td></tr><tr><td align=""left"">Subcortical gray matter</td><td align=""left"">4.069 ± 0.379</td><td align=""left"">3.885 ± 0.236</td><td align=""left"">294.000<sup>U</sup></td><td align=""left"">0.136</td><td align=""left"">0,056</td></tr><tr><td align=""left"">Cerebral white matter</td><td align=""left"">15.883 ± 1.565</td><td align=""left"">14.676 ± 1.129</td><td align=""left"">175.000<sup>U</sup></td><td align=""left""><bold>0.001</bold><sup><bold>*</bold></sup></td><td",27_59,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left""><bold>0,013</bold><sup><bold>*</bold></sup></td></tr><tr><td align=""left"">Mean cortical thickness</td><td align=""left"">2.521 ± 0.080</td><td align=""left"">2.535 ± 0.068</td><td align=""left"">-0.723<sup>t</sup></td><td align=""left"">0.236</td><td align=""left"">0,507</td></tr><tr><td align=""left"">Total estimated intracranial volume (cm<sup>3</sup>)</td><td align=""left"">1443.684 ± 198.753</td><td align=""left"">1509.057 ± 187.899</td><td align=""left"">-1.251<sup>t</sup></td><td",27_60,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"align=""left"">-1.251<sup>t</sup></td><td align=""left"">0.216</td><td align=""left"">0,327</td></tr></tbody></table><table-wrap-foot><p>Values denote the mean ± SD of volumetric ratio scores</p><p>Statistical tests used: <sup>t</sup>t-test, <sup>U</sup>Mann-Whitney, FDR correction</p><p><italic toggle=""yes"">Abbreviations</italic>: <italic toggle=""yes"">HC</italic> healthy controls, <italic toggle=""yes"">PKU/HPA</italic> patients with phenylketonuria/hyperphenylalaninemia</p><p><sup>*</sup>Statistical significance",27_61,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"significance highlight, treshold set at p<0.05</p></table-wrap-foot></table-wrap><fig id=""Fig1""><label>Fig. 1</label><caption><p>PKU showed statistically significant lower volumes, presented as ratio scores (volume/intracranial volume*100), in the pallidum (U = 224.000; <italic toggle=""yes"">p</italic> = .008), hippocampus (U = 243.000; <italic toggle=""yes"">p</italic> = .020), amygdala (U = 200.000; <italic toggle=""yes"">p</italic> = .002), brainstem (t = 3.17; <italic toggle=""yes"">p</italic> = .006) and",27_62,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"<italic toggle=""yes"">p</italic> = .006) and total cerebral white matter (U = 175.000; <italic toggle=""yes"">p</italic> = .001), in comparison with HC</p></caption><graphic http://www.w3.org/1999/xlink href=""11689_2024_9553_Fig1_HTML"" id=""MO1""></graphic></fig> IDC in PKU patients was negatively correlated with the pallidum (<italic toggle=""yes"">r</italic> = -0.417; <italic toggle=""yes"">p</italic> = 0.013) and brainstem (<italic toggle=""yes"">r</italic> = -0.455, <italic toggle=""yes"">p</italic> = 0.006)",27_63,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"<italic toggle=""yes"">p</italic> = 0.006) volumes (Fig. <xref rid=""Fig2"" ref-type=""fig"">2</xref>). No correlations were found between volume and neuropsychological performance or natural protein intake.<fig id=""Fig2""><label>Fig. 2</label><caption><p>Significant negative correlations between brainstem and IDC (<italic toggle=""yes"">r</italic> = -0.455, <italic toggle=""yes"">p</italic> = .006) and pallidum and blood IDC (<italic toggle=""yes"">r</italic> = -0.417; <italic toggle=""yes"">p</italic> = .013) in the",27_64,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"<italic toggle=""yes"">p</italic> = .013) in the PKU/HPA group</p></caption><graphic http://www.w3.org/1999/xlink href=""11689_2024_9553_Fig2_HTML"" id=""MO2""></graphic></fig> We found gray matter reductions in subcortical gray matter in PKU. Specifically, patients differed from controls in the volumes of pallidum, hippocampus, amygdala, and brainstem. In addition, whereas total cerebral white matter volume was decreased, no changes were detected in the volumetric or thickness measures of cortical gray matter",27_65,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"or thickness measures of cortical gray matter in early treated adult PKU. Basal ganglia abnormalities have previously been reported in both directions i.e. increased [<xref ref-type=""bibr"" rid=""CR25"">25</xref>, <xref ref-type=""bibr"" rid=""CR27"">27</xref>] and decreased [<xref ref-type=""bibr"" rid=""CR31"">31</xref>] volumes. Since volumetric increases have only been seen in samples including children and adolescents, it can be argued that the effects of Phe in basal ganglia may depend on the degree of",27_66,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"Phe in basal ganglia may depend on the degree of maturation and/or the long-term effects of Phe levels. Our results on basal ganglia are consistent with the only previous study performed in adults with PKU [<xref ref-type=""bibr"" rid=""CR31"">31</xref>]. However, a discrepancy with our observations should be highlighted. Whereas Pilotto et al. [<xref ref-type=""bibr"" rid=""CR31"">31</xref>] reported significant differences in the putamen, we found significant results in the pallidum. Both basal ganglia",27_67,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"results in the pallidum. Both basal ganglia structures have a high density of dopamine receptors, as does the brainstem, which was also reduced in volume in our sample. In patients with PKU, intracerebral dopamine depletion has been postulated due to reduced Tyr uptake and altered dopamine synthesis [<xref ref-type=""bibr"" rid=""CR38"">38</xref>]. Therefore, we speculate that Phe toxicity could be associated with specific abnormalities in dopaminergic structures. In this regard, brainstem reduction has also",27_68,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"In this regard, brainstem reduction has also been described in neuropathological studies of non-treated patients with PKU [<xref ref-type=""bibr"" rid=""CR39"">39</xref>]. Our study provides the first evidence on brainstem volume reduction in treated PKU patients using an automatic MRI segmentation procedure. Moreover, we also found volumetric decreases in limbic structures i.e. the hippocampus and amygdala. Hippocampal reduction in adult PKU patients was reported by Pfaendner et al. [<xref ref-type=""bibr""",27_69,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"by Pfaendner et al. [<xref ref-type=""bibr"" rid=""CR24"">24</xref>] using a manual volumetry approach. They found a 14.5% reduction in patients compared to controls. Wesonga et al. [<xref ref-type=""bibr"" rid=""CR20"">20</xref>] found that MD values of the hippocampus differed between patients with PKU and controls, and also reported increased values with aging in PKU individuals but not in controls. The age by group interaction was also significant. Similar results were reported by Hawks et al. [<xref",27_70,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"results were reported by Hawks et al. [<xref ref-type=""bibr"" rid=""CR19"">19</xref>] Thus, hippocampal involvement in PKU seems to be a consistent finding. Interestingly, we also found amygdala reductions that could be related to the emotional changes seen in some patients. This structure was not included in the ROI analyses [<xref ref-type=""bibr"" rid=""CR22"">22</xref>, <xref ref-type=""bibr"" rid=""CR24"">24</xref>, <xref ref-type=""bibr"" rid=""CR27"">27</xref>]. Our results point to the need to pay special",27_71,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"Our results point to the need to pay special attention to this structure in further multicenter studies. Moreover, we found no significant differences in whole brain gray matter volume, global cortical thickness, or cortical thickness maps. Whereas these results are consistent with the findings of Hawks et al. [<xref ref-type=""bibr"" rid=""CR19"">19</xref>], who applied a similar MRI approach to our group, they conflict with recent results from Muri et al. [<xref ref-type=""bibr"" rid=""CR30"">30</xref>], who",27_72,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"[<xref ref-type=""bibr"" rid=""CR30"">30</xref>], who suggested that cortical thickness is a particularly sensitive marker for gray matter alterations. It is noteworthy that previous results on cortical thickness were based on mean cortical thickness measures using global or ROI measurements. The ROI approach reduces problems related to multiple comparisons and is advantageous when an a priori hypothesis is clearly stated but not when the objective is the study of whole-brain cortical involvement. In this",27_73,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"of whole-brain cortical involvement. In this regard, no whole-brain vertex-wise approaches had been reported before the current study. Previous research has even identified variations in the gray matter of the cerebellum [<xref ref-type=""bibr"" rid=""CR40"">40</xref>]; however, this region was not examined in our study. Finally, our correlation analyses showed that IDC was negatively correlated with pallidum shrinkage. Of note, this correlation was congruent with the results obtained in group comparisons",27_74,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"with the results obtained in group comparisons showing reductions in this subcortical structure. In our sample, patients with PKU presented a reduced brainstem volume, and this reduction was related to higher levels of Phe. The strengths of our study lie in the inclusion of a relatively large sample of early-treated adults with PKU/HPA and well-matched HC, along with a detailed and comprehensive neuropsychological examination. Furthermore, we implemented a neuroimaging approach including both gray and",27_75,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"a neuroimaging approach including both gray and white matter volumetric metrics, but also mean global measures and a surface-based approach to study whole-brain vertex-wise cortical changes. However, several limitations should also be acknowledged. First, although our cohort was more homogeneous (adults) compared to previous studies in the field, 26 individuals were diagnosed with NBS, and four were diagnosed between 2 months and 3 years old, so dietary treatment was initiated later for them. However, as",27_76,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"was initiated later for them. However, as patients with an estimated intelligence quotient < 70 (WAIS-IV) were not included, it is unlikely that our results were subjected to significant bias due to sample variability. Second, while classically the IDC is calculated as the median of Phe levels and the mean of all medians throughout the period of interest (childhood, youth, adulthood) [<xref ref-type=""bibr"" rid=""CR32"">32</xref>], we focused on the median of Phe-DBS levels in the year prior to study",27_77,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"of Phe-DBS levels in the year prior to study inclusion. The average lifetime Phe levels for participants were not quantitatively available. This limitation arose because while pediatric history records were accessible for 18 participants, data were not available for all participants. As the calculated 1-year IDC allows the standardization of the same measure for the whole group and correction for sporadic decompensations (e.g., illness, dietary abandon), the selected approach offers a good picture of",27_78,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"the selected approach offers a good picture of adults’ metabolic control. Finally, our study did not include an exhaustive assessment of executive functions such as the n-back task [<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. The executive functions in our study were assessed using the fluency test and the Trail Making test. In addition we used The BRIEF as a screening tool, but this is not able to detect the clinical phenotype of those individuals showing mild executive dysfunction or to detect the",27_79,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"mild executive dysfunction or to detect the correlates of basal ganglia volumetric reductions. In this regard, previous studies reported consistent differences between groups in certain executive domains [<xref ref-type=""bibr"" rid=""CR34"">34</xref>], and new toolboxes, which also integrate cognitive indices and additional motor evaluations, have recently been introduced for this purpose [<xref ref-type=""bibr"" rid=""CR41"">41</xref>]. The incorporation of MRI and neuropsychological assessments is important in",27_80,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"neuropsychological assessments is important in the initial evaluation and subsequent monitoring of PKU patients. These diagnostic tools may enhance our understanding of how metabolic control influences neuropsychological outcomes, to achieve individualized care strategies. Therefore, future research with multicenter cohorts is crucial, as it will enable the development of predictive models that can guide personalized treatment approaches more effectively. In conclusion, this study expands on previous",27_81,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"In conclusion, this study expands on previous findings showing global white matter reduction but also gray matter abnormalities in adult patients with PKU. Early-treated PKU mainly gives rise to volumetric reductions in basal ganglia, brainstem, and limbic subcortical structures that are related to poorer metabolic control, without evidence of neocortical involvement.",27_82,Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels,21 6 2024,,Phenylketonuria
"The struggle that is phenylketonuria: What do the patients and caregivers suffer from To assess stress levels and life hardships of patients with phenylketonuria and their parents. Between January 2020 and June 2020, 156 patients with PKU and their parents who arrived for regular examinations were included. Parents were asked to complete the parenting stress index, Zarit Burden Scale, and the Strengths and Difficulties Questionnaire (SDQ), and children over the age of 11 were asked to fill the Rosenberg",28_0,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"the age of 11 were asked to fill the Rosenberg Self-Esteem Scale, the State-Trait Anxiety Inventory, and the SDQ. We found a significant negative correlation between the Rosenberg Self-Esteem Scale and age at diagnosis (<italic toggle=""yes"">r</italic> = −0.27, <italic toggle=""yes"">P</italic> = .035), mother’s age (<italic toggle=""yes"">r</italic> = −0.33, <italic toggle=""yes"">P</italic> = .009), and father’s age (<italic toggle=""yes"">r</italic> = −0.38, <italic toggle=""yes"">P</italic> = .004). There was a",28_1,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"toggle=""yes"">P</italic> = .004). There was a significant positive correlation between the State-Trait Anxiety Inventory and patient’s age (<italic toggle=""yes"">r</italic> = 0.36, <italic toggle=""yes"">P</italic> = .006), mother’s age (<italic toggle=""yes"">r</italic> = 0.29, <italic toggle=""yes"">P</italic> = .031) and father’s age (<italic toggle=""yes"">r</italic> = 0.38, <italic toggle=""yes"">P</italic> = .024). In the child form of the SDQ, emotional problems were significantly positively correlated with",28_2,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"were significantly positively correlated with serum phenylalanine (Phe) levels at diagnosis (<italic toggle=""yes"">r</italic> = 0.35, <italic toggle=""yes"">P</italic> = .036), total points were significantly positively correlated with serum Phe levels at clinical examination (<italic toggle=""yes"">r</italic> = −0.34, <italic toggle=""yes"">P</italic> = .004), and social problems were significantly negatively correlated with the father’s age (<italic toggle=""yes"">r</italic> = −0.34, <italic",28_3,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"(<italic toggle=""yes"">r</italic> = −0.34, <italic toggle=""yes"">P</italic> = .047). We found a significant positive correlation between the Zarit Burden Scale and number of siblings (<italic toggle=""yes"">r</italic> = 0.195, <italic toggle=""yes"">P</italic> = .023). In the parent form of the SDQ, emotional problems were significantly positively correlated with patient age (<italic toggle=""yes"">r</italic> = 0.217, <italic toggle=""yes"">P</italic> = .032), peer problems were significantly positively correlated",28_4,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"problems were significantly positively correlated with age at diagnosis (<italic toggle=""yes"">r</italic> = 0.211, <italic toggle=""yes"">P</italic> = .037), behavioral problems (<italic toggle=""yes"">r</italic> = 0.203, <italic toggle=""yes"">P</italic> = .045), and attention deficit and hyperactivity (<italic toggle=""yes"">r</italic> = 0.203, <italic toggle=""yes"">P</italic> = .045) were significantly positively correlated with serum Phe levels at diagnosis. Phenylketonuria is difficult to cope with both for the",28_5,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"is difficult to cope with both for the patients and their parents because of diet obligation, high expenditures for the formulas required for the diet, requirement of regular clinical examinations, and possible development of mental disability and psychiatric disorders. Patients and their families should be psychologically evaluated and support should be provided if needed. Phenylalanine (phenylalanine) is an essential amino acid. It is required for protein production and cellular function in the human",28_6,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"production and cellular function in the human body. Thyroxine production is also dependent on phenylalanine intake since it is synthetized in liver from phenylalanine in a reaction catalyzed by enzyme “Phenylalanine Hydroxylase (PAH).”<sup>[<xref rid=""R1"" ref-type=""bibr"">1</xref>]</sup> Therefore discrepancies in enzyme function cause phenylalanine abundance. Phenylalanine accumulates in the body (especially in the central nervous system) and is excreted by the kidneys as phenylpiruvic acid.<sup>[<xref",28_7,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"by the kidneys as phenylpiruvic acid.<sup>[<xref rid=""R2"" ref-type=""bibr"">2</xref>]</sup> This abundance of phenylalanine is known as hyperphenylalaninemia, and blood levels help define the borders of the disease. Biochemical definition is a blood phenylalanine level above 2 mg/dL (120 μmol/L), but the clinical spectrum is wide and symptoms worsen as levels rise.<sup>[<xref rid=""R3"" ref-type=""bibr"">3</xref>]</sup> Deficiency of the PAH enzyme (EC 1.14.16.1) causes the illness, which is known as <italic",28_8,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"causes the illness, which is known as <italic toggle=""yes"">Phenylketonuria</italic> (OMIM #261600) and the urinary products give urine a specific musty odor. phenylketonuria (PKU) has an autosomal recessive inheritance pattern, and the PAH gene is located on chromosome 12q23.2.<sup>[<xref rid=""R4"" ref-type=""bibr"">4</xref>]</sup> This genetic inheritance pattern causes an increased number of patients in countries where consanguineous marriage is common, such as in Turkey. The frequency of phenylketonuria is",28_9,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"as in Turkey. The frequency of phenylketonuria is 1 in every 4000 children in Turkey, as opposed to Europe, where it is 1 in every 10,000 children.<sup>[<xref rid=""R2"" ref-type=""bibr"">2</xref>,<xref rid=""R5"" ref-type=""bibr"">5</xref>–<xref rid=""R8"" ref-type=""bibr"">8</xref>]</sup> As misfortunate as it is, this facilitates observation of the disease and the hardships it causes. The severity of the clinical spectrum depends on blood levels of phenylalanine. Therefore, disease classification was made according",28_10,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"disease classification was made according to phenylalanine measurements. Blood levels between 2 and 6 mg/dL were defined as mild hyperphenylalaninemia, 6 to 10 mg/dL as mild phenylketonuria, 10 to 20 mg/dL as moderate phenylketonuria, and levels above 20 mg/dL were defined as classical phenylketonuria.<sup>[<xref rid=""R2"" ref-type=""bibr"">2</xref>,<xref rid=""R9"" ref-type=""bibr"">9</xref>]</sup> Disorders of tetrahydrobiopterin (BH<sub>4</sub>) metabolism which is the coenzyme of PAH, causes BH<sub>4</sub>",28_11,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"is the coenzyme of PAH, causes BH<sub>4</sub> responsive hyperphenylalaninemia.<sup>[<xref rid=""R10"" ref-type=""bibr"">10</xref>]</sup> The most important factor in the treatment of phenylketonuria is <italic toggle=""yes"">a phenylalanine-restricted diet</italic>, which should be lifelong. The aim of the treatment is to keep the blood phenylalanine level within the recommended range, <italic toggle=""yes"">a 6 mg/dL limit is accepted for children</italic> aged < 12 years, <italic toggle=""yes"">and a 10 mg/dL",28_12,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"years, <italic toggle=""yes"">and a 10 mg/dL limit is accepted for children and adults</italic> aged 12 to 18 years.<sup>[<xref rid=""R11"" ref-type=""bibr"">11</xref>]</sup> For this purpose, blood phenylalanine levels should be measured at regular intervals, <italic toggle=""yes"">and physical examination evaluations and clinical follow-ups are required</italic> to monitor the dietary compliance of patients. Apart from diet, some patients can have a partially or completely normal diet if they take a",28_13,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"or completely normal diet if they take a pharmacological agent containing tetrahydrobiopterin orally.<sup>[<xref rid=""R12"" ref-type=""bibr"">12</xref>]</sup> Reasons such as emotional strain on food restriction, difficulty in giving the child an appropriate diet due to social pressure, difficulty in obtaining dietary products because of high costs, and difficulty in complying with the diet in social gatherings make dietary continuity difficult.<sup>[<xref rid=""R13"" ref-type=""bibr"">13</xref>]</sup> In",28_14,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"rid=""R13"" ref-type=""bibr"">13</xref>]</sup> In addition, patients or their caregivers have many financial and temporal losses to ensure dietary compliance.<sup>[<xref rid=""R14"" ref-type=""bibr"">14</xref>]</sup> Therefore, in our study, we aimed to evaluate the quality of life and stress levels of patients diagnosed with phenylketonuria and their parents. This study was conducted at Hacettepe University, İhsan Doğramaci Children’s Hospital, Department of Metabolism between January 2020 and June 2020. We",28_15,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"Metabolism between January 2020 and June 2020. We planned to include patients who were followed up with the diagnosis of phenylketonuria with diet or sapropterin hydrochloride therapy, and who did not have BH4 metabolism disorder or any other health problem. Pregnant women were excluded from the study. We aimed to evaluate the quality of life and stress levels of these patients and their families. The research sample consisted of patients with PKU, followed by Hacettepe University, İhsan Doğramaci",28_16,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"followed by Hacettepe University, İhsan Doğramaci Children’s Hospital, Department of Metabolism. The institutional ethics committee approved this study in accordance with the Declaration of Helsinki (Project Number: GO20/296). After the participants were physically evaluated in the Department of Child Metabolism, scales to evaluate their quality of life and stress levels were applied to them and their parents. Rosenberg Self Esteem Scale,<sup>[<xref rid=""R15"" ref-type=""bibr"">15</xref>,<xref rid=""R16""",28_17,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"ref-type=""bibr"">15</xref>,<xref rid=""R16"" ref-type=""bibr"">16</xref>]</sup> State-Trait Anxiety Inventory,<sup>[<xref rid=""R17"" ref-type=""bibr"">17</xref>,<xref rid=""R18"" ref-type=""bibr"">18</xref>]</sup> and Strengths and Difficulties Questionnaire Child Form<sup>[<xref rid=""R19"" ref-type=""bibr"">19</xref>,<xref rid=""R20"" ref-type=""bibr"">20</xref>]</sup> were applied to children as Zarit Burden Scale,<sup>[<xref rid=""R21"" ref-type=""bibr"">21</xref>,<xref rid=""R22"" ref-type=""bibr"">22</xref>]</sup> Parenting",28_18,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"ref-type=""bibr"">22</xref>]</sup> Parenting Stress Index,<sup>[<xref rid=""R23"" ref-type=""bibr"">23</xref>,<xref rid=""R24"" ref-type=""bibr"">24</xref>]</sup> and Strengths and Difficulties Questionnaire (SDQ) Parent Form were applied to parents. In our department, phenylketonuria patients were tested for phenylalanine levels every 3 months for routine control. The results of the blood test taken from the patients when they came for their routine control and the results of the blood tests taken from the other",28_19,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"results of the blood tests taken from the other controls were obtained from the database. We tried to avoid bias by accepting each and every patient who arrived in our clinic, conducting the interviews in the same setting by the same clinician without the knowledge of disease severity of the patient.  Phenylketonuria is a chronic disease that is difficult to cope with owing to the necessity of diet. Patients face many difficulties in complying with their diet, obtaining special foods, coping with the",28_20,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"diet, obtaining special foods, coping with the economic burden of special foods and regular controls, and adapting to social life.<sup>[<xref rid=""R13"" ref-type=""bibr"">13</xref>,<xref rid=""R14"" ref-type=""bibr"">14</xref>]</sup> Conditions such as hyperactivity, depression, and anxiety, which can be observed owing to the nature of the disease, also create a burden on both parents and patients.<sup>[<xref rid=""R25"" ref-type=""bibr"">25</xref>]</sup> The stress caused by these difficulties affects the quality of",28_21,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"by these difficulties affects the quality of life. In this study, the difficulties and stress situations faced by the patients and their parents were evaluated. The results are discussed separately for both groups. The authors thank Aysegul Tokatli for her supervision and help throughout the project. <bold>Conceptualization:</bold> Dilara Demirel, Serap Sivri. <bold>Data curation:</bold> Dilara Demirel. <bold>Formal analysis:</bold> Dilara Demirel. <bold>Investigation:</bold> Dilara Demirel.",28_22,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"<bold>Investigation:</bold> Dilara Demirel. <bold>Methodology:</bold> Dilara Demirel. <bold>Project administration:</bold> Dilara Demirel, Serap Sivri. <bold>Resources:</bold> Dilara Demirel. <bold>Software:</bold> Dilara Demirel. <bold>Validation:</bold> Dilara Demirel. <bold>Visualization:</bold> Dilara Demirel. <bold>Writing – original draft:</bold> Dilara Demirel. <bold>Writing – review & editing:</bold> Dilara Demirel, Serap Sivri.",28_23,The struggle that is phenylketonuria: What do the patients and caregivers suffer from,21 6 2024,,Phenylketonuria
"Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review Morphofunctional assessment was developed to evaluate disease-related malnutrition. However, it can also be used to assess cardiometabolic risk, as excess adiposity increases this risk. Phenylketonuria (PKU) is the most prevalent inherited metabolic disease among adults, and obesity in PKU has recently gained interest, although fat mass correlates better with cardiometabolic risk",29_0,Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review,11 6 2024,,Phenylketonuria
"mass correlates better with cardiometabolic risk than body mass index. In this systematic review, the objective was to assess whether adult patients with PKU have higher fat mass than healthy controls. Studies of adult PKU patients undergoing dietary treatment in a metabolic clinic reporting fat mass were included. The PubMed and EMBASE databases were searched. Relevance of articles, data collection, and risk of bias were evaluated by two independent reviewers. Ten articles were evaluated, six with a",29_1,Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review,11 6 2024,,Phenylketonuria
"Ten articles were evaluated, six with a control group, including 310 subjects with PKU, 62 with mild hyperphenylalaninemia, and 157 controls. One study reported a significant and four a tendency towards an increased fat mass in all patients or only females with PKU. Limitations included not having a healthy control group, not reporting sex-specific results and using different techniques to assess fat mass. Evaluation of fat mass should be included in the morphofunctional assessment of cardiometabolic risk",29_2,Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review,11 6 2024,,Phenylketonuria
"assessment of cardiometabolic risk in adult patients with PKU. Morphofunctional assessment of patients’ nutritional status was first developed for disease-related malnutrition [<xref rid=""B1-nutrients-16-01833"" ref-type=""bibr"">1</xref>,<xref rid=""B2-nutrients-16-01833"" ref-type=""bibr"">2</xref>]. Malnutrition is an issue of concern in patients with inherited metabolic diseases (IMDs), some of whom have neurological manifestations, and most of whom are on restrictive dietary treatment. Nevertheless, there",29_3,Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review,11 6 2024,,Phenylketonuria
"dietary treatment. Nevertheless, there are IMDs with a known increased cardiometabolic risk, such as homocystinuria and glycogen storage disease type III, while most patients with IMDs in adult metabolic clinics are patients with phenylketonuria (PKU), in whom a possible increased risk and prevalence of obesity have recently been discussed [<xref rid=""B3-nutrients-16-01833"" ref-type=""bibr"">3</xref>,<xref rid=""B4-nutrients-16-01833"" ref-type=""bibr"">4</xref>,<xref rid=""B5-nutrients-16-01833""",29_4,Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review,11 6 2024,,Phenylketonuria
"rid=""B5-nutrients-16-01833"" ref-type=""bibr"">5</xref>]. Newborn screening programs, together with dietary treatment, have led to an increase in the life expectancy of patients with PKU, with a growing number of patients aged 50 or older, in whom prevention of acquired cardiovascular and metabolic diseases should be considered, although it is not known whether the risk of cardiometabolic disease is similar or different to that of the general population. Obesity, as an excess of total body adiposity, could",29_5,Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review,11 6 2024,,Phenylketonuria
"as an excess of total body adiposity, could increase the risk of acquired cardiometabolic disease. Adipose tissue has different biological endocrine, autocrine, and paracrine functions [<xref rid=""B6-nutrients-16-01833"" ref-type=""bibr"">6</xref>], and may increase the risk of cardiometabolic disease depending on its type and location [<xref rid=""B7-nutrients-16-01833"" ref-type=""bibr"">7</xref>,<xref rid=""B8-nutrients-16-01833"" ref-type=""bibr"">8</xref>]. In a global morphofunctional assessment of a patient’s",29_6,Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review,11 6 2024,,Phenylketonuria
"global morphofunctional assessment of a patient’s nutritional status, fat mass should be evaluated as a morphological assessment of cardiometabolic risk. Excess adiposity and visceral fat are not well evaluated by body mass index (BMI) or other anthropometric methods. The Global Leadership Initiative on Malnutrition recommends anthropometry, only when technical approaches to assess muscle mass are not available [<xref rid=""B9-nutrients-16-01833"" ref-type=""bibr"">9</xref>]. Most available clinical fat",29_7,Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review,11 6 2024,,Phenylketonuria
"Most available clinical fat assessment techniques are bioelectrical impedance analysis (BIA), and nutritional ultrasound, while others such as dual X-ray absorptiometry (DXA), computed tomography (CT), or magnetic resonance imaging (MRI) are less available or only opportunistic [<xref rid=""B10-nutrients-16-01833"" ref-type=""bibr"">10</xref>]. The objective of this systematic review was to evaluate whether patients with PKU have a higher cardiometabolic risk due to excess fat mass than people without",29_8,Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review,11 6 2024,,Phenylketonuria
"risk due to excess fat mass than people without hyperphenylalaninemia (hPA).   Morphofunctional assessment of patients’ nutritional status was first developed for disease-related malnutrition [<xref rid=""B1-nutrients-16-01833"" ref-type=""bibr"">1</xref>,<xref rid=""B2-nutrients-16-01833"" ref-type=""bibr"">2</xref>]. Malnutrition is an issue of concern in patients with IMDs with severe neurological complications, but there are IMDs with known increased cardiometabolic risk, and most patients with IMDs in adult",29_9,Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review,11 6 2024,,Phenylketonuria
"risk, and most patients with IMDs in adult metabolic clinics are patients with PKU, in whom a possible risk and prevalence of obesity has recently been discussed [<xref rid=""B3-nutrients-16-01833"" ref-type=""bibr"">3</xref>,<xref rid=""B4-nutrients-16-01833"" ref-type=""bibr"">4</xref>,<xref rid=""B5-nutrients-16-01833"" ref-type=""bibr"">5</xref>], as obesity could increase acquired cardiometabolic risk. Fat mass (namely ectopic fat mass) correlates with cardiometabolic risk better than BMI, and therefore fat mass",29_10,Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review,11 6 2024,,Phenylketonuria
"risk better than BMI, and therefore fat mass should be assessed preferentially, as a global morphofunctional assessment of nutritional state should include not only disease-related malnutrition but also cardiometabolic risk. There were no significant differences in fat mass between adult patients with PKU and healthy controls, although a tendency towards higher fat mass in patients, particularly among women, was shown. The quality of the evidence was very low due to the risk of bias in the studies",29_11,Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review,11 6 2024,,Phenylketonuria
"very low due to the risk of bias in the studies reviewed, but it may be enough to raise the possibility of an increased cardiometabolic risk in people with PKU. As a second part of morphofunctional assessment, after morphological fat mass assessment, functional evaluation of dyslipidemia, insulin resistance, and systemic inflammation should be performed. More evidence is needed on body composition, body and ectopic fat mass, and cardiometabolic risk in patients with PKU.",29_12,Morphofunctional Assessment beyond Malnutrition: Fat Mass Assessment in Adult Patients with Phenylketonuria—Systematic Review,11 6 2024,,Phenylketonuria
